{"text":"A randomized Phase III trial demonstrated noninferiority of APF530 500 mg SC ( granisetron 10 mg ) to intravenous palonosetron 0.25 mg in preventing CINV in patients receiving MEC or HEC in acute ( 0 - 24 hours ) and delayed ( 24 - 120 hours ) settings , with activity over 120 hours .","paragraph":"<h3><u>Biochronomer\u2122 technology and the development of APF530, a sustained release formulation of granisetron.</u></h3><b style='color:Tomato;'><i>granisetron</i></b> and other 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are first-line agents for preventing chemotherapy-induced nausea and vomiting (CINV). Current treatment guidelines prefer the longer-acting agent, <b style='color:Tomato;'><i>palonosetron</i></b>, for CINV prevention in some chemotherapy regimens. A new <b style='color:Tomato;'><i>granisetron</i></b> formulation, APF530, has been developed as an alternative long-acting agent. APF530 utilizes Biochronomer(\u2122) technology to formulate a viscous tri(ethylene glycol) poly(orthoester)-based formulation that delivers - by single subcutaneous (SC) injection - therapeutic <b style='color:Tomato;'><i>granisetron</i></b> concentrations over 5 days. The poly(orthoester) polymer family contain an orthoester linkage; these bioerodible polymer systems are specifically designed for controlled, sustained drug delivery. Pharmacokinetics and pharmacodynamics of APF530 250, 500, or 750 mg SC (<b style='color:Tomato;'><i>granisetron</i></b> 5, 10, or 15 mg, respectively) administered 30-60 minutes before chemotherapy were evaluated in two Phase II trials in cancer patients receiving moderately (MEC) or highly (HEC) emetogenic chemotherapy. Pharmacokinetics were dose proportional, with slow <b style='color:Tomato;'><i>granisetron</i></b> absorption and elimination. Both trials demonstrated similar results for median half-life, time to maximum concentration, and exposure for APF530 250 and 500 mg, with no differences between patients receiving MEC or HEC. <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>Phase</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>noninferiority</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>APF530</i></b> <b style='color:DodgerBlue;'><i>500</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>SC</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>granisetron</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:MediumOrchid;'><i>palonosetron</i></b> <b style='color:DodgerBlue;'><i>0.25</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>preventing</i></b> <b style='color:DodgerBlue;'><i>CINV</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>receiving</i></b> <b style='color:DodgerBlue;'><i>MEC</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>HEC</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>0</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>24</i></b> <b style='color:DodgerBlue;'><i>hours</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>delayed</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>24</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>120</i></b> <b style='color:DodgerBlue;'><i>hours</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>settings</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>over</i></b> <b style='color:DodgerBlue;'><i>120</i></b> <b style='color:DodgerBlue;'><i>hours</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Mean maximum <b style='color:Tomato;'><i>granisetron</i></b> plasma concentrations were 10.8 and 17.8 ng/mL, and mean half-lives were 30.8 and 35.9 hours after SC administration of APF530 250 and 500 mg, respectively. Therapeutic <b style='color:Tomato;'><i>granisetron</i></b> concentrations were maintained for greater than 120 hours (5 days) in both APF530 dose groups. These data suggest that APF530 - an SC-administered formulation of <b style='color:Tomato;'><i>granisetron</i></b> delivered via Biochronomer technology - represents an effective treatment option for the prevention of both acute and delayed CINV in patients receiving either MEC or HEC.","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"randomized","start":2,"end":12,"id":1,"ws":true},{"text":"Phase","start":13,"end":18,"id":2,"ws":true},{"text":"III","start":19,"end":22,"id":3,"ws":true},{"text":"trial","start":23,"end":28,"id":4,"ws":true},{"text":"demonstrated","start":29,"end":41,"id":5,"ws":true},{"text":"noninferiority","start":42,"end":56,"id":6,"ws":true},{"text":"of","start":57,"end":59,"id":7,"ws":true},{"text":"APF530","start":60,"end":66,"id":8,"ws":true},{"text":"500","start":67,"end":70,"id":9,"ws":true},{"text":"mg","start":71,"end":73,"id":10,"ws":true},{"text":"SC","start":74,"end":76,"id":11,"ws":true},{"text":"(","start":77,"end":78,"id":12,"ws":true},{"text":"granisetron","start":79,"end":90,"id":13,"ws":true},{"text":"10","start":91,"end":93,"id":14,"ws":true},{"text":"mg","start":94,"end":96,"id":15,"ws":true},{"text":")","start":97,"end":98,"id":16,"ws":true},{"text":"to","start":99,"end":101,"id":17,"ws":true},{"text":"intravenous","start":102,"end":113,"id":18,"ws":true},{"text":"palonosetron","start":114,"end":126,"id":19,"ws":true},{"text":"0.25","start":127,"end":131,"id":20,"ws":true},{"text":"mg","start":132,"end":134,"id":21,"ws":true},{"text":"in","start":135,"end":137,"id":22,"ws":true},{"text":"preventing","start":138,"end":148,"id":23,"ws":true},{"text":"CINV","start":149,"end":153,"id":24,"ws":true},{"text":"in","start":154,"end":156,"id":25,"ws":true},{"text":"patients","start":157,"end":165,"id":26,"ws":true},{"text":"receiving","start":166,"end":175,"id":27,"ws":true},{"text":"MEC","start":176,"end":179,"id":28,"ws":true},{"text":"or","start":180,"end":182,"id":29,"ws":true},{"text":"HEC","start":183,"end":186,"id":30,"ws":true},{"text":"in","start":187,"end":189,"id":31,"ws":true},{"text":"acute","start":190,"end":195,"id":32,"ws":true},{"text":"(","start":196,"end":197,"id":33,"ws":true},{"text":"0","start":198,"end":199,"id":34,"ws":true},{"text":"-","start":200,"end":201,"id":35,"ws":true},{"text":"24","start":202,"end":204,"id":36,"ws":true},{"text":"hours","start":205,"end":210,"id":37,"ws":true},{"text":")","start":211,"end":212,"id":38,"ws":true},{"text":"and","start":213,"end":216,"id":39,"ws":true},{"text":"delayed","start":217,"end":224,"id":40,"ws":true},{"text":"(","start":225,"end":226,"id":41,"ws":true},{"text":"24","start":227,"end":229,"id":42,"ws":true},{"text":"-","start":230,"end":231,"id":43,"ws":true},{"text":"120","start":232,"end":235,"id":44,"ws":true},{"text":"hours","start":236,"end":241,"id":45,"ws":true},{"text":")","start":242,"end":243,"id":46,"ws":true},{"text":"settings","start":244,"end":252,"id":47,"ws":true},{"text":",","start":253,"end":254,"id":48,"ws":true},{"text":"with","start":255,"end":259,"id":49,"ws":true},{"text":"activity","start":260,"end":268,"id":50,"ws":true},{"text":"over","start":269,"end":273,"id":51,"ws":true},{"text":"120","start":274,"end":277,"id":52,"ws":true},{"text":"hours","start":278,"end":283,"id":53,"ws":true},{"text":".","start":284,"end":285,"id":54,"ws":false}],"spans":[{"start":79,"end":90,"token_start":13,"token_end":13,"label":"DRUG"},{"start":114,"end":126,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/27186139/","_input_hash":710174417,"_task_hash":-2112930405,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Classical NSAIDs are still the most logical choice for agents that will slow the progression or delay the onset of AD and other neurodegenerative diseases despite failures of naproxen , celecoxib and rofecoxib in AD clinical trials .","paragraph":"<h3><u>Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease.</u></h3>Inflammation is characteristic of a broad spectrum of neurodegenerative diseases. These include Alzheimer's (AD), Parkinson's (PD), and Huntington's diseases, amyotrophic lateral sclerosis, all of the tauopathies, multiple sclerosis and many other less common conditions. Morphologically, the level of inflammation is determined by the concentration and degree of activation of microglial cells. Biochemically, it is judged by the presence of a spectrum of inflammatory mediators. Epidemiological evidence indicates that anti-inflammatory agents such as non-steroidal anti-inflammatory drugs (NSAIDs) have a sparing effect on AD and PD indicating that inflammation exacerbates the pathology in these diseases. NSAIDs are protective in transgenic animal models of AD, providing further evidence of the negative consequences of inflammation. Here we describe an in vitro model, which was used to study the protective effects of NSAIDs in AD. This model is based on neuronal cell killing by stimulated microglia or microglia-like cells. In this model NSAIDs show protective effects at a therapeutically relevant level, which is in the low micromolar range. There are reports suggesting that NSAIDs act independently of cyclooxygenase (COX) inhibition, but only at higher doses. <b style='color:DodgerBlue;'><i>Classical</i></b> <b style='color:DodgerBlue;'><i>NSAIDs</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>still</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>most</i></b> <b style='color:DodgerBlue;'><i>logical</i></b> <b style='color:DodgerBlue;'><i>choice</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>will</i></b> <b style='color:DodgerBlue;'><i>slow</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>progression</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>delay</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>onset</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>AD</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>neurodegenerative</i></b> <b style='color:DodgerBlue;'><i>diseases</i></b> <b style='color:DodgerBlue;'><i>despite</i></b> <b style='color:DodgerBlue;'><i>failures</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>naproxen</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>celecoxib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rofecoxib</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>AD</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Several other classes of anti-inflammatory drugs have been identified as potentially beneficial in this and similar assay systems. Therefore combination therapy with other anti-inflammatory agents that work through different mechanisms of action might prove to be a superior therapeutic strategy.","tokens":[{"text":"Classical","start":0,"end":9,"id":0,"ws":true},{"text":"NSAIDs","start":10,"end":16,"id":1,"ws":true},{"text":"are","start":17,"end":20,"id":2,"ws":true},{"text":"still","start":21,"end":26,"id":3,"ws":true},{"text":"the","start":27,"end":30,"id":4,"ws":true},{"text":"most","start":31,"end":35,"id":5,"ws":true},{"text":"logical","start":36,"end":43,"id":6,"ws":true},{"text":"choice","start":44,"end":50,"id":7,"ws":true},{"text":"for","start":51,"end":54,"id":8,"ws":true},{"text":"agents","start":55,"end":61,"id":9,"ws":true},{"text":"that","start":62,"end":66,"id":10,"ws":true},{"text":"will","start":67,"end":71,"id":11,"ws":true},{"text":"slow","start":72,"end":76,"id":12,"ws":true},{"text":"the","start":77,"end":80,"id":13,"ws":true},{"text":"progression","start":81,"end":92,"id":14,"ws":true},{"text":"or","start":93,"end":95,"id":15,"ws":true},{"text":"delay","start":96,"end":101,"id":16,"ws":true},{"text":"the","start":102,"end":105,"id":17,"ws":true},{"text":"onset","start":106,"end":111,"id":18,"ws":true},{"text":"of","start":112,"end":114,"id":19,"ws":true},{"text":"AD","start":115,"end":117,"id":20,"ws":true},{"text":"and","start":118,"end":121,"id":21,"ws":true},{"text":"other","start":122,"end":127,"id":22,"ws":true},{"text":"neurodegenerative","start":128,"end":145,"id":23,"ws":true},{"text":"diseases","start":146,"end":154,"id":24,"ws":true},{"text":"despite","start":155,"end":162,"id":25,"ws":true},{"text":"failures","start":163,"end":171,"id":26,"ws":true},{"text":"of","start":172,"end":174,"id":27,"ws":true},{"text":"naproxen","start":175,"end":183,"id":28,"ws":true},{"text":",","start":184,"end":185,"id":29,"ws":true},{"text":"celecoxib","start":186,"end":195,"id":30,"ws":true},{"text":"and","start":196,"end":199,"id":31,"ws":true},{"text":"rofecoxib","start":200,"end":209,"id":32,"ws":true},{"text":"in","start":210,"end":212,"id":33,"ws":true},{"text":"AD","start":213,"end":215,"id":34,"ws":true},{"text":"clinical","start":216,"end":224,"id":35,"ws":true},{"text":"trials","start":225,"end":231,"id":36,"ws":true},{"text":".","start":232,"end":233,"id":37,"ws":false}],"spans":[{"start":175,"end":183,"token_start":28,"token_end":28,"label":"DRUG"},{"start":186,"end":195,"token_start":30,"token_end":30,"label":"DRUG"},{"start":200,"end":209,"token_start":32,"token_end":32,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/15974901/","_input_hash":-796826148,"_task_hash":-107330078,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Between 1987 and 2003 , patients 18 years old were given adjuvant chemotherapy consisting of one of two ' paediatric ' regimens ( depending on the time of presentation ) and craniospinal local-boost radiotherapy : regimen A ( n = 12 ) , vincristine ( VCR ) , intrathecal and/or intravenous methotrexate and conventional radiotherapy ; or regimen B ( n = 11 ) sequencing intensive doses of multiple agents followed by hyperfractionated accelerated radiotherapy ( HART ) .","paragraph":"<h3><u>Survival of adults treated for medulloblastoma using paediatric protocols.</u></h3>We retrospectively studied 26 consecutive adults treated for medulloblastoma using paediatric protocols. <b style='color:DodgerBlue;'><i>Between</i></b> <b style='color:DodgerBlue;'><i>1987</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>2003</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>18</i></b> <b style='color:DodgerBlue;'><i>years</i></b> <b style='color:DodgerBlue;'><i>old</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>adjuvant</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>consisting</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>one</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>'</i></b> <b style='color:DodgerBlue;'><i>paediatric</i></b> <b style='color:DodgerBlue;'><i>'</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>depending</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>time</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>presentation</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>craniospinal</i></b> <b style='color:DodgerBlue;'><i>local-boost</i></b> <b style='color:DodgerBlue;'><i>radiotherapy</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>12</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>VCR</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>intrathecal</i></b> <b style='color:DodgerBlue;'><i>and/or</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>conventional</i></b> <b style='color:DodgerBlue;'><i>radiotherapy</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>11</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>sequencing</i></b> <b style='color:DodgerBlue;'><i>intensive</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>multiple</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>hyperfractionated</i></b> <b style='color:DodgerBlue;'><i>accelerated</i></b> <b style='color:DodgerBlue;'><i>radiotherapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>HART</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A VCR-<b style='color:Tomato;'><i>lomustine</i></b>-based maintenance followed both regimens. Three additional patients received a tailored treatment due to their impaired neurological status after surgery. The median age at diagnosis was 26 years (range 18-41 years). With a median follow-up of 46 months, 5-year disease-free and overall survival rates were 65+/-11% and 73+/-10%, respectively, for the series as a whole. All patients who received regimen B (5 of whom had metastatic Chang M2-M3 disease) are alive with no evidence of disease at 39 months. Although the number of patients is limited, our data suggest that the sandwich sequential, moderately intensive chemotherapy in combination with HART is an effective treatment for medulloblastoma in adults, and this approach seems to overcome previously-recognised risk factors.","tokens":[{"text":"Between","start":0,"end":7,"id":0,"ws":true},{"text":"1987","start":8,"end":12,"id":1,"ws":true},{"text":"and","start":13,"end":16,"id":2,"ws":true},{"text":"2003","start":17,"end":21,"id":3,"ws":true},{"text":",","start":22,"end":23,"id":4,"ws":true},{"text":"patients","start":24,"end":32,"id":5,"ws":true},{"text":"18","start":33,"end":35,"id":6,"ws":true},{"text":"years","start":36,"end":41,"id":7,"ws":true},{"text":"old","start":42,"end":45,"id":8,"ws":true},{"text":"were","start":46,"end":50,"id":9,"ws":true},{"text":"given","start":51,"end":56,"id":10,"ws":true},{"text":"adjuvant","start":57,"end":65,"id":11,"ws":true},{"text":"chemotherapy","start":66,"end":78,"id":12,"ws":true},{"text":"consisting","start":79,"end":89,"id":13,"ws":true},{"text":"of","start":90,"end":92,"id":14,"ws":true},{"text":"one","start":93,"end":96,"id":15,"ws":true},{"text":"of","start":97,"end":99,"id":16,"ws":true},{"text":"two","start":100,"end":103,"id":17,"ws":true},{"text":"'","start":104,"end":105,"id":18,"ws":true},{"text":"paediatric","start":106,"end":116,"id":19,"ws":true},{"text":"'","start":117,"end":118,"id":20,"ws":true},{"text":"regimens","start":119,"end":127,"id":21,"ws":true},{"text":"(","start":128,"end":129,"id":22,"ws":true},{"text":"depending","start":130,"end":139,"id":23,"ws":true},{"text":"on","start":140,"end":142,"id":24,"ws":true},{"text":"the","start":143,"end":146,"id":25,"ws":true},{"text":"time","start":147,"end":151,"id":26,"ws":true},{"text":"of","start":152,"end":154,"id":27,"ws":true},{"text":"presentation","start":155,"end":167,"id":28,"ws":true},{"text":")","start":168,"end":169,"id":29,"ws":true},{"text":"and","start":170,"end":173,"id":30,"ws":true},{"text":"craniospinal","start":174,"end":186,"id":31,"ws":true},{"text":"local-boost","start":187,"end":198,"id":32,"ws":true},{"text":"radiotherapy","start":199,"end":211,"id":33,"ws":true},{"text":":","start":212,"end":213,"id":34,"ws":true},{"text":"regimen","start":214,"end":221,"id":35,"ws":true},{"text":"A","start":222,"end":223,"id":36,"ws":true},{"text":"(","start":224,"end":225,"id":37,"ws":true},{"text":"n","start":226,"end":227,"id":38,"ws":true},{"text":"=","start":228,"end":229,"id":39,"ws":true},{"text":"12","start":230,"end":232,"id":40,"ws":true},{"text":")","start":233,"end":234,"id":41,"ws":true},{"text":",","start":235,"end":236,"id":42,"ws":true},{"text":"vincristine","start":237,"end":248,"id":43,"ws":true},{"text":"(","start":249,"end":250,"id":44,"ws":true},{"text":"VCR","start":251,"end":254,"id":45,"ws":true},{"text":")","start":255,"end":256,"id":46,"ws":true},{"text":",","start":257,"end":258,"id":47,"ws":true},{"text":"intrathecal","start":259,"end":270,"id":48,"ws":true},{"text":"and/or","start":271,"end":277,"id":49,"ws":true},{"text":"intravenous","start":278,"end":289,"id":50,"ws":true},{"text":"methotrexate","start":290,"end":302,"id":51,"ws":true},{"text":"and","start":303,"end":306,"id":52,"ws":true},{"text":"conventional","start":307,"end":319,"id":53,"ws":true},{"text":"radiotherapy","start":320,"end":332,"id":54,"ws":true},{"text":";","start":333,"end":334,"id":55,"ws":true},{"text":"or","start":335,"end":337,"id":56,"ws":true},{"text":"regimen","start":338,"end":345,"id":57,"ws":true},{"text":"B","start":346,"end":347,"id":58,"ws":true},{"text":"(","start":348,"end":349,"id":59,"ws":true},{"text":"n","start":350,"end":351,"id":60,"ws":true},{"text":"=","start":352,"end":353,"id":61,"ws":true},{"text":"11","start":354,"end":356,"id":62,"ws":true},{"text":")","start":357,"end":358,"id":63,"ws":true},{"text":"sequencing","start":359,"end":369,"id":64,"ws":true},{"text":"intensive","start":370,"end":379,"id":65,"ws":true},{"text":"doses","start":380,"end":385,"id":66,"ws":true},{"text":"of","start":386,"end":388,"id":67,"ws":true},{"text":"multiple","start":389,"end":397,"id":68,"ws":true},{"text":"agents","start":398,"end":404,"id":69,"ws":true},{"text":"followed","start":405,"end":413,"id":70,"ws":true},{"text":"by","start":414,"end":416,"id":71,"ws":true},{"text":"hyperfractionated","start":417,"end":434,"id":72,"ws":true},{"text":"accelerated","start":435,"end":446,"id":73,"ws":true},{"text":"radiotherapy","start":447,"end":459,"id":74,"ws":true},{"text":"(","start":460,"end":461,"id":75,"ws":true},{"text":"HART","start":462,"end":466,"id":76,"ws":true},{"text":")","start":467,"end":468,"id":77,"ws":true},{"text":".","start":469,"end":470,"id":78,"ws":false}],"spans":[{"start":237,"end":248,"token_start":43,"token_end":43,"label":"DRUG"},{"start":290,"end":302,"token_start":51,"token_end":51,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/15869875/","_input_hash":-1431707466,"_task_hash":104155681,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":51,"child":43,"head_span":{"start":290,"end":302,"token_start":51,"token_end":51,"label":"DRUG"},"child_span":{"start":237,"end":248,"token_start":43,"token_end":43,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"The US Food and Drug Administration ( FDA ) recommends that \" concomitant use of drugs that inhibit CYP2C19 ( e.g. , omeprazole ) should be discouraged . \" As the presence of PPIs and clopidogrel in plasma is short lived , separation by 12 - 20 h should in theory prevent competitive inhibition of CYP metabolism and minimize any potential , though unproven , clinical interaction .","paragraph":"<h3><u>Proton pump inhibitor and clopidogrel interaction: fact or fiction?</u></h3>Current consensus recommendations state that patients prescribed <b style='color:Tomato;'><i>clopidogrel</i></b> plus <b style='color:Tomato;'><i>aspirin</i></b> should receive a proton pump inhibitor (PPI) to reduce gastrointestinal bleeding. <b style='color:Tomato;'><i>clopidogrel</i></b> is converted to its active metabolite by cytochrome P450 (CYP) enzymes. <b style='color:Tomato;'><i>clopidogrel</i></b> users with decreased CYP2C19 function have less inhibition of platelet aggregation and increased cardiovascular (CV) events. As PPI metabolism also involves CYP2C19, it was hypothesized that competition by PPIs might interfere with <b style='color:Tomato;'><i>clopidogrel</i></b>'s action. <b style='color:Tomato;'><i>omeprazole</i></b>, but not other PPIs, worsens surrogate markers of <b style='color:Tomato;'><i>clopidogrel</i></b> efficacy. Some (but not all) observational studies show that <b style='color:Tomato;'><i>clopidogrel</i></b> users prescribed PPIs have increased risks of CV events (hazard/odds ratios=1.25-1.5). When effect sizes are small to moderate (relative risks<1.5-2.0), however, it is only possible to conclude whether statistical associations are valid in randomized trials. A randomized trial of <b style='color:Tomato;'><i>omeprazole</i></b> vs. placebo in <b style='color:Tomato;'><i>clopidogrel</i></b> users showed no difference in CV events (hazard ratio=1.02,0.70-1.51). Thus, current evidence does not justify a conclusion that PPIs are associated with CV events among <b style='color:Tomato;'><i>clopidogrel</i></b> users, let alone a judgment of causality. Nonetheless, positive results from some observational studies and biological plausibility have led some health-care providers to accept that PPIs reduce <b style='color:Tomato;'><i>clopidogrel</i></b>'s efficacy. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>US</i></b> <b style='color:DodgerBlue;'><i>Food</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Drug</i></b> <b style='color:DodgerBlue;'><i>Administration</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>FDA</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>recommends</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>\"</i></b> <b style='color:DodgerBlue;'><i>concomitant</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>inhibit</i></b> <b style='color:DodgerBlue;'><i>CYP2C19</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>e.g.</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>should</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>discouraged</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>\"</i></b> <b style='color:DodgerBlue;'><i>As</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>presence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>PPIs</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>clopidogrel</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>plasma</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>short</i></b> <b style='color:DodgerBlue;'><i>lived</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>separation</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>12</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>h</i></b> <b style='color:DodgerBlue;'><i>should</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>theory</i></b> <b style='color:DodgerBlue;'><i>prevent</i></b> <b style='color:DodgerBlue;'><i>competitive</i></b> <b style='color:DodgerBlue;'><i>inhibition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>CYP</i></b> <b style='color:DodgerBlue;'><i>metabolism</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>minimize</i></b> <b style='color:DodgerBlue;'><i>any</i></b> <b style='color:DodgerBlue;'><i>potential</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>though</i></b> <b style='color:DodgerBlue;'><i>unproven</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>interaction</i></b> <b style='color:DodgerBlue;'><i>.</i></b> PPI may be given before breakfast and <b style='color:Tomato;'><i>clopidogrel</i></b> at bedtime, or PPI may be taken before dinner and <b style='color:Tomato;'><i>clopidogrel</i></b> at lunchtime.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"US","start":4,"end":6,"id":1,"ws":true},{"text":"Food","start":7,"end":11,"id":2,"ws":true},{"text":"and","start":12,"end":15,"id":3,"ws":true},{"text":"Drug","start":16,"end":20,"id":4,"ws":true},{"text":"Administration","start":21,"end":35,"id":5,"ws":true},{"text":"(","start":36,"end":37,"id":6,"ws":true},{"text":"FDA","start":38,"end":41,"id":7,"ws":true},{"text":")","start":42,"end":43,"id":8,"ws":true},{"text":"recommends","start":44,"end":54,"id":9,"ws":true},{"text":"that","start":55,"end":59,"id":10,"ws":true},{"text":"\"","start":60,"end":61,"id":11,"ws":true},{"text":"concomitant","start":62,"end":73,"id":12,"ws":true},{"text":"use","start":74,"end":77,"id":13,"ws":true},{"text":"of","start":78,"end":80,"id":14,"ws":true},{"text":"drugs","start":81,"end":86,"id":15,"ws":true},{"text":"that","start":87,"end":91,"id":16,"ws":true},{"text":"inhibit","start":92,"end":99,"id":17,"ws":true},{"text":"CYP2C19","start":100,"end":107,"id":18,"ws":true},{"text":"(","start":108,"end":109,"id":19,"ws":true},{"text":"e.g.","start":110,"end":114,"id":20,"ws":true},{"text":",","start":115,"end":116,"id":21,"ws":true},{"text":"omeprazole","start":117,"end":127,"id":22,"ws":true},{"text":")","start":128,"end":129,"id":23,"ws":true},{"text":"should","start":130,"end":136,"id":24,"ws":true},{"text":"be","start":137,"end":139,"id":25,"ws":true},{"text":"discouraged","start":140,"end":151,"id":26,"ws":true},{"text":".","start":152,"end":153,"id":27,"ws":true},{"text":"\"","start":154,"end":155,"id":28,"ws":true},{"text":"As","start":156,"end":158,"id":29,"ws":true},{"text":"the","start":159,"end":162,"id":30,"ws":true},{"text":"presence","start":163,"end":171,"id":31,"ws":true},{"text":"of","start":172,"end":174,"id":32,"ws":true},{"text":"PPIs","start":175,"end":179,"id":33,"ws":true},{"text":"and","start":180,"end":183,"id":34,"ws":true},{"text":"clopidogrel","start":184,"end":195,"id":35,"ws":true},{"text":"in","start":196,"end":198,"id":36,"ws":true},{"text":"plasma","start":199,"end":205,"id":37,"ws":true},{"text":"is","start":206,"end":208,"id":38,"ws":true},{"text":"short","start":209,"end":214,"id":39,"ws":true},{"text":"lived","start":215,"end":220,"id":40,"ws":true},{"text":",","start":221,"end":222,"id":41,"ws":true},{"text":"separation","start":223,"end":233,"id":42,"ws":true},{"text":"by","start":234,"end":236,"id":43,"ws":true},{"text":"12","start":237,"end":239,"id":44,"ws":true},{"text":"-","start":240,"end":241,"id":45,"ws":true},{"text":"20","start":242,"end":244,"id":46,"ws":true},{"text":"h","start":245,"end":246,"id":47,"ws":true},{"text":"should","start":247,"end":253,"id":48,"ws":true},{"text":"in","start":254,"end":256,"id":49,"ws":true},{"text":"theory","start":257,"end":263,"id":50,"ws":true},{"text":"prevent","start":264,"end":271,"id":51,"ws":true},{"text":"competitive","start":272,"end":283,"id":52,"ws":true},{"text":"inhibition","start":284,"end":294,"id":53,"ws":true},{"text":"of","start":295,"end":297,"id":54,"ws":true},{"text":"CYP","start":298,"end":301,"id":55,"ws":true},{"text":"metabolism","start":302,"end":312,"id":56,"ws":true},{"text":"and","start":313,"end":316,"id":57,"ws":true},{"text":"minimize","start":317,"end":325,"id":58,"ws":true},{"text":"any","start":326,"end":329,"id":59,"ws":true},{"text":"potential","start":330,"end":339,"id":60,"ws":true},{"text":",","start":340,"end":341,"id":61,"ws":true},{"text":"though","start":342,"end":348,"id":62,"ws":true},{"text":"unproven","start":349,"end":357,"id":63,"ws":true},{"text":",","start":358,"end":359,"id":64,"ws":true},{"text":"clinical","start":360,"end":368,"id":65,"ws":true},{"text":"interaction","start":369,"end":380,"id":66,"ws":true},{"text":".","start":381,"end":382,"id":67,"ws":false}],"spans":[{"start":117,"end":127,"token_start":22,"token_end":22,"label":"DRUG"},{"start":184,"end":195,"token_start":35,"token_end":35,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/19904241/","_input_hash":-388572547,"_task_hash":1928480581,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":22,"child":35,"head_span":{"start":117,"end":127,"token_start":22,"token_end":22,"label":"DRUG"},"child_span":{"start":184,"end":195,"token_start":35,"token_end":35,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG11"],"answer":"accept"}
{"text":"Long-term overall- and progression-free survival after pentostatin , cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Long-term</i></b> <b style='color:DodgerBlue;'><i>overall-</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>progression-free</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>pentostatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>indolent</i></b> <b style='color:DodgerBlue;'><i>non-Hodgkin</i></b> <b style='color:DodgerBlue;'><i>lymphoma</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>In a prospective phase II trial, pentostatin combined with <b style='color:Tomato;'><i>cyclophosphamide</i></b> and <b style='color:Tomato;'><i>rituximab</i></b> (PCR) induced strong responses and was well-tolerated in previously untreated patients with advanced-stage, indolent non-Hodgkin lymphoma (iNHL). After a median patient follow-up of more than 108\u00a0months, we performed an intent-to-treat analysis of our 83 participants. Progression-free survival (PFS) rates at 108\u00a0months for follicular lymphoma (FL), marginal zone lymphoma (MZL) and small lymphocytic lymphoma (SLL) were 71%, 67% and 15%, respectively, and were affected by clinicopathological characteristics. Ten-year PFS rates for those with beta-2-microglobulin levels <2\u00b72 and \u22652\u00b72\u00a0mg/l prior to treatment were 71% and 21%, respectively. Patients without bone marrow involvement had 10-year PFS rates of 72% vs. 29% for those with involvement. At time of analysis, the median overall survival (OS) had not been reached. The OS rate was 64% at 10\u00a0years and differed significantly based on histology: 94% for FL, 66% for MZL and 39% for SLL. Long-term toxicities included 18 (21\u00b77%) patients with second malignancies and 2 (2\u00b74%) who developed myelodysplastic syndrome after receiving additional lines of chemotherapy. Our 10-year follow-up analysis confirms that PCR is an effective, robust and tolerable treatment regimen for patients with iNHL.","tokens":[{"text":"Long-term","start":0,"end":9,"id":0,"ws":true},{"text":"overall-","start":10,"end":18,"id":1,"ws":true},{"text":"and","start":19,"end":22,"id":2,"ws":true},{"text":"progression-free","start":23,"end":39,"id":3,"ws":true},{"text":"survival","start":40,"end":48,"id":4,"ws":true},{"text":"after","start":49,"end":54,"id":5,"ws":true},{"text":"pentostatin","start":55,"end":66,"id":6,"ws":true},{"text":",","start":67,"end":68,"id":7,"ws":true},{"text":"cyclophosphamide","start":69,"end":85,"id":8,"ws":true},{"text":"and","start":86,"end":89,"id":9,"ws":true},{"text":"rituximab","start":90,"end":99,"id":10,"ws":true},{"text":"therapy","start":100,"end":107,"id":11,"ws":true},{"text":"for","start":108,"end":111,"id":12,"ws":true},{"text":"indolent","start":112,"end":120,"id":13,"ws":true},{"text":"non-Hodgkin","start":121,"end":132,"id":14,"ws":true},{"text":"lymphoma","start":133,"end":141,"id":15,"ws":true},{"text":".","start":142,"end":143,"id":16,"ws":false}],"spans":[{"start":69,"end":85,"token_start":8,"token_end":8,"label":"DRUG"},{"start":90,"end":99,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30820940/","_input_hash":541687394,"_task_hash":-382835800,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":6,"child":8,"head_span":{"start":55,"end":66,"token_start":6,"token_end":6,"label":null},"child_span":{"start":69,"end":85,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":8,"child":10,"head_span":{"start":69,"end":85,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":90,"end":99,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Once-weekly isoniazid and rifapentine for 3 months is a treatment option in persons with human immunodeficiency virus and latent tuberculosis infection .","paragraph":"<h3><u>Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine.</u></h3> <b style='color:DodgerBlue;'><i>Once-weekly</i></b> <b style='color:MediumOrchid;'><i>isoniazid</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rifapentine</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>option</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>persons</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>human</i></b> <b style='color:DodgerBlue;'><i>immunodeficiency</i></b> <b style='color:DodgerBlue;'><i>virus</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>latent</i></b> <b style='color:DodgerBlue;'><i>tuberculosis</i></b> <b style='color:DodgerBlue;'><i>infection</i></b> <b style='color:DodgerBlue;'><i>.</i></b> This study aimed to examine pharmacokinetic drug-drug interactions between this regimen and <b style='color:Tomato;'><i>dolutegravir</i></b>, a first-line antiretroviral medication. ### methods This was a single-center, open-label, fixed-sequence, drug-drug interaction study in healthy volunteers. Subjects received oral <b style='color:Tomato;'><i>dolutegravir</i></b> 50 mg once daily alone (days 1-4) and concomitantly with once-weekly <b style='color:Tomato;'><i>isoniazid</i></b> 900 mg, <b style='color:Tomato;'><i>rifapentine</i></b> 900 mg, and <b style='color:Tomato;'><i>pyridoxine</i></b> 50 mg (days 5-19). <b style='color:Tomato;'><i>dolutegravir</i></b> concentrations were measured on days 4, 14, and 19, and <b style='color:Tomato;'><i>rifapentine</i></b>, 25-desacetyl-<b style='color:Tomato;'><i>rifapentine</i></b>, and <b style='color:Tomato;'><i>isoniazid</i></b> concentrations were measured on day 19. Cytokines and antidrug antibodies to <b style='color:Tomato;'><i>isoniazid</i></b> and <b style='color:Tomato;'><i>rifapentine</i></b> were examined at select time points. ### results The study was terminated following the development of flu-like syndrome and elevated aminotransferase levels in 2 of 4 subjects after the third <b style='color:Tomato;'><i>isoniazid</i></b>-<b style='color:Tomato;'><i>rifapentine</i></b> dose. Markedly elevated levels of interferon-\u03b3, CXCL10, C-reactive protein, and other cytokines were temporally associated with symptoms. Antidrug antibodies were infrequently detected. <b style='color:Tomato;'><i>dolutegravir</i></b> area under the curve (AUC) was decreased by 46% (90% confidence interval, 27-110%; P = .13) on day 14. <b style='color:Tomato;'><i>rifapentine</i></b> and 25-desacetyl <b style='color:Tomato;'><i>rifapentine</i></b> levels on day 19 were comparable to reference data, whereas <b style='color:Tomato;'><i>isoniazid</i></b> AUCs were approximately 67%-92% higher in the subjects who developed toxicities. ### conclusions The combined use of <b style='color:Tomato;'><i>dolutegravir</i></b> with once-weekly <b style='color:Tomato;'><i>isoniazid</i></b>-<b style='color:Tomato;'><i>rifapentine</i></b> resulted in unexpected and serious toxicities that were mediated by endogenous cytokine release. Additional investigations are necessary to examine the safety and efficacy of coadministering these medications. ### Clinical Trials Registration NCT02771249.","tokens":[{"text":"Once-weekly","start":0,"end":11,"id":0,"ws":true},{"text":"isoniazid","start":12,"end":21,"id":1,"ws":true},{"text":"and","start":22,"end":25,"id":2,"ws":true},{"text":"rifapentine","start":26,"end":37,"id":3,"ws":true},{"text":"for","start":38,"end":41,"id":4,"ws":true},{"text":"3","start":42,"end":43,"id":5,"ws":true},{"text":"months","start":44,"end":50,"id":6,"ws":true},{"text":"is","start":51,"end":53,"id":7,"ws":true},{"text":"a","start":54,"end":55,"id":8,"ws":true},{"text":"treatment","start":56,"end":65,"id":9,"ws":true},{"text":"option","start":66,"end":72,"id":10,"ws":true},{"text":"in","start":73,"end":75,"id":11,"ws":true},{"text":"persons","start":76,"end":83,"id":12,"ws":true},{"text":"with","start":84,"end":88,"id":13,"ws":true},{"text":"human","start":89,"end":94,"id":14,"ws":true},{"text":"immunodeficiency","start":95,"end":111,"id":15,"ws":true},{"text":"virus","start":112,"end":117,"id":16,"ws":true},{"text":"and","start":118,"end":121,"id":17,"ws":true},{"text":"latent","start":122,"end":128,"id":18,"ws":true},{"text":"tuberculosis","start":129,"end":141,"id":19,"ws":true},{"text":"infection","start":142,"end":151,"id":20,"ws":true},{"text":".","start":152,"end":153,"id":21,"ws":false}],"spans":[{"start":12,"end":21,"token_start":1,"token_end":1,"label":"DRUG"},{"start":26,"end":37,"token_start":3,"token_end":3,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29415190/","_input_hash":-655714867,"_task_hash":645335847,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":1,"child":3,"head_span":{"start":12,"end":21,"token_start":1,"token_end":1,"label":"DRUG"},"child_span":{"start":26,"end":37,"token_start":3,"token_end":3,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"We investigated the effects of these inhibitors on other anticancer drugs including docetaxel , vinblastine , doxorubicin , 10-Hydroxycamptothecin ( 10-HCPT ) and cisplatin and find that both inhibitors induces DU145-TxR cells to be more sensitive only to the microtubule-targeting drugs ( paclitaxel , docetaxel and vinblastine ) .","paragraph":"<h3><u>The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer.</u></h3>Resistance is a significant limitation to the effectiveness of cancer therapies. The PI3K/Akt and MAP kinase pathways play important roles in a variety of normal cellular processes and tumorigenesis. This study is designed to explore the relationship of these signaling pathways with multidrug resistance in prostate cancer (PCa). The PI3K/Akt and MAP kinase pathways were investigated utilizing <b style='color:Tomato;'><i>paclitaxel</i></b> resistant DU145-TxR PCa cells and their parental non-resistant DU145 cells to determine their relationship with resistance to <b style='color:Tomato;'><i>paclitaxel</i></b> and other anticancer drugs. Our results demonstrate that the PI3K/Akt and MAP kinase pathways are upregulated in DU145-TxR cells compared to the DU145 cells. Inactivating these pathways using the PI3K/Akt pathway inhibitor LY294002 or the MAP kinase pathway inhibitor PD98059 renders the DU145-TxR cells more sensitive to <b style='color:Tomato;'><i>paclitaxel</i></b>. <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>investigated</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>anticancer</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vinblastine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>10-Hydroxycamptothecin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10-HCPT</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>find</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>induces</i></b> <b style='color:DodgerBlue;'><i>DU145-TxR</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>sensitive</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>microtubule-targeting</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>vinblastine</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Furthermore, the treatment with these inhibitors induces cleaved-PARP production in DU145-TxR cells, suggesting that apoptosis induction might be one of the mechanisms for the reversal of drug resistance. In conclusion, the PI3K/Akt and MAP kinase pathways are associated with resistance to multiple chemotherapeutic drugs. Inactivating these pathways renders these PCa cells more sensitive to microtubule-targeting drugs such as <b style='color:Tomato;'><i>paclitaxel</i></b>, <b style='color:Tomato;'><i>docetaxel</i></b> and <b style='color:Tomato;'><i>vinblastine</i></b>. Combination therapies with novel inhibitors of these two signaling pathways potentially represents a more effective treatment for drug resistant PCa.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"investigated","start":3,"end":15,"id":1,"ws":true},{"text":"the","start":16,"end":19,"id":2,"ws":true},{"text":"effects","start":20,"end":27,"id":3,"ws":true},{"text":"of","start":28,"end":30,"id":4,"ws":true},{"text":"these","start":31,"end":36,"id":5,"ws":true},{"text":"inhibitors","start":37,"end":47,"id":6,"ws":true},{"text":"on","start":48,"end":50,"id":7,"ws":true},{"text":"other","start":51,"end":56,"id":8,"ws":true},{"text":"anticancer","start":57,"end":67,"id":9,"ws":true},{"text":"drugs","start":68,"end":73,"id":10,"ws":true},{"text":"including","start":74,"end":83,"id":11,"ws":true},{"text":"docetaxel","start":84,"end":93,"id":12,"ws":true},{"text":",","start":94,"end":95,"id":13,"ws":true},{"text":"vinblastine","start":96,"end":107,"id":14,"ws":true},{"text":",","start":108,"end":109,"id":15,"ws":true},{"text":"doxorubicin","start":110,"end":121,"id":16,"ws":true},{"text":",","start":122,"end":123,"id":17,"ws":true},{"text":"10-Hydroxycamptothecin","start":124,"end":146,"id":18,"ws":true},{"text":"(","start":147,"end":148,"id":19,"ws":true},{"text":"10-HCPT","start":149,"end":156,"id":20,"ws":true},{"text":")","start":157,"end":158,"id":21,"ws":true},{"text":"and","start":159,"end":162,"id":22,"ws":true},{"text":"cisplatin","start":163,"end":172,"id":23,"ws":true},{"text":"and","start":173,"end":176,"id":24,"ws":true},{"text":"find","start":177,"end":181,"id":25,"ws":true},{"text":"that","start":182,"end":186,"id":26,"ws":true},{"text":"both","start":187,"end":191,"id":27,"ws":true},{"text":"inhibitors","start":192,"end":202,"id":28,"ws":true},{"text":"induces","start":203,"end":210,"id":29,"ws":true},{"text":"DU145-TxR","start":211,"end":220,"id":30,"ws":true},{"text":"cells","start":221,"end":226,"id":31,"ws":true},{"text":"to","start":227,"end":229,"id":32,"ws":true},{"text":"be","start":230,"end":232,"id":33,"ws":true},{"text":"more","start":233,"end":237,"id":34,"ws":true},{"text":"sensitive","start":238,"end":247,"id":35,"ws":true},{"text":"only","start":248,"end":252,"id":36,"ws":true},{"text":"to","start":253,"end":255,"id":37,"ws":true},{"text":"the","start":256,"end":259,"id":38,"ws":true},{"text":"microtubule-targeting","start":260,"end":281,"id":39,"ws":true},{"text":"drugs","start":282,"end":287,"id":40,"ws":true},{"text":"(","start":288,"end":289,"id":41,"ws":true},{"text":"paclitaxel","start":290,"end":300,"id":42,"ws":true},{"text":",","start":301,"end":302,"id":43,"ws":true},{"text":"docetaxel","start":303,"end":312,"id":44,"ws":true},{"text":"and","start":313,"end":316,"id":45,"ws":true},{"text":"vinblastine","start":317,"end":328,"id":46,"ws":true},{"text":")","start":329,"end":330,"id":47,"ws":true},{"text":".","start":331,"end":332,"id":48,"ws":false}],"spans":[{"start":84,"end":93,"token_start":12,"token_end":12,"label":"DRUG"},{"start":96,"end":107,"token_start":14,"token_end":14,"label":"DRUG"},{"start":110,"end":121,"token_start":16,"token_end":16,"label":"DRUG"},{"start":163,"end":172,"token_start":23,"token_end":23,"label":"DRUG"},{"start":290,"end":300,"token_start":42,"token_end":42,"label":"DRUG"},{"start":303,"end":312,"token_start":44,"token_end":44,"label":"DRUG"},{"start":317,"end":328,"token_start":46,"token_end":46,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25640606/","_input_hash":1870680176,"_task_hash":-553437953,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Group B : From January , 1976 to December , 1980 , 55 evaluable patients participated in a consecutive study that added Adriamycin ( doxorubicin ) and cyclophosphamide to the former induction regimen .","paragraph":"<h3><u>Comparison of two consecutive trials for treatment of childhood non-Hodgkin's lymphoma.</u></h3>Two consecutive trials for the treatment of childhood non-Hodgkin's lymphoma were evaluated, carried out by the same cooperative groups. Group A: From June, 1973 to December, 1975, 50 evaluable patients under 16 years of age participated in a study that included <b style='color:Tomato;'><i>vincristine</i></b> and <b style='color:Tomato;'><i>prednisone</i></b> plus surgery and/or radiotherapy as induction. This was followed by 2400 rad of cranial radiotherapy plus 5 doses of intrathecal <b style='color:Tomato;'><i>methotrexate</i></b>-<b style='color:Tomato;'><i>dexamethasone</i></b> and anti-leukemia (6-<b style='color:Tomato;'><i>mercaptopurine</i></b>, <b style='color:Tomato;'><i>methotrexate</i></b>, <b style='color:Tomato;'><i>cyclophosphamide</i></b>) or anti-lymphoma (<b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>vincristine</i></b>, <b style='color:Tomato;'><i>procarbazine</i></b>, and <b style='color:Tomato;'><i>prednisone</i></b>) maintenance treatment. <b style='color:DodgerBlue;'><i>Group</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>From</i></b> <b style='color:DodgerBlue;'><i>January</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>1976</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>December</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>1980</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>55</i></b> <b style='color:DodgerBlue;'><i>evaluable</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>participated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>consecutive</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>added</i></b> <b style='color:DodgerBlue;'><i>Adriamycin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>former</i></b> <b style='color:DodgerBlue;'><i>induction</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Central nervous system (CNS) prevention was performed with 5 doses of intrathecal <b style='color:Tomato;'><i>methotrexate</i></b>-<b style='color:Tomato;'><i>dexamethasone</i></b>. Maintenance treatment was the same. Prognostic factors as stage and primary site were comparable in both groups. A total of 33 (66%) of 50 children of Group A and 48 (87%) of 55 children of Group B achieved complete remission (P less than 0.005). Disease-free survival at 60 months was 27% in Group A and 49% in Group B; for Stage I-II, 30% in Group A and 85% in Group B (P less than 0.025); for Stage III-IV 28% in Group A and 36% in Group B (not significant). In Group A, 9.1% and in Group B, 8.3% had primary CNS relapse. Both maintenance schedules had the same relapse rate. It was concluded that: (1) the addition of Adriamycin and <b style='color:Tomato;'><i>cyclophosphamide</i></b> to <b style='color:Tomato;'><i>vincristine</i></b>-<b style='color:Tomato;'><i>prednisone</i></b> in Group B produces a higher rate of complete remission in Stage III-IV, a higher rate of disease-free survival in Stage I-II, and a higher survival rate in all stages; (2) CNS prevention with intrathecal <b style='color:Tomato;'><i>methotrexate</i></b>-<b style='color:Tomato;'><i>dexamethasone</i></b> is equally effective as cranial radiation plus intrathecal <b style='color:Tomato;'><i>methotrexate</i></b>-<b style='color:Tomato;'><i>dexamethasone</i></b>; and (3) anti-leukemia and anti-lymphoma maintenance are equally effective in the context of this study.","tokens":[{"text":"Group","start":0,"end":5,"id":0,"ws":true},{"text":"B","start":6,"end":7,"id":1,"ws":true},{"text":":","start":8,"end":9,"id":2,"ws":true},{"text":"From","start":10,"end":14,"id":3,"ws":true},{"text":"January","start":15,"end":22,"id":4,"ws":true},{"text":",","start":23,"end":24,"id":5,"ws":true},{"text":"1976","start":25,"end":29,"id":6,"ws":true},{"text":"to","start":30,"end":32,"id":7,"ws":true},{"text":"December","start":33,"end":41,"id":8,"ws":true},{"text":",","start":42,"end":43,"id":9,"ws":true},{"text":"1980","start":44,"end":48,"id":10,"ws":true},{"text":",","start":49,"end":50,"id":11,"ws":true},{"text":"55","start":51,"end":53,"id":12,"ws":true},{"text":"evaluable","start":54,"end":63,"id":13,"ws":true},{"text":"patients","start":64,"end":72,"id":14,"ws":true},{"text":"participated","start":73,"end":85,"id":15,"ws":true},{"text":"in","start":86,"end":88,"id":16,"ws":true},{"text":"a","start":89,"end":90,"id":17,"ws":true},{"text":"consecutive","start":91,"end":102,"id":18,"ws":true},{"text":"study","start":103,"end":108,"id":19,"ws":true},{"text":"that","start":109,"end":113,"id":20,"ws":true},{"text":"added","start":114,"end":119,"id":21,"ws":true},{"text":"Adriamycin","start":120,"end":130,"id":22,"ws":true},{"text":"(","start":131,"end":132,"id":23,"ws":true},{"text":"doxorubicin","start":133,"end":144,"id":24,"ws":true},{"text":")","start":145,"end":146,"id":25,"ws":true},{"text":"and","start":147,"end":150,"id":26,"ws":true},{"text":"cyclophosphamide","start":151,"end":167,"id":27,"ws":true},{"text":"to","start":168,"end":170,"id":28,"ws":true},{"text":"the","start":171,"end":174,"id":29,"ws":true},{"text":"former","start":175,"end":181,"id":30,"ws":true},{"text":"induction","start":182,"end":191,"id":31,"ws":true},{"text":"regimen","start":192,"end":199,"id":32,"ws":true},{"text":".","start":200,"end":201,"id":33,"ws":false}],"spans":[{"start":133,"end":144,"token_start":24,"token_end":24,"label":"DRUG"},{"start":151,"end":167,"token_start":27,"token_end":27,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/6388820/","_input_hash":2014933255,"_task_hash":1016909622,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"When given in repeated doses from 6 h on , 50 g followed by 12.5 g at 6-h intervals , charcoal shortened the serum half-life of amitriptyline by 20 % and that of nortriptyline by 35 % ( p less than 0.05 ) .","paragraph":"<h3><u>Pharmacokinetics of amitriptyline influenced by oral charcoal and urine pH.</u></h3>The effects of orally given <b style='color:Tomato;'><i>activated charcoal</i></b>, sodium bicarbonate and ammonium chloride on the pharmacokinetics of <b style='color:Tomato;'><i>amitriptyline</i></b> were studied in 6 volunteers in a randomized, cross-over study. The serum and urine concentrations of <b style='color:Tomato;'><i>amitriptyline</i></b> and <b style='color:Tomato;'><i>nortriptyline</i></b> were determined by HPLC for up to 72 h. <b style='color:Tomato;'><i>activated charcoal</i></b> (50 g), given within 5 min of the <b style='color:Tomato;'><i>amitriptyline</i></b> hydrochloride dose (75 mg), reduced its absorption by 99%. <b style='color:DodgerBlue;'><i>When</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>repeated</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>h</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>g</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>12.5</i></b> <b style='color:DodgerBlue;'><i>g</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>6-h</i></b> <b style='color:DodgerBlue;'><i>intervals</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>charcoal</i></b> <b style='color:DodgerBlue;'><i>shortened</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>half-life</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>amitriptyline</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>nortriptyline</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>35</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>p</i></b> <b style='color:DodgerBlue;'><i>less</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>0.05</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The renal excretions of <b style='color:Tomato;'><i>amitriptyline</i></b> and <b style='color:Tomato;'><i>nortriptyline</i></b> increased 1000-fold by the acidification of urine pH to 4. However, the cumulative excretion of <b style='color:Tomato;'><i>amitriptyline</i></b> and <b style='color:Tomato;'><i>nortriptyline</i></b> even into acidic urine only accounted for up to 5% of the dose during 72 h. Since urinary pH has a great influence on the ratio of urinary versus serum <b style='color:Tomato;'><i>amitriptyline</i></b> and <b style='color:Tomato;'><i>nortriptyline</i></b> concentrations, pH should be taken into consideration, when the clinical significance of their concentrations in urine is evaluated. <b style='color:Tomato;'><i>activated charcoal</i></b> in adequate doses very effectively prevents the absorption of that fraction of <b style='color:Tomato;'><i>amitriptyline</i></b> which is in the stomach at the time of charcoal administration. Furthermore, given in repeated oral doses, charcoal increases, to some extent, the rate of elimination of <b style='color:Tomato;'><i>amitriptyline</i></b> and <b style='color:Tomato;'><i>nortriptyline</i></b>, probably by interrupting their enterohepatic or enteroenteric circulation.","tokens":[{"text":"When","start":0,"end":4,"id":0,"ws":true},{"text":"given","start":5,"end":10,"id":1,"ws":true},{"text":"in","start":11,"end":13,"id":2,"ws":true},{"text":"repeated","start":14,"end":22,"id":3,"ws":true},{"text":"doses","start":23,"end":28,"id":4,"ws":true},{"text":"from","start":29,"end":33,"id":5,"ws":true},{"text":"6","start":34,"end":35,"id":6,"ws":true},{"text":"h","start":36,"end":37,"id":7,"ws":true},{"text":"on","start":38,"end":40,"id":8,"ws":true},{"text":",","start":41,"end":42,"id":9,"ws":true},{"text":"50","start":43,"end":45,"id":10,"ws":true},{"text":"g","start":46,"end":47,"id":11,"ws":true},{"text":"followed","start":48,"end":56,"id":12,"ws":true},{"text":"by","start":57,"end":59,"id":13,"ws":true},{"text":"12.5","start":60,"end":64,"id":14,"ws":true},{"text":"g","start":65,"end":66,"id":15,"ws":true},{"text":"at","start":67,"end":69,"id":16,"ws":true},{"text":"6-h","start":70,"end":73,"id":17,"ws":true},{"text":"intervals","start":74,"end":83,"id":18,"ws":true},{"text":",","start":84,"end":85,"id":19,"ws":true},{"text":"charcoal","start":86,"end":94,"id":20,"ws":true},{"text":"shortened","start":95,"end":104,"id":21,"ws":true},{"text":"the","start":105,"end":108,"id":22,"ws":true},{"text":"serum","start":109,"end":114,"id":23,"ws":true},{"text":"half-life","start":115,"end":124,"id":24,"ws":true},{"text":"of","start":125,"end":127,"id":25,"ws":true},{"text":"amitriptyline","start":128,"end":141,"id":26,"ws":true},{"text":"by","start":142,"end":144,"id":27,"ws":true},{"text":"20","start":145,"end":147,"id":28,"ws":true},{"text":"%","start":148,"end":149,"id":29,"ws":true},{"text":"and","start":150,"end":153,"id":30,"ws":true},{"text":"that","start":154,"end":158,"id":31,"ws":true},{"text":"of","start":159,"end":161,"id":32,"ws":true},{"text":"nortriptyline","start":162,"end":175,"id":33,"ws":true},{"text":"by","start":176,"end":178,"id":34,"ws":true},{"text":"35","start":179,"end":181,"id":35,"ws":true},{"text":"%","start":182,"end":183,"id":36,"ws":true},{"text":"(","start":184,"end":185,"id":37,"ws":true},{"text":"p","start":186,"end":187,"id":38,"ws":true},{"text":"less","start":188,"end":192,"id":39,"ws":true},{"text":"than","start":193,"end":197,"id":40,"ws":true},{"text":"0.05","start":198,"end":202,"id":41,"ws":true},{"text":")","start":203,"end":204,"id":42,"ws":true},{"text":".","start":205,"end":206,"id":43,"ws":false}],"spans":[{"start":128,"end":141,"token_start":26,"token_end":26,"label":"DRUG"},{"start":162,"end":175,"token_start":33,"token_end":33,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/3015809/","_input_hash":1971499379,"_task_hash":889539826,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The molecular subtypes of breast cancer can predict responses to the combinational treatment of doxorubicin with docetaxel , and ERBB2","paragraph":"<h3><u>Combinational Treatment of Doxorubicin With Neoadjuvant Docetaxel for Different Subtypes of Patients With Breast Cancer.</u></h3>The aim of this study is to characterize the effect of chemotherapy drug <b style='color:Tomato;'><i>doxorubicin</i></b> with neoadjuvant drug <b style='color:Tomato;'><i>docetaxel</i></b> for different molecular subtypes. ### methods A total of 83 patients with late-stage breast cancer were chosen to undergo treatment and compared to these patients to the combinational treatment to identify the molecular characteristics that can predict the responses. ### results Total response rate is 81.9% (68/83 patients). Among them, 7 patients show pathological complete response of 8.4%, 12 patients show clinical complete response of 14.5%, 49 patients show partial response of 59%, and 15 patients show stable disease of 18.1%. The comparison among different subtypes of breast cancer, including luminal A, luminal B, basal-like, and ERBB2 ### conclusion <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>molecular</i></b> <b style='color:DodgerBlue;'><i>subtypes</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>can</i></b> <b style='color:DodgerBlue;'><i>predict</i></b> <b style='color:DodgerBlue;'><i>responses</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combinational</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>ERBB2</i></b>","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"molecular","start":4,"end":13,"id":1,"ws":true},{"text":"subtypes","start":14,"end":22,"id":2,"ws":true},{"text":"of","start":23,"end":25,"id":3,"ws":true},{"text":"breast","start":26,"end":32,"id":4,"ws":true},{"text":"cancer","start":33,"end":39,"id":5,"ws":true},{"text":"can","start":40,"end":43,"id":6,"ws":true},{"text":"predict","start":44,"end":51,"id":7,"ws":true},{"text":"responses","start":52,"end":61,"id":8,"ws":true},{"text":"to","start":62,"end":64,"id":9,"ws":true},{"text":"the","start":65,"end":68,"id":10,"ws":true},{"text":"combinational","start":69,"end":82,"id":11,"ws":true},{"text":"treatment","start":83,"end":92,"id":12,"ws":true},{"text":"of","start":93,"end":95,"id":13,"ws":true},{"text":"doxorubicin","start":96,"end":107,"id":14,"ws":true},{"text":"with","start":108,"end":112,"id":15,"ws":true},{"text":"docetaxel","start":113,"end":122,"id":16,"ws":true},{"text":",","start":123,"end":124,"id":17,"ws":true},{"text":"and","start":125,"end":128,"id":18,"ws":true},{"text":"ERBB2","start":129,"end":134,"id":19,"ws":false}],"spans":[{"start":96,"end":107,"token_start":14,"token_end":14,"label":"DRUG"},{"start":113,"end":122,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/32508292/","_input_hash":2029760008,"_task_hash":37814328,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":14,"child":16,"head_span":{"start":96,"end":107,"token_start":14,"token_end":14,"label":"DRUG"},"child_span":{"start":113,"end":122,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The median overall survival time was 22.7 months in the docetaxel arm and 22.4 months in the paclitaxel arm .","paragraph":"<h3><u>A phase II randomized study of two taxanes and cisplatin for metastatic breast cancer after anthracycline: a final analysis.</u></h3>The purpose of the study is to compare two taxanes/<b style='color:Tomato;'><i>cisplatin</i></b> combinations for metastatic breast cancer in terms of time to disease progression, response rates and toxicity. ### methods Between April 2000 and December 2002, 101 patients with advanced breast carcinoma, previously treated with an anthracycline but not with a taxane, were enrolled. Fifty patients were treated with <b style='color:Tomato;'><i>docetaxel</i></b> 60 mg/m2 and <b style='color:Tomato;'><i>cisplatin</i></b> 50 mg/m2, and 51 patients were treated with <b style='color:Tomato;'><i>paclitaxel</i></b> 175 mg/m2 and <b style='color:Tomato;'><i>cisplatin</i></b> 50 mg/m2. Each cycle repeated every 3 weeks. ### results The overall response rate was 62.5 and 42.6% in the <b style='color:Tomato;'><i>docetaxel</i></b> and palcitaxel groups respectively (P = 0.06). Median time to disease progression was 9.8 and 6.5 months in <b style='color:Tomato;'><i>docetaxel</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b> groups respectively (P = 0.15). <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>median</i></b> <b style='color:DodgerBlue;'><i>overall</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>time</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>22.7</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>arm</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>22.4</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>arm</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Grade 3/4 arthralgia/myalgia, sensory neuropathy and anemia occurred more frequently in the <b style='color:Tomato;'><i>paclitaxel</i></b> arm, while more mucositis, fatigue and neutropenia occurred in the <b style='color:Tomato;'><i>docetaxel</i></b> arm. ### conclusion Taxane/<b style='color:Tomato;'><i>cisplatin</i></b> combinations were active for advanced breast cancer, while there appeared to be evidence in favor of a <b style='color:Tomato;'><i>docetaxel</i></b>/<b style='color:Tomato;'><i>cisplatin</i></b> combination. The toxicity in favor of <b style='color:Tomato;'><i>docetaxel</i></b>/<b style='color:Tomato;'><i>cisplatin</i></b> warrants future first-line clinical trials.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"median","start":4,"end":10,"id":1,"ws":true},{"text":"overall","start":11,"end":18,"id":2,"ws":true},{"text":"survival","start":19,"end":27,"id":3,"ws":true},{"text":"time","start":28,"end":32,"id":4,"ws":true},{"text":"was","start":33,"end":36,"id":5,"ws":true},{"text":"22.7","start":37,"end":41,"id":6,"ws":true},{"text":"months","start":42,"end":48,"id":7,"ws":true},{"text":"in","start":49,"end":51,"id":8,"ws":true},{"text":"the","start":52,"end":55,"id":9,"ws":true},{"text":"docetaxel","start":56,"end":65,"id":10,"ws":true},{"text":"arm","start":66,"end":69,"id":11,"ws":true},{"text":"and","start":70,"end":73,"id":12,"ws":true},{"text":"22.4","start":74,"end":78,"id":13,"ws":true},{"text":"months","start":79,"end":85,"id":14,"ws":true},{"text":"in","start":86,"end":88,"id":15,"ws":true},{"text":"the","start":89,"end":92,"id":16,"ws":true},{"text":"paclitaxel","start":93,"end":103,"id":17,"ws":true},{"text":"arm","start":104,"end":107,"id":18,"ws":true},{"text":".","start":108,"end":109,"id":19,"ws":false}],"spans":[{"start":56,"end":65,"token_start":10,"token_end":10,"label":"DRUG"},{"start":93,"end":103,"token_start":17,"token_end":17,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/17172351/","_input_hash":307082636,"_task_hash":1430457115,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"We hypothesized that Aurora A kinase ( AK ) contributes to castrate resistance in prostate cancer ( PCa ) and that inhibiting AK with alisertib can resensitize PCa cells to androgen receptor ( AR ) inhibitor abiraterone .","paragraph":"<h3><u>A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone.</u></h3>Patients with metastatic castration-resistant prostate cancer did not tolerate the combination of <b style='color:Tomato;'><i>alisertib</i></b> with <b style='color:Tomato;'><i>abiraterone</i></b> and <b style='color:Tomato;'><i>prednisone</i></b>.There was no clear signal indicating that adding <b style='color:Tomato;'><i>alisertib</i></b> might be beneficial for those patients progressing on <b style='color:Tomato;'><i>abiraterone</i></b>. ### background <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>hypothesized</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>Aurora</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>kinase</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AK</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>contributes</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>castrate</i></b> <b style='color:DodgerBlue;'><i>resistance</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>PCa</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>inhibiting</i></b> <b style='color:DodgerBlue;'><i>AK</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>alisertib</i></b> <b style='color:DodgerBlue;'><i>can</i></b> <b style='color:DodgerBlue;'><i>resensitize</i></b> <b style='color:DodgerBlue;'><i>PCa</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>androgen</i></b> <b style='color:DodgerBlue;'><i>receptor</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AR</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:MediumOrchid;'><i>abiraterone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods This was a phase I/II trial to determine the safety and efficacy of <b style='color:Tomato;'><i>alisertib</i></b> when given in combination with <b style='color:Tomato;'><i>abiraterone</i></b> plus <b style='color:Tomato;'><i>prednisone</i></b> (AP). Metastatic castration-resistant prostate cancer (mCRPC) patients were treated with dose escalation (<b style='color:Tomato;'><i>alisertib</i></b> at 30, 40, and 50 mg orally b.i.d., days 1-7 every 21 days) per standard 3+3 design. ### results Nine of 43 planned subjects were enrolled. The maximum tolerated dose (MTD) was not reached, and the dose-limiting toxicities (DLTs) included neutropenic fever (1 of 9), neutropenia (1 of 9), fatigue with memory impairment (1 of 9), and diarrhea/mucositis (1 of 9). No prostate-specific antigen (PSA) decrease or circulating tumor cell (CTC) changes were observed during the study. Pharmacodynamically, adding <b style='color:Tomato;'><i>alisertib</i></b> did not affect total testosterone or <b style='color:Tomato;'><i>dehydroepiandrosterone</i></b> (DHEA) levels. There was some change in neuroendocrine markers after therapy. Mean duration on study was 2.5 months. The trial was terminated early. ### conclusion A tolerable dose of <b style='color:Tomato;'><i>alisertib</i></b> in combination with AP in mCRPC was not established in this study. There was no clear signal indicating that <b style='color:Tomato;'><i>alisertib</i></b> might be beneficial for patients with mCRPC progressing on <b style='color:Tomato;'><i>abiraterone</i></b>.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"hypothesized","start":3,"end":15,"id":1,"ws":true},{"text":"that","start":16,"end":20,"id":2,"ws":true},{"text":"Aurora","start":21,"end":27,"id":3,"ws":true},{"text":"A","start":28,"end":29,"id":4,"ws":true},{"text":"kinase","start":30,"end":36,"id":5,"ws":true},{"text":"(","start":37,"end":38,"id":6,"ws":true},{"text":"AK","start":39,"end":41,"id":7,"ws":true},{"text":")","start":42,"end":43,"id":8,"ws":true},{"text":"contributes","start":44,"end":55,"id":9,"ws":true},{"text":"to","start":56,"end":58,"id":10,"ws":true},{"text":"castrate","start":59,"end":67,"id":11,"ws":true},{"text":"resistance","start":68,"end":78,"id":12,"ws":true},{"text":"in","start":79,"end":81,"id":13,"ws":true},{"text":"prostate","start":82,"end":90,"id":14,"ws":true},{"text":"cancer","start":91,"end":97,"id":15,"ws":true},{"text":"(","start":98,"end":99,"id":16,"ws":true},{"text":"PCa","start":100,"end":103,"id":17,"ws":true},{"text":")","start":104,"end":105,"id":18,"ws":true},{"text":"and","start":106,"end":109,"id":19,"ws":true},{"text":"that","start":110,"end":114,"id":20,"ws":true},{"text":"inhibiting","start":115,"end":125,"id":21,"ws":true},{"text":"AK","start":126,"end":128,"id":22,"ws":true},{"text":"with","start":129,"end":133,"id":23,"ws":true},{"text":"alisertib","start":134,"end":143,"id":24,"ws":true},{"text":"can","start":144,"end":147,"id":25,"ws":true},{"text":"resensitize","start":148,"end":159,"id":26,"ws":true},{"text":"PCa","start":160,"end":163,"id":27,"ws":true},{"text":"cells","start":164,"end":169,"id":28,"ws":true},{"text":"to","start":170,"end":172,"id":29,"ws":true},{"text":"androgen","start":173,"end":181,"id":30,"ws":true},{"text":"receptor","start":182,"end":190,"id":31,"ws":true},{"text":"(","start":191,"end":192,"id":32,"ws":true},{"text":"AR","start":193,"end":195,"id":33,"ws":true},{"text":")","start":196,"end":197,"id":34,"ws":true},{"text":"inhibitor","start":198,"end":207,"id":35,"ws":true},{"text":"abiraterone","start":208,"end":219,"id":36,"ws":true},{"text":".","start":220,"end":221,"id":37,"ws":false}],"spans":[{"start":134,"end":143,"token_start":24,"token_end":24,"label":"DRUG"},{"start":208,"end":219,"token_start":36,"token_end":36,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/28178640/","_input_hash":-849461923,"_task_hash":-275457113,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":36,"child":24,"head_span":{"start":208,"end":219,"token_start":36,"token_end":36,"label":"DRUG"},"child_span":{"start":134,"end":143,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Tanespimycin plus trastuzumab is well tolerated and has antitumor activity in patients with HER-2 + breast cancer whose tumors have progressed during treatment with trastuzumab .","paragraph":"<h3><u>Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.</u></h3>This phase I study examined whether a heat shock protein (Hsp) 90 inhibitor <b style='color:Tomato;'><i>tanespimycin</i></b> (17-AAG; KOS-953) could be administered safely in combination with <b style='color:Tomato;'><i>trastuzumab</i></b> at a dose that inhibits Hsp90 function in vivo in lymphocytes. ### Patients And Methods Patients with an advanced solid tumor progressing during standard therapy were eligible. Patients were treated with weekly <b style='color:Tomato;'><i>trastuzumab</i></b> followed by intravenous <b style='color:Tomato;'><i>tanespimycin</i></b>, assessed in escalating dose levels. ### results Twenty-five patients were enrolled onto four <b style='color:Tomato;'><i>tanespimycin</i></b> dose levels: 225 (n = 4), 300 (n = 3), 375 (n = 8), and 450 mg/m2 (n = 10). Dose-limiting toxicity (DLT) was observed at the third and fourth cohort (1 patient each): more than 2-week delay for grade 4 fatigue/grade 2 nausea and anorexia (375 mg/m2); more than 2-week delay for thrombocytopenia (450 mg/m2). Drug-related grade 3 toxicity included emesis, increased ALT, hypersensitivity reactions (two patients each), and drug-induced thrombocytopenia (n = 1). Common mild to moderate toxicities included fatigue, nausea, diarrhea, emesis, headache, rash/pruritus, increased AST/ALT, and anorexia. Pharmacokinetic analysis demonstrated no difference in <b style='color:Tomato;'><i>tanespimycin</i></b> kinetics with or without <b style='color:Tomato;'><i>trastuzumab</i></b>. Pharmacodynamic testing showed reactive induction of Hsp70 (a marker of Hsp90 inhibition) in lymphocytes at all dose levels. Antitumor activity was noted (partial response, n = 1; minor response, n = 4; stable disease > or = 4 months, n = 4). Tumor regressions were seen only in patients with human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer. ### conclusion <b style='color:MediumOrchid;'><i>Tanespimycin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>tolerated</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>antitumor</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>HER-2</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>whose</i></b> <b style='color:DodgerBlue;'><i>tumors</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>progressed</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These data suggest that Hsp90 function can be inhibited in vivo to a degree sufficient to cause inhibition of tumor growth.","tokens":[{"text":"Tanespimycin","start":0,"end":12,"id":0,"ws":true},{"text":"plus","start":13,"end":17,"id":1,"ws":true},{"text":"trastuzumab","start":18,"end":29,"id":2,"ws":true},{"text":"is","start":30,"end":32,"id":3,"ws":true},{"text":"well","start":33,"end":37,"id":4,"ws":true},{"text":"tolerated","start":38,"end":47,"id":5,"ws":true},{"text":"and","start":48,"end":51,"id":6,"ws":true},{"text":"has","start":52,"end":55,"id":7,"ws":true},{"text":"antitumor","start":56,"end":65,"id":8,"ws":true},{"text":"activity","start":66,"end":74,"id":9,"ws":true},{"text":"in","start":75,"end":77,"id":10,"ws":true},{"text":"patients","start":78,"end":86,"id":11,"ws":true},{"text":"with","start":87,"end":91,"id":12,"ws":true},{"text":"HER-2","start":92,"end":97,"id":13,"ws":true},{"text":"+","start":98,"end":99,"id":14,"ws":true},{"text":"breast","start":100,"end":106,"id":15,"ws":true},{"text":"cancer","start":107,"end":113,"id":16,"ws":true},{"text":"whose","start":114,"end":119,"id":17,"ws":true},{"text":"tumors","start":120,"end":126,"id":18,"ws":true},{"text":"have","start":127,"end":131,"id":19,"ws":true},{"text":"progressed","start":132,"end":142,"id":20,"ws":true},{"text":"during","start":143,"end":149,"id":21,"ws":true},{"text":"treatment","start":150,"end":159,"id":22,"ws":true},{"text":"with","start":160,"end":164,"id":23,"ws":true},{"text":"trastuzumab","start":165,"end":176,"id":24,"ws":true},{"text":".","start":177,"end":178,"id":25,"ws":false}],"spans":[{"start":0,"end":12,"token_start":0,"token_end":0,"label":"DRUG"},{"start":18,"end":29,"token_start":2,"token_end":2,"label":"DRUG"},{"start":165,"end":176,"token_start":24,"token_end":24,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/18048823/","_input_hash":-2143703813,"_task_hash":1502847177,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":2,"child":0,"head_span":{"start":18,"end":29,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":0,"end":12,"token_start":0,"token_end":0,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"It contains data on prophylaxis with mefloquine ( n = 48,264 ) , with chloroquine ( 6,752 ) , with chloroquine plus proguanil ( 19,727 ) , and with no prophylaxis ( 3,871 ) .","paragraph":"<h3><u>Tolerability and Effectiveness of Malaria Chemoprophylaxis with Mefloquine or Chloroquine with or without Co-medication.</u></h3>Background: To determine the relevance of drug interactions with co-medication for effectiveness and tolerability of antimalarial chemoprophylaxis. Method: A database (MALPRO2) on travelers on their flight home from Africa to Europe between July 1988 and December 1991 was reanalyzed. <b style='color:DodgerBlue;'><i>It</i></b> <b style='color:DodgerBlue;'><i>contains</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>prophylaxis</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>mefloquine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>48,264</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>chloroquine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>6,752</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>chloroquine</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>proguanil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>19,727</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>prophylaxis</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>3,871</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The comparison of rates of malaria incidence and adverse events (AEs) between users and nonusers of co-medication was expressed by relative risk (RR). Results: Fifty-three percent of travelers (63% of females, 43% of males) used co-medication in all prophylaxis groups, with an average of 1.35 additional drugs per person and about two AEs reported per person. With the exception of antidiarrheals plus <b style='color:Tomato;'><i>mefloquine</i></b>, malaria incidence with co-medication was lower (RR = 0.8) than without co-medication. In all regimens, the proportion of travelers reporting AEs was about 1.5-fold with co-medication (p<.01); that reporting severe AEs was twice as high as compared to with no co-medication. <b style='color:Tomato;'><i>mefloquine</i></b> AE rates for various classes of co-medication were similar to that of <b style='color:Tomato;'><i>chloroquine</i></b>, with highest AE and severity rates with neuropsychiatric drugs (excluding antiepileptics, RR = 1.9 and 2.9), and lowest rates with cardiovasculars (RR = 1.1 and 1.0). Various co-medications were used with different frequencies in males and females, and the latter reported more AEs. Conclusion: These data suggest that co-medications commonly used by travelers have no significant clinical impact on safety and effectiveness of prophylaxis with <b style='color:Tomato;'><i>mefloquine</i></b> or <b style='color:Tomato;'><i>chloroquine</i></b>. Increased frequency and severity of AEs when using co-medication rather is explained by underlying illness.","tokens":[{"text":"It","start":0,"end":2,"id":0,"ws":true},{"text":"contains","start":3,"end":11,"id":1,"ws":true},{"text":"data","start":12,"end":16,"id":2,"ws":true},{"text":"on","start":17,"end":19,"id":3,"ws":true},{"text":"prophylaxis","start":20,"end":31,"id":4,"ws":true},{"text":"with","start":32,"end":36,"id":5,"ws":true},{"text":"mefloquine","start":37,"end":47,"id":6,"ws":true},{"text":"(","start":48,"end":49,"id":7,"ws":true},{"text":"n","start":50,"end":51,"id":8,"ws":true},{"text":"=","start":52,"end":53,"id":9,"ws":true},{"text":"48,264","start":54,"end":60,"id":10,"ws":true},{"text":")","start":61,"end":62,"id":11,"ws":true},{"text":",","start":63,"end":64,"id":12,"ws":true},{"text":"with","start":65,"end":69,"id":13,"ws":true},{"text":"chloroquine","start":70,"end":81,"id":14,"ws":true},{"text":"(","start":82,"end":83,"id":15,"ws":true},{"text":"6,752","start":84,"end":89,"id":16,"ws":true},{"text":")","start":90,"end":91,"id":17,"ws":true},{"text":",","start":92,"end":93,"id":18,"ws":true},{"text":"with","start":94,"end":98,"id":19,"ws":true},{"text":"chloroquine","start":99,"end":110,"id":20,"ws":true},{"text":"plus","start":111,"end":115,"id":21,"ws":true},{"text":"proguanil","start":116,"end":125,"id":22,"ws":true},{"text":"(","start":126,"end":127,"id":23,"ws":true},{"text":"19,727","start":128,"end":134,"id":24,"ws":true},{"text":")","start":135,"end":136,"id":25,"ws":true},{"text":",","start":137,"end":138,"id":26,"ws":true},{"text":"and","start":139,"end":142,"id":27,"ws":true},{"text":"with","start":143,"end":147,"id":28,"ws":true},{"text":"no","start":148,"end":150,"id":29,"ws":true},{"text":"prophylaxis","start":151,"end":162,"id":30,"ws":true},{"text":"(","start":163,"end":164,"id":31,"ws":true},{"text":"3,871","start":165,"end":170,"id":32,"ws":true},{"text":")","start":171,"end":172,"id":33,"ws":true},{"text":".","start":173,"end":174,"id":34,"ws":false}],"spans":[{"start":37,"end":47,"token_start":6,"token_end":6,"label":"DRUG"},{"start":70,"end":81,"token_start":14,"token_end":14,"label":"DRUG"},{"start":99,"end":110,"token_start":20,"token_end":20,"label":"DRUG"},{"start":116,"end":125,"token_start":22,"token_end":22,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9815496/","_input_hash":-419400048,"_task_hash":1005784915,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":20,"child":22,"head_span":{"start":99,"end":110,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":116,"end":125,"token_start":22,"token_end":22,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"We hypothesized that the brain damage mitigating effect of mild hypothermia after cardiac arrest can be enhanced with thiopental loading , and even more so with the further addition of phenytoin and methylprednisolone .","paragraph":"<h3><u>Thiopental combination treatments for cerebral resuscitation after prolonged cardiac arrest in dogs. Exploratory outcome study.</u></h3>We postulate that mitigating the multifactorial pathogenesis of postischemic encephalopathy requires multifaceted treatments. In preparation for expensive definitive studies, we are reporting here the results of small exploratory series, compared with historic controls with the same model. <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>hypothesized</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>brain</i></b> <b style='color:DodgerBlue;'><i>damage</i></b> <b style='color:DodgerBlue;'><i>mitigating</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>mild</i></b> <b style='color:DodgerBlue;'><i>hypothermia</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>cardiac</i></b> <b style='color:DodgerBlue;'><i>arrest</i></b> <b style='color:DodgerBlue;'><i>can</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>enhanced</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>thiopental</i></b> <b style='color:DodgerBlue;'><i>loading</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>even</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>so</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>further</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>phenytoin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>methylprednisolone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Twenty-four dogs (four groups of six dogs each) received VF 12.5 min no-flow, reversed with brief cardiopulmonary bypass (CPB), controlled ventilation to 20 h, and intensive care to 96 h. Group 1 with normothermia throughout and randomized group 2 with mild hypothermia (from reperfusion to 2 h) were controls. Then, group 3 received in addition, thiopental 90 mg/kg i.v. over the first 6 h. Then, group 4 received, in addition to group 2 treatment, thiopental 30 mg/kg i.v. over the first 90 min (because the larger dose had produced cardiopulmonary complications), plus <b style='color:Tomato;'><i>phenytoin</i></b> 15 mg/kg i.v. at 15 min after reperfusion, and <b style='color:Tomato;'><i>methyl<b style='color:Tomato;'><i>prednisolone</i></b></i></b> 130 mg/kg i.v. over 20 h. All dogs survived. Best overall performance categories (OPC) achieved (OPC 1 = normal, OPC 5 = brain death) were better in group 2 than group 1 (< 0.05) and numerically better in groups 3 or 4 than in groups 1 or 2. Good cerebral outcome (OPC 1 or 2) was achieved by all six dogs only in group 4 (P < 0.05 group 4 vs. 2). Best NDS were 44 +/- 3% in group 1; 20 +/- 14% in group 2 (P = 0.002); 21 +/- 15% in group 3 (NS vs. group 2); and 7 +/- 8% in group 4 (P = 0.08 vs. group 2). Total brain histologic damage scores (HDS) at 96 h were 156 +/- 38 in group 1; 81 +/- 12 in group 2 (P < 0.001 vs. group 1); 53 +/- 25 in group 3 (P = 0.02 vs. group 2); and 48 +/- 5 in group 4 (P = 0.02 vs. group 2). We conclude that after prolonged cardiac arrest, the already established brain damage mitigating effect of mild immediate postarrest hypothermia might be enhanced by thiopental, and perhaps then further enhanced by adding <b style='color:Tomato;'><i>phenytoin</i></b> and <b style='color:Tomato;'><i>methyl<b style='color:Tomato;'><i>prednisolone</i></b></i></b>.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"hypothesized","start":3,"end":15,"id":1,"ws":true},{"text":"that","start":16,"end":20,"id":2,"ws":true},{"text":"the","start":21,"end":24,"id":3,"ws":true},{"text":"brain","start":25,"end":30,"id":4,"ws":true},{"text":"damage","start":31,"end":37,"id":5,"ws":true},{"text":"mitigating","start":38,"end":48,"id":6,"ws":true},{"text":"effect","start":49,"end":55,"id":7,"ws":true},{"text":"of","start":56,"end":58,"id":8,"ws":true},{"text":"mild","start":59,"end":63,"id":9,"ws":true},{"text":"hypothermia","start":64,"end":75,"id":10,"ws":true},{"text":"after","start":76,"end":81,"id":11,"ws":true},{"text":"cardiac","start":82,"end":89,"id":12,"ws":true},{"text":"arrest","start":90,"end":96,"id":13,"ws":true},{"text":"can","start":97,"end":100,"id":14,"ws":true},{"text":"be","start":101,"end":103,"id":15,"ws":true},{"text":"enhanced","start":104,"end":112,"id":16,"ws":true},{"text":"with","start":113,"end":117,"id":17,"ws":true},{"text":"thiopental","start":118,"end":128,"id":18,"ws":true},{"text":"loading","start":129,"end":136,"id":19,"ws":true},{"text":",","start":137,"end":138,"id":20,"ws":true},{"text":"and","start":139,"end":142,"id":21,"ws":true},{"text":"even","start":143,"end":147,"id":22,"ws":true},{"text":"more","start":148,"end":152,"id":23,"ws":true},{"text":"so","start":153,"end":155,"id":24,"ws":true},{"text":"with","start":156,"end":160,"id":25,"ws":true},{"text":"the","start":161,"end":164,"id":26,"ws":true},{"text":"further","start":165,"end":172,"id":27,"ws":true},{"text":"addition","start":173,"end":181,"id":28,"ws":true},{"text":"of","start":182,"end":184,"id":29,"ws":true},{"text":"phenytoin","start":185,"end":194,"id":30,"ws":true},{"text":"and","start":195,"end":198,"id":31,"ws":true},{"text":"methylprednisolone","start":199,"end":217,"id":32,"ws":true},{"text":".","start":218,"end":219,"id":33,"ws":false}],"spans":[{"start":185,"end":194,"token_start":30,"token_end":30,"label":"DRUG"},{"start":199,"end":217,"token_start":32,"token_end":32,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/10950320/","_input_hash":-209864772,"_task_hash":1917055471,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":30,"child":32,"head_span":{"start":185,"end":194,"token_start":30,"token_end":30,"label":"DRUG"},"child_span":{"start":199,"end":217,"token_start":32,"token_end":32,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Caspase-independent mechanisms , mainly based on increased oxidative stress , result from 2-methoxyestradiol , Artesunate , ascorbic acid , Dihydroartemisinin , Evodiamine , b-AP15 , VLX1570 , Erw-ASNase , and TAK-242 .","paragraph":"<h3><u>Promising Anti-Mitochondrial Agents for Overcoming Acquired Drug Resistance in Multiple Myeloma.</u></h3>Multiple myeloma (MM) remains an incurable tumor due to the high rate of relapse that still occurs. Acquired drug resistance represents the most challenging obstacle to the extension of survival and several studies have been conducted to understand the mechanisms of this phenomenon. Mitochondrial pathways have been extensively investigated, demonstrating that cancer cells become resistant to drugs by reprogramming their metabolic assessment. MM cells acquire resistance to proteasome inhibitors (PIs), activating protection programs, such as a reduction in oxidative stress, down-regulating pro-apoptotic, and up-regulating anti-apoptotic signals. Knowledge of the mechanisms through which tumor cells escape control of the immune system and acquire resistance to drugs has led to the creation of new compounds that can restore the response by leading to cell death. In this scenario, based on all literature data available, our review represents the first collection of anti-mitochondrial compounds able to overcome drug resistance in MM. <b style='color:DodgerBlue;'><i>Caspase-independent</i></b> <b style='color:DodgerBlue;'><i>mechanisms</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>mainly</i></b> <b style='color:DodgerBlue;'><i>based</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:DodgerBlue;'><i>oxidative</i></b> <b style='color:DodgerBlue;'><i>stress</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>result</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>2-methoxyestradiol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>Artesunate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>ascorbic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>Dihydroartemisinin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Evodiamine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>b-AP15</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>VLX1570</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Erw-ASNase</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>TAK-242</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Other agents restore PIs' efficacy through caspase-dependent tools, such as CDDO-Im, NOXA-inhibitors, FTY720, GCS-100, LBH589, a derivative of ellipticine, AT-101, KD5170, SMAC-mimetics, glutaminase-1 (GLS1)-inhibitors, and thenoyltrifluoroacetone. Each of these substances improved the efficacy rates when employed in combination with the most frequently used antimyeloma drugs.","tokens":[{"text":"Caspase-independent","start":0,"end":19,"id":0,"ws":true},{"text":"mechanisms","start":20,"end":30,"id":1,"ws":true},{"text":",","start":31,"end":32,"id":2,"ws":true},{"text":"mainly","start":33,"end":39,"id":3,"ws":true},{"text":"based","start":40,"end":45,"id":4,"ws":true},{"text":"on","start":46,"end":48,"id":5,"ws":true},{"text":"increased","start":49,"end":58,"id":6,"ws":true},{"text":"oxidative","start":59,"end":68,"id":7,"ws":true},{"text":"stress","start":69,"end":75,"id":8,"ws":true},{"text":",","start":76,"end":77,"id":9,"ws":true},{"text":"result","start":78,"end":84,"id":10,"ws":true},{"text":"from","start":85,"end":89,"id":11,"ws":true},{"text":"2-methoxyestradiol","start":90,"end":108,"id":12,"ws":true},{"text":",","start":109,"end":110,"id":13,"ws":true},{"text":"Artesunate","start":111,"end":121,"id":14,"ws":true},{"text":",","start":122,"end":123,"id":15,"ws":true},{"text":"ascorbic","start":124,"end":132,"id":16,"ws":true},{"text":"acid","start":133,"end":137,"id":17,"ws":true},{"text":",","start":138,"end":139,"id":18,"ws":true},{"text":"Dihydroartemisinin","start":140,"end":158,"id":19,"ws":true},{"text":",","start":159,"end":160,"id":20,"ws":true},{"text":"Evodiamine","start":161,"end":171,"id":21,"ws":true},{"text":",","start":172,"end":173,"id":22,"ws":true},{"text":"b-AP15","start":174,"end":180,"id":23,"ws":true},{"text":",","start":181,"end":182,"id":24,"ws":true},{"text":"VLX1570","start":183,"end":190,"id":25,"ws":true},{"text":",","start":191,"end":192,"id":26,"ws":true},{"text":"Erw-ASNase","start":193,"end":203,"id":27,"ws":true},{"text":",","start":204,"end":205,"id":28,"ws":true},{"text":"and","start":206,"end":209,"id":29,"ws":true},{"text":"TAK-242","start":210,"end":217,"id":30,"ws":true},{"text":".","start":218,"end":219,"id":31,"ws":false}],"spans":[{"start":111,"end":121,"token_start":14,"token_end":14,"label":"DRUG"},{"start":140,"end":158,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33669515/","_input_hash":442754413,"_task_hash":392199556,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"In the xenograft model , more augmented effects were achieved when bortezomib was combined with gemcitabine than gemcitabine alone .","paragraph":"<h3><u>Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer.</u></h3>Earlier studies that dealt with the combination therapy of <b style='color:Tomato;'><i>gemcitabine</i></b> and histone deacetylation inhibitors for pancreatic cancer revealed unsatisfactory results. The activation of nuclear factor \u03baB (NF-\u03baB) was referred as one of the attributable causes, and we attempted to overcome this resistance by the addition of a proteasome inhibitor. ### methods The influences of suberoylanilide hydroxamic acid (<b style='color:Tomato;'><i>vorinostat</i></b>, SAHA), a histone deacetylase inhibitor, and <b style='color:Tomato;'><i>bortezomib</i></b>, a novel selective antagonist of 26S proteasome, with or without <b style='color:Tomato;'><i>gemcitabine</i></b> on cell growth and apoptosis and the expressions of related proteins were observed in pancreatic cancer cell lines (MiaPaCa-2 and ASPC-1). The xenograft model of pancreatic cancer was used to notice effects in vivo. ### results <b style='color:Tomato;'><i>vorinostat</i></b> and <b style='color:Tomato;'><i>bortezomib</i></b> had independent inhibitory effects and potentiated the antitumor property of <b style='color:Tomato;'><i>gemcitabine</i></b> in vitro. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>xenograft</i></b> <b style='color:DodgerBlue;'><i>model</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>augmented</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>achieved</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:MediumOrchid;'><i>bortezomib</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The down-regulation of pAkt and suppression of NF-\u03baB activity was induced by the triple combination. ### conclusions The triple combination of <b style='color:Tomato;'><i>vorinostat</i></b>, <b style='color:Tomato;'><i>bortezomib</i></b>, and <b style='color:Tomato;'><i>gemcitabine</i></b> resulted in the strongest antitumor effects both in vitro and in vivo and pAkt and NF-\u03baB seems to be involved in this process.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"the","start":3,"end":6,"id":1,"ws":true},{"text":"xenograft","start":7,"end":16,"id":2,"ws":true},{"text":"model","start":17,"end":22,"id":3,"ws":true},{"text":",","start":23,"end":24,"id":4,"ws":true},{"text":"more","start":25,"end":29,"id":5,"ws":true},{"text":"augmented","start":30,"end":39,"id":6,"ws":true},{"text":"effects","start":40,"end":47,"id":7,"ws":true},{"text":"were","start":48,"end":52,"id":8,"ws":true},{"text":"achieved","start":53,"end":61,"id":9,"ws":true},{"text":"when","start":62,"end":66,"id":10,"ws":true},{"text":"bortezomib","start":67,"end":77,"id":11,"ws":true},{"text":"was","start":78,"end":81,"id":12,"ws":true},{"text":"combined","start":82,"end":90,"id":13,"ws":true},{"text":"with","start":91,"end":95,"id":14,"ws":true},{"text":"gemcitabine","start":96,"end":107,"id":15,"ws":true},{"text":"than","start":108,"end":112,"id":16,"ws":true},{"text":"gemcitabine","start":113,"end":124,"id":17,"ws":true},{"text":"alone","start":125,"end":130,"id":18,"ws":true},{"text":".","start":131,"end":132,"id":19,"ws":false}],"spans":[{"start":67,"end":77,"token_start":11,"token_end":11,"label":"DRUG"},{"start":96,"end":107,"token_start":15,"token_end":15,"label":"DRUG"},{"start":113,"end":124,"token_start":17,"token_end":17,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/21487323/","_input_hash":-559122592,"_task_hash":-1979398455,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":11,"child":15,"head_span":{"start":67,"end":77,"token_start":11,"token_end":11,"label":"DRUG"},"child_span":{"start":96,"end":107,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The effectiveness of combination therapy with afatinib and bevacizumab may provide a new therapeutic option for these patients .","paragraph":"<h3><u>Combination therapy with afatinib and bevacizumab in an EGFR-mutated non-small cell lung cancer patient with acquired ERBB2 amplification: A case report.</u></h3>Acquired resistance to reversible EGFR tyrosine kinase inhibitors remains a significant obstacle, and acquired ERBB2 amplification is the most common \"bypass\" mechanism. For patients with sensitizing EGFR mutation who experience resistance via ERBB2 amplification, no targeted drug has been demonstrated to be effective. ### Patient Concerns A 56-year-old female nonsmoker suffered from left leg paralysis and low back pain. Imaging examination revealed a mass in the anterior segment of the right upper lobe lung and possible multiple metastases in the right hilar, mediastinal lymph nodes, bone metastases, and soft tissue invasion. ### diagnosis Transbronchial lung biopsy revealed a moderately differentiated adenocarcinoma (cT4N2M1c, stage IV). An EGFR exon 19 deletion was identified using amplification refractory mutation system. ### interventions After the patient was treated with <b style='color:Tomato;'><i>gefitinib</i></b> initiation (250\u200amg/d) for 15\u200amonths, the tumor progressed with ERBB2 amplification revealed by next-generation sequencing test. Then, the patient was started on <b style='color:Tomato;'><i>afatinib</i></b> (40\u200amg/d) plus <b style='color:Tomato;'><i>bevacizumab</i></b> (7.5\u200amg/kg every 3\u200aweeks). ### outcomes The combination therapy of <b style='color:Tomato;'><i>afatinib</i></b> and <b style='color:Tomato;'><i>bevacizumab</i></b> in this patient was effective with some slight side effects. Computed tomography scans showed the tumor shrinkage and the pleural effusion disappeared in the right lung. The overall survival was 23.5\u200amonths. ### conclusion To date, there is no targeted therapy approved and demonstrated to be effective for non-small cell lung cancer patients with EGFR sensitizing mutations, and ERBB2 amplification. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>effectiveness</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>afatinib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>provide</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>new</i></b> <b style='color:DodgerBlue;'><i>therapeutic</i></b> <b style='color:DodgerBlue;'><i>option</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"effectiveness","start":4,"end":17,"id":1,"ws":true},{"text":"of","start":18,"end":20,"id":2,"ws":true},{"text":"combination","start":21,"end":32,"id":3,"ws":true},{"text":"therapy","start":33,"end":40,"id":4,"ws":true},{"text":"with","start":41,"end":45,"id":5,"ws":true},{"text":"afatinib","start":46,"end":54,"id":6,"ws":true},{"text":"and","start":55,"end":58,"id":7,"ws":true},{"text":"bevacizumab","start":59,"end":70,"id":8,"ws":true},{"text":"may","start":71,"end":74,"id":9,"ws":true},{"text":"provide","start":75,"end":82,"id":10,"ws":true},{"text":"a","start":83,"end":84,"id":11,"ws":true},{"text":"new","start":85,"end":88,"id":12,"ws":true},{"text":"therapeutic","start":89,"end":100,"id":13,"ws":true},{"text":"option","start":101,"end":107,"id":14,"ws":true},{"text":"for","start":108,"end":111,"id":15,"ws":true},{"text":"these","start":112,"end":117,"id":16,"ws":true},{"text":"patients","start":118,"end":126,"id":17,"ws":true},{"text":".","start":127,"end":128,"id":18,"ws":false}],"spans":[{"start":46,"end":54,"token_start":6,"token_end":6,"label":"DRUG"},{"start":59,"end":70,"token_start":8,"token_end":8,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33663050/","_input_hash":-1094798157,"_task_hash":-258752655,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":8,"child":6,"head_span":{"start":59,"end":70,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":46,"end":54,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Clinical</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>enzalutamide</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>men</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>castration-resistant</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>progressing</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:MediumOrchid;'><i>abiraterone</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>The optimal sequencing of the multiple active agents now available for metastatic castration-resistant prostate cancer (mCRPC) is unclear. Prior reports have suggested diminished responses to sequential lines of androgen receptor (AR)-targeted therapies, but it is unknown whether subsequent taxane-based chemotherapy may be more effective than sequential AR-targeting treatment. We sought to evaluate the clinical activity of <b style='color:Tomato;'><i>enzalutamide</i></b> versus <b style='color:Tomato;'><i>docetaxel</i></b> in men with mCRPC who progressed on <b style='color:Tomato;'><i>abiraterone</i></b>. ### methods We performed a single-institution retrospective analysis of consecutive mCRPC patients who had progressed on <b style='color:Tomato;'><i>abiraterone</i></b> therapy and subsequently received either <b style='color:Tomato;'><i>enzalutamide</i></b> (n=30) or <b style='color:Tomato;'><i>docetaxel</i></b> (n=31). We evaluated clinical outcomes including prostate-specific antigen decline of >30% (PSA30) or >50% (PSA50), PSA-progression-free survival (PSA-PFS), and clinical/radiographic PFS. We performed multivariable modeling to control for baseline and on-treatment differences between groups. ### results Compared to subjects who received <b style='color:Tomato;'><i>enzalutamide</i></b> post-<b style='color:Tomato;'><i>abiraterone</i></b>, subjects who received <b style='color:Tomato;'><i>docetaxel</i></b> post-<b style='color:Tomato;'><i>abiraterone</i></b> had more bone metastases, more visceral metastases, higher baseline PSA, and had more frequent PSA tests while on-treatment. There were no significant differences in PSA30 (41% for <b style='color:Tomato;'><i>enzalutamide</i></b> vs. 53% for <b style='color:Tomato;'><i>docetaxel</i></b>) or PSA50 (34% vs. 40%) response rates between the two groups; there remained no difference after stratifying by presence/absence of prior response to <b style='color:Tomato;'><i>abiraterone</i></b>. Median PSA-PFS was 4.1 versus 4.1 months for the <b style='color:Tomato;'><i>enzalutamide</i></b> and <b style='color:Tomato;'><i>docetaxel</i></b> cohorts, respectively (HR 1.35, 95% CI, 0.53-3.66, P=0.502). Median PFS was 4.7 versus 4.4 months, respectively (HR 1.44, 95% CI, 0.77-2.71, P=0.257). PSA-PFS and PFS did not differ after stratifying by prior response to <b style='color:Tomato;'><i>abiraterone</i></b>. In multivariable analyses, there were no significant differences in PSA-PFS or PFS between the two groups. ### conclusions Treatment with either <b style='color:Tomato;'><i>enzalutamide</i></b> or <b style='color:Tomato;'><i>docetaxel</i></b> produced modest PSA responses and PFS intervals in this <b style='color:Tomato;'><i>abiraterone</i></b>-pretreated mCRPC population. In this retrospective study with small sample size, no significant differences in outcomes were observed between groups. Therefore, either <b style='color:Tomato;'><i>enzalutamide</i></b> or <b style='color:Tomato;'><i>docetaxel</i></b> may be a reasonable option in men who have progressed on <b style='color:Tomato;'><i>abiraterone</i></b>.","tokens":[{"text":"Clinical","start":0,"end":8,"id":0,"ws":true},{"text":"activity","start":9,"end":17,"id":1,"ws":true},{"text":"of","start":18,"end":20,"id":2,"ws":true},{"text":"enzalutamide","start":21,"end":33,"id":3,"ws":true},{"text":"versus","start":34,"end":40,"id":4,"ws":true},{"text":"docetaxel","start":41,"end":50,"id":5,"ws":true},{"text":"in","start":51,"end":53,"id":6,"ws":true},{"text":"men","start":54,"end":57,"id":7,"ws":true},{"text":"with","start":58,"end":62,"id":8,"ws":true},{"text":"castration-resistant","start":63,"end":83,"id":9,"ws":true},{"text":"prostate","start":84,"end":92,"id":10,"ws":true},{"text":"cancer","start":93,"end":99,"id":11,"ws":true},{"text":"progressing","start":100,"end":111,"id":12,"ws":true},{"text":"after","start":112,"end":117,"id":13,"ws":true},{"text":"abiraterone","start":118,"end":129,"id":14,"ws":true},{"text":".","start":130,"end":131,"id":15,"ws":false}],"spans":[{"start":21,"end":33,"token_start":3,"token_end":3,"label":"DRUG"},{"start":41,"end":50,"token_start":5,"token_end":5,"label":"DRUG"},{"start":118,"end":129,"token_start":14,"token_end":14,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25053178/","_input_hash":-60183356,"_task_hash":-289039574,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":3,"child":14,"head_span":{"start":21,"end":33,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":118,"end":129,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":5,"child":14,"head_span":{"start":41,"end":50,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":118,"end":129,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS11","POS21"],"answer":"accept"}
{"text":"The use of cyclophosphamide in patients with NSVN is controversial , but recent retrospective data suggest that those treated with prednisone and cyclophosphamide from the outset fare better than those initially treated only with prednisone .","paragraph":"<h3><u>Therapy for vasculitic neuropathies.</u></h3>The term vasculitis refers to a pathologic condition defined by inflammatory cell infiltration and destruction of blood vessels. Systemic vasculitis is classified as primary (eg, polyarteritis nodosa, Churg-Strauss syndrome) or secondary, the latter associated with connective tissue disorders, infections, medications, and rarely, as a paraneoplastic phenomenon. Neuropathy is a common complication of systemic vasculitis and is related to ischemic nerve fiber damage with axon loss. Peripheral neuropathy may be the sole manifestation of vasculitis, a condition termed nonsystemic vasculitic neuropathy (NSVN). Treatment of vasculitic neuropathy requires long-term immunosuppressive therapies with potential side effects. The diagnosis of vasculitis should be established by tissue (preferably nerve) biopsy. High-dose <b style='color:Tomato;'><i>prednisone</i></b> is the standard platform therapy for patients with systemic and NSVN; for those with systemic vasculitis, at least 3 to 12 months of treatment with <b style='color:Tomato;'><i>cyclophosphamide</i></b> (monthly intravenous pulse or daily oral therapy) is also necessary to sustain remission and allow successful <b style='color:Tomato;'><i>prednisone</i></b> tapering. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>NSVN</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>controversial</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>recent</i></b> <b style='color:DodgerBlue;'><i>retrospective</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>suggest</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>outset</i></b> <b style='color:DodgerBlue;'><i>fare</i></b> <b style='color:DodgerBlue;'><i>better</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>initially</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> If <b style='color:Tomato;'><i>prednisone</i></b> is administered as monotherapy, <b style='color:Tomato;'><i>cyclophosphamide</i></b> should be added after several months if there is no improvement or relapse occurs with tapering of <b style='color:Tomato;'><i>prednisone</i></b>. Intravenous pulse and daily oral <b style='color:Tomato;'><i>cyclophosphamide</i></b> probably offer similar efficacy, although the risk of complications is greater with oral therapy. <b style='color:Tomato;'><i>azathioprine</i></b> can be safely substituted for <b style='color:Tomato;'><i>cyclophosphamide</i></b> after 3 months without an increased relapse rate. <b style='color:Tomato;'><i>azathioprine</i></b>, <b style='color:Tomato;'><i>methotrexate</i></b>, intravenous immune globulin, <b style='color:Tomato;'><i>mycophenolate</i></b> mofetil, plasma exchange, and <b style='color:Tomato;'><i>rituximab</i></b> can be offered to patients who are intolerant or have a contraindication to <b style='color:Tomato;'><i>cyclophosphamide</i></b>. However, efficacy is unproven for any of these therapies. Interferon-alpha, sometimes combined with plasma exchange, is used to treat vasculitis associated with hepatitis B infection. Some patients also may improve with corticosteroids. The classification of diabetic lumbosacral radiculoplexus neuropathy as a vasculitic disorder remains controversial. However, there is compelling pathological evidence that this condition represents a T-cell-mediated microvasculitis. Some patients treated with intravenous corticosteroids may have greater recovery and improved pain control.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"use","start":4,"end":7,"id":1,"ws":true},{"text":"of","start":8,"end":10,"id":2,"ws":true},{"text":"cyclophosphamide","start":11,"end":27,"id":3,"ws":true},{"text":"in","start":28,"end":30,"id":4,"ws":true},{"text":"patients","start":31,"end":39,"id":5,"ws":true},{"text":"with","start":40,"end":44,"id":6,"ws":true},{"text":"NSVN","start":45,"end":49,"id":7,"ws":true},{"text":"is","start":50,"end":52,"id":8,"ws":true},{"text":"controversial","start":53,"end":66,"id":9,"ws":true},{"text":",","start":67,"end":68,"id":10,"ws":true},{"text":"but","start":69,"end":72,"id":11,"ws":true},{"text":"recent","start":73,"end":79,"id":12,"ws":true},{"text":"retrospective","start":80,"end":93,"id":13,"ws":true},{"text":"data","start":94,"end":98,"id":14,"ws":true},{"text":"suggest","start":99,"end":106,"id":15,"ws":true},{"text":"that","start":107,"end":111,"id":16,"ws":true},{"text":"those","start":112,"end":117,"id":17,"ws":true},{"text":"treated","start":118,"end":125,"id":18,"ws":true},{"text":"with","start":126,"end":130,"id":19,"ws":true},{"text":"prednisone","start":131,"end":141,"id":20,"ws":true},{"text":"and","start":142,"end":145,"id":21,"ws":true},{"text":"cyclophosphamide","start":146,"end":162,"id":22,"ws":true},{"text":"from","start":163,"end":167,"id":23,"ws":true},{"text":"the","start":168,"end":171,"id":24,"ws":true},{"text":"outset","start":172,"end":178,"id":25,"ws":true},{"text":"fare","start":179,"end":183,"id":26,"ws":true},{"text":"better","start":184,"end":190,"id":27,"ws":true},{"text":"than","start":191,"end":195,"id":28,"ws":true},{"text":"those","start":196,"end":201,"id":29,"ws":true},{"text":"initially","start":202,"end":211,"id":30,"ws":true},{"text":"treated","start":212,"end":219,"id":31,"ws":true},{"text":"only","start":220,"end":224,"id":32,"ws":true},{"text":"with","start":225,"end":229,"id":33,"ws":true},{"text":"prednisone","start":230,"end":240,"id":34,"ws":true},{"text":".","start":241,"end":242,"id":35,"ws":false}],"spans":[{"start":11,"end":27,"token_start":3,"token_end":3,"label":"DRUG"},{"start":131,"end":141,"token_start":20,"token_end":20,"label":"DRUG"},{"start":146,"end":162,"token_start":22,"token_end":22,"label":"DRUG"},{"start":230,"end":240,"token_start":34,"token_end":34,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16464407/","_input_hash":1157918086,"_task_hash":-2064001050,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":22,"child":20,"head_span":{"start":146,"end":162,"token_start":22,"token_end":22,"label":"DRUG"},"child_span":{"start":131,"end":141,"token_start":20,"token_end":20,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"This was a multi-center randomized , two-armed , double-blinded phase II study comparing cediranib plus gefitinib versus cediranib plus placebo in subjects with first relapse/first progression of glioblastoma following surgery and chemoradiotherapy .","paragraph":"<h3><u>Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.</u></h3><b style='color:Tomato;'><i>cediranib</i></b>, an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, failed to show benefit over <b style='color:Tomato;'><i>lomustine</i></b> in relapsed glioblastoma. One resistance mechanism for <b style='color:Tomato;'><i>cediranib</i></b> is up-regulation of epidermal growth factor receptor (EGFR). This study aimed to determine if dual therapy with <b style='color:Tomato;'><i>cediranib</i></b> and the oral EGFR inhibitor <b style='color:Tomato;'><i>gefitinib</i></b> improved outcome in recurrent glioblastoma. ### Methods And Findings <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>multi-center</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>two-armed</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>double-blinded</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>comparing</i></b> <b style='color:MediumOrchid;'><i>cediranib</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>gefitinib</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:MediumOrchid;'><i>cediranib</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:DodgerBlue;'><i>placebo</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>subjects</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>relapse/first</i></b> <b style='color:DodgerBlue;'><i>progression</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>glioblastoma</i></b> <b style='color:DodgerBlue;'><i>following</i></b> <b style='color:DodgerBlue;'><i>surgery</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>chemoradiotherapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The primary outcome measure was progression free survival (PFS). Secondary outcome measures included overall survival (OS) and radiologic response rate. Recruitment was terminated early following suspension of the <b style='color:Tomato;'><i>cediranib</i></b> program. 38 subjects (112 planned) were enrolled with 19 subjects in each treatment arm. Median PFS with <b style='color:Tomato;'><i>cediranib</i></b> plus <b style='color:Tomato;'><i>gefitinib</i></b> was 3.6 months compared to 2.8 months for <b style='color:Tomato;'><i>cediranib</i></b> plus placebo (HR; 0.72, 90% CI; 0.41 to 1.26). Median OS was 7.2 months with <b style='color:Tomato;'><i>cediranib</i></b> plus <b style='color:Tomato;'><i>gefitinib</i></b> and 5.5 months with <b style='color:Tomato;'><i>cediranib</i></b> plus placebo (HR; 0.68, 90% CI; 0.39 to 1.19). Eight subjects (42%) had a partial response in the <b style='color:Tomato;'><i>cediranib</i></b> plus <b style='color:Tomato;'><i>gefitinib</i></b> arm versus five patients (26%) in the <b style='color:Tomato;'><i>cediranib</i></b> plus placebo arm. ### conclusions <b style='color:Tomato;'><i>cediranib</i></b> and <b style='color:Tomato;'><i>gefitinib</i></b> in combination is tolerated in patients with glioblastoma. Incomplete recruitment led to the study being underpowered. However, a trend towards improved survival and response rates with the addition of <b style='color:Tomato;'><i>gefitinib</i></b> to <b style='color:Tomato;'><i>cediranib</i></b> was observed. Further studies of the combination incorporating EGFR and VEGF inhibition are warranted. ### Trial Registration ClinicalTrials.gov NCT01310855.","tokens":[{"text":"This","start":0,"end":4,"id":0,"ws":true},{"text":"was","start":5,"end":8,"id":1,"ws":true},{"text":"a","start":9,"end":10,"id":2,"ws":true},{"text":"multi-center","start":11,"end":23,"id":3,"ws":true},{"text":"randomized","start":24,"end":34,"id":4,"ws":true},{"text":",","start":35,"end":36,"id":5,"ws":true},{"text":"two-armed","start":37,"end":46,"id":6,"ws":true},{"text":",","start":47,"end":48,"id":7,"ws":true},{"text":"double-blinded","start":49,"end":63,"id":8,"ws":true},{"text":"phase","start":64,"end":69,"id":9,"ws":true},{"text":"II","start":70,"end":72,"id":10,"ws":true},{"text":"study","start":73,"end":78,"id":11,"ws":true},{"text":"comparing","start":79,"end":88,"id":12,"ws":true},{"text":"cediranib","start":89,"end":98,"id":13,"ws":true},{"text":"plus","start":99,"end":103,"id":14,"ws":true},{"text":"gefitinib","start":104,"end":113,"id":15,"ws":true},{"text":"versus","start":114,"end":120,"id":16,"ws":true},{"text":"cediranib","start":121,"end":130,"id":17,"ws":true},{"text":"plus","start":131,"end":135,"id":18,"ws":true},{"text":"placebo","start":136,"end":143,"id":19,"ws":true},{"text":"in","start":144,"end":146,"id":20,"ws":true},{"text":"subjects","start":147,"end":155,"id":21,"ws":true},{"text":"with","start":156,"end":160,"id":22,"ws":true},{"text":"first","start":161,"end":166,"id":23,"ws":true},{"text":"relapse/first","start":167,"end":180,"id":24,"ws":true},{"text":"progression","start":181,"end":192,"id":25,"ws":true},{"text":"of","start":193,"end":195,"id":26,"ws":true},{"text":"glioblastoma","start":196,"end":208,"id":27,"ws":true},{"text":"following","start":209,"end":218,"id":28,"ws":true},{"text":"surgery","start":219,"end":226,"id":29,"ws":true},{"text":"and","start":227,"end":230,"id":30,"ws":true},{"text":"chemoradiotherapy","start":231,"end":248,"id":31,"ws":true},{"text":".","start":249,"end":250,"id":32,"ws":false}],"spans":[{"start":89,"end":98,"token_start":13,"token_end":13,"label":"DRUG"},{"start":104,"end":113,"token_start":15,"token_end":15,"label":"DRUG"},{"start":121,"end":130,"token_start":17,"token_end":17,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/27232884/","_input_hash":1881848093,"_task_hash":-212303019,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":13,"child":15,"head_span":{"start":89,"end":98,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":104,"end":113,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"This study aims to compare the biological , molecular , pharmacological , and clinical characteristics of these three treatment modalities for SARS-COV-2 infections , Chloroquine and Hydroxychloroquine , Convalescent Plasma , and Remdesivir .","paragraph":"<h3><u>Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis.</u></h3>The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, also known as COVID-19 pandemic has caused an alarming situation worldwide. Since the first detection, in December 2019, there have been no effective drug therapy options for treating the SARS-CoV-2 pandemic. However, healthcare professionals are using <b style='color:Tomato;'><i>chloroquine</i></b>, hydroxy<b style='color:Tomato;'><i>chloroquine</i></b>, <b style='color:Tomato;'><i>remdesivir</i></b>, convalescent plasma and some other options of treatments. <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>aims</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>compare</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>biological</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>molecular</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>pharmacological</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>characteristics</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>three</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>modalities</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>SARS-COV-2</i></b> <b style='color:DodgerBlue;'><i>infections</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>Chloroquine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Hydroxychloroquine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Convalescent</i></b> <b style='color:DodgerBlue;'><i>Plasma</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Remdesivir</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods A search was conducted in the \"Institute of Science Information (ISI)-Web of Science, PubMed, EMBASE, ClinicalTrials.gov, Cochrane Library databases, Scopus, and Google Scholar\" for peer reviewed, published studies and clinical trials through July 30, 2020. The search was based on keywords \"COVID-19\" SARS-COV-2, <b style='color:Tomato;'><i>chloroquine</i></b>, hydroxy<b style='color:Tomato;'><i>chloroquine</i></b>, convalescent plasma, <b style='color:Tomato;'><i>remdesivir</i></b> and treatment modalities. ### results As of July 30, 2020, a total of 36,640 relevant documents were published. From them 672 peer reviewed, published articles, and clinical trials were screened. We selected 17 relevant published original articles and clinical trials: 05 for <b style='color:Tomato;'><i>chloroquine</i></b> and/or hydroxy<b style='color:Tomato;'><i>chloroquine</i></b> with total sample size (n\u202f=\u202f220), 05 for <b style='color:Tomato;'><i>remdesivir</i></b> (n\u202f=\u202f1,781), and 07 for Convalescent Plasma therapy (n\u202f=\u202f398), with a combined total sample size (n\u202f=\u202f2,399). Based on the available data, convalescent plasma therapy showed clinical advantages in SARS-COV-2 patients. ### conclusions All three treatment modalities have both favorable and unfavorable characteristics, but none showed clear evidence of benefit for early outpatient disease or prophylaxis. Based on the current available data, convalescent plasma therapy appears to show clinical advantages for inpatient use. In the future, ongoing large sample size randomized controlled clinical trials may further clarify the comparative efficacy and safety of these three treatment classes, to conclusively determine whom to treat with which drug and when to treat them.","tokens":[{"text":"This","start":0,"end":4,"id":0,"ws":true},{"text":"study","start":5,"end":10,"id":1,"ws":true},{"text":"aims","start":11,"end":15,"id":2,"ws":true},{"text":"to","start":16,"end":18,"id":3,"ws":true},{"text":"compare","start":19,"end":26,"id":4,"ws":true},{"text":"the","start":27,"end":30,"id":5,"ws":true},{"text":"biological","start":31,"end":41,"id":6,"ws":true},{"text":",","start":42,"end":43,"id":7,"ws":true},{"text":"molecular","start":44,"end":53,"id":8,"ws":true},{"text":",","start":54,"end":55,"id":9,"ws":true},{"text":"pharmacological","start":56,"end":71,"id":10,"ws":true},{"text":",","start":72,"end":73,"id":11,"ws":true},{"text":"and","start":74,"end":77,"id":12,"ws":true},{"text":"clinical","start":78,"end":86,"id":13,"ws":true},{"text":"characteristics","start":87,"end":102,"id":14,"ws":true},{"text":"of","start":103,"end":105,"id":15,"ws":true},{"text":"these","start":106,"end":111,"id":16,"ws":true},{"text":"three","start":112,"end":117,"id":17,"ws":true},{"text":"treatment","start":118,"end":127,"id":18,"ws":true},{"text":"modalities","start":128,"end":138,"id":19,"ws":true},{"text":"for","start":139,"end":142,"id":20,"ws":true},{"text":"SARS-COV-2","start":143,"end":153,"id":21,"ws":true},{"text":"infections","start":154,"end":164,"id":22,"ws":true},{"text":",","start":165,"end":166,"id":23,"ws":true},{"text":"Chloroquine","start":167,"end":178,"id":24,"ws":true},{"text":"and","start":179,"end":182,"id":25,"ws":true},{"text":"Hydroxychloroquine","start":183,"end":201,"id":26,"ws":true},{"text":",","start":202,"end":203,"id":27,"ws":true},{"text":"Convalescent","start":204,"end":216,"id":28,"ws":true},{"text":"Plasma","start":217,"end":223,"id":29,"ws":true},{"text":",","start":224,"end":225,"id":30,"ws":true},{"text":"and","start":226,"end":229,"id":31,"ws":true},{"text":"Remdesivir","start":230,"end":240,"id":32,"ws":true},{"text":".","start":241,"end":242,"id":33,"ws":false}],"spans":[{"start":167,"end":178,"token_start":24,"token_end":24,"label":"DRUG"},{"start":183,"end":201,"token_start":26,"token_end":26,"label":"DRUG"},{"start":230,"end":240,"token_start":32,"token_end":32,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/32921965/","_input_hash":-1164581320,"_task_hash":-1670352699,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Patients received a mean ( \u00b1standard deviation ) of 8.8 \u00b1 4.9 intravitreal bevacizumab injections prior to the switch to intravitreal ranibizumab .","paragraph":"<h3><u>Diabetic macular edema treated with ranibizumab following bevacizumab failure in Israel (DERBI study).</u></h3>To evaluate the outcome of second-line intravitreal <b style='color:Tomato;'><i>ranibizumab</i></b> treatment in eyes with diabetic macular edema having persistent edema following initial therapy with intravitreal <b style='color:Tomato;'><i>bevacizumab</i></b>. ### Methods Diabetic macular edema treated with <b style='color:Tomato;'><i>ranibizumab</i></b> following <b style='color:Tomato;'><i>bevacizumab</i></b> failure in Israel was a retrospective, multi-center study. Consecutive eyes with persistent diabetic macular edema following at least three previous intravitreal <b style='color:Tomato;'><i>bevacizumab</i></b> injections prior to intravitreal <b style='color:Tomato;'><i>ranibizumab</i></b>, at least three-monthly intravitreal <b style='color:Tomato;'><i>ranibizumab</i></b> injections and at least 12\u2009months of follow-up were included. Data collected included demographics, ocular findings, diabetes control, details of intravitreal <b style='color:Tomato;'><i>bevacizumab</i></b> and <b style='color:Tomato;'><i>ranibizumab</i></b> injections, and visual and anatomical measurements before and after intravitreal <b style='color:Tomato;'><i>ranibizumab</i></b> treatment. ### Results In total, 202 eyes of 162 patients treated at 11 medical centers across Israel were included. <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>mean</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>\u00b1standard</i></b> <b style='color:DodgerBlue;'><i>deviation</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>8.8</i></b> <b style='color:DodgerBlue;'><i>\u00b1</i></b> <b style='color:DodgerBlue;'><i>4.9</i></b> <b style='color:DodgerBlue;'><i>intravitreal</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>injections</i></b> <b style='color:DodgerBlue;'><i>prior</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>switch</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>intravitreal</i></b> <b style='color:MediumOrchid;'><i>ranibizumab</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A mean of 7.0\u2009\u00b1\u20092.7 intravitreal <b style='color:Tomato;'><i>ranibizumab</i></b> injections were given during the 12\u2009months following the switch to intravitreal <b style='color:Tomato;'><i>ranibizumab</i></b>. The median central subfield retinal thickness (\u00b1interquartile range) by spectral-domain optical coherence tomography decreased from 436\u2009\u00b1\u2009162\u2009\u00b5m at baseline to 319\u2009\u00b1\u2009113\u2009\u00b5m at month 12 (p\u2009<\u20090.001). Median logMAR visual acuity (\u00b1interquartile range) improved from 0.40\u2009\u00b1\u20090.48 at baseline to 0.38\u2009\u00b1\u20090.40 at month 12 (p\u2009=\u20090.001). Linear regression suggested that higher number of intravitreal <b style='color:Tomato;'><i>ranibizumab</i></b> injections and higher pre-switch central subfield retinal thickness were associated with favorable visual outcome. Higher number of intravitreal <b style='color:Tomato;'><i>bevacizumab</i></b> injections and the presence of intraretinal fluid before the switch lessened the odds of favorable outcome. ### Conclusion Switching from <b style='color:Tomato;'><i>bevacizumab</i></b> to <b style='color:Tomato;'><i>ranibizumab</i></b> in persistent diabetic macular edema was associated with anatomical improvement in the majority of eyes and \u2a7e2 lines of vision improvement in 22% of eyes.","tokens":[{"text":"Patients","start":0,"end":8,"id":0,"ws":true},{"text":"received","start":9,"end":17,"id":1,"ws":true},{"text":"a","start":18,"end":19,"id":2,"ws":true},{"text":"mean","start":20,"end":24,"id":3,"ws":true},{"text":"(","start":25,"end":26,"id":4,"ws":true},{"text":"\u00b1standard","start":27,"end":36,"id":5,"ws":true},{"text":"deviation","start":37,"end":46,"id":6,"ws":true},{"text":")","start":47,"end":48,"id":7,"ws":true},{"text":"of","start":49,"end":51,"id":8,"ws":true},{"text":"8.8","start":52,"end":55,"id":9,"ws":true},{"text":"\u00b1","start":56,"end":57,"id":10,"ws":true},{"text":"4.9","start":58,"end":61,"id":11,"ws":true},{"text":"intravitreal","start":62,"end":74,"id":12,"ws":true},{"text":"bevacizumab","start":75,"end":86,"id":13,"ws":true},{"text":"injections","start":87,"end":97,"id":14,"ws":true},{"text":"prior","start":98,"end":103,"id":15,"ws":true},{"text":"to","start":104,"end":106,"id":16,"ws":true},{"text":"the","start":107,"end":110,"id":17,"ws":true},{"text":"switch","start":111,"end":117,"id":18,"ws":true},{"text":"to","start":118,"end":120,"id":19,"ws":true},{"text":"intravitreal","start":121,"end":133,"id":20,"ws":true},{"text":"ranibizumab","start":134,"end":145,"id":21,"ws":true},{"text":".","start":146,"end":147,"id":22,"ws":false}],"spans":[{"start":75,"end":86,"token_start":13,"token_end":13,"label":"DRUG"},{"start":134,"end":145,"token_start":21,"token_end":21,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29916263/","_input_hash":571835589,"_task_hash":1057049130,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Combinations of penicillin and streptomycin and penicillin and amikacin were synergistic only against those strains that were not highly resistant to streptomycin and kanamycin , respectively .","paragraph":"<h3><u>Species-specific resistance to antimocrobial synergism in Streptococcus faecium and Streptococcus faecalis.</u></h3>Combinations of penicillin with various aminoglycosidic aminocyclitols were tested against a collection of clinical isolates of Streptococcus faecium in vitro and were used to treat endocarditis caused by S. faecium in the rabbit model. S. faecium proved more resistant to penicillin than Streptococcus faecalis. Even more striking, however, was the resistance to in vitro synergism by combinations of penicillin and various aminoglycosides. At clinically achievable concentrations, penicillin-<b style='color:Tomato;'><i>gentamicin</i></b> was the only combination that was synergistic against all strains that were tested. <b style='color:DodgerBlue;'><i>Combinations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>penicillin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>streptomycin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>penicillin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>amikacin</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>synergistic</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>strains</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>highly</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>streptomycin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>kanamycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Combinations of penicillin with <b style='color:Tomato;'><i>kanamycin</i></b>, <b style='color:Tomato;'><i>tobramycin</i></b>, <b style='color:Tomato;'><i>sisomicin</i></b>, or <b style='color:Tomato;'><i>netilmicin</i></b> failed to produce synergism against any of these strains. The possible clinical significance of these findings was verified by use of the rabbit model of endocarditis. Combinations of penicillin with <b style='color:Tomato;'><i>gentamicin</i></b> or <b style='color:Tomato;'><i>streptomycin</i></b> were synergistic in the therapy of endocarditis that was produced by a strain of S. faecium that did not have a high level of resistance to aminoglycosides. However, the combination of penicillin and <b style='color:Tomato;'><i>netilmicin</i></b> was no more effective than penicillin alone.","tokens":[{"text":"Combinations","start":0,"end":12,"id":0,"ws":true},{"text":"of","start":13,"end":15,"id":1,"ws":true},{"text":"penicillin","start":16,"end":26,"id":2,"ws":true},{"text":"and","start":27,"end":30,"id":3,"ws":true},{"text":"streptomycin","start":31,"end":43,"id":4,"ws":true},{"text":"and","start":44,"end":47,"id":5,"ws":true},{"text":"penicillin","start":48,"end":58,"id":6,"ws":true},{"text":"and","start":59,"end":62,"id":7,"ws":true},{"text":"amikacin","start":63,"end":71,"id":8,"ws":true},{"text":"were","start":72,"end":76,"id":9,"ws":true},{"text":"synergistic","start":77,"end":88,"id":10,"ws":true},{"text":"only","start":89,"end":93,"id":11,"ws":true},{"text":"against","start":94,"end":101,"id":12,"ws":true},{"text":"those","start":102,"end":107,"id":13,"ws":true},{"text":"strains","start":108,"end":115,"id":14,"ws":true},{"text":"that","start":116,"end":120,"id":15,"ws":true},{"text":"were","start":121,"end":125,"id":16,"ws":true},{"text":"not","start":126,"end":129,"id":17,"ws":true},{"text":"highly","start":130,"end":136,"id":18,"ws":true},{"text":"resistant","start":137,"end":146,"id":19,"ws":true},{"text":"to","start":147,"end":149,"id":20,"ws":true},{"text":"streptomycin","start":150,"end":162,"id":21,"ws":true},{"text":"and","start":163,"end":166,"id":22,"ws":true},{"text":"kanamycin","start":167,"end":176,"id":23,"ws":true},{"text":",","start":177,"end":178,"id":24,"ws":true},{"text":"respectively","start":179,"end":191,"id":25,"ws":true},{"text":".","start":192,"end":193,"id":26,"ws":false}],"spans":[{"start":31,"end":43,"token_start":4,"token_end":4,"label":"DRUG"},{"start":63,"end":71,"token_start":8,"token_end":8,"label":"DRUG"},{"start":150,"end":162,"token_start":21,"token_end":21,"label":"DRUG"},{"start":167,"end":176,"token_start":23,"token_end":23,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/113469/","_input_hash":175357667,"_task_hash":-1271017010,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":2,"child":4,"head_span":{"start":16,"end":26,"token_start":2,"token_end":2,"label":null},"child_span":{"start":31,"end":43,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":8,"child":6,"head_span":{"start":63,"end":71,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":48,"end":58,"token_start":6,"token_end":6,"label":null},"color":"#ffd882","label":"POS2"}],"radio":["POS10","POS20"],"answer":"accept"}
{"text":"Treatment with a combination chemotherapeutic regimen consisting of cyclophosphamide , vincristine , and dacarbazine for malignant paraganglioma with hepatic metastasis is reported .","paragraph":"<h3><u>Combination chemotherapy for malignant paraganglioma.</u></h3> <b style='color:DodgerBlue;'><i>Treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>chemotherapeutic</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>consisting</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>dacarbazine</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>malignant</i></b> <b style='color:DodgerBlue;'><i>paraganglioma</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>hepatic</i></b> <b style='color:DodgerBlue;'><i>metastasis</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>reported</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A 51-year-old male presented with tumors in the retroperitoneal space and liver. The patient was diagnosed as having paraganglioma based on elevated levels of serum neuron-specific enolase, urinary catecholamine and vanillylmandelic acid, and on histological findings of the liver specimen. The patient was treated with this combination chemotherapy in repeated 21-day cycles. Temporary improvement in laboratory findings and a 20% reduction in the size of the hepatic masses were observed without severe adverse effects.","tokens":[{"text":"Treatment","start":0,"end":9,"id":0,"ws":true},{"text":"with","start":10,"end":14,"id":1,"ws":true},{"text":"a","start":15,"end":16,"id":2,"ws":true},{"text":"combination","start":17,"end":28,"id":3,"ws":true},{"text":"chemotherapeutic","start":29,"end":45,"id":4,"ws":true},{"text":"regimen","start":46,"end":53,"id":5,"ws":true},{"text":"consisting","start":54,"end":64,"id":6,"ws":true},{"text":"of","start":65,"end":67,"id":7,"ws":true},{"text":"cyclophosphamide","start":68,"end":84,"id":8,"ws":true},{"text":",","start":85,"end":86,"id":9,"ws":true},{"text":"vincristine","start":87,"end":98,"id":10,"ws":true},{"text":",","start":99,"end":100,"id":11,"ws":true},{"text":"and","start":101,"end":104,"id":12,"ws":true},{"text":"dacarbazine","start":105,"end":116,"id":13,"ws":true},{"text":"for","start":117,"end":120,"id":14,"ws":true},{"text":"malignant","start":121,"end":130,"id":15,"ws":true},{"text":"paraganglioma","start":131,"end":144,"id":16,"ws":true},{"text":"with","start":145,"end":149,"id":17,"ws":true},{"text":"hepatic","start":150,"end":157,"id":18,"ws":true},{"text":"metastasis","start":158,"end":168,"id":19,"ws":true},{"text":"is","start":169,"end":171,"id":20,"ws":true},{"text":"reported","start":172,"end":180,"id":21,"ws":true},{"text":".","start":181,"end":182,"id":22,"ws":false}],"spans":[{"start":68,"end":84,"token_start":8,"token_end":8,"label":"DRUG"},{"start":87,"end":98,"token_start":10,"token_end":10,"label":"DRUG"},{"start":105,"end":116,"token_start":13,"token_end":13,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9058098/","_input_hash":-1922423655,"_task_hash":-164068088,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":8,"child":10,"head_span":{"start":68,"end":84,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":87,"end":98,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":10,"child":13,"head_span":{"start":87,"end":98,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":105,"end":116,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The aim of this study was to evaluate the in vitro effect of single antibiotic ( ciprofloxacin , ceftazidime , or ampicillin ) treatment on adherence of Escherichia coli and Enterococcus to plastic stents .","paragraph":"<h3><u>In vitro evaluation of antibiotic prophylaxis in the prevention of biliary stent blockage.</u></h3>Bacterial adherence and biofilm formation are important factors in the blockage of biliary stents. Clinical studies with oral antibiotic prophylaxis to prevent stent blockage have produced conflicting results. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>aim</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>antibiotic</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>ciprofloxacin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ceftazidime</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>ampicillin</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>adherence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Escherichia</i></b> <b style='color:DodgerBlue;'><i>coli</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Enterococcus</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>plastic</i></b> <b style='color:DodgerBlue;'><i>stents</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods Selected clinical isolates of E coli and Enterococcus were perfused through a modified Robbins device containing segments of polyethylene stents. The stents were removed daily and the number of bacteria attached was measured. The effect of antibiotic treatment on bacterial adherence was tested by the perfusion of individual antibiotics into separate modified Robbins devices using a side-arm adaptor and the results were compared with saline controls. ### results Compared with the saline controls, <b style='color:Tomato;'><i>ciprofloxacin</i></b> and <b style='color:Tomato;'><i>ceftazidime</i></b> caused a 10- to 100-fold reduction in the number of E coli attached to the stents, whereas <b style='color:Tomato;'><i>ampicillin</i></b> had no effect on adherence of E coli. <b style='color:Tomato;'><i>ampicillin</i></b> caused a 5- to 10-fold reduction in Enterococcus adherence but there was no change with <b style='color:Tomato;'><i>ceftazidime</i></b>. Sustained reduction in E coli adherence was observed with prolonged <b style='color:Tomato;'><i>ciprofloxacin</i></b> perfusion. ### conclusion Timely treatment with appropriate antibiotics reduced bacterial adherence in vitro and may be potentially beneficial in the prevention of stent blockage.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"aim","start":4,"end":7,"id":1,"ws":true},{"text":"of","start":8,"end":10,"id":2,"ws":true},{"text":"this","start":11,"end":15,"id":3,"ws":true},{"text":"study","start":16,"end":21,"id":4,"ws":true},{"text":"was","start":22,"end":25,"id":5,"ws":true},{"text":"to","start":26,"end":28,"id":6,"ws":true},{"text":"evaluate","start":29,"end":37,"id":7,"ws":true},{"text":"the","start":38,"end":41,"id":8,"ws":true},{"text":"in","start":42,"end":44,"id":9,"ws":true},{"text":"vitro","start":45,"end":50,"id":10,"ws":true},{"text":"effect","start":51,"end":57,"id":11,"ws":true},{"text":"of","start":58,"end":60,"id":12,"ws":true},{"text":"single","start":61,"end":67,"id":13,"ws":true},{"text":"antibiotic","start":68,"end":78,"id":14,"ws":true},{"text":"(","start":79,"end":80,"id":15,"ws":true},{"text":"ciprofloxacin","start":81,"end":94,"id":16,"ws":true},{"text":",","start":95,"end":96,"id":17,"ws":true},{"text":"ceftazidime","start":97,"end":108,"id":18,"ws":true},{"text":",","start":109,"end":110,"id":19,"ws":true},{"text":"or","start":111,"end":113,"id":20,"ws":true},{"text":"ampicillin","start":114,"end":124,"id":21,"ws":true},{"text":")","start":125,"end":126,"id":22,"ws":true},{"text":"treatment","start":127,"end":136,"id":23,"ws":true},{"text":"on","start":137,"end":139,"id":24,"ws":true},{"text":"adherence","start":140,"end":149,"id":25,"ws":true},{"text":"of","start":150,"end":152,"id":26,"ws":true},{"text":"Escherichia","start":153,"end":164,"id":27,"ws":true},{"text":"coli","start":165,"end":169,"id":28,"ws":true},{"text":"and","start":170,"end":173,"id":29,"ws":true},{"text":"Enterococcus","start":174,"end":186,"id":30,"ws":true},{"text":"to","start":187,"end":189,"id":31,"ws":true},{"text":"plastic","start":190,"end":197,"id":32,"ws":true},{"text":"stents","start":198,"end":204,"id":33,"ws":true},{"text":".","start":205,"end":206,"id":34,"ws":false}],"spans":[{"start":81,"end":94,"token_start":16,"token_end":16,"label":"DRUG"},{"start":97,"end":108,"token_start":18,"token_end":18,"label":"DRUG"},{"start":114,"end":124,"token_start":21,"token_end":21,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/10699774/","_input_hash":84121731,"_task_hash":-1431098532,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Paclitaxel and docetaxel as single agents have yielded overall response rates of 7 % to 56 % , depending on whether the patients have received prior chemotherapy for metastatic disease .","paragraph":"<h3><u>Current and future perspectives in advanced bladder cancer: is there a new standard?</u></h3>The <b style='color:Tomato;'><i>methotrexate</i></b>/<b style='color:Tomato;'><i>vinblastine</i></b>/<b style='color:Tomato;'><i>doxorubicin</i></b>/<b style='color:Tomato;'><i>cisplatin</i></b> (MVAC) regimen has been the standard treatment in patients with locally advanced and metastatic urothelial cancer for the past 15 years. The minimal or moderate survival benefit-depending on prognostic features-and the severe toxicity associated with the MVAC regimen have made the search for new drugs and drug combinations of utmost importance to increase efficacy and/or decrease toxicity. In this respect, the taxanes and <b style='color:Tomato;'><i>gemcitabine</i></b> are promising new drugs. <b style='color:MediumOrchid;'><i>Paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>yielded</i></b> <b style='color:DodgerBlue;'><i>overall</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>rates</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>7</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>56</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>depending</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>whether</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>prior</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The combination of <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>cisplatin</i></b> has been explored in three studies with a total of 104 evaluable patients, a pooled overall response (OR) rate of 61%, and a complete response (CR) rate of 20%. There are two studies of <b style='color:Tomato;'><i>docetaxel</i></b> and <b style='color:Tomato;'><i>cisplatin</i></b> with a total of 91 evaluable patients, an OR rate of 54%, and a CR rate of 16%. The OR rate for <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b> in six studies was 43%, with a CR rate of 13%; however, the reported median survival was only 8.5 to 9.5 months. The OR rate for single-agent <b style='color:Tomato;'><i>gemcitabine</i></b> based on five studies was 26%, with a CR rate of 9%, which was apparently independent of whether the patients had received prior chemotherapy. The OR rate for <b style='color:Tomato;'><i>gemcitabine</i></b> and <b style='color:Tomato;'><i>cisplatin</i></b> in four phase II studies ranged from 41% to 57%, with a CR rate of 15% to 22% and a median survival of 12.5 to 14.3 months. Based on the encouraging results for the combination of <b style='color:Tomato;'><i>gemcitabine</i></b> and <b style='color:Tomato;'><i>cisplatin</i></b> (GC), a randomized phase III trial comparing GC and MVAC was begun in late 1996. This study of 405 randomized patients showed that the two regimens were associated with similar response rates, time to progression, and overall survival, whereas GC was associated with less toxicity than MVAC. On the basis of this superior risk-benefit ratio, the GC regimen should be favored as a new standard treatment in patients with locally advanced and metastatic urothelial cancer. Other promising combinations include <b style='color:Tomato;'><i>gemcitabine</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b>, with or without <b style='color:Tomato;'><i>cisplatin</i></b>, and the combination of <b style='color:Tomato;'><i>ifosfamide</i></b>, <b style='color:Tomato;'><i>paclitaxel</i></b>, and <b style='color:Tomato;'><i>cisplatin</i></b>. The triple combination of <b style='color:Tomato;'><i>gemcitabine</i></b>, <b style='color:Tomato;'><i>paclitaxel</i></b>, and <b style='color:Tomato;'><i>cisplatin</i></b> has yielded an OR rate of 78%, a CR rate of 28%, and a median survival of 24 months. An international phase III trial comparing this triple combination with GC in patients with locally advanced and metastatic urothelial cancer has now been initiated.","tokens":[{"text":"Paclitaxel","start":0,"end":10,"id":0,"ws":true},{"text":"and","start":11,"end":14,"id":1,"ws":true},{"text":"docetaxel","start":15,"end":24,"id":2,"ws":true},{"text":"as","start":25,"end":27,"id":3,"ws":true},{"text":"single","start":28,"end":34,"id":4,"ws":true},{"text":"agents","start":35,"end":41,"id":5,"ws":true},{"text":"have","start":42,"end":46,"id":6,"ws":true},{"text":"yielded","start":47,"end":54,"id":7,"ws":true},{"text":"overall","start":55,"end":62,"id":8,"ws":true},{"text":"response","start":63,"end":71,"id":9,"ws":true},{"text":"rates","start":72,"end":77,"id":10,"ws":true},{"text":"of","start":78,"end":80,"id":11,"ws":true},{"text":"7","start":81,"end":82,"id":12,"ws":true},{"text":"%","start":83,"end":84,"id":13,"ws":true},{"text":"to","start":85,"end":87,"id":14,"ws":true},{"text":"56","start":88,"end":90,"id":15,"ws":true},{"text":"%","start":91,"end":92,"id":16,"ws":true},{"text":",","start":93,"end":94,"id":17,"ws":true},{"text":"depending","start":95,"end":104,"id":18,"ws":true},{"text":"on","start":105,"end":107,"id":19,"ws":true},{"text":"whether","start":108,"end":115,"id":20,"ws":true},{"text":"the","start":116,"end":119,"id":21,"ws":true},{"text":"patients","start":120,"end":128,"id":22,"ws":true},{"text":"have","start":129,"end":133,"id":23,"ws":true},{"text":"received","start":134,"end":142,"id":24,"ws":true},{"text":"prior","start":143,"end":148,"id":25,"ws":true},{"text":"chemotherapy","start":149,"end":161,"id":26,"ws":true},{"text":"for","start":162,"end":165,"id":27,"ws":true},{"text":"metastatic","start":166,"end":176,"id":28,"ws":true},{"text":"disease","start":177,"end":184,"id":29,"ws":true},{"text":".","start":185,"end":186,"id":30,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":15,"end":24,"token_start":2,"token_end":2,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/11894002/","_input_hash":120739995,"_task_hash":-239446350,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The most effective treatment regimens for advanced nonseminomatous testicular tumors employ vinblastine , CDDP and bleomycin and adjunctive surgery .","paragraph":"<h3><u>[Preoperative chemotherapy of testicular cancer and Wilm's tumor].</u></h3>Of the various urogenital malignancies, preoperative chemotherapy is most effective for testicular cancer and Wilms' tumor. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>most</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>nonseminomatous</i></b> <b style='color:DodgerBlue;'><i>testicular</i></b> <b style='color:DodgerBlue;'><i>tumors</i></b> <b style='color:DodgerBlue;'><i>employ</i></b> <b style='color:MediumOrchid;'><i>vinblastine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>CDDP</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bleomycin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>adjunctive</i></b> <b style='color:DodgerBlue;'><i>surgery</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Another effective chemotherapy regimen is combination of <b style='color:Tomato;'><i>vinblastine</i></b>, actinomycin D, <b style='color:Tomato;'><i>bleomycin</i></b>, <b style='color:Tomato;'><i>cyclophosphamide</i></b> and CDDP presented by MSKCC. Available pretreatment with 4 courses of platinum, <b style='color:Tomato;'><i>vinblastine</i></b> and <b style='color:Tomato;'><i>bleomycin</i></b> before any surgical treatment in those with massive bulk metastatic disease seems to provide the most effective cytoreduction and best survival. Donohue has shown that in a primary chemotherapy group, there is only 20% active carcinoma after primary chemotherapy, whereas in a salvage chemotherapy group there is approximately 50% active carcinoma at surgery. It must therefore be emphasized that complete remission should be obtained by primary chemotherapy and adjunctive surgery. In Wilms' tumor preoperative chemotherapy with <b style='color:Tomato;'><i>vincristine</i></b> and actinomycin D should be given.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"most","start":4,"end":8,"id":1,"ws":true},{"text":"effective","start":9,"end":18,"id":2,"ws":true},{"text":"treatment","start":19,"end":28,"id":3,"ws":true},{"text":"regimens","start":29,"end":37,"id":4,"ws":true},{"text":"for","start":38,"end":41,"id":5,"ws":true},{"text":"advanced","start":42,"end":50,"id":6,"ws":true},{"text":"nonseminomatous","start":51,"end":66,"id":7,"ws":true},{"text":"testicular","start":67,"end":77,"id":8,"ws":true},{"text":"tumors","start":78,"end":84,"id":9,"ws":true},{"text":"employ","start":85,"end":91,"id":10,"ws":true},{"text":"vinblastine","start":92,"end":103,"id":11,"ws":true},{"text":",","start":104,"end":105,"id":12,"ws":true},{"text":"CDDP","start":106,"end":110,"id":13,"ws":true},{"text":"and","start":111,"end":114,"id":14,"ws":true},{"text":"bleomycin","start":115,"end":124,"id":15,"ws":true},{"text":"and","start":125,"end":128,"id":16,"ws":true},{"text":"adjunctive","start":129,"end":139,"id":17,"ws":true},{"text":"surgery","start":140,"end":147,"id":18,"ws":true},{"text":".","start":148,"end":149,"id":19,"ws":false}],"spans":[{"start":92,"end":103,"token_start":11,"token_end":11,"label":"DRUG"},{"start":115,"end":124,"token_start":15,"token_end":15,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/2581512/","_input_hash":1927771666,"_task_hash":-259598406,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":11,"child":15,"head_span":{"start":92,"end":103,"token_start":11,"token_end":11,"label":"DRUG"},"child_span":{"start":115,"end":124,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"27 patients suffering from disseminated carcinoma of the breast with at least two visceral metastases , and two had become resistant to conventional chemotherpy and hormones , received a combination of , in the present trial , vincristine followed by cyclophosphamide with 5-fluoro-uracil .","paragraph":"<h3><u>[Chemotherapeutic combinations of mutually potentializing drugs. 1-Application to the treatment of breast cancers].</u></h3> <b style='color:DodgerBlue;'><i>27</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>suffering</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>disseminated</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>least</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>visceral</i></b> <b style='color:DodgerBlue;'><i>metastases</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>become</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>conventional</i></b> <b style='color:DodgerBlue;'><i>chemotherpy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>hormones</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>5-fluoro-uracil</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Chemotherapy was administered intermittently: each cycle of treatment lasted 6 days and was followed by a period without treatment of 25 days. Haematological tolerance was satisfactory. No serious incidents occurred during two years use of the combination. 20 out of 27 patients showed objective tumour regression of more than 50 p.cent lasting for more than 6 months, whilst 9 showed apparent complete regression of the malignant lesions. There was one complete failure. Chemotherapy was continued in all cases after regression of the neoplastic process was obtained.","tokens":[{"text":"27","start":0,"end":2,"id":0,"ws":true},{"text":"patients","start":3,"end":11,"id":1,"ws":true},{"text":"suffering","start":12,"end":21,"id":2,"ws":true},{"text":"from","start":22,"end":26,"id":3,"ws":true},{"text":"disseminated","start":27,"end":39,"id":4,"ws":true},{"text":"carcinoma","start":40,"end":49,"id":5,"ws":true},{"text":"of","start":50,"end":52,"id":6,"ws":true},{"text":"the","start":53,"end":56,"id":7,"ws":true},{"text":"breast","start":57,"end":63,"id":8,"ws":true},{"text":"with","start":64,"end":68,"id":9,"ws":true},{"text":"at","start":69,"end":71,"id":10,"ws":true},{"text":"least","start":72,"end":77,"id":11,"ws":true},{"text":"two","start":78,"end":81,"id":12,"ws":true},{"text":"visceral","start":82,"end":90,"id":13,"ws":true},{"text":"metastases","start":91,"end":101,"id":14,"ws":true},{"text":",","start":102,"end":103,"id":15,"ws":true},{"text":"and","start":104,"end":107,"id":16,"ws":true},{"text":"two","start":108,"end":111,"id":17,"ws":true},{"text":"had","start":112,"end":115,"id":18,"ws":true},{"text":"become","start":116,"end":122,"id":19,"ws":true},{"text":"resistant","start":123,"end":132,"id":20,"ws":true},{"text":"to","start":133,"end":135,"id":21,"ws":true},{"text":"conventional","start":136,"end":148,"id":22,"ws":true},{"text":"chemotherpy","start":149,"end":160,"id":23,"ws":true},{"text":"and","start":161,"end":164,"id":24,"ws":true},{"text":"hormones","start":165,"end":173,"id":25,"ws":true},{"text":",","start":174,"end":175,"id":26,"ws":true},{"text":"received","start":176,"end":184,"id":27,"ws":true},{"text":"a","start":185,"end":186,"id":28,"ws":true},{"text":"combination","start":187,"end":198,"id":29,"ws":true},{"text":"of","start":199,"end":201,"id":30,"ws":true},{"text":",","start":202,"end":203,"id":31,"ws":true},{"text":"in","start":204,"end":206,"id":32,"ws":true},{"text":"the","start":207,"end":210,"id":33,"ws":true},{"text":"present","start":211,"end":218,"id":34,"ws":true},{"text":"trial","start":219,"end":224,"id":35,"ws":true},{"text":",","start":225,"end":226,"id":36,"ws":true},{"text":"vincristine","start":227,"end":238,"id":37,"ws":true},{"text":"followed","start":239,"end":247,"id":38,"ws":true},{"text":"by","start":248,"end":250,"id":39,"ws":true},{"text":"cyclophosphamide","start":251,"end":267,"id":40,"ws":true},{"text":"with","start":268,"end":272,"id":41,"ws":true},{"text":"5-fluoro-uracil","start":273,"end":288,"id":42,"ws":true},{"text":".","start":289,"end":290,"id":43,"ws":false}],"spans":[{"start":227,"end":238,"token_start":37,"token_end":37,"label":"DRUG"},{"start":251,"end":267,"token_start":40,"token_end":40,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/1129034/","_input_hash":355587438,"_task_hash":-1711097268,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":37,"child":40,"head_span":{"start":227,"end":238,"token_start":37,"token_end":37,"label":"DRUG"},"child_span":{"start":251,"end":267,"token_start":40,"token_end":40,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":40,"child":42,"head_span":{"start":251,"end":267,"token_start":40,"token_end":40,"label":"DRUG"},"child_span":{"start":273,"end":288,"token_start":42,"token_end":42,"label":null},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"We previously demonstrated that the combination of oral estramustine ( 15 mg/kg/day ) and oral etoposide ( 50 mg/m2/day ) is effective first-line therapy for the treatment of hormone refractory prostate cancer .","paragraph":"<h3><u>A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer.</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>previously</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>estramustine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>15</i></b> <b style='color:DodgerBlue;'><i>mg/kg/day</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>mg/m2/day</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>hormone</i></b> <b style='color:DodgerBlue;'><i>refractory</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We initiated a new Phase II trial utilizing a lower dose of <b style='color:Tomato;'><i>estramustine</i></b> (10 mg/kg/day) and allowing previous chemotherapy treatment. ### methods <b style='color:Tomato;'><i>estramustine</i></b> (10 mg/kg/day) and <b style='color:Tomato;'><i>etoposide</i></b> (50 mg/m2/day) were administered orally for 21 of 28 days. Sixty-two patients were enrolled with a minimum of 26 weeks of follow-up. ### results Of 15 patients with measurable soft tissue disease, 8 (53%) had a partial response (PR). Seven of these 8 patients also demonstrated a decrease in baseline prostate-specific antigen (PSA) of more than 50%. The median survival of all patients was 56 weeks. Of 47 patients with disease limited to the bone, 16 (34%) had a PR to therapy based on decrease in pretreatment PSA of more than 50%. Overall, 24 (39%) of 62 patients demonstrated a decrease in pretreatment PSA levels of at least 50% from baseline. Twenty-two patients received previous chemotherapy. There were no differences in survival or disease response in patients treated with previous chemotherapy compared with untreated patients. Pretreatment hemoglobin, PSA, alkaline phosphatase and lactate dehydrogenase levels were not significant prognostic factors, but performance status was an important predictor of survival. ### conclusions We conclude that the combination of oral <b style='color:Tomato;'><i>estramustine</i></b> (10 mg/kg/day) and oral <b style='color:Tomato;'><i>etoposide</i></b> (50 mg/m2/day) is an active regimen for hormone refractory prostate cancer.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"previously","start":3,"end":13,"id":1,"ws":true},{"text":"demonstrated","start":14,"end":26,"id":2,"ws":true},{"text":"that","start":27,"end":31,"id":3,"ws":true},{"text":"the","start":32,"end":35,"id":4,"ws":true},{"text":"combination","start":36,"end":47,"id":5,"ws":true},{"text":"of","start":48,"end":50,"id":6,"ws":true},{"text":"oral","start":51,"end":55,"id":7,"ws":true},{"text":"estramustine","start":56,"end":68,"id":8,"ws":true},{"text":"(","start":69,"end":70,"id":9,"ws":true},{"text":"15","start":71,"end":73,"id":10,"ws":true},{"text":"mg/kg/day","start":74,"end":83,"id":11,"ws":true},{"text":")","start":84,"end":85,"id":12,"ws":true},{"text":"and","start":86,"end":89,"id":13,"ws":true},{"text":"oral","start":90,"end":94,"id":14,"ws":true},{"text":"etoposide","start":95,"end":104,"id":15,"ws":true},{"text":"(","start":105,"end":106,"id":16,"ws":true},{"text":"50","start":107,"end":109,"id":17,"ws":true},{"text":"mg/m2/day","start":110,"end":119,"id":18,"ws":true},{"text":")","start":120,"end":121,"id":19,"ws":true},{"text":"is","start":122,"end":124,"id":20,"ws":true},{"text":"effective","start":125,"end":134,"id":21,"ws":true},{"text":"first-line","start":135,"end":145,"id":22,"ws":true},{"text":"therapy","start":146,"end":153,"id":23,"ws":true},{"text":"for","start":154,"end":157,"id":24,"ws":true},{"text":"the","start":158,"end":161,"id":25,"ws":true},{"text":"treatment","start":162,"end":171,"id":26,"ws":true},{"text":"of","start":172,"end":174,"id":27,"ws":true},{"text":"hormone","start":175,"end":182,"id":28,"ws":true},{"text":"refractory","start":183,"end":193,"id":29,"ws":true},{"text":"prostate","start":194,"end":202,"id":30,"ws":true},{"text":"cancer","start":203,"end":209,"id":31,"ws":true},{"text":".","start":210,"end":211,"id":32,"ws":false}],"spans":[{"start":56,"end":68,"token_start":8,"token_end":8,"label":"DRUG"},{"start":95,"end":104,"token_start":15,"token_end":15,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9301705/","_input_hash":769126920,"_task_hash":-953504087,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":8,"child":15,"head_span":{"start":56,"end":68,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":95,"end":104,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Therapy consisted of bendamustine ( 70 mg/m(2 ) ) for 2 consecutive days every 28 days , and ofatumumab 300 mg on day 1 and 1000 mg on day 8 during the first cycle , and 1000 mg on day 1 subsequently .","paragraph":"<h3><u>Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial.</u></h3>We conducted a phase II, noncomparative, open-label, multicenter GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) study (CLL0809) to assess the efficacy and safety of <b style='color:Tomato;'><i>bendamustine</i></b> in combination with <b style='color:Tomato;'><i>ofatumumab</i></b> (BendOfa) in relapsed/refractory chronic lymphocytic leukemia (CLL). Forty-seven patients from 14 centers were evaluated. <b style='color:DodgerBlue;'><i>Therapy</i></b> <b style='color:DodgerBlue;'><i>consisted</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>bendamustine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>70</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>consecutive</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>28</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ofatumumab</i></b> <b style='color:DodgerBlue;'><i>300</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>1000</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>8</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>cycle</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>1000</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>subsequently</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Treatment was administered up to six cycles. The overall response rate (ORR), as per intention-to-treat analysis, was 72.3% (95% confidence of interval (CI), 57-84%), with 17% complete responses. After a median follow-up of 24.2 months, the overall survival was 83.6% (95% CI, 73.0-95.7%) and the progression-free survival (PFS) was 49.6% (95% CI, 35.9-68.6%). The median PFS was 23.6 months. Univariate and multivariate analyses were used to identify clinical and biological characteristics associated with ORR and PFS. Myelosuppression was the most common toxicity; grade \u22653 neutropenia was observed in 61.7% of patients; however, grade \u22653 infections occurred in 6% of patients. BendOfa is feasible and effective in relapsed/refractory CLL patients, including patients with high-risk clinical and biological features.","tokens":[{"text":"Therapy","start":0,"end":7,"id":0,"ws":true},{"text":"consisted","start":8,"end":17,"id":1,"ws":true},{"text":"of","start":18,"end":20,"id":2,"ws":true},{"text":"bendamustine","start":21,"end":33,"id":3,"ws":true},{"text":"(","start":34,"end":35,"id":4,"ws":true},{"text":"70","start":36,"end":38,"id":5,"ws":true},{"text":"mg/m(2","start":39,"end":45,"id":6,"ws":true},{"text":")","start":46,"end":47,"id":7,"ws":true},{"text":")","start":48,"end":49,"id":8,"ws":true},{"text":"for","start":50,"end":53,"id":9,"ws":true},{"text":"2","start":54,"end":55,"id":10,"ws":true},{"text":"consecutive","start":56,"end":67,"id":11,"ws":true},{"text":"days","start":68,"end":72,"id":12,"ws":true},{"text":"every","start":73,"end":78,"id":13,"ws":true},{"text":"28","start":79,"end":81,"id":14,"ws":true},{"text":"days","start":82,"end":86,"id":15,"ws":true},{"text":",","start":87,"end":88,"id":16,"ws":true},{"text":"and","start":89,"end":92,"id":17,"ws":true},{"text":"ofatumumab","start":93,"end":103,"id":18,"ws":true},{"text":"300","start":104,"end":107,"id":19,"ws":true},{"text":"mg","start":108,"end":110,"id":20,"ws":true},{"text":"on","start":111,"end":113,"id":21,"ws":true},{"text":"day","start":114,"end":117,"id":22,"ws":true},{"text":"1","start":118,"end":119,"id":23,"ws":true},{"text":"and","start":120,"end":123,"id":24,"ws":true},{"text":"1000","start":124,"end":128,"id":25,"ws":true},{"text":"mg","start":129,"end":131,"id":26,"ws":true},{"text":"on","start":132,"end":134,"id":27,"ws":true},{"text":"day","start":135,"end":138,"id":28,"ws":true},{"text":"8","start":139,"end":140,"id":29,"ws":true},{"text":"during","start":141,"end":147,"id":30,"ws":true},{"text":"the","start":148,"end":151,"id":31,"ws":true},{"text":"first","start":152,"end":157,"id":32,"ws":true},{"text":"cycle","start":158,"end":163,"id":33,"ws":true},{"text":",","start":164,"end":165,"id":34,"ws":true},{"text":"and","start":166,"end":169,"id":35,"ws":true},{"text":"1000","start":170,"end":174,"id":36,"ws":true},{"text":"mg","start":175,"end":177,"id":37,"ws":true},{"text":"on","start":178,"end":180,"id":38,"ws":true},{"text":"day","start":181,"end":184,"id":39,"ws":true},{"text":"1","start":185,"end":186,"id":40,"ws":true},{"text":"subsequently","start":187,"end":199,"id":41,"ws":true},{"text":".","start":200,"end":201,"id":42,"ws":false}],"spans":[{"start":21,"end":33,"token_start":3,"token_end":3,"label":"DRUG"},{"start":93,"end":103,"token_start":18,"token_end":18,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/24220274/","_input_hash":-946523501,"_task_hash":648212012,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":3,"child":18,"head_span":{"start":21,"end":33,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":93,"end":103,"token_start":18,"token_end":18,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"All consecutive patients with advanced BTC received the GEMOX regimen in a setting outside a study : gemcitabine 1,000 mg/m(2 ) on day 1 , and oxaliplatin 100 mg/m(2 ) on day 2 , treatment repeated every 2 weeks until progression or unacceptable toxicity .","paragraph":"<h3><u>Experience of gemcitabine plus oxaliplatin chemotherapy in patients with advanced biliary tract carcinoma.</u></h3>The combination <b style='color:Tomato;'><i>gemcitabine</i></b>-<b style='color:Tomato;'><i>oxaliplatin</i></b> (GEMOX) is frequently used in patients with advanced biliary tract carcinoma (BTC). However, this is only based on phase II studies performed in selected patients.We assessed the efficacy and safety of the GEMOX regimen in non-selected patients with advanced BTC. ### methods <b style='color:DodgerBlue;'><i>All</i></b> <b style='color:DodgerBlue;'><i>consecutive</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>BTC</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>GEMOX</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>setting</i></b> <b style='color:DodgerBlue;'><i>outside</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>1,000</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>repeated</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>until</i></b> <b style='color:DodgerBlue;'><i>progression</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>unacceptable</i></b> <b style='color:DodgerBlue;'><i>toxicity</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results Forty-four patients were enrolled. ### efficacy 1 complete and 6 partial responses (objective response rate = 16.3%), 18 tumour stabilizations (41.9%, disease control rate = 58.1%), median progression-free survival was 5.0 months and median overall survival was 11.0 months. ### toxicity grade 3 neuropathy in 4 patients, grade 3 asthenia in 5 patients. ### conclusion The GEMOX combination was well tolerated, with a modest activity in non-selected patients with advanced BTC. This regimen should be compared to the new standard <b style='color:Tomato;'><i>gemcitabine</i></b>-<b style='color:Tomato;'><i>cisplatin</i></b> combination.","tokens":[{"text":"All","start":0,"end":3,"id":0,"ws":true},{"text":"consecutive","start":4,"end":15,"id":1,"ws":true},{"text":"patients","start":16,"end":24,"id":2,"ws":true},{"text":"with","start":25,"end":29,"id":3,"ws":true},{"text":"advanced","start":30,"end":38,"id":4,"ws":true},{"text":"BTC","start":39,"end":42,"id":5,"ws":true},{"text":"received","start":43,"end":51,"id":6,"ws":true},{"text":"the","start":52,"end":55,"id":7,"ws":true},{"text":"GEMOX","start":56,"end":61,"id":8,"ws":true},{"text":"regimen","start":62,"end":69,"id":9,"ws":true},{"text":"in","start":70,"end":72,"id":10,"ws":true},{"text":"a","start":73,"end":74,"id":11,"ws":true},{"text":"setting","start":75,"end":82,"id":12,"ws":true},{"text":"outside","start":83,"end":90,"id":13,"ws":true},{"text":"a","start":91,"end":92,"id":14,"ws":true},{"text":"study","start":93,"end":98,"id":15,"ws":true},{"text":":","start":99,"end":100,"id":16,"ws":true},{"text":"gemcitabine","start":101,"end":112,"id":17,"ws":true},{"text":"1,000","start":113,"end":118,"id":18,"ws":true},{"text":"mg/m(2","start":119,"end":125,"id":19,"ws":true},{"text":")","start":126,"end":127,"id":20,"ws":true},{"text":"on","start":128,"end":130,"id":21,"ws":true},{"text":"day","start":131,"end":134,"id":22,"ws":true},{"text":"1","start":135,"end":136,"id":23,"ws":true},{"text":",","start":137,"end":138,"id":24,"ws":true},{"text":"and","start":139,"end":142,"id":25,"ws":true},{"text":"oxaliplatin","start":143,"end":154,"id":26,"ws":true},{"text":"100","start":155,"end":158,"id":27,"ws":true},{"text":"mg/m(2","start":159,"end":165,"id":28,"ws":true},{"text":")","start":166,"end":167,"id":29,"ws":true},{"text":"on","start":168,"end":170,"id":30,"ws":true},{"text":"day","start":171,"end":174,"id":31,"ws":true},{"text":"2","start":175,"end":176,"id":32,"ws":true},{"text":",","start":177,"end":178,"id":33,"ws":true},{"text":"treatment","start":179,"end":188,"id":34,"ws":true},{"text":"repeated","start":189,"end":197,"id":35,"ws":true},{"text":"every","start":198,"end":203,"id":36,"ws":true},{"text":"2","start":204,"end":205,"id":37,"ws":true},{"text":"weeks","start":206,"end":211,"id":38,"ws":true},{"text":"until","start":212,"end":217,"id":39,"ws":true},{"text":"progression","start":218,"end":229,"id":40,"ws":true},{"text":"or","start":230,"end":232,"id":41,"ws":true},{"text":"unacceptable","start":233,"end":245,"id":42,"ws":true},{"text":"toxicity","start":246,"end":254,"id":43,"ws":true},{"text":".","start":255,"end":256,"id":44,"ws":false}],"spans":[{"start":101,"end":112,"token_start":17,"token_end":17,"label":"DRUG"},{"start":143,"end":154,"token_start":26,"token_end":26,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/20551640/","_input_hash":1963669052,"_task_hash":462076968,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":17,"child":26,"head_span":{"start":101,"end":112,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":143,"end":154,"token_start":26,"token_end":26,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Recent randomized controlled trials ( RCT ) have failed to demonstrate the efficacy of widely used therapies , such as rituximab plus intravenous immunoglobulin or proteasome inhibition ( bortezomib ) , reinforcing a great need for new therapeutic concepts .","paragraph":"<h3><u>Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial.</u></h3>Late antibody-mediated rejection (ABMR) triggered by donor-specific antibodies (DSA) is a cardinal cause of kidney allograft dysfunction and loss. Diagnostic criteria for this rejection type are well established, but effective treatment remains a major challenge. <b style='color:DodgerBlue;'><i>Recent</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>controlled</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>RCT</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>failed</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>demonstrate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>widely</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:DodgerBlue;'><i>immunoglobulin</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>proteasome</i></b> <b style='color:DodgerBlue;'><i>inhibition</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>bortezomib</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>reinforcing</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>great</i></b> <b style='color:DodgerBlue;'><i>need</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>new</i></b> <b style='color:DodgerBlue;'><i>therapeutic</i></b> <b style='color:DodgerBlue;'><i>concepts</i></b> <b style='color:DodgerBlue;'><i>.</i></b> One promising target in this context may be interleukin-6 (IL-6), a pleiotropic cytokine known to play an important role in inflammation and adaptive immunity. ### methods This investigator-driven RCT was designed to assess the safety and efficacy of <b style='color:Tomato;'><i>clazakizumab</i></b>, a genetically engineered humanized monoclonal antibody directed against IL-6. The study will include 20 DSA-positive kidney allograft recipients diagnosed with ABMR \u2265\u2009365\u2009days after transplantation. Participants will be recruited at two study sites in Austria and Germany (Medical University of Vienna; Charit\u00e9 University Medicine Berlin). First, patients will enter a three-month double-blind RCT (1,1 randomization, stratification according to ABMR phenotype and study site) and will receive either <b style='color:Tomato;'><i>clazakizumab</i></b> (subcutaneous administration of 25\u2009mg in monthly intervals) or placebo. In a second open-label part of the trial (months 4-12), all patients will receive <b style='color:Tomato;'><i>clazakizumab</i></b> at 25\u2009mg every month. The primary endpoint is safety and tolerability. Secondary endpoints are the pharmacokinetics and pharmacodynamics of <b style='color:Tomato;'><i>clazakizumab</i></b>, its effect on drug metabolism in the liver, DSA characteristics, morphological ABMR lesions and molecular gene expression patterns in three- and 12-month protocol biopsies, serum/urinary biomarkers of inflammation and endothelial activation/injury, Torque Teno viral load as a measure of overall immunosuppression, kidney function, urinary protein excretion, as well as transplant and patient survival. ### discussion Currently, there is no treatment proven to be effective in halting the progression of late ABMR. Based on the hypothesis that antagonizing the effects of IL-6 improves the outcome of DSA-positive late ABMR by counteracting DSA-triggered inflammation and B cell/plasma cell-driven alloimmunity, we suggest that our trial has the potential to provide proof of concept of a novel treatment of this type of rejection. ### Trial Registration ClinicalTrials.gov, NCT03444103 . Registered on 23 February 2018 (retrospective registration).","tokens":[{"text":"Recent","start":0,"end":6,"id":0,"ws":true},{"text":"randomized","start":7,"end":17,"id":1,"ws":true},{"text":"controlled","start":18,"end":28,"id":2,"ws":true},{"text":"trials","start":29,"end":35,"id":3,"ws":true},{"text":"(","start":36,"end":37,"id":4,"ws":true},{"text":"RCT","start":38,"end":41,"id":5,"ws":true},{"text":")","start":42,"end":43,"id":6,"ws":true},{"text":"have","start":44,"end":48,"id":7,"ws":true},{"text":"failed","start":49,"end":55,"id":8,"ws":true},{"text":"to","start":56,"end":58,"id":9,"ws":true},{"text":"demonstrate","start":59,"end":70,"id":10,"ws":true},{"text":"the","start":71,"end":74,"id":11,"ws":true},{"text":"efficacy","start":75,"end":83,"id":12,"ws":true},{"text":"of","start":84,"end":86,"id":13,"ws":true},{"text":"widely","start":87,"end":93,"id":14,"ws":true},{"text":"used","start":94,"end":98,"id":15,"ws":true},{"text":"therapies","start":99,"end":108,"id":16,"ws":true},{"text":",","start":109,"end":110,"id":17,"ws":true},{"text":"such","start":111,"end":115,"id":18,"ws":true},{"text":"as","start":116,"end":118,"id":19,"ws":true},{"text":"rituximab","start":119,"end":128,"id":20,"ws":true},{"text":"plus","start":129,"end":133,"id":21,"ws":true},{"text":"intravenous","start":134,"end":145,"id":22,"ws":true},{"text":"immunoglobulin","start":146,"end":160,"id":23,"ws":true},{"text":"or","start":161,"end":163,"id":24,"ws":true},{"text":"proteasome","start":164,"end":174,"id":25,"ws":true},{"text":"inhibition","start":175,"end":185,"id":26,"ws":true},{"text":"(","start":186,"end":187,"id":27,"ws":true},{"text":"bortezomib","start":188,"end":198,"id":28,"ws":true},{"text":")","start":199,"end":200,"id":29,"ws":true},{"text":",","start":201,"end":202,"id":30,"ws":true},{"text":"reinforcing","start":203,"end":214,"id":31,"ws":true},{"text":"a","start":215,"end":216,"id":32,"ws":true},{"text":"great","start":217,"end":222,"id":33,"ws":true},{"text":"need","start":223,"end":227,"id":34,"ws":true},{"text":"for","start":228,"end":231,"id":35,"ws":true},{"text":"new","start":232,"end":235,"id":36,"ws":true},{"text":"therapeutic","start":236,"end":247,"id":37,"ws":true},{"text":"concepts","start":248,"end":256,"id":38,"ws":true},{"text":".","start":257,"end":258,"id":39,"ws":false}],"spans":[{"start":119,"end":128,"token_start":20,"token_end":20,"label":"DRUG"},{"start":134,"end":160,"token_start":22,"token_end":23,"label":"DRUG"},{"start":188,"end":198,"token_start":28,"token_end":28,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30635033/","_input_hash":-623695755,"_task_hash":-1489410173,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":20,"child":23,"head_span":{"start":119,"end":128,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":134,"end":160,"token_start":22,"token_end":23,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":20,"child":28,"head_span":{"start":119,"end":128,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":188,"end":198,"token_start":28,"token_end":28,"label":"DRUG"},"color":"#ffdaf9","label":"NEG2"}],"radio":["NEG10","NEG20"],"answer":"accept"}
{"text":"The aim of this study was to find an experimental model of a donor-recipient rat strain combination that , under triple drug immunosuppressive treatment ( methylprednisolone , cyclosporine , and azathioprine ) , would develop chronic rejection within a few weeks .","paragraph":"<h3><u>An experimental model of chronic renal allograft rejection in the rat using triple drug immunosuppression.</u></h3>Chronic rejection is a major problem in renal transplantation. Various experimental models have been developed to study vasculopathy of chronic rejection. However, animal models resembling the clinical situation of renal transplantation with combination therapy of basic immunosuppression are not available. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>aim</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>find</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>experimental</i></b> <b style='color:DodgerBlue;'><i>model</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>donor-recipient</i></b> <b style='color:DodgerBlue;'><i>rat</i></b> <b style='color:DodgerBlue;'><i>strain</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>under</i></b> <b style='color:DodgerBlue;'><i>triple</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>immunosuppressive</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>methylprednisolone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclosporine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>azathioprine</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>would</i></b> <b style='color:DodgerBlue;'><i>develop</i></b> <b style='color:DodgerBlue;'><i>chronic</i></b> <b style='color:DodgerBlue;'><i>rejection</i></b> <b style='color:DodgerBlue;'><i>within</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>few</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods Renal transplantations were performed in strain combinations of DA-->AO, PVG-->BN, and DA-->BN. In each group, 5-8 animals received triple drug treatment of <b style='color:Tomato;'><i>methyl<b style='color:Tomato;'><i>prednisolone</i></b></i></b> (2 mg/kg), <b style='color:Tomato;'><i>azathioprine</i></b> (2 mg/kg), and <b style='color:Tomato;'><i>cyclosporin</i></b>e (5 mg/kg) daily, 5-10 animals were left without treatment, and 6 syngenic transplantations were performed. The grafts were monitored with ultrasound-guided fine needle aspiration biopsies to quantify the inflammation in the graft. Graft histology was performed in parallel and quantified by using the chronic allograft damage index (CADI). ### results In nonimmunosuppressed animals, irreversible acute rejection with a high peak of inflammation appeared in every strain combination within 5-8 days. In triple drug-treated rats, the DA-->AO combination demonstrated a prolonged acute rejection but no characteristic chronic changes, and the PVG-->BN combination showed practically no inflammation and did not develop any signs of chronic rejection within 60 days (CADI: 2.7+/-2.1), but the DA-->BN combination showed an early, mild inflammatory response 5-7 days after transplantation and developed chronic rejection within 40-60 days after transplantation (CADI: 7.9+/-3.1). Syngenic animals showed no inflammation or histological alterations (CADI: 1.7+/-2.0). ### conclusions In conclusion, in the DA-->BN combination with triple drug treatment, early mild inflammation was followed by the development of chronic rejection and can be used as an experimental model that resembles the clinical situation in renal transplantation.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"aim","start":4,"end":7,"id":1,"ws":true},{"text":"of","start":8,"end":10,"id":2,"ws":true},{"text":"this","start":11,"end":15,"id":3,"ws":true},{"text":"study","start":16,"end":21,"id":4,"ws":true},{"text":"was","start":22,"end":25,"id":5,"ws":true},{"text":"to","start":26,"end":28,"id":6,"ws":true},{"text":"find","start":29,"end":33,"id":7,"ws":true},{"text":"an","start":34,"end":36,"id":8,"ws":true},{"text":"experimental","start":37,"end":49,"id":9,"ws":true},{"text":"model","start":50,"end":55,"id":10,"ws":true},{"text":"of","start":56,"end":58,"id":11,"ws":true},{"text":"a","start":59,"end":60,"id":12,"ws":true},{"text":"donor-recipient","start":61,"end":76,"id":13,"ws":true},{"text":"rat","start":77,"end":80,"id":14,"ws":true},{"text":"strain","start":81,"end":87,"id":15,"ws":true},{"text":"combination","start":88,"end":99,"id":16,"ws":true},{"text":"that","start":100,"end":104,"id":17,"ws":true},{"text":",","start":105,"end":106,"id":18,"ws":true},{"text":"under","start":107,"end":112,"id":19,"ws":true},{"text":"triple","start":113,"end":119,"id":20,"ws":true},{"text":"drug","start":120,"end":124,"id":21,"ws":true},{"text":"immunosuppressive","start":125,"end":142,"id":22,"ws":true},{"text":"treatment","start":143,"end":152,"id":23,"ws":true},{"text":"(","start":153,"end":154,"id":24,"ws":true},{"text":"methylprednisolone","start":155,"end":173,"id":25,"ws":true},{"text":",","start":174,"end":175,"id":26,"ws":true},{"text":"cyclosporine","start":176,"end":188,"id":27,"ws":true},{"text":",","start":189,"end":190,"id":28,"ws":true},{"text":"and","start":191,"end":194,"id":29,"ws":true},{"text":"azathioprine","start":195,"end":207,"id":30,"ws":true},{"text":")","start":208,"end":209,"id":31,"ws":true},{"text":",","start":210,"end":211,"id":32,"ws":true},{"text":"would","start":212,"end":217,"id":33,"ws":true},{"text":"develop","start":218,"end":225,"id":34,"ws":true},{"text":"chronic","start":226,"end":233,"id":35,"ws":true},{"text":"rejection","start":234,"end":243,"id":36,"ws":true},{"text":"within","start":244,"end":250,"id":37,"ws":true},{"text":"a","start":251,"end":252,"id":38,"ws":true},{"text":"few","start":253,"end":256,"id":39,"ws":true},{"text":"weeks","start":257,"end":262,"id":40,"ws":true},{"text":".","start":263,"end":264,"id":41,"ws":false}],"spans":[{"start":155,"end":173,"token_start":25,"token_end":25,"label":"DRUG"},{"start":176,"end":188,"token_start":27,"token_end":27,"label":"DRUG"},{"start":195,"end":207,"token_start":30,"token_end":30,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9448142/","_input_hash":-1433669124,"_task_hash":-654271239,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":25,"child":27,"head_span":{"start":155,"end":173,"token_start":25,"token_end":25,"label":"DRUG"},"child_span":{"start":176,"end":188,"token_start":27,"token_end":27,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":27,"child":30,"head_span":{"start":176,"end":188,"token_start":27,"token_end":27,"label":"DRUG"},"child_span":{"start":195,"end":207,"token_start":30,"token_end":30,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"In FOLL05 trial , R-CHOP was compared with R-CVP ( cyclophosphamide , vincristine , prednisone ) and R-FM ( fludarabine , mitoxantrone ) .","paragraph":"<h3><u>Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting.</u></h3>Indolent lymphoma (IL), the second most common lymphoma, remains incurable with chemotherapy alone. While R-CHOP (<b style='color:Tomato;'><i>rituximab</i></b>, <b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>vincristine</i></b>, <b style='color:Tomato;'><i>prednisone</i></b>) remains the standard frontline regimen for diffuse Large B -cell lymphoma, the optimal chemotherapy regimen for frontline therapy of advanced IL remains uncertain. FCR (<b style='color:Tomato;'><i>fludarabine</i></b>, <b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>rituximab</i></b>) has been shown to be better than <b style='color:Tomato;'><i>fludarabine</i></b> alone and <b style='color:Tomato;'><i>fludarabine</i></b> plus <b style='color:Tomato;'><i>cyclophosphamide</i></b> for IL. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>FOLL05</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>R-CHOP</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>R-CVP</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>R-FM</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>fludarabine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>mitoxantrone</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The study showed that R-CHOP appears to have the best risk-benefit ratio for IL. The StiL NHL1 trial showed that BR (<b style='color:Tomato;'><i>bendamustine</i></b>, <b style='color:Tomato;'><i>rituximab</i></b>) has longer progression free survival and is better tolerated than R-CHOP. Long-term complications with secondary malignancies between the two regimens appear to be comparable. In this review, new combination regimens reported at 2012 ASCO annual meeting were evaluated for frontline and salvage therapy of indolent lymphoma.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"FOLL05","start":3,"end":9,"id":1,"ws":true},{"text":"trial","start":10,"end":15,"id":2,"ws":true},{"text":",","start":16,"end":17,"id":3,"ws":true},{"text":"R-CHOP","start":18,"end":24,"id":4,"ws":true},{"text":"was","start":25,"end":28,"id":5,"ws":true},{"text":"compared","start":29,"end":37,"id":6,"ws":true},{"text":"with","start":38,"end":42,"id":7,"ws":true},{"text":"R-CVP","start":43,"end":48,"id":8,"ws":true},{"text":"(","start":49,"end":50,"id":9,"ws":true},{"text":"cyclophosphamide","start":51,"end":67,"id":10,"ws":true},{"text":",","start":68,"end":69,"id":11,"ws":true},{"text":"vincristine","start":70,"end":81,"id":12,"ws":true},{"text":",","start":82,"end":83,"id":13,"ws":true},{"text":"prednisone","start":84,"end":94,"id":14,"ws":true},{"text":")","start":95,"end":96,"id":15,"ws":true},{"text":"and","start":97,"end":100,"id":16,"ws":true},{"text":"R-FM","start":101,"end":105,"id":17,"ws":true},{"text":"(","start":106,"end":107,"id":18,"ws":true},{"text":"fludarabine","start":108,"end":119,"id":19,"ws":true},{"text":",","start":120,"end":121,"id":20,"ws":true},{"text":"mitoxantrone","start":122,"end":134,"id":21,"ws":true},{"text":")","start":135,"end":136,"id":22,"ws":true},{"text":".","start":137,"end":138,"id":23,"ws":false}],"spans":[{"start":18,"end":24,"token_start":4,"token_end":4,"label":"DRUG"},{"start":51,"end":67,"token_start":10,"token_end":10,"label":"DRUG"},{"start":70,"end":81,"token_start":12,"token_end":12,"label":"DRUG"},{"start":84,"end":94,"token_start":14,"token_end":14,"label":"DRUG"},{"start":108,"end":119,"token_start":19,"token_end":19,"label":"DRUG"},{"start":122,"end":134,"token_start":21,"token_end":21,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22913602/","_input_hash":1595252911,"_task_hash":989709433,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":10,"child":12,"head_span":{"start":51,"end":67,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":70,"end":81,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":12,"child":14,"head_span":{"start":70,"end":81,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":84,"end":94,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":19,"child":21,"head_span":{"start":108,"end":119,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":122,"end":134,"token_start":21,"token_end":21,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"}],"radio":[],"answer":"accept"}
{"text":"All patients underwent 3 cycles of neoadjuvant gemcitabine , paclitaxel , and capecitabine .","paragraph":"<h3><u>Direct percutaneous transhepatic portomesenteric venous stenting in management of locally advanced pancreatic cancer.</u></h3>Pancreatectomy with portal and/or superior mesenteric vein resection remains a controversial procedure because of high complexity and morbidity. Neoadjuvant chemotherapy has been shown to increase resectability of these locally advanced lesions. We aimed to assess the utility and efficacy of direct percutaneous transhepatic portomesenteric venous stenting (THVS) with neoadjuvant chemotherapy in increasing surgical resectability of locally advanced pancreatic carcinoma. ### methods Forty pancreatic carcinoma patients with tumor thrombus involving the portal vein and superior mesenteric vein were identified. Patients underwent THVS followed by neoadjuvant chemotherapy. Whipple procedure was offered to responders. ### results THVS was attempted in all. The tumor thrombus could not be crossed in 2 patients (95% technical success rate). <b style='color:DodgerBlue;'><i>All</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>underwent</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>neoadjuvant</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Disease progression was noted in 16 patients and surgery was not offered. Twenty-two patients were explored with intent-to-perform a Whipple procedure. In 7 of these (32%), extensive disease precluding surgical resection was identified and the procedure was abandoned. Whipple procedure without vascular resection was performed successfully in 15 patients (68%). There were no perioperative deaths. Negative vascular margins were noted in 3 patients and negative peripancreatic lymph nodes in 5 patients. Median survival was 17 months (range, 5 to 70 mo). In the stented nonoperative group, median survival was 9 months (range, 3 to 19 mo). The stented and resected group achieved a statistically significant (P=0.0422) survival advantage. ### conclusions THVS in combination with neoadjuvant chemotherapy can increase tumor resectability and survival in a select group of locally advanced pancreatic cancer patients.","tokens":[{"text":"All","start":0,"end":3,"id":0,"ws":true},{"text":"patients","start":4,"end":12,"id":1,"ws":true},{"text":"underwent","start":13,"end":22,"id":2,"ws":true},{"text":"3","start":23,"end":24,"id":3,"ws":true},{"text":"cycles","start":25,"end":31,"id":4,"ws":true},{"text":"of","start":32,"end":34,"id":5,"ws":true},{"text":"neoadjuvant","start":35,"end":46,"id":6,"ws":true},{"text":"gemcitabine","start":47,"end":58,"id":7,"ws":true},{"text":",","start":59,"end":60,"id":8,"ws":true},{"text":"paclitaxel","start":61,"end":71,"id":9,"ws":true},{"text":",","start":72,"end":73,"id":10,"ws":true},{"text":"and","start":74,"end":77,"id":11,"ws":true},{"text":"capecitabine","start":78,"end":90,"id":12,"ws":true},{"text":".","start":91,"end":92,"id":13,"ws":false}],"spans":[{"start":47,"end":58,"token_start":7,"token_end":7,"label":"DRUG"},{"start":61,"end":71,"token_start":9,"token_end":9,"label":"DRUG"},{"start":78,"end":90,"token_start":12,"token_end":12,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/23608832/","_input_hash":652974832,"_task_hash":1577574596,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":7,"child":9,"head_span":{"start":47,"end":58,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":61,"end":71,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":12,"child":9,"head_span":{"start":78,"end":90,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":61,"end":71,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The aim of the present investigation was to study and characterize the effect of voriconazole on the fungicidal activity of amphotericin B.","paragraph":"<h3><u>Characterization of the inhibitory effect of voriconazole on the fungicidal activity of amphotericin B against Candida albicans in an in vitro kinetic model.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>aim</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>investigation</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>characterize</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>voriconazole</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>fungicidal</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>amphotericin</i></b> <b style='color:DodgerBlue;'><i>B.</i></b> ### methods Four strains of Candida albicans susceptible to <b style='color:Tomato;'><i>voriconazole</i></b> were exposed to <b style='color:Tomato;'><i>voriconazole</i></b> and <b style='color:Tomato;'><i>amphotericin</i></b> B, either alone, simultaneously or sequentially in an in vitro kinetic model. Bolus doses resulting in <b style='color:Tomato;'><i>voriconazole</i></b> and <b style='color:Tomato;'><i>amphotericin</i></b> B concentrations of 0.005-5 and 2.5 mg/L, respectively, were administered. Antifungal-containing RPMI 1640 was eliminated and replaced by a fresh medium using a peristaltic pump, with a flow rate adjusted to obtain the desired half-lives. With two drugs tested, a computer-controlled dosing pump compensated for differences in the elimination rates. Using static time-kill methodology, one C. albicans strain was exposed to 5 mg/L <b style='color:Tomato;'><i>voriconazole</i></b> for varying durations followed by 2.5 mg/L <b style='color:Tomato;'><i>amphotericin</i></b> B after three repeated washes of <b style='color:Tomato;'><i>voriconazole</i></b>. ### results <b style='color:Tomato;'><i>voriconazole</i></b> and <b style='color:Tomato;'><i>amphotericin</i></b> B treatment alone resulted in fungistatic and fungicidal activities, respectively. Simultaneous administration of <b style='color:Tomato;'><i>voriconazole</i></b> and <b style='color:Tomato;'><i>amphotericin</i></b> B resulted in fungicidal activity, whereas only fungistatic activity was observed when repeated doses of <b style='color:Tomato;'><i>amphotericin</i></b> B were administered sequentially after <b style='color:Tomato;'><i>voriconazole</i></b> at 24-96 h. The inhibition of the fungicidal activity of <b style='color:Tomato;'><i>amphotericin</i></b> B was <b style='color:Tomato;'><i>voriconazole</i></b> dose-dependent, but seemed to be recovered once the <b style='color:Tomato;'><i>voriconazole</i></b> concentration fell below the MIC. The fungicidal activity was quickly regained after the removal of <b style='color:Tomato;'><i>voriconazole</i></b>, irrespective of the duration of <b style='color:Tomato;'><i>voriconazole</i></b> pre-exposure. ### conclusions <b style='color:Tomato;'><i>voriconazole</i></b> inhibited the fungicidal effect of sequentially administered <b style='color:Tomato;'><i>amphotericin</i></b> B in a concentration- and time-dependent manner; the clinical significance of this needs further investigation.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"aim","start":4,"end":7,"id":1,"ws":true},{"text":"of","start":8,"end":10,"id":2,"ws":true},{"text":"the","start":11,"end":14,"id":3,"ws":true},{"text":"present","start":15,"end":22,"id":4,"ws":true},{"text":"investigation","start":23,"end":36,"id":5,"ws":true},{"text":"was","start":37,"end":40,"id":6,"ws":true},{"text":"to","start":41,"end":43,"id":7,"ws":true},{"text":"study","start":44,"end":49,"id":8,"ws":true},{"text":"and","start":50,"end":53,"id":9,"ws":true},{"text":"characterize","start":54,"end":66,"id":10,"ws":true},{"text":"the","start":67,"end":70,"id":11,"ws":true},{"text":"effect","start":71,"end":77,"id":12,"ws":true},{"text":"of","start":78,"end":80,"id":13,"ws":true},{"text":"voriconazole","start":81,"end":93,"id":14,"ws":true},{"text":"on","start":94,"end":96,"id":15,"ws":true},{"text":"the","start":97,"end":100,"id":16,"ws":true},{"text":"fungicidal","start":101,"end":111,"id":17,"ws":true},{"text":"activity","start":112,"end":120,"id":18,"ws":true},{"text":"of","start":121,"end":123,"id":19,"ws":true},{"text":"amphotericin","start":124,"end":136,"id":20,"ws":true},{"text":"B.","start":137,"end":139,"id":21,"ws":false}],"spans":[{"start":81,"end":93,"token_start":14,"token_end":14,"label":"DRUG"},{"start":124,"end":136,"token_start":20,"token_end":20,"label":"DRUG"},{"start":137,"end":139,"token_start":21,"token_end":21,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/18408237/","_input_hash":536835514,"_task_hash":1903509668,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":20,"child":21,"head_span":{"start":124,"end":136,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":137,"end":139,"token_start":21,"token_end":21,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":14,"child":20,"head_span":{"start":81,"end":93,"token_start":14,"token_end":14,"label":"DRUG"},"child_span":{"start":124,"end":136,"token_start":20,"token_end":20,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Dual Therapy with Aspirin and Cilostazol May Improve Platelet Aggregation in Noncardioembolic Stroke Patients : A Pilot Study .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Dual</i></b> <b style='color:DodgerBlue;'><i>Therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>Aspirin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Cilostazol</i></b> <b style='color:DodgerBlue;'><i>May</i></b> <b style='color:DodgerBlue;'><i>Improve</i></b> <b style='color:DodgerBlue;'><i>Platelet</i></b> <b style='color:DodgerBlue;'><i>Aggregation</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Noncardioembolic</i></b> <b style='color:DodgerBlue;'><i>Stroke</i></b> <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>Pilot</i></b> <b style='color:DodgerBlue;'><i>Study</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Objective Some previous studies have found clinical benefit of dual antiplatelet therapy with <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>cilostazol</i></b> for prevention of secondary stroke, but the physiological mechanism involved remains unknown. We aimed to clarify the effects of <b style='color:Tomato;'><i>aspirin</i></b>/<b style='color:Tomato;'><i>cilostazol</i></b> therapy on the platelet and endothelial functions of patients with acute noncardioembolic ischemic stroke, in comparison to patients who were treated with <b style='color:Tomato;'><i>aspirin</i></b> alone. Methods The present randomized prospective pilot study enrolled 24 patients within a week after the onset of noncardioembolic ischemic stroke. The patients were randomly allocated to receive <b style='color:Tomato;'><i>aspirin</i></b> (100 mg/day) (A group; 11 patients) or <b style='color:Tomato;'><i>cilostazol</i></b> (200 mg/day) plus <b style='color:Tomato;'><i>aspirin</i></b> (100 mg/day) (CA group; 13 patients). We measured platelet aggregation, platelet activation, and the thrombomodulin (TM), highly sensitive C-reactive protein (hs-CRP), intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and von Willebrand (vWF) antigen levels and vWF activity over a 4-week period after enrollment. Results There was no significant difference in the platelet functions of the A and CA groups. However, the platelet aggregation induced by adenosine diphosphate (ADP) was decreased at 2 and 4 weeks (p<0.05) after treatment in comparison to the pre-treatment values in the CA group, but not in the A group. Platelet activation, and the hs-CRP, TM, ICAM-1, VCAM-1 and vWF values did not significantly decrease after treatment in either group. Conclusion Although there were no significant differences in platelet aggregation, platelet activation or the endothelial biomarker levels of the A and CA groups, dual therapy with <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>cilostazol</i></b> inhibited platelet aggregation in comparison to the pre-treatment values, similarly to patients who received <b style='color:Tomato;'><i>aspirin</i></b> alone. This may suggest the clinical usefulness of dual therapy with <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>cilostazol</i></b> in the treatment of patients with noncardioembolic ischemic stroke.","tokens":[{"text":"Dual","start":0,"end":4,"id":0,"ws":true},{"text":"Therapy","start":5,"end":12,"id":1,"ws":true},{"text":"with","start":13,"end":17,"id":2,"ws":true},{"text":"Aspirin","start":18,"end":25,"id":3,"ws":true},{"text":"and","start":26,"end":29,"id":4,"ws":true},{"text":"Cilostazol","start":30,"end":40,"id":5,"ws":true},{"text":"May","start":41,"end":44,"id":6,"ws":true},{"text":"Improve","start":45,"end":52,"id":7,"ws":true},{"text":"Platelet","start":53,"end":61,"id":8,"ws":true},{"text":"Aggregation","start":62,"end":73,"id":9,"ws":true},{"text":"in","start":74,"end":76,"id":10,"ws":true},{"text":"Noncardioembolic","start":77,"end":93,"id":11,"ws":true},{"text":"Stroke","start":94,"end":100,"id":12,"ws":true},{"text":"Patients","start":101,"end":109,"id":13,"ws":true},{"text":":","start":110,"end":111,"id":14,"ws":true},{"text":"A","start":112,"end":113,"id":15,"ws":true},{"text":"Pilot","start":114,"end":119,"id":16,"ws":true},{"text":"Study","start":120,"end":125,"id":17,"ws":true},{"text":".","start":126,"end":127,"id":18,"ws":false}],"spans":[{"start":18,"end":25,"token_start":3,"token_end":3,"label":"DRUG"},{"start":30,"end":40,"token_start":5,"token_end":5,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/28566591/","_input_hash":-347463043,"_task_hash":830545149,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":3,"child":5,"head_span":{"start":18,"end":25,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":30,"end":40,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Gemcitabine and vinorelbine have shown activity in the first-line setting .","paragraph":"<h3><u>Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.</u></h3><b style='color:Tomato;'><i>pemetrexed</i></b>-<b style='color:Tomato;'><i>cisplatin</i></b> chemotherapy is the standard of care in the first-line treatment of unresectable malignant pleural mesothelioma (MPM). Second-line cytotoxic therapy is considered for a growing group of patients, but the optimal treatment has not been defined to date. <b style='color:MediumOrchid;'><i>Gemcitabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>vinorelbine</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>shown</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>setting</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The objective of this study was to evaluate the activity and toxicity of the <b style='color:Tomato;'><i>gemcitabine</i></b>-<b style='color:Tomato;'><i>vinorelbine</i></b> combination in <b style='color:Tomato;'><i>pemetrexed</i></b>-pretreated patients with MPM. ### methods From January 2004 to September 2006, 30 consecutive patients who were pretreated with <b style='color:Tomato;'><i>pemetrexed</i></b> with or without a platinum-derivative were enrolled. <b style='color:Tomato;'><i>gemcitabine</i></b> 1000 mg/m(2) and <b style='color:Tomato;'><i>vinorelbine</i></b> 25 mg/m(2) were administered intravenously on Days 1 and 8 every 3 weeks. Treatment was repeated for a maximum of 6 cycles or until progression or unacceptable toxicity. ### results A partial response was observed in 3 patients (10%; 95% confidence interval [CI], 2.1-26.5%), and 10 patients (33.3%; 95% CI, 17.3-52.8%) had stable disease after treatment. Overall, 13 patients (43.3%; 95% CI, 25.5-62.6%) achieved disease control. The median time to progression was 2.8 months (range, 0.6-12.1 months), and the median survival was 10.9 months (range, 0.8-25.3 months). Hematologic toxicity was acceptable, with grade 3 or 4 neutropenia occurring in 11% of patients and thrombocytopenia occurring in 4% of patients; no case of febrile neutropenia was observed. Nonhematologic toxicity generally was mild. ### conclusions The <b style='color:Tomato;'><i>gemcitabine</i></b> and <b style='color:Tomato;'><i>vinorelbine</i></b> combination was moderately active and had an acceptable toxicity profile in <b style='color:Tomato;'><i>pemetrexed</i></b>-pretreated patients with MPM. The role of second-line treatment in MPM needs to be evaluated in prospective trials in large series of patients who are stratified according to previous treatment and prognostic factors.","tokens":[{"text":"Gemcitabine","start":0,"end":11,"id":0,"ws":true},{"text":"and","start":12,"end":15,"id":1,"ws":true},{"text":"vinorelbine","start":16,"end":27,"id":2,"ws":true},{"text":"have","start":28,"end":32,"id":3,"ws":true},{"text":"shown","start":33,"end":38,"id":4,"ws":true},{"text":"activity","start":39,"end":47,"id":5,"ws":true},{"text":"in","start":48,"end":50,"id":6,"ws":true},{"text":"the","start":51,"end":54,"id":7,"ws":true},{"text":"first-line","start":55,"end":65,"id":8,"ws":true},{"text":"setting","start":66,"end":73,"id":9,"ws":true},{"text":".","start":74,"end":75,"id":10,"ws":false}],"spans":[{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},{"start":16,"end":27,"token_start":2,"token_end":2,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/18286536/","_input_hash":292449858,"_task_hash":-2047803560,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":0,"child":2,"head_span":{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":16,"end":27,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The combination of tenofovir disoproxil fumarate ( TDF ) plus emtricitabine ( FTC ) is used extensively to treat HIV infection and also has potent activity against hepatitis B virus ( HBV ) infection .","paragraph":"<h3><u>Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>tenofovir</i></b> <b style='color:DodgerBlue;'><i>disoproxil</i></b> <b style='color:DodgerBlue;'><i>fumarate</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>TDF</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>emtricitabine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>FTC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>extensively</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>treat</i></b> <b style='color:DodgerBlue;'><i>HIV</i></b> <b style='color:DodgerBlue;'><i>infection</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>potent</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>hepatitis</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>virus</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>HBV</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>infection</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The aim of this study was to assess the efficacy and tolerance of TDF + FTC in patients with chronic hepatitis B (CHB). ### methods Seventy eight consecutive CHB patients from five European centers were included. All started a TDF + FTC combination between October 2005 and March 2010. Virological, biochemical, and clinical data were recorded during follow-up. Tolerance was also monitored. Patients were classified into either treatment simplification (TS), where efficacy of the previous treatment was obtained at TDF + FTC initiation, and treatment intensification (TI), where the previous line of therapy had failed. ### results TDF + FTC was given as a TI to 54 patients (69%) and as a TS to 24 (31%). Among patients with TI, 83% were males. The median baseline HBV-DNA was 4.4 log10 IU/mL, and median alanine-transaminase (ALT) was 1.10 \u00d7 ULN. Sixty percent were HBeAg positive, 47% had significant fibrosis (\u2265 F3 Metavir equivalent), and 29% had confirmed cirrhosis. Median treatment duration was 76 weeks (interquartile range 60-116). Kaplan-Meier analysis showed that, 48 weeks after TI, the probability of being HBV-DNA becoming undetectable was 76%, and reached 94% at week 96. No viral breakthrough occurred. Patients with TS (87% males, median baseline HBV-DNA 1.1 log10 IU/mL, median ALT 0.79 \u00d7 ULN, 33% HBeAg positive, 61% with significant fibrosis) were treated for a median duration of 76 weeks. In this subgroup, all patients but one remained HBV-DNA undetectable and no ALT flare-up occurred during follow-up. Creatinine levels did not show kidney-function deterioration in either group of patients. ### conclusions After a median follow-up of > 76 weeks, the TDF + FTC combination showed encouraging antiviral efficacy and a good safety profile in all patients with CHB. TDF + FTC may represent an interesting clinical option to simplify therapy and increase the barrier to resistance, which should be assessed in the long term.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"combination","start":4,"end":15,"id":1,"ws":true},{"text":"of","start":16,"end":18,"id":2,"ws":true},{"text":"tenofovir","start":19,"end":28,"id":3,"ws":true},{"text":"disoproxil","start":29,"end":39,"id":4,"ws":true},{"text":"fumarate","start":40,"end":48,"id":5,"ws":true},{"text":"(","start":49,"end":50,"id":6,"ws":true},{"text":"TDF","start":51,"end":54,"id":7,"ws":true},{"text":")","start":55,"end":56,"id":8,"ws":true},{"text":"plus","start":57,"end":61,"id":9,"ws":true},{"text":"emtricitabine","start":62,"end":75,"id":10,"ws":true},{"text":"(","start":76,"end":77,"id":11,"ws":true},{"text":"FTC","start":78,"end":81,"id":12,"ws":true},{"text":")","start":82,"end":83,"id":13,"ws":true},{"text":"is","start":84,"end":86,"id":14,"ws":true},{"text":"used","start":87,"end":91,"id":15,"ws":true},{"text":"extensively","start":92,"end":103,"id":16,"ws":true},{"text":"to","start":104,"end":106,"id":17,"ws":true},{"text":"treat","start":107,"end":112,"id":18,"ws":true},{"text":"HIV","start":113,"end":116,"id":19,"ws":true},{"text":"infection","start":117,"end":126,"id":20,"ws":true},{"text":"and","start":127,"end":130,"id":21,"ws":true},{"text":"also","start":131,"end":135,"id":22,"ws":true},{"text":"has","start":136,"end":139,"id":23,"ws":true},{"text":"potent","start":140,"end":146,"id":24,"ws":true},{"text":"activity","start":147,"end":155,"id":25,"ws":true},{"text":"against","start":156,"end":163,"id":26,"ws":true},{"text":"hepatitis","start":164,"end":173,"id":27,"ws":true},{"text":"B","start":174,"end":175,"id":28,"ws":true},{"text":"virus","start":176,"end":181,"id":29,"ws":true},{"text":"(","start":182,"end":183,"id":30,"ws":true},{"text":"HBV","start":184,"end":187,"id":31,"ws":true},{"text":")","start":188,"end":189,"id":32,"ws":true},{"text":"infection","start":190,"end":199,"id":33,"ws":true},{"text":".","start":200,"end":201,"id":34,"ws":false}],"spans":[{"start":19,"end":48,"token_start":3,"token_end":5,"label":"DRUG"},{"start":62,"end":75,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/21767570/","_input_hash":147048421,"_task_hash":-498901064,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":3,"child":10,"head_span":{"start":19,"end":48,"token_start":3,"token_end":5,"label":"DRUG"},"child_span":{"start":62,"end":75,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"HRQOL was better in Japanese postmenopausal women treated with tamoxifen than those treated with exemestane or anastrozole .","paragraph":"<h3><u>Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04).</u></h3>Health-related quality of life (HRQOL), symptoms of depression, and adverse events (AEs) were compared between Japanese postmenopausal patients with hormone-sensitive breast cancer (BC) who received adjuvant <b style='color:Tomato;'><i>tamoxifen</i></b>, <b style='color:Tomato;'><i>exemestane</i></b>, or <b style='color:Tomato;'><i>anastrozole</i></b> in an open-labeled, randomized, multicenter trial designated as the National Surgical Adjuvant Study of Breast Cancer (N-SAS BC) 04 substudy of the <b style='color:Tomato;'><i>tamoxifen</i></b> <b style='color:Tomato;'><i>exemestane</i></b> Adjuvant Multinational (TEAM) trial. During the first year of treatment, HRQOL and symptoms of depression were analyzed using the Functional Assessment of Cancer Therapy-Breast (FACT-B) and its Endocrine Symptom Subscale (ES), and the Center for Epidemiologic Studies Depression Scale (CES-D), respectively. In addition, predefined AEs were analyzed. A total of 166 eligible patients were randomly assigned to receive adjuvant <b style='color:Tomato;'><i>tamoxifen</i></b>, <b style='color:Tomato;'><i>exemestane</i></b>, or <b style='color:Tomato;'><i>anastrozole</i></b>. FACT-B scores increased after treatment began and remained significantly higher in the <b style='color:Tomato;'><i>tamoxifen</i></b> group than in the <b style='color:Tomato;'><i>exemestane</i></b> group or <b style='color:Tomato;'><i>anastrozole</i></b> group during the first year (P\u00a0=\u00a00.045). FACT-B scores were similar in the <b style='color:Tomato;'><i>exemestane</i></b> group and <b style='color:Tomato;'><i>anastrozole</i></b> group. ES scores and CES-D scores were similar in all treatment groups. Arthralgia and fatigue were less frequent, but vaginal discharge was more frequent in the <b style='color:Tomato;'><i>tamoxifen</i></b> group than in the <b style='color:Tomato;'><i>exemestane</i></b> group or <b style='color:Tomato;'><i>anastrozole</i></b> group. <b style='color:DodgerBlue;'><i>HRQOL</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>better</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Japanese</i></b> <b style='color:DodgerBlue;'><i>postmenopausal</i></b> <b style='color:DodgerBlue;'><i>women</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>exemestane</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>anastrozole</i></b> <b style='color:DodgerBlue;'><i>.</i></b> HRQOL and AEs were similar with <b style='color:Tomato;'><i>exemestane</i></b> and <b style='color:Tomato;'><i>anastrozole</i></b>. Given the results of the TEAM trial, upfront use of <b style='color:Tomato;'><i>tamoxifen</i></b> followed by an aromatase inhibitor (AI) may be an important option for adjuvant endocrine therapy in Japanese postmenopausal women.","tokens":[{"text":"HRQOL","start":0,"end":5,"id":0,"ws":true},{"text":"was","start":6,"end":9,"id":1,"ws":true},{"text":"better","start":10,"end":16,"id":2,"ws":true},{"text":"in","start":17,"end":19,"id":3,"ws":true},{"text":"Japanese","start":20,"end":28,"id":4,"ws":true},{"text":"postmenopausal","start":29,"end":43,"id":5,"ws":true},{"text":"women","start":44,"end":49,"id":6,"ws":true},{"text":"treated","start":50,"end":57,"id":7,"ws":true},{"text":"with","start":58,"end":62,"id":8,"ws":true},{"text":"tamoxifen","start":63,"end":72,"id":9,"ws":true},{"text":"than","start":73,"end":77,"id":10,"ws":true},{"text":"those","start":78,"end":83,"id":11,"ws":true},{"text":"treated","start":84,"end":91,"id":12,"ws":true},{"text":"with","start":92,"end":96,"id":13,"ws":true},{"text":"exemestane","start":97,"end":107,"id":14,"ws":true},{"text":"or","start":108,"end":110,"id":15,"ws":true},{"text":"anastrozole","start":111,"end":122,"id":16,"ws":true},{"text":".","start":123,"end":124,"id":17,"ws":false}],"spans":[{"start":63,"end":72,"token_start":9,"token_end":9,"label":"DRUG"},{"start":97,"end":107,"token_start":14,"token_end":14,"label":"DRUG"},{"start":111,"end":122,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22234519/","_input_hash":1239761749,"_task_hash":795155084,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"This was driven by the relative advantage of weight loss compared with rosiglitazone , glimepiride , and insulin glargine , and administration frequency compared with exenatide .","paragraph":"<h3><u>Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.</u></h3>The purpose of this study was to investigate the preferences of people with diabetes for <b style='color:Tomato;'><i>liraglutide</i></b> vs other glucose lowering drugs, based on outcomes of clinical trials. ### methods Willingness to pay (WTP) for diabetes drug treatment was assessed by combining results from a recent WTP study with analysis of results from the <b style='color:Tomato;'><i>liraglutide</i></b> Effect and Action in Diabetes (LEAD) programme. The LEAD programme included six randomised clinical trials with 3967 participants analysing efficacy and safety of <b style='color:Tomato;'><i>liraglutide</i></b> 1.2 mg (LEAD 1-6 trials), <b style='color:Tomato;'><i>rosiglitazone</i></b> (LEAD 1 trial), <b style='color:Tomato;'><i>glimepiride</i></b> (LEAD 2-3 trials), insulin glargine (LEAD 5 trial), and exenatide (LEAD 6 trial). The WTP survey used discrete choice experimental (DCE) methodology to evaluate the convenience and clinical effects of glucose lowering treatments. ### results People with type 2 diabetes were prepared to pay an extra \u20ac2.64/day for <b style='color:Tomato;'><i>liraglutide</i></b> compared with <b style='color:Tomato;'><i>rosiglitazone</i></b>, an extra \u20ac1.94/day compared with <b style='color:Tomato;'><i>glimepiride</i></b>, an extra \u20ac3.36/day compared with insulin glargine, and an extra \u20ac0.81/day compared with exenatide. Weight loss was the largest component of WTP for <b style='color:Tomato;'><i>liraglutide</i></b> compared with <b style='color:Tomato;'><i>rosiglitazone</i></b>, <b style='color:Tomato;'><i>glimepiride</i></b>, and insulin glargine. Differences in the administration of the two drugs was the largest component of WTP for <b style='color:Tomato;'><i>liraglutide</i></b> (once daily anytime) compared with exenatide (twice daily with meals). A limitation of the study was that it was based on six clinical trials where <b style='color:Tomato;'><i>liraglutide</i></b> was the test drug, but each trial had a different comparator, therefore the clinical effects of <b style='color:Tomato;'><i>liraglutide</i></b> were much better documented than the comparators. ### conclusions WTP analyses of the clinical results from the LEAD programme suggested that participants with type 2 diabetes were willing to pay appreciably more for <b style='color:Tomato;'><i>liraglutide</i></b> than other glucose lowering treatments. <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>driven</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>relative</i></b> <b style='color:DodgerBlue;'><i>advantage</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>weight</i></b> <b style='color:DodgerBlue;'><i>loss</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>rosiglitazone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>glimepiride</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>insulin</i></b> <b style='color:DodgerBlue;'><i>glargine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>frequency</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>exenatide</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"This","start":0,"end":4,"id":0,"ws":true},{"text":"was","start":5,"end":8,"id":1,"ws":true},{"text":"driven","start":9,"end":15,"id":2,"ws":true},{"text":"by","start":16,"end":18,"id":3,"ws":true},{"text":"the","start":19,"end":22,"id":4,"ws":true},{"text":"relative","start":23,"end":31,"id":5,"ws":true},{"text":"advantage","start":32,"end":41,"id":6,"ws":true},{"text":"of","start":42,"end":44,"id":7,"ws":true},{"text":"weight","start":45,"end":51,"id":8,"ws":true},{"text":"loss","start":52,"end":56,"id":9,"ws":true},{"text":"compared","start":57,"end":65,"id":10,"ws":true},{"text":"with","start":66,"end":70,"id":11,"ws":true},{"text":"rosiglitazone","start":71,"end":84,"id":12,"ws":true},{"text":",","start":85,"end":86,"id":13,"ws":true},{"text":"glimepiride","start":87,"end":98,"id":14,"ws":true},{"text":",","start":99,"end":100,"id":15,"ws":true},{"text":"and","start":101,"end":104,"id":16,"ws":true},{"text":"insulin","start":105,"end":112,"id":17,"ws":true},{"text":"glargine","start":113,"end":121,"id":18,"ws":true},{"text":",","start":122,"end":123,"id":19,"ws":true},{"text":"and","start":124,"end":127,"id":20,"ws":true},{"text":"administration","start":128,"end":142,"id":21,"ws":true},{"text":"frequency","start":143,"end":152,"id":22,"ws":true},{"text":"compared","start":153,"end":161,"id":23,"ws":true},{"text":"with","start":162,"end":166,"id":24,"ws":true},{"text":"exenatide","start":167,"end":176,"id":25,"ws":true},{"text":".","start":177,"end":178,"id":26,"ws":false}],"spans":[{"start":71,"end":84,"token_start":12,"token_end":12,"label":"DRUG"},{"start":87,"end":98,"token_start":14,"token_end":14,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22853443/","_input_hash":1512374233,"_task_hash":-276708399,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer : results of the phase II CAPRICE study .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Pegylated</i></b> <b style='color:DodgerBlue;'><i>liposomal</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>primary</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>elderly</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>cardiotoxicity-prone</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>high-risk</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>CAPRICE</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Anthracycline and taxane-based primary chemotherapy (PCT) is the standard treatment for high-risk breast cancer (HRBC). However, conventional anthracyclines are not commonly used in elderly patients or those prone to cardiotoxicity. Pegylated liposomal <b style='color:Tomato;'><i>doxorubicin</i></b>, (PLD) has comparable efficacy, but less cardiotoxicity than conventional anthracyclines. We conducted a phase II single-arm trial to assess the efficacy and safety of PCT based on PLD followed by <b style='color:Tomato;'><i>paclitaxel</i></b> (PTX) in a HRBC population usually undertreated. Fifty patients with stage II-IIIB breast cancer and at least one risk factor for developing cardiotoxicity initiated PLD 35\u00a0mg/m(2) plus <b style='color:Tomato;'><i>cyclophosphamide</i></b> 600\u00a0mg/m(2) every 4\u00a0weeks for four cycles, followed by 80\u00a0mg/m(2) weekly PTX for 12. Close cardiac monitoring was performed. Primary endpoint was the pathological complete response rate (pCR) in the breast. Treatment delivery and toxicities were assessed. Eighty-four per cent of patients were older than 65\u00a0years, 64\u00a0% suffered from hypertension, and 10\u00a0% had prior cardiac disease. In an intention-to-treat analysis, breast pCR was 32\u00a0% (95\u00a0% CI 19.5-46.7\u00a0%) and pCR in breast and axilla was 24\u00a0% (95\u00a0% CI 12.1-35.8\u00a0%). At diagnosis only, 26\u00a0% of patients were candidates for breast conservative surgery, which increased to 58.7\u00a0% after PCT. No significant decrease in left ventricular ejection fraction was seen. PLD followed by PTX was feasible in a fragile population of patients who were not candidates for conventional <b style='color:Tomato;'><i>doxorubicin</i></b>. Moreover, it achieved a pCR similar to standard therapy and could therefore be an option for elderly patients or cardiotoxicity-prone who present HRBC.","tokens":[{"text":"Pegylated","start":0,"end":9,"id":0,"ws":true},{"text":"liposomal","start":10,"end":19,"id":1,"ws":true},{"text":"doxorubicin","start":20,"end":31,"id":2,"ws":true},{"text":"plus","start":32,"end":36,"id":3,"ws":true},{"text":"cyclophosphamide","start":37,"end":53,"id":4,"ws":true},{"text":"followed","start":54,"end":62,"id":5,"ws":true},{"text":"by","start":63,"end":65,"id":6,"ws":true},{"text":"paclitaxel","start":66,"end":76,"id":7,"ws":true},{"text":"as","start":77,"end":79,"id":8,"ws":true},{"text":"primary","start":80,"end":87,"id":9,"ws":true},{"text":"chemotherapy","start":88,"end":100,"id":10,"ws":true},{"text":"in","start":101,"end":103,"id":11,"ws":true},{"text":"elderly","start":104,"end":111,"id":12,"ws":true},{"text":"or","start":112,"end":114,"id":13,"ws":true},{"text":"cardiotoxicity-prone","start":115,"end":135,"id":14,"ws":true},{"text":"patients","start":136,"end":144,"id":15,"ws":true},{"text":"with","start":145,"end":149,"id":16,"ws":true},{"text":"high-risk","start":150,"end":159,"id":17,"ws":true},{"text":"breast","start":160,"end":166,"id":18,"ws":true},{"text":"cancer","start":167,"end":173,"id":19,"ws":true},{"text":":","start":174,"end":175,"id":20,"ws":true},{"text":"results","start":176,"end":183,"id":21,"ws":true},{"text":"of","start":184,"end":186,"id":22,"ws":true},{"text":"the","start":187,"end":190,"id":23,"ws":true},{"text":"phase","start":191,"end":196,"id":24,"ws":true},{"text":"II","start":197,"end":199,"id":25,"ws":true},{"text":"CAPRICE","start":200,"end":207,"id":26,"ws":true},{"text":"study","start":208,"end":213,"id":27,"ws":true},{"text":".","start":214,"end":215,"id":28,"ws":false}],"spans":[{"start":20,"end":31,"token_start":2,"token_end":2,"label":"DRUG"},{"start":37,"end":53,"token_start":4,"token_end":4,"label":"DRUG"},{"start":66,"end":76,"token_start":7,"token_end":7,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25981896/","_input_hash":-1383242339,"_task_hash":259977807,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":2,"child":4,"head_span":{"start":20,"end":31,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":37,"end":53,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":4,"child":7,"head_span":{"start":37,"end":53,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":66,"end":76,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"We randomly assigned 410 women with advanced ovarian cancer and residual masses larger than 1 cm after initial surgery to receive cisplatin ( 75 mg per square meter of body-surface area ) with either cyclophosphamide ( 750 mg per square meter ) or paclitaxel ( 135 mg per square meter over 24 hours ) .","paragraph":"<h3><u>Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.</u></h3>Chemotherapy combinations that include an alkylating agent and a platinum coordination complex have high response rates in women with advanced ovarian cancer. Such combinations provide long-term control of disease in few patients, however. We compared two combinations, cisplatin and <b style='color:Tomato;'><i>cyclophosphamide</i></b> and cisplatin and <b style='color:Tomato;'><i>paclitaxel</i></b>, in women with ovarian cancer. ### methods <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>randomly</i></b> <b style='color:DodgerBlue;'><i>assigned</i></b> <b style='color:DodgerBlue;'><i>410</i></b> <b style='color:DodgerBlue;'><i>women</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>residual</i></b> <b style='color:DodgerBlue;'><i>masses</i></b> <b style='color:DodgerBlue;'><i>larger</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>cm</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>initial</i></b> <b style='color:DodgerBlue;'><i>surgery</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>75</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>per</i></b> <b style='color:DodgerBlue;'><i>square</i></b> <b style='color:DodgerBlue;'><i>meter</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>body-surface</i></b> <b style='color:DodgerBlue;'><i>area</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>750</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>per</i></b> <b style='color:DodgerBlue;'><i>square</i></b> <b style='color:DodgerBlue;'><i>meter</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>135</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>per</i></b> <b style='color:DodgerBlue;'><i>square</i></b> <b style='color:DodgerBlue;'><i>meter</i></b> <b style='color:DodgerBlue;'><i>over</i></b> <b style='color:DodgerBlue;'><i>24</i></b> <b style='color:DodgerBlue;'><i>hours</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results Three hundred eighty-six women met all the eligibility criteria. Known prognostic factors were similar in the two treatment groups. Alopecia, neutropenia, fever, and allergic reactions were reported more frequently in the cisplatin-<b style='color:Tomato;'><i>paclitaxel</i></b> group. Among 216 women with measurable disease, 73 percent in the cisplatin-<b style='color:Tomato;'><i>paclitaxel</i></b> group responded to therapy, as compared with 60 percent in the cisplatin-<b style='color:Tomato;'><i>cyclophosphamide</i></b> group (P = 0.01). The frequency of surgically verified complete response was similar in the two groups. Progression-free survival was significantly longer (P < 0.001) in the cisplatin-<b style='color:Tomato;'><i>paclitaxel</i></b> group than in the cisplatin-<b style='color:Tomato;'><i>cyclophosphamide</i></b> group (median, 18 vs. 13 months). Survival was also significantly longer (P < 0.001) in the cisplatin-<b style='color:Tomato;'><i>paclitaxel</i></b> group (median, 38 vs. 24 months). ### conclusions Incorporating <b style='color:Tomato;'><i>paclitaxel</i></b> into first-line therapy improves the duration of progression-free survival and of overall survival in women with incompletely resected stage III and stage IV ovarian cancer.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"randomly","start":3,"end":11,"id":1,"ws":true},{"text":"assigned","start":12,"end":20,"id":2,"ws":true},{"text":"410","start":21,"end":24,"id":3,"ws":true},{"text":"women","start":25,"end":30,"id":4,"ws":true},{"text":"with","start":31,"end":35,"id":5,"ws":true},{"text":"advanced","start":36,"end":44,"id":6,"ws":true},{"text":"ovarian","start":45,"end":52,"id":7,"ws":true},{"text":"cancer","start":53,"end":59,"id":8,"ws":true},{"text":"and","start":60,"end":63,"id":9,"ws":true},{"text":"residual","start":64,"end":72,"id":10,"ws":true},{"text":"masses","start":73,"end":79,"id":11,"ws":true},{"text":"larger","start":80,"end":86,"id":12,"ws":true},{"text":"than","start":87,"end":91,"id":13,"ws":true},{"text":"1","start":92,"end":93,"id":14,"ws":true},{"text":"cm","start":94,"end":96,"id":15,"ws":true},{"text":"after","start":97,"end":102,"id":16,"ws":true},{"text":"initial","start":103,"end":110,"id":17,"ws":true},{"text":"surgery","start":111,"end":118,"id":18,"ws":true},{"text":"to","start":119,"end":121,"id":19,"ws":true},{"text":"receive","start":122,"end":129,"id":20,"ws":true},{"text":"cisplatin","start":130,"end":139,"id":21,"ws":true},{"text":"(","start":140,"end":141,"id":22,"ws":true},{"text":"75","start":142,"end":144,"id":23,"ws":true},{"text":"mg","start":145,"end":147,"id":24,"ws":true},{"text":"per","start":148,"end":151,"id":25,"ws":true},{"text":"square","start":152,"end":158,"id":26,"ws":true},{"text":"meter","start":159,"end":164,"id":27,"ws":true},{"text":"of","start":165,"end":167,"id":28,"ws":true},{"text":"body-surface","start":168,"end":180,"id":29,"ws":true},{"text":"area","start":181,"end":185,"id":30,"ws":true},{"text":")","start":186,"end":187,"id":31,"ws":true},{"text":"with","start":188,"end":192,"id":32,"ws":true},{"text":"either","start":193,"end":199,"id":33,"ws":true},{"text":"cyclophosphamide","start":200,"end":216,"id":34,"ws":true},{"text":"(","start":217,"end":218,"id":35,"ws":true},{"text":"750","start":219,"end":222,"id":36,"ws":true},{"text":"mg","start":223,"end":225,"id":37,"ws":true},{"text":"per","start":226,"end":229,"id":38,"ws":true},{"text":"square","start":230,"end":236,"id":39,"ws":true},{"text":"meter","start":237,"end":242,"id":40,"ws":true},{"text":")","start":243,"end":244,"id":41,"ws":true},{"text":"or","start":245,"end":247,"id":42,"ws":true},{"text":"paclitaxel","start":248,"end":258,"id":43,"ws":true},{"text":"(","start":259,"end":260,"id":44,"ws":true},{"text":"135","start":261,"end":264,"id":45,"ws":true},{"text":"mg","start":265,"end":267,"id":46,"ws":true},{"text":"per","start":268,"end":271,"id":47,"ws":true},{"text":"square","start":272,"end":278,"id":48,"ws":true},{"text":"meter","start":279,"end":284,"id":49,"ws":true},{"text":"over","start":285,"end":289,"id":50,"ws":true},{"text":"24","start":290,"end":292,"id":51,"ws":true},{"text":"hours","start":293,"end":298,"id":52,"ws":true},{"text":")","start":299,"end":300,"id":53,"ws":true},{"text":".","start":301,"end":302,"id":54,"ws":false}],"spans":[{"start":130,"end":139,"token_start":21,"token_end":21,"label":"DRUG"},{"start":200,"end":216,"token_start":34,"token_end":34,"label":"DRUG"},{"start":248,"end":258,"token_start":43,"token_end":43,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/7494563/","_input_hash":-574521188,"_task_hash":1260243567,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":21,"child":43,"head_span":{"start":130,"end":139,"token_start":21,"token_end":21,"label":"DRUG"},"child_span":{"start":248,"end":258,"token_start":43,"token_end":43,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":21,"child":34,"head_span":{"start":130,"end":139,"token_start":21,"token_end":21,"label":"DRUG"},"child_span":{"start":200,"end":216,"token_start":34,"token_end":34,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Changes</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>cholesterol</i></b> <b style='color:DodgerBlue;'><i>absorption</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>cholesterol</i></b> <b style='color:DodgerBlue;'><i>synthesis</i></b> <b style='color:DodgerBlue;'><i>caused</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>ezetimibe</i></b> <b style='color:DodgerBlue;'><i>and/or</i></b> <b style='color:MediumOrchid;'><i>simvastatin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>men</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>This study evaluates changes in cholesterol balance in hypercholesterolemic subjects following treatment with an inhibitor of cholesterol absorption or cholesterol synthesis or coadministration of both agents. This was a randomized, double blind, placebo-controlled, four-period crossover study to evaluate the effects of coadministering 10 mg <b style='color:Tomato;'><i>ezetimibe</i></b> with 20 mg <b style='color:Tomato;'><i>simvastatin</i></b> (<b style='color:Tomato;'><i>ezetimibe</i></b>/<b style='color:Tomato;'><i>simvastatin</i></b>) on cholesterol absorption and synthesis relative to either drug alone or placebo in 41 subjects. Each treatment period lasted 7 weeks. <b style='color:Tomato;'><i>ezetimibe</i></b> and <b style='color:Tomato;'><i>ezetimibe</i></b>/<b style='color:Tomato;'><i>simvastatin</i></b> decreased fractional cholesterol absorption by 65% and 59%, respectively (P < 0.001 for both relative to placebo). <b style='color:Tomato;'><i>simvastatin</i></b> did not significantly affect cholesterol absorption. <b style='color:Tomato;'><i>ezetimibe</i></b> and <b style='color:Tomato;'><i>ezetimibe</i></b>/<b style='color:Tomato;'><i>simvastatin</i></b> increased fecal sterol excretion (corrected for dietary cholesterol), which also represents net steady state cholesterol synthesis, by 109% and 79%, respectively (P < 0.001). <b style='color:Tomato;'><i>ezetimibe</i></b>, <b style='color:Tomato;'><i>simvastatin</i></b>, and <b style='color:Tomato;'><i>ezetimibe</i></b>/<b style='color:Tomato;'><i>simvastatin</i></b> decreased plasma LDL-cholesterol by 20, 38, and 55%, respectively. The coadministered therapy was well tolerated. The decreases in net cholesterol synthesis and increased fecal sterol excretion yielded nearly additive reductions in LDL-cholesterol for the coadministration of <b style='color:Tomato;'><i>ezetimibe</i></b> and <b style='color:Tomato;'><i>simvastatin</i></b>.","tokens":[{"text":"Changes","start":0,"end":7,"id":0,"ws":true},{"text":"in","start":8,"end":10,"id":1,"ws":true},{"text":"cholesterol","start":11,"end":22,"id":2,"ws":true},{"text":"absorption","start":23,"end":33,"id":3,"ws":true},{"text":"and","start":34,"end":37,"id":4,"ws":true},{"text":"cholesterol","start":38,"end":49,"id":5,"ws":true},{"text":"synthesis","start":50,"end":59,"id":6,"ws":true},{"text":"caused","start":60,"end":66,"id":7,"ws":true},{"text":"by","start":67,"end":69,"id":8,"ws":true},{"text":"ezetimibe","start":70,"end":79,"id":9,"ws":true},{"text":"and/or","start":80,"end":86,"id":10,"ws":true},{"text":"simvastatin","start":87,"end":98,"id":11,"ws":true},{"text":"in","start":99,"end":101,"id":12,"ws":true},{"text":"men","start":102,"end":105,"id":13,"ws":true},{"text":".","start":106,"end":107,"id":14,"ws":false}],"spans":[{"start":70,"end":79,"token_start":9,"token_end":9,"label":"DRUG"},{"start":87,"end":98,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/19380898/","_input_hash":2060678417,"_task_hash":-580376587,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":9,"child":11,"head_span":{"start":70,"end":79,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":87,"end":98,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The US government regulated precursor chemicals , ephedrine and pseudoephedrine , multiple times to limit methamphetamine production/availability and thus methamphetamine problems .","paragraph":"<h3><u>Impacts of federal precursor chemical regulations on methamphetamine arrests.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>US</i></b> <b style='color:DodgerBlue;'><i>government</i></b> <b style='color:DodgerBlue;'><i>regulated</i></b> <b style='color:DodgerBlue;'><i>precursor</i></b> <b style='color:DodgerBlue;'><i>chemicals</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>ephedrine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>pseudoephedrine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>multiple</i></b> <b style='color:DodgerBlue;'><i>times</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>limit</i></b> <b style='color:MediumOrchid;'><i>methamphetamine</i></b> <b style='color:DodgerBlue;'><i>production/availability</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>thus</i></b> <b style='color:MediumOrchid;'><i>methamphetamine</i></b> <b style='color:DodgerBlue;'><i>problems</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Research has found that the regulations reduced <b style='color:Tomato;'><i>methamphetamine</i></b> hospital admissions, but authors have argued that other problems were unaffected. This study examines whether the regulations impacted <b style='color:Tomato;'><i>methamphetamine</i></b> arrests. ### design ARIMA-intervention time-series analysis with control series. ### setting California (1982-2001). ### measurements Dependent variable series: monthly <b style='color:Tomato;'><i>methamphetamine</i></b> arrests. Control series: monthly marijuana arrests and cocaine/heroin arrests. ### interventions Bulk powder ephedrine and <b style='color:Tomato;'><i>pseudoephedrine</i></b>: regulated November 1989. Products containing ephedrine as the single active medicinal ingredient: regulated August 1995. <b style='color:Tomato;'><i>pseudoephedrine</i></b> products: regulated October 1997. Large-scale producers used ephedrine and <b style='color:Tomato;'><i>pseudoephedrine</i></b> in these forms. Ephedrine combined with other active medicinal ingredients (e.g. various cold medicines)-used mainly by small-scale producers: regulated October 1996. ### findings The regulation targeting small-scale producers (1996) had no significant impact. In contrast, <b style='color:Tomato;'><i>methamphetamine</i></b> arrests stopped rising and dropped 31% to 45% each of the three times precursor chemicals used by large-scale producers were regulated. Within 3 years of the bulk powder regulation (1989) and again within 2 years of the ephedrine single ingredient regulation (1995), arrests fully rebounded. During the 4 years following the last regulation (<b style='color:Tomato;'><i>pseudoephedrine</i></b> products, 1997) arrests only partially rebounded. These effects parallel those reported on hospital admissions. The control series were generally unaffected. ### conclusions Precursor regulations targeting large-scale producers impacted <b style='color:Tomato;'><i>methamphetamine</i></b> arrests, a criminal justice problem, much as they impacted the public health problem of <b style='color:Tomato;'><i>methamphetamine</i></b> hospital admissions. Ongoing research is needed to determine whether these problems eventually fully rebound from the last regulation.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"US","start":4,"end":6,"id":1,"ws":true},{"text":"government","start":7,"end":17,"id":2,"ws":true},{"text":"regulated","start":18,"end":27,"id":3,"ws":true},{"text":"precursor","start":28,"end":37,"id":4,"ws":true},{"text":"chemicals","start":38,"end":47,"id":5,"ws":true},{"text":",","start":48,"end":49,"id":6,"ws":true},{"text":"ephedrine","start":50,"end":59,"id":7,"ws":true},{"text":"and","start":60,"end":63,"id":8,"ws":true},{"text":"pseudoephedrine","start":64,"end":79,"id":9,"ws":true},{"text":",","start":80,"end":81,"id":10,"ws":true},{"text":"multiple","start":82,"end":90,"id":11,"ws":true},{"text":"times","start":91,"end":96,"id":12,"ws":true},{"text":"to","start":97,"end":99,"id":13,"ws":true},{"text":"limit","start":100,"end":105,"id":14,"ws":true},{"text":"methamphetamine","start":106,"end":121,"id":15,"ws":true},{"text":"production/availability","start":122,"end":145,"id":16,"ws":true},{"text":"and","start":146,"end":149,"id":17,"ws":true},{"text":"thus","start":150,"end":154,"id":18,"ws":true},{"text":"methamphetamine","start":155,"end":170,"id":19,"ws":true},{"text":"problems","start":171,"end":179,"id":20,"ws":true},{"text":".","start":180,"end":181,"id":21,"ws":false}],"spans":[{"start":64,"end":79,"token_start":9,"token_end":9,"label":"DRUG"},{"start":106,"end":121,"token_start":15,"token_end":15,"label":"DRUG"},{"start":155,"end":170,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/15784062/","_input_hash":-629534182,"_task_hash":-1189202745,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"We now present the long-term follow-up findings of a randomized phase III study on the addition of six cycles of procarbazine , lomustine , and vincristine ( PCV ) chemotherapy to radiotherapy ( RT ) .","paragraph":"<h3><u>Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.</u></h3>Anaplastic oligodendroglioma are chemotherapy-sensitive tumors. <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>now</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>long-term</i></b> <b style='color:DodgerBlue;'><i>follow-up</i></b> <b style='color:DodgerBlue;'><i>findings</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>six</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>procarbazine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>lomustine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>PCV</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>radiotherapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>RT</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### Patients And Methods Adult patients with newly diagnosed anaplastic oligodendroglial tumors were randomly assigned to either 59.4 Gy of RT or the same RT followed by six cycles of adjuvant PCV. An exploratory analysis of the correlation between 1p/19q status and survival was part of the study. Retrospectively, the methylation status of the methyl-guanine methyl transferase gene promoter and the mutational status of the isocitrate dehydrogenase (IDH) gene were determined. The primary end points were overall survival (OS) and progression-free survival based on intent-to-treat analysis. ### results A total of 368 patients were enrolled. With a median follow-up of 140 months, OS in the RT/PCV arm was significantly longer (42.3 v 30.6 months in the RT arm, hazard ratio [HR], 0.75; 95% CI, 0.60 to 0.95). In the 80 patients with a 1p/19q codeletion, OS was increased, with a trend toward more benefit from adjuvant PCV (OS not reached in the RT/PCV group v 112 months in the RT group; HR, 0.56; 95% CI, 0.31 to 1.03). IDH mutational status was also of prognostic significance. ### conclusion The addition of six cycles of PCV after 59.4 Gy of RT increases both OS and PFS in anaplastic oligodendroglial tumors. 1p/19q-codeleted tumors derive more benefit from adjuvant PCV compared with non-1p/19q-deleted tumors.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"now","start":3,"end":6,"id":1,"ws":true},{"text":"present","start":7,"end":14,"id":2,"ws":true},{"text":"the","start":15,"end":18,"id":3,"ws":true},{"text":"long-term","start":19,"end":28,"id":4,"ws":true},{"text":"follow-up","start":29,"end":38,"id":5,"ws":true},{"text":"findings","start":39,"end":47,"id":6,"ws":true},{"text":"of","start":48,"end":50,"id":7,"ws":true},{"text":"a","start":51,"end":52,"id":8,"ws":true},{"text":"randomized","start":53,"end":63,"id":9,"ws":true},{"text":"phase","start":64,"end":69,"id":10,"ws":true},{"text":"III","start":70,"end":73,"id":11,"ws":true},{"text":"study","start":74,"end":79,"id":12,"ws":true},{"text":"on","start":80,"end":82,"id":13,"ws":true},{"text":"the","start":83,"end":86,"id":14,"ws":true},{"text":"addition","start":87,"end":95,"id":15,"ws":true},{"text":"of","start":96,"end":98,"id":16,"ws":true},{"text":"six","start":99,"end":102,"id":17,"ws":true},{"text":"cycles","start":103,"end":109,"id":18,"ws":true},{"text":"of","start":110,"end":112,"id":19,"ws":true},{"text":"procarbazine","start":113,"end":125,"id":20,"ws":true},{"text":",","start":126,"end":127,"id":21,"ws":true},{"text":"lomustine","start":128,"end":137,"id":22,"ws":true},{"text":",","start":138,"end":139,"id":23,"ws":true},{"text":"and","start":140,"end":143,"id":24,"ws":true},{"text":"vincristine","start":144,"end":155,"id":25,"ws":true},{"text":"(","start":156,"end":157,"id":26,"ws":true},{"text":"PCV","start":158,"end":161,"id":27,"ws":true},{"text":")","start":162,"end":163,"id":28,"ws":true},{"text":"chemotherapy","start":164,"end":176,"id":29,"ws":true},{"text":"to","start":177,"end":179,"id":30,"ws":true},{"text":"radiotherapy","start":180,"end":192,"id":31,"ws":true},{"text":"(","start":193,"end":194,"id":32,"ws":true},{"text":"RT","start":195,"end":197,"id":33,"ws":true},{"text":")","start":198,"end":199,"id":34,"ws":true},{"text":".","start":200,"end":201,"id":35,"ws":false}],"spans":[{"start":113,"end":125,"token_start":20,"token_end":20,"label":"DRUG"},{"start":128,"end":137,"token_start":22,"token_end":22,"label":"DRUG"},{"start":144,"end":155,"token_start":25,"token_end":25,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/23071237/","_input_hash":1994652939,"_task_hash":-432329763,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":20,"child":22,"head_span":{"start":113,"end":125,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":128,"end":137,"token_start":22,"token_end":22,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":25,"child":22,"head_span":{"start":144,"end":155,"token_start":25,"token_end":25,"label":"DRUG"},"child_span":{"start":128,"end":137,"token_start":22,"token_end":22,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":25,"child":31,"head_span":{"start":144,"end":155,"token_start":25,"token_end":25,"label":"DRUG"},"child_span":{"start":180,"end":192,"token_start":31,"token_end":31,"label":null},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"A phase II clinical trial was conducted to evaluate the efficacy and toxicity of vinorelbine plus gemcitabine in very old patients with inoperable ( stage IIIb or IV ) NSCLC .","paragraph":"<h3><u>A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older.</u></h3><b style='color:Tomato;'><i>vinorelbine</i></b> and <b style='color:Tomato;'><i>gemcitabine</i></b> are two active single agents with mild toxicity profiles that are used in the treatment of non-small-cell lung cancer (NSCLC). Whether or not very old NSCLC patients, such as those aged 80 years or older, should still be considered for chemotherapy is unknown, since their response to the treatment is also unknown. <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>toxicity</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>vinorelbine</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>very</i></b> <b style='color:DodgerBlue;'><i>old</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>inoperable</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>IIIb</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>IV</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>NSCLC</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>vinorelbine</i></b> 20 mg/m(2) was given as a 10-min intravenous infusion, followed by a 30-min intravenous infusion of <b style='color:Tomato;'><i>gemcitabine</i></b> 800 mg/m(2) on days 1, 8, and 15 of each 28-day cycle. From March 1998 to December 2001, 20 patients (16 males, four females) were enrolled in the study. The median age was 83 years, within the range 80-88 years. The median number of treatment cycles per patient was four. With the exception of one, all patients received at least two cycles of treatment. Thirteen patients achieved a partial response, with an overall response rate of 65% (95% confidence interval, 44.1-85.9%). Median survival was 10 months. The significant (WHO grade 3/4) toxicities were myelosuppression, including leukopenia in five (25%) patients, neutropenia in eight (40%), anaemia in six (30%), and thrombocytopenia in three (15%) patients. Febrile neutropenia occurred in two patients and accounted for one treatment-related death. Non-haematological toxicity was generally mild, except one patient who suffered from grade 3 interstitial pneumonitis. Another patient suffered from a cerebral infarction after three cycles of treatment. In conclusion, the combination of <b style='color:Tomato;'><i>vinorelbine</i></b> and <b style='color:Tomato;'><i>gemcitabine</i></b> in very old patients with advanced NSCLC is a highly active regimen with an acceptable toxicity profile.","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"phase","start":2,"end":7,"id":1,"ws":true},{"text":"II","start":8,"end":10,"id":2,"ws":true},{"text":"clinical","start":11,"end":19,"id":3,"ws":true},{"text":"trial","start":20,"end":25,"id":4,"ws":true},{"text":"was","start":26,"end":29,"id":5,"ws":true},{"text":"conducted","start":30,"end":39,"id":6,"ws":true},{"text":"to","start":40,"end":42,"id":7,"ws":true},{"text":"evaluate","start":43,"end":51,"id":8,"ws":true},{"text":"the","start":52,"end":55,"id":9,"ws":true},{"text":"efficacy","start":56,"end":64,"id":10,"ws":true},{"text":"and","start":65,"end":68,"id":11,"ws":true},{"text":"toxicity","start":69,"end":77,"id":12,"ws":true},{"text":"of","start":78,"end":80,"id":13,"ws":true},{"text":"vinorelbine","start":81,"end":92,"id":14,"ws":true},{"text":"plus","start":93,"end":97,"id":15,"ws":true},{"text":"gemcitabine","start":98,"end":109,"id":16,"ws":true},{"text":"in","start":110,"end":112,"id":17,"ws":true},{"text":"very","start":113,"end":117,"id":18,"ws":true},{"text":"old","start":118,"end":121,"id":19,"ws":true},{"text":"patients","start":122,"end":130,"id":20,"ws":true},{"text":"with","start":131,"end":135,"id":21,"ws":true},{"text":"inoperable","start":136,"end":146,"id":22,"ws":true},{"text":"(","start":147,"end":148,"id":23,"ws":true},{"text":"stage","start":149,"end":154,"id":24,"ws":true},{"text":"IIIb","start":155,"end":159,"id":25,"ws":true},{"text":"or","start":160,"end":162,"id":26,"ws":true},{"text":"IV","start":163,"end":165,"id":27,"ws":true},{"text":")","start":166,"end":167,"id":28,"ws":true},{"text":"NSCLC","start":168,"end":173,"id":29,"ws":true},{"text":".","start":174,"end":175,"id":30,"ws":false}],"spans":[{"start":81,"end":92,"token_start":14,"token_end":14,"label":"DRUG"},{"start":98,"end":109,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/12711125/","_input_hash":2080813707,"_task_hash":-1542936782,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":14,"child":16,"head_span":{"start":81,"end":92,"token_start":14,"token_end":14,"label":"DRUG"},"child_span":{"start":98,"end":109,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Tobramycin was probably less effective than gentamicin in combination with the penicillinase-resistant penicillins against enterococci .","paragraph":"<h3><u>Comparative in vitro activity of nafcillin, oxacillin, and methicillin in combination with gentamicin and tobramycin against enterococci.</u></h3>The in vitro activity of <b style='color:Tomato;'><i>nafcillin</i></b>, <b style='color:Tomato;'><i>oxacillin</i></b>, and methicillin alone and in combination with <b style='color:Tomato;'><i>gentamicin</i></b> and <b style='color:Tomato;'><i>tobramycin</i></b> against 30 strains of enterococci was investigated. The penicillinase-resistant penicillins were less active than penicillin and <b style='color:Tomato;'><i>ampicillin</i></b> against the enterococci. <b style='color:Tomato;'><i>nafcillin</i></b> was more active than <b style='color:Tomato;'><i>oxacillin</i></b> and methicillin. Sixty-six percent of strains were inhibited by <b style='color:Tomato;'><i>nafcillin</i></b> at 6.25 mug/ml, but none was inhibited by <b style='color:Tomato;'><i>oxacillin</i></b> and methicillin at the same concentration. At 12.5 mug/ml, 83, 16, and 0% were inhibited by <b style='color:Tomato;'><i>nafcillin</i></b>, <b style='color:Tomato;'><i>oxacillin</i></b>, and methicillin, respectively. By using a variety of criteria and analyses, it was shown that none of the antibiotic combinations studied demonstrated enhanced killing of all strains of enterococci. <b style='color:Tomato;'><i>nafcillin</i></b>-<b style='color:Tomato;'><i>gentamicin</i></b> was the best combination, and enhanced killing was demonstrated against most strains. <b style='color:Tomato;'><i>oxacillin</i></b> was more effective than methicillin when combined with <b style='color:Tomato;'><i>gentamicin</i></b>. <b style='color:MediumOrchid;'><i>Tobramycin</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>probably</i></b> <b style='color:DodgerBlue;'><i>less</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:MediumOrchid;'><i>gentamicin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>penicillinase-resistant</i></b> <b style='color:DodgerBlue;'><i>penicillins</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>enterococci</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"Tobramycin","start":0,"end":10,"id":0,"ws":true},{"text":"was","start":11,"end":14,"id":1,"ws":true},{"text":"probably","start":15,"end":23,"id":2,"ws":true},{"text":"less","start":24,"end":28,"id":3,"ws":true},{"text":"effective","start":29,"end":38,"id":4,"ws":true},{"text":"than","start":39,"end":43,"id":5,"ws":true},{"text":"gentamicin","start":44,"end":54,"id":6,"ws":true},{"text":"in","start":55,"end":57,"id":7,"ws":true},{"text":"combination","start":58,"end":69,"id":8,"ws":true},{"text":"with","start":70,"end":74,"id":9,"ws":true},{"text":"the","start":75,"end":78,"id":10,"ws":true},{"text":"penicillinase-resistant","start":79,"end":102,"id":11,"ws":true},{"text":"penicillins","start":103,"end":114,"id":12,"ws":true},{"text":"against","start":115,"end":122,"id":13,"ws":true},{"text":"enterococci","start":123,"end":134,"id":14,"ws":true},{"text":".","start":135,"end":136,"id":15,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":44,"end":54,"token_start":6,"token_end":6,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/836017/","_input_hash":611981779,"_task_hash":1981686877,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":6,"child":12,"head_span":{"start":44,"end":54,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":103,"end":114,"token_start":12,"token_end":12,"label":null},"color":"#c5bdf4","label":"POS1"},{"head":0,"child":12,"head_span":{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":103,"end":114,"token_start":12,"token_end":12,"label":null},"color":"#96e8ce","label":"COMB1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Despite the absence of strong data , entecavir and telbivudine seem to be the preferred options for nucleoside analogue-naive CHB patients with chronic kidney disease , depending on viraemia and severity of renal dysfunction .","paragraph":"<h3><u>Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease.</u></h3>The treatment of chronic hepatitis B (CHB) in patients with chronic kidney disease (CKD) is based on nucleoside (<b style='color:Tomato;'><i>lamivudine</i></b>, <b style='color:Tomato;'><i>telbivudine</i></b>, <b style='color:Tomato;'><i>entecavir</i></b>) or nucleotide (<b style='color:Tomato;'><i>adefovir</i></b>, <b style='color:Tomato;'><i>tenofovir</i></b>) analogues (NAs), but it may be complex and the information is scarce. <b style='color:Tomato;'><i>entecavir</i></b> and <b style='color:Tomato;'><i>tenofovir</i></b> represent the currently recommended first-line NAs for NA-naive CHB patients, while <b style='color:Tomato;'><i>tenofovir</i></b> is the NA of choice for CHB patients with resistance to nucleosides. ### aim To review the efficacy and safety of NAs in adult CHB patients with CKD and to provide reasonable recommendations for their optimal management. ### methods Literature search in PubMed/Medline and manual search of relevant articles, reviews and book chapters. ### results NAs are cleared by kidneys and their dosage should be adjusted in patients with creatinine clearance <50\u00a0mL/min. There are concerns about nephrotoxic potential of the nucleotides, particularly <b style='color:Tomato;'><i>adefovir</i></b>, while improvements of creatinine clearance have been reported under <b style='color:Tomato;'><i>telbivudine</i></b>. Most existing data in CHB patients with CKD are for <b style='color:Tomato;'><i>lamivudine</i></b> and, less frequently, for other NAs, mostly <b style='color:Tomato;'><i>entecavir</i></b>. Besides CHB, NA should be used in case of immunosuppressive therapy in any HBsAg-positive patient with CKD including renal transplant (RT) recipients and in anti-HBs-positive recipients of kidney grafts from HBsAg-positive donors. ### conclusions Chronic hepatitis B patients with chronic kidney disease receiving nucleoside analogues should be followed carefully for treatment efficacy and renal safety. <b style='color:DodgerBlue;'><i>Despite</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>absence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>strong</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>entecavir</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>telbivudine</i></b> <b style='color:DodgerBlue;'><i>seem</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>preferred</i></b> <b style='color:DodgerBlue;'><i>options</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>nucleoside</i></b> <b style='color:DodgerBlue;'><i>analogue-naive</i></b> <b style='color:DodgerBlue;'><i>CHB</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>chronic</i></b> <b style='color:DodgerBlue;'><i>kidney</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>depending</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>viraemia</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>severity</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>renal</i></b> <b style='color:DodgerBlue;'><i>dysfunction</i></b> <b style='color:DodgerBlue;'><i>.</i></b> More studies are certainly needed in this setting.","tokens":[{"text":"Despite","start":0,"end":7,"id":0,"ws":true},{"text":"the","start":8,"end":11,"id":1,"ws":true},{"text":"absence","start":12,"end":19,"id":2,"ws":true},{"text":"of","start":20,"end":22,"id":3,"ws":true},{"text":"strong","start":23,"end":29,"id":4,"ws":true},{"text":"data","start":30,"end":34,"id":5,"ws":true},{"text":",","start":35,"end":36,"id":6,"ws":true},{"text":"entecavir","start":37,"end":46,"id":7,"ws":true},{"text":"and","start":47,"end":50,"id":8,"ws":true},{"text":"telbivudine","start":51,"end":62,"id":9,"ws":true},{"text":"seem","start":63,"end":67,"id":10,"ws":true},{"text":"to","start":68,"end":70,"id":11,"ws":true},{"text":"be","start":71,"end":73,"id":12,"ws":true},{"text":"the","start":74,"end":77,"id":13,"ws":true},{"text":"preferred","start":78,"end":87,"id":14,"ws":true},{"text":"options","start":88,"end":95,"id":15,"ws":true},{"text":"for","start":96,"end":99,"id":16,"ws":true},{"text":"nucleoside","start":100,"end":110,"id":17,"ws":true},{"text":"analogue-naive","start":111,"end":125,"id":18,"ws":true},{"text":"CHB","start":126,"end":129,"id":19,"ws":true},{"text":"patients","start":130,"end":138,"id":20,"ws":true},{"text":"with","start":139,"end":143,"id":21,"ws":true},{"text":"chronic","start":144,"end":151,"id":22,"ws":true},{"text":"kidney","start":152,"end":158,"id":23,"ws":true},{"text":"disease","start":159,"end":166,"id":24,"ws":true},{"text":",","start":167,"end":168,"id":25,"ws":true},{"text":"depending","start":169,"end":178,"id":26,"ws":true},{"text":"on","start":179,"end":181,"id":27,"ws":true},{"text":"viraemia","start":182,"end":190,"id":28,"ws":true},{"text":"and","start":191,"end":194,"id":29,"ws":true},{"text":"severity","start":195,"end":203,"id":30,"ws":true},{"text":"of","start":204,"end":206,"id":31,"ws":true},{"text":"renal","start":207,"end":212,"id":32,"ws":true},{"text":"dysfunction","start":213,"end":224,"id":33,"ws":true},{"text":".","start":225,"end":226,"id":34,"ws":false}],"spans":[{"start":37,"end":46,"token_start":7,"token_end":7,"label":"DRUG"},{"start":51,"end":62,"token_start":9,"token_end":9,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/24299322/","_input_hash":1590525858,"_task_hash":1765201580,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Results from clinical trials evaluating agents such as ixabepilone , albumin-bound paclitaxel , capecitabine , vinorelbine , pemetrexed , and irinotecan are presented .","paragraph":"<h3><u>Management of metastatic breast cancer: monotherapy options for patients resistant to anthracyclines and taxanes.</u></h3>Resistance to chemotherapeutic agents is a significant obstacle to the effective treatment of metastatic breast cancer (MBC). Anthracycline- and taxane-based regimens are active as first-line treatment for MBC; however, MBC often progresses because of primary or acquired resistance to anthracyclines and taxanes. There are few options for the treatment of patients with anthracycline- and taxane-resistant or taxane-refractory MBC. This article reviews several single agents that have demonstrated activity as treatment for patients with MBC who progress during, or rapidly following, treatment with anthracyclines and taxanes. <b style='color:DodgerBlue;'><i>Results</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>evaluating</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>ixabepilone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>albumin-bound</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vinorelbine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>pemetrexed</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>presented</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Single-agent <b style='color:Tomato;'><i>capecitabine</i></b> is approved for the treatment of patients after failure of anthracyclines and taxanes. <b style='color:Tomato;'><i>ixabepilone</i></b> has demonstrated efficacy in patients with MBC resistant to multiple chemotherapeutic agents and is the only agent approved by the Food and Drug Administration as monotherapy for anthracycline-, taxane-, and <b style='color:Tomato;'><i>capecitabine</i></b>-resistant MBC. Improved treatment strategies and further evaluation of newer agents may reduce the current burden of treatment-resistant or treatment-refractory MBC.","tokens":[{"text":"Results","start":0,"end":7,"id":0,"ws":true},{"text":"from","start":8,"end":12,"id":1,"ws":true},{"text":"clinical","start":13,"end":21,"id":2,"ws":true},{"text":"trials","start":22,"end":28,"id":3,"ws":true},{"text":"evaluating","start":29,"end":39,"id":4,"ws":true},{"text":"agents","start":40,"end":46,"id":5,"ws":true},{"text":"such","start":47,"end":51,"id":6,"ws":true},{"text":"as","start":52,"end":54,"id":7,"ws":true},{"text":"ixabepilone","start":55,"end":66,"id":8,"ws":true},{"text":",","start":67,"end":68,"id":9,"ws":true},{"text":"albumin-bound","start":69,"end":82,"id":10,"ws":true},{"text":"paclitaxel","start":83,"end":93,"id":11,"ws":true},{"text":",","start":94,"end":95,"id":12,"ws":true},{"text":"capecitabine","start":96,"end":108,"id":13,"ws":true},{"text":",","start":109,"end":110,"id":14,"ws":true},{"text":"vinorelbine","start":111,"end":122,"id":15,"ws":true},{"text":",","start":123,"end":124,"id":16,"ws":true},{"text":"pemetrexed","start":125,"end":135,"id":17,"ws":true},{"text":",","start":136,"end":137,"id":18,"ws":true},{"text":"and","start":138,"end":141,"id":19,"ws":true},{"text":"irinotecan","start":142,"end":152,"id":20,"ws":true},{"text":"are","start":153,"end":156,"id":21,"ws":true},{"text":"presented","start":157,"end":166,"id":22,"ws":true},{"text":".","start":167,"end":168,"id":23,"ws":false}],"spans":[{"start":55,"end":66,"token_start":8,"token_end":8,"label":"DRUG"},{"start":83,"end":93,"token_start":11,"token_end":11,"label":"DRUG"},{"start":96,"end":108,"token_start":13,"token_end":13,"label":"DRUG"},{"start":111,"end":122,"token_start":15,"token_end":15,"label":"DRUG"},{"start":125,"end":135,"token_start":17,"token_end":17,"label":"DRUG"},{"start":142,"end":152,"token_start":20,"token_end":20,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/19675449/","_input_hash":234088543,"_task_hash":2101921619,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The clinical studies provide evidence that combined fluticasone/formoterol is more efficacious than fluticasone or formoterol given alone , and provides similar improvements in lung function to fluticasone ( Flixotide ( \u00ae ) ) and formoterol ( Foradil ( \u00ae ) ) administered concurrently .","paragraph":"<h3><u>[A new fixed dose combination of fluticasone and formoterol in a pressurised metered-dose inhaler for the treatment of asthma].</u></h3>The combination of an inhaled corticosteroid and a long acting beta-2 agonist is indicated for the regular treatment of persistent moderate-to-severe asthmatics whose asthma is not controlled by inhaled corticosteroids and the occasional use of a short acting beta-2 agonist. The aim of this review is to give an overview of the rationale of combining <b style='color:Tomato;'><i>formoterol</i></b> and <b style='color:Tomato;'><i>fluticasone</i></b> and to analyze the clinical data concerning a new fixed combination of <b style='color:Tomato;'><i>fluticasone</i></b> and <b style='color:Tomato;'><i>formoterol</i></b> in a pressurised metered-dose inhaler with a dose counter (Flutiform(\u00ae)) that was approved for the treatment of asthma in France in 2013. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>provide</i></b> <b style='color:DodgerBlue;'><i>evidence</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>fluticasone/formoterol</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>efficacious</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:MediumOrchid;'><i>fluticasone</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>formoterol</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>provides</i></b> <b style='color:DodgerBlue;'><i>similar</i></b> <b style='color:DodgerBlue;'><i>improvements</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>function</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>fluticasone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Flixotide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>\u00ae</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>formoterol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Foradil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>\u00ae</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>concurrently</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The combination of <b style='color:Tomato;'><i>fluticasone</i></b>/<b style='color:Tomato;'><i>formoterol</i></b> gave a more rapid bronchodilatation than the combination <b style='color:Tomato;'><i>fluticasone</i></b>/<b style='color:Tomato;'><i>salmeterol</i></b>. As a whole, the combination of <b style='color:Tomato;'><i>fluticasone</i></b>/<b style='color:Tomato;'><i>formoterol</i></b> had similar efficacy and tolerability profiles to the combinations of either <b style='color:Tomato;'><i>bu<b style='color:Tomato;'><i>desonide</i></b></i></b>/<b style='color:Tomato;'><i>formoterol</i></b> or <b style='color:Tomato;'><i>fluticasone</i></b>/<b style='color:Tomato;'><i>salmeterol</i></b>.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"clinical","start":4,"end":12,"id":1,"ws":true},{"text":"studies","start":13,"end":20,"id":2,"ws":true},{"text":"provide","start":21,"end":28,"id":3,"ws":true},{"text":"evidence","start":29,"end":37,"id":4,"ws":true},{"text":"that","start":38,"end":42,"id":5,"ws":true},{"text":"combined","start":43,"end":51,"id":6,"ws":true},{"text":"fluticasone/formoterol","start":52,"end":74,"id":7,"ws":true},{"text":"is","start":75,"end":77,"id":8,"ws":true},{"text":"more","start":78,"end":82,"id":9,"ws":true},{"text":"efficacious","start":83,"end":94,"id":10,"ws":true},{"text":"than","start":95,"end":99,"id":11,"ws":true},{"text":"fluticasone","start":100,"end":111,"id":12,"ws":true},{"text":"or","start":112,"end":114,"id":13,"ws":true},{"text":"formoterol","start":115,"end":125,"id":14,"ws":true},{"text":"given","start":126,"end":131,"id":15,"ws":true},{"text":"alone","start":132,"end":137,"id":16,"ws":true},{"text":",","start":138,"end":139,"id":17,"ws":true},{"text":"and","start":140,"end":143,"id":18,"ws":true},{"text":"provides","start":144,"end":152,"id":19,"ws":true},{"text":"similar","start":153,"end":160,"id":20,"ws":true},{"text":"improvements","start":161,"end":173,"id":21,"ws":true},{"text":"in","start":174,"end":176,"id":22,"ws":true},{"text":"lung","start":177,"end":181,"id":23,"ws":true},{"text":"function","start":182,"end":190,"id":24,"ws":true},{"text":"to","start":191,"end":193,"id":25,"ws":true},{"text":"fluticasone","start":194,"end":205,"id":26,"ws":true},{"text":"(","start":206,"end":207,"id":27,"ws":true},{"text":"Flixotide","start":208,"end":217,"id":28,"ws":true},{"text":"(","start":218,"end":219,"id":29,"ws":true},{"text":"\u00ae","start":220,"end":221,"id":30,"ws":true},{"text":")","start":222,"end":223,"id":31,"ws":true},{"text":")","start":224,"end":225,"id":32,"ws":true},{"text":"and","start":226,"end":229,"id":33,"ws":true},{"text":"formoterol","start":230,"end":240,"id":34,"ws":true},{"text":"(","start":241,"end":242,"id":35,"ws":true},{"text":"Foradil","start":243,"end":250,"id":36,"ws":true},{"text":"(","start":251,"end":252,"id":37,"ws":true},{"text":"\u00ae","start":253,"end":254,"id":38,"ws":true},{"text":")","start":255,"end":256,"id":39,"ws":true},{"text":")","start":257,"end":258,"id":40,"ws":true},{"text":"administered","start":259,"end":271,"id":41,"ws":true},{"text":"concurrently","start":272,"end":284,"id":42,"ws":true},{"text":".","start":285,"end":286,"id":43,"ws":false}],"spans":[{"start":100,"end":111,"token_start":12,"token_end":12,"label":"DRUG"},{"start":115,"end":125,"token_start":14,"token_end":14,"label":"DRUG"},{"start":194,"end":205,"token_start":26,"token_end":26,"label":"DRUG"},{"start":230,"end":240,"token_start":34,"token_end":34,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25391505/","_input_hash":1811966118,"_task_hash":671597530,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":34,"child":26,"head_span":{"start":230,"end":240,"token_start":34,"token_end":34,"label":"DRUG"},"child_span":{"start":194,"end":205,"token_start":26,"token_end":26,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen : a TransATAC study .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Prediction</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>risk</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>distant</i></b> <b style='color:DodgerBlue;'><i>recurrence</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>21-gene</i></b> <b style='color:DodgerBlue;'><i>recurrence</i></b> <b style='color:DodgerBlue;'><i>score</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>node-negative</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>node-positive</i></b> <b style='color:DodgerBlue;'><i>postmenopausal</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>anastrozole</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>TransATAC</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>PURPOSE To determine whether the Recurrence Score (RS) provided independent information on risk of distant recurrence (DR) in the <b style='color:Tomato;'><i>tamoxifen</i></b> and <b style='color:Tomato;'><i>anastrozole</i></b> arms of the Arimidex, <b style='color:Tomato;'><i>tamoxifen</i></b>, Alone or in Combination (ATAC) Trial. PATIENTS AND METHODS RNA was extracted from 1,372 tumor blocks from postmenopausal patients with hormone receptor-positive primary breast cancer in the monotherapy arms of ATAC. Twenty-one genes were assessed by quantitative reverse transcriptase polymerase chain reaction, and the RS was calculated. Cox proportional hazards models assessed the value of adding RS to a model with clinical variables (age, tumor size, grade, and treatment) in node-negative (N0) and node-positive (N+) women. RESULTS Reportable scores were available from 1,231 evaluable patients (N0, n = 872; N+, n = 306; and node status unknown, n = 53); 72, 74, and six DRs occurred in N0, N+, and node status unknown patients, respectively. For both N0 and N+ patients, RS was significantly associated with time to DR in multivariate analyses (P < .001 for N0 and P = .002 for N+). RS also showed significant prognostic value beyond that provided by Adjuvant! Online (P < .001). Nine-year DR rates in low (RS < 18), intermediate (RS = 18 to 30), and high RS (RS > or = 31) groups were 4%, 12%, and 25%, respectively, in N0 patients and 17%, 28%, and 49%, respectively, in N+ patients. The prognostic value of RS was similar in <b style='color:Tomato;'><i>anastrozole</i></b>- and <b style='color:Tomato;'><i>tamoxifen</i></b>-treated patients. CONCLUSION This study confirmed the performance of RS in postmenopausal HR+ patients treated with <b style='color:Tomato;'><i>tamoxifen</i></b> in a large contemporary population and demonstrated that RS is an independent predictor of DR in N0 and N+ hormone receptor-positive patients treated with <b style='color:Tomato;'><i>anastrozole</i></b>, adding value to estimates with standard clinicopathologic features.","tokens":[{"text":"Prediction","start":0,"end":10,"id":0,"ws":true},{"text":"of","start":11,"end":13,"id":1,"ws":true},{"text":"risk","start":14,"end":18,"id":2,"ws":true},{"text":"of","start":19,"end":21,"id":3,"ws":true},{"text":"distant","start":22,"end":29,"id":4,"ws":true},{"text":"recurrence","start":30,"end":40,"id":5,"ws":true},{"text":"using","start":41,"end":46,"id":6,"ws":true},{"text":"the","start":47,"end":50,"id":7,"ws":true},{"text":"21-gene","start":51,"end":58,"id":8,"ws":true},{"text":"recurrence","start":59,"end":69,"id":9,"ws":true},{"text":"score","start":70,"end":75,"id":10,"ws":true},{"text":"in","start":76,"end":78,"id":11,"ws":true},{"text":"node-negative","start":79,"end":92,"id":12,"ws":true},{"text":"and","start":93,"end":96,"id":13,"ws":true},{"text":"node-positive","start":97,"end":110,"id":14,"ws":true},{"text":"postmenopausal","start":111,"end":125,"id":15,"ws":true},{"text":"patients","start":126,"end":134,"id":16,"ws":true},{"text":"with","start":135,"end":139,"id":17,"ws":true},{"text":"breast","start":140,"end":146,"id":18,"ws":true},{"text":"cancer","start":147,"end":153,"id":19,"ws":true},{"text":"treated","start":154,"end":161,"id":20,"ws":true},{"text":"with","start":162,"end":166,"id":21,"ws":true},{"text":"anastrozole","start":167,"end":178,"id":22,"ws":true},{"text":"or","start":179,"end":181,"id":23,"ws":true},{"text":"tamoxifen","start":182,"end":191,"id":24,"ws":true},{"text":":","start":192,"end":193,"id":25,"ws":true},{"text":"a","start":194,"end":195,"id":26,"ws":true},{"text":"TransATAC","start":196,"end":205,"id":27,"ws":true},{"text":"study","start":206,"end":211,"id":28,"ws":true},{"text":".","start":212,"end":213,"id":29,"ws":false}],"spans":[{"start":167,"end":178,"token_start":22,"token_end":22,"label":"DRUG"},{"start":182,"end":191,"token_start":24,"token_end":24,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/20212256/","_input_hash":1790719554,"_task_hash":-1109752328,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"When novel DMARDs were used as monotherapies , greater ACR20/50/70 responses were observed with tocilizumab than with anti-tumor necrosis factor agents ( aTNF ) or tofacitinib .","paragraph":"<h3><u>Comparative Efficacy of Novel DMARDs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with Inadequate Response to Conventional DMARDs: A Network Meta-Analysis.</u></h3>Given the availability of a number of alternative biologic treatment options and other novel disease-modifying antirheumatic drugs (DMARDs) for the treatment of patients with rheumatoid arthritis (RA), clinicians are faced with an increasingly challenging choice regarding optimal treatment. Biologics are usually combined with traditional DMARDs, primarily <b style='color:Tomato;'><i>methotrexate</i></b> (MTX), but some biologics and <b style='color:Tomato;'><i>tofacitinib</i></b> (together referred to in this article as novel DMARDs) have been shown to be efficacious as monotherapy as well. In real-world practice, approximately one-third of RA patients receiving biologics are on monotherapy, primarily because of intolerance of, or noncompliance with, MTX. Limited data, however, are available analyzing the effectiveness of monotherapy compared with combination therapy across novel DMARDs. ### objective To compare American College of Rheumatology (ACR) responses to approved novel DMARDs used as monotherapy or as combination therapy with <b style='color:Tomato;'><i>methotrexate</i></b> (MTX) at 24 weeks in RA patients who have shown inadequate response to conventional DMARDs (DMARD-IR). ### methods Through a systematic review of the literature, we identified randomized controlled trials that assessed approved novel DMARDs used as monotherapy or as combination therapy with MTX in DMARD-IR RA patients. Twenty-eight RCTs were identified that evaluated <b style='color:Tomato;'><i>abatacept</i></b>, <b style='color:Tomato;'><i>anakinra</i></b>, <b style='color:Tomato;'><i>adalimumab</i></b>, <b style='color:Tomato;'><i>certolizumab pegol</i></b>, <b style='color:Tomato;'><i>etanercept</i></b>, <b style='color:Tomato;'><i>golimumab</i></b>, <b style='color:Tomato;'><i>infliximab</i></b>, <b style='color:Tomato;'><i>tocilizumab</i></b>, or <b style='color:Tomato;'><i>tofacitinib</i></b>. ACR responses at 24 weeks were extracted and combined by means of Bayesian network meta-analyses. ### results With the exception of <b style='color:Tomato;'><i>anakinra</i></b> plus MTX, which was less efficacious, most novel DMARDs, when used in combination with MTX, demonstrated comparable ACR responses. <b style='color:DodgerBlue;'><i>When</i></b> <b style='color:DodgerBlue;'><i>novel</i></b> <b style='color:DodgerBlue;'><i>DMARDs</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>monotherapies</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>greater</i></b> <b style='color:DodgerBlue;'><i>ACR20/50/70</i></b> <b style='color:DodgerBlue;'><i>responses</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>observed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>tocilizumab</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>anti-tumor</i></b> <b style='color:DodgerBlue;'><i>necrosis</i></b> <b style='color:DodgerBlue;'><i>factor</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>aTNF</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>tofacitinib</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Furthermore, ACR20/50/70 responses with <b style='color:Tomato;'><i>tocilizumab</i></b> plus MTX were similar to those with <b style='color:Tomato;'><i>tocilizumab</i></b> monotherapy (odds ratio [OR] for the indirect comparison\u2009=\u20091.08, 95% credible interval [CrI]\u2009=\u20090.40-2.84; OR\u2009=\u20091.24, CrI\u2009=\u20090.44-3.61; OR\u2009=\u20090.95, CrI\u2009=\u20090.33-2.72, respectively), whereas greater responses were observed with aTNF plus MTX than with aTNF monotherapy (OR\u2009=\u20092.41, CrI\u2009=\u20090.51-11.61; OR\u2009=\u20092.85, CrI\u2009=\u20090.51-17.67; OR\u2009=\u20091.28, CrI\u2009=\u20090.21-8.42, respectively). Relative efficacy estimates for the indirect comparison of <b style='color:Tomato;'><i>tofacitinib</i></b> plus MTX with <b style='color:Tomato;'><i>tofacitinib</i></b> monotherapy were very uncertain. ### conclusions Results suggest that in combination with MTX most of the available novel DMARDs have similar levels of efficacy in DMARD-IR patients. As monotherapy, however, <b style='color:Tomato;'><i>tocilizumab</i></b> displayed higher ACR responses than aTNF or <b style='color:Tomato;'><i>tofacitinib</i></b>. ACR responses with <b style='color:Tomato;'><i>tocilizumab</i></b> plus MTX were similar to those with <b style='color:Tomato;'><i>tocilizumab</i></b> as monotherapy, whereas aTNF in combination with MTX demonstrated greater ACR responses than aTNF as monotherapy.","tokens":[{"text":"When","start":0,"end":4,"id":0,"ws":true},{"text":"novel","start":5,"end":10,"id":1,"ws":true},{"text":"DMARDs","start":11,"end":17,"id":2,"ws":true},{"text":"were","start":18,"end":22,"id":3,"ws":true},{"text":"used","start":23,"end":27,"id":4,"ws":true},{"text":"as","start":28,"end":30,"id":5,"ws":true},{"text":"monotherapies","start":31,"end":44,"id":6,"ws":true},{"text":",","start":45,"end":46,"id":7,"ws":true},{"text":"greater","start":47,"end":54,"id":8,"ws":true},{"text":"ACR20/50/70","start":55,"end":66,"id":9,"ws":true},{"text":"responses","start":67,"end":76,"id":10,"ws":true},{"text":"were","start":77,"end":81,"id":11,"ws":true},{"text":"observed","start":82,"end":90,"id":12,"ws":true},{"text":"with","start":91,"end":95,"id":13,"ws":true},{"text":"tocilizumab","start":96,"end":107,"id":14,"ws":true},{"text":"than","start":108,"end":112,"id":15,"ws":true},{"text":"with","start":113,"end":117,"id":16,"ws":true},{"text":"anti-tumor","start":118,"end":128,"id":17,"ws":true},{"text":"necrosis","start":129,"end":137,"id":18,"ws":true},{"text":"factor","start":138,"end":144,"id":19,"ws":true},{"text":"agents","start":145,"end":151,"id":20,"ws":true},{"text":"(","start":152,"end":153,"id":21,"ws":true},{"text":"aTNF","start":154,"end":158,"id":22,"ws":true},{"text":")","start":159,"end":160,"id":23,"ws":true},{"text":"or","start":161,"end":163,"id":24,"ws":true},{"text":"tofacitinib","start":164,"end":175,"id":25,"ws":true},{"text":".","start":176,"end":177,"id":26,"ws":false}],"spans":[{"start":96,"end":107,"token_start":14,"token_end":14,"label":"DRUG"},{"start":164,"end":175,"token_start":25,"token_end":25,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25943002/","_input_hash":-768717398,"_task_hash":930325306,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Paclitaxel showed synergistic anti-proliferative impacts with fulvestrant .","paragraph":"<h3><u>Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer.</u></h3>To investigate the prognostic role of the estrogen receptor (ER) in gastric cancer (GC) patients, tumor tissues from 932 patients with advanced GC were assessed for ER expression using immunohistochemistry, and their clinicopathologic features were evaluated. Forty patients (4.3%) had ER expression and they were more frequently associated with diffuse type gastric cancer and shorter disease free survival. Furthermore, we carried out in vitro analysis to evaluate the effect of ER modulation on the proliferation of GC cell lines. Estradiol enhanced proliferation of ER positive GC cells while it did not show any effect on ER negative GC cells. When ER was inhibited by <b style='color:Tomato;'><i>fulvestrant</i></b> and ER siRNA, estradiol-induced proliferation of ER positive GC cell was suppressed. <b style='color:MediumOrchid;'><i>Paclitaxel</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>synergistic</i></b> <b style='color:DodgerBlue;'><i>anti-proliferative</i></b> <b style='color:DodgerBlue;'><i>impacts</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>fulvestrant</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Suppressing ER by <b style='color:Tomato;'><i>fulvestrant</i></b>, <b style='color:Tomato;'><i>paclitaxel</i></b> and ER siRNA showed increased expression of E-cadherin, which is a crucial factor in diffuse-type carcinogenesis.","tokens":[{"text":"Paclitaxel","start":0,"end":10,"id":0,"ws":true},{"text":"showed","start":11,"end":17,"id":1,"ws":true},{"text":"synergistic","start":18,"end":29,"id":2,"ws":true},{"text":"anti-proliferative","start":30,"end":48,"id":3,"ws":true},{"text":"impacts","start":49,"end":56,"id":4,"ws":true},{"text":"with","start":57,"end":61,"id":5,"ws":true},{"text":"fulvestrant","start":62,"end":73,"id":6,"ws":true},{"text":".","start":74,"end":75,"id":7,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":62,"end":73,"token_start":6,"token_end":6,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25534230/","_input_hash":1047854151,"_task_hash":-1333371023,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":0,"child":6,"head_span":{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":62,"end":73,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"The experimental protocol was as follows : ( 1 ) at time zero , intravenous infusion of ritodrine was begun ; ( 2 ) at 120 min , 2 % lidocaine was given epidurally to achieve a sensory level of at least T6 ; and ( 3 ) at 135 min , an intravenous bolus of either ephedrine , phenylephrine , or normal saline-control was given , followed by a continuous intravenous infusion of the same agent for 30 min .","paragraph":"<h3><u>Ephedrine remains the vasopressor of choice for treatment of hypotension during ritodrine infusion and epidural anesthesia.</u></h3>Historically, ephedrine has been the vasopressor of choice for treatment of most cases of hypotension in obstetric patients. However, the choice of vasopressor in the parturient receiving a beta-adrenergic agent for tocolysis has not been evaluated extensively. The current study evaluated whether ephedrine or <b style='color:Tomato;'><i>phenylephrine</i></b> better restores uterine blood flow and fetal oxygenation during <b style='color:Tomato;'><i>ritodrine</i></b> infusion and epidural anesthesia-induced hypotension in gravid ewes. ### methods Fourteen chronically instrumented gravid ewes between 0.8 and 0.9 timed gestational age were used. On separate days, each animal underwent the experimental protocol with one of three agents: ephedrine, <b style='color:Tomato;'><i>phenylephrine</i></b>, and normal saline-control. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>experimental</i></b> <b style='color:DodgerBlue;'><i>protocol</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>follows</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>time</i></b> <b style='color:DodgerBlue;'><i>zero</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>ritodrine</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>begun</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>120</i></b> <b style='color:DodgerBlue;'><i>min</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:MediumOrchid;'><i>lidocaine</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>epidurally</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>achieve</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>sensory</i></b> <b style='color:DodgerBlue;'><i>level</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>least</i></b> <b style='color:DodgerBlue;'><i>T6</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>135</i></b> <b style='color:DodgerBlue;'><i>min</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:DodgerBlue;'><i>bolus</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:DodgerBlue;'><i>ephedrine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>phenylephrine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>normal</i></b> <b style='color:DodgerBlue;'><i>saline-control</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>continuous</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>same</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>30</i></b> <b style='color:DodgerBlue;'><i>min</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In the ephedrine and <b style='color:Tomato;'><i>phenylephrine</i></b> experiments, the rate of infusion was adjusted to maintain maternal mean arterial pressure close to baseline. ### results <b style='color:Tomato;'><i>ritodrine</i></b> infusion alone significantly increased maternal heart rate and cardiac output in all three groups. Epidural anesthesia during <b style='color:Tomato;'><i>ritodrine</i></b> infusion significantly decreased maternal mean arterial pressure, heart rate, cardiac output, uterine blood flow, and fetal arterial oxygen tension for each of the three groups. Both ephedrine and <b style='color:Tomato;'><i>phenylephrine</i></b> restored maternal mean arterial pressure to baseline, as designed. Ephedrine significantly increased uterine blood flow and fetal arterial oxygen tension when compared with normal saline--control, but <b style='color:Tomato;'><i>phenylephrine</i></b> did not. <b style='color:Tomato;'><i>phenylephrine</i></b> significantly increased uterine vascular resistance when compared with normal saline--control, but ephedrine did not. ### conclusions Although ephedrine and <b style='color:Tomato;'><i>phenylephrine</i></b> provided similar restoration of maternal mean arterial pressure, ephedrine was superior to <b style='color:Tomato;'><i>phenylephrine</i></b> in restoring uterine blood flow during <b style='color:Tomato;'><i>ritodrine</i></b> infusion and epidural anesthesia-induced hypotension in gravid ewes. Also, ephedrine, but not <b style='color:Tomato;'><i>phenylephrine</i></b>, significantly improved fetal oxygenation, when compared to normal saline--control.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"experimental","start":4,"end":16,"id":1,"ws":true},{"text":"protocol","start":17,"end":25,"id":2,"ws":true},{"text":"was","start":26,"end":29,"id":3,"ws":true},{"text":"as","start":30,"end":32,"id":4,"ws":true},{"text":"follows","start":33,"end":40,"id":5,"ws":true},{"text":":","start":41,"end":42,"id":6,"ws":true},{"text":"(","start":43,"end":44,"id":7,"ws":true},{"text":"1","start":45,"end":46,"id":8,"ws":true},{"text":")","start":47,"end":48,"id":9,"ws":true},{"text":"at","start":49,"end":51,"id":10,"ws":true},{"text":"time","start":52,"end":56,"id":11,"ws":true},{"text":"zero","start":57,"end":61,"id":12,"ws":true},{"text":",","start":62,"end":63,"id":13,"ws":true},{"text":"intravenous","start":64,"end":75,"id":14,"ws":true},{"text":"infusion","start":76,"end":84,"id":15,"ws":true},{"text":"of","start":85,"end":87,"id":16,"ws":true},{"text":"ritodrine","start":88,"end":97,"id":17,"ws":true},{"text":"was","start":98,"end":101,"id":18,"ws":true},{"text":"begun","start":102,"end":107,"id":19,"ws":true},{"text":";","start":108,"end":109,"id":20,"ws":true},{"text":"(","start":110,"end":111,"id":21,"ws":true},{"text":"2","start":112,"end":113,"id":22,"ws":true},{"text":")","start":114,"end":115,"id":23,"ws":true},{"text":"at","start":116,"end":118,"id":24,"ws":true},{"text":"120","start":119,"end":122,"id":25,"ws":true},{"text":"min","start":123,"end":126,"id":26,"ws":true},{"text":",","start":127,"end":128,"id":27,"ws":true},{"text":"2","start":129,"end":130,"id":28,"ws":true},{"text":"%","start":131,"end":132,"id":29,"ws":true},{"text":"lidocaine","start":133,"end":142,"id":30,"ws":true},{"text":"was","start":143,"end":146,"id":31,"ws":true},{"text":"given","start":147,"end":152,"id":32,"ws":true},{"text":"epidurally","start":153,"end":163,"id":33,"ws":true},{"text":"to","start":164,"end":166,"id":34,"ws":true},{"text":"achieve","start":167,"end":174,"id":35,"ws":true},{"text":"a","start":175,"end":176,"id":36,"ws":true},{"text":"sensory","start":177,"end":184,"id":37,"ws":true},{"text":"level","start":185,"end":190,"id":38,"ws":true},{"text":"of","start":191,"end":193,"id":39,"ws":true},{"text":"at","start":194,"end":196,"id":40,"ws":true},{"text":"least","start":197,"end":202,"id":41,"ws":true},{"text":"T6","start":203,"end":205,"id":42,"ws":true},{"text":";","start":206,"end":207,"id":43,"ws":true},{"text":"and","start":208,"end":211,"id":44,"ws":true},{"text":"(","start":212,"end":213,"id":45,"ws":true},{"text":"3","start":214,"end":215,"id":46,"ws":true},{"text":")","start":216,"end":217,"id":47,"ws":true},{"text":"at","start":218,"end":220,"id":48,"ws":true},{"text":"135","start":221,"end":224,"id":49,"ws":true},{"text":"min","start":225,"end":228,"id":50,"ws":true},{"text":",","start":229,"end":230,"id":51,"ws":true},{"text":"an","start":231,"end":233,"id":52,"ws":true},{"text":"intravenous","start":234,"end":245,"id":53,"ws":true},{"text":"bolus","start":246,"end":251,"id":54,"ws":true},{"text":"of","start":252,"end":254,"id":55,"ws":true},{"text":"either","start":255,"end":261,"id":56,"ws":true},{"text":"ephedrine","start":262,"end":271,"id":57,"ws":true},{"text":",","start":272,"end":273,"id":58,"ws":true},{"text":"phenylephrine","start":274,"end":287,"id":59,"ws":true},{"text":",","start":288,"end":289,"id":60,"ws":true},{"text":"or","start":290,"end":292,"id":61,"ws":true},{"text":"normal","start":293,"end":299,"id":62,"ws":true},{"text":"saline-control","start":300,"end":314,"id":63,"ws":true},{"text":"was","start":315,"end":318,"id":64,"ws":true},{"text":"given","start":319,"end":324,"id":65,"ws":true},{"text":",","start":325,"end":326,"id":66,"ws":true},{"text":"followed","start":327,"end":335,"id":67,"ws":true},{"text":"by","start":336,"end":338,"id":68,"ws":true},{"text":"a","start":339,"end":340,"id":69,"ws":true},{"text":"continuous","start":341,"end":351,"id":70,"ws":true},{"text":"intravenous","start":352,"end":363,"id":71,"ws":true},{"text":"infusion","start":364,"end":372,"id":72,"ws":true},{"text":"of","start":373,"end":375,"id":73,"ws":true},{"text":"the","start":376,"end":379,"id":74,"ws":true},{"text":"same","start":380,"end":384,"id":75,"ws":true},{"text":"agent","start":385,"end":390,"id":76,"ws":true},{"text":"for","start":391,"end":394,"id":77,"ws":true},{"text":"30","start":395,"end":397,"id":78,"ws":true},{"text":"min","start":398,"end":401,"id":79,"ws":true},{"text":".","start":402,"end":403,"id":80,"ws":false}],"spans":[{"start":88,"end":97,"token_start":17,"token_end":17,"label":"DRUG"},{"start":133,"end":142,"token_start":30,"token_end":30,"label":"DRUG"},{"start":274,"end":287,"token_start":59,"token_end":59,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8017645/","_input_hash":990949207,"_task_hash":1588274997,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":17,"child":30,"head_span":{"start":88,"end":97,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":133,"end":142,"token_start":30,"token_end":30,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":30,"child":57,"head_span":{"start":133,"end":142,"token_start":30,"token_end":30,"label":"DRUG"},"child_span":{"start":262,"end":271,"token_start":57,"token_end":57,"label":null},"color":"#c5bdf4","label":"POS1"},{"head":17,"child":30,"head_span":{"start":88,"end":97,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":133,"end":142,"token_start":30,"token_end":30,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":30,"child":59,"head_span":{"start":133,"end":142,"token_start":30,"token_end":30,"label":"DRUG"},"child_span":{"start":274,"end":287,"token_start":59,"token_end":59,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["POS11"],"answer":"accept"}
{"text":"compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>busulfan</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>conditioning</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>allogeneic</i></b> <b style='color:DodgerBlue;'><i>stem</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>transplant</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>matched</i></b> <b style='color:DodgerBlue;'><i>siblings</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>unrelated</i></b> <b style='color:DodgerBlue;'><i>donors</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>myeloid</i></b> <b style='color:DodgerBlue;'><i>leukemia</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3><b style='color:Tomato;'><i>busulfan</i></b> plus <b style='color:Tomato;'><i>cyclophosphamide</i></b> (BuCy) is the traditional conditioning regimen for allogeneic stem cell transplant (allo-SCT) for young, fit patients with acute myeloid leukemia (AML). The <b style='color:Tomato;'><i>thiotepa</i></b>-<b style='color:Tomato;'><i>busulfan</i></b>-<b style='color:Tomato;'><i>fludarabine</i></b> (TBF) protocol has recently demonstrated promising outcome in cord blood and haploidentical SCT; however, there is limited evidence about this regimen in transplant from matched siblings (MSD) and unrelated donors (UD). We retrospectively compared outcomes of 2523 patients aged 18-50 with AML in remission, undergoing transplant from MSD or UD prepared with either TBF or BuCy conditioning. A 1:3 pair-matched analysis was performed: 146 patients receiving TBF were compared with 438 patients receiving BuCy. Relapse risk was significantly lower in the TBF when compared with BuCy group (HR 0.6, P\u2009=\u2009.02), while NRM did not differ. No significant difference was observed in LFS and OS between the two regimens. TBF was associated with a trend towards higher risk of grades III-IV aGVHD (HR 1.8, P\u2009=\u2009.06) and inferior cGVHD (HR 0.7, P\u2009=\u2009.04) when compared with BuCy. In patients undergoing transplant in first remission, the advantage for TBF in terms of relapse was more evident (HR 0.4, P\u2009=\u2009.02), leading to a trend for better LFS in favor of TBF (HR 0.7, P\u2009=\u2009.10), while OS did not differ between the two cohorts. In conclusion, TBF represents a valid myeloablative conditioning regimen providing significantly lower relapse and similar survival when compared with BuCy. Patients in first remission appear to gain the most from this protocol, as in this subgroup a tendency for better LFS was observed when compared with BuCy.","tokens":[{"text":"compared","start":0,"end":8,"id":0,"ws":true},{"text":"to","start":9,"end":11,"id":1,"ws":true},{"text":"busulfan","start":12,"end":20,"id":2,"ws":true},{"text":"and","start":21,"end":24,"id":3,"ws":true},{"text":"cyclophosphamide","start":25,"end":41,"id":4,"ws":true},{"text":"as","start":42,"end":44,"id":5,"ws":true},{"text":"conditioning","start":45,"end":57,"id":6,"ws":true},{"text":"regimen","start":58,"end":65,"id":7,"ws":true},{"text":"for","start":66,"end":69,"id":8,"ws":true},{"text":"allogeneic","start":70,"end":80,"id":9,"ws":true},{"text":"stem","start":81,"end":85,"id":10,"ws":true},{"text":"cell","start":86,"end":90,"id":11,"ws":true},{"text":"transplant","start":91,"end":101,"id":12,"ws":true},{"text":"from","start":102,"end":106,"id":13,"ws":true},{"text":"matched","start":107,"end":114,"id":14,"ws":true},{"text":"siblings","start":115,"end":123,"id":15,"ws":true},{"text":"and","start":124,"end":127,"id":16,"ws":true},{"text":"unrelated","start":128,"end":137,"id":17,"ws":true},{"text":"donors","start":138,"end":144,"id":18,"ws":true},{"text":"for","start":145,"end":148,"id":19,"ws":true},{"text":"acute","start":149,"end":154,"id":20,"ws":true},{"text":"myeloid","start":155,"end":162,"id":21,"ws":true},{"text":"leukemia","start":163,"end":171,"id":22,"ws":true},{"text":".","start":172,"end":173,"id":23,"ws":false}],"spans":[{"start":12,"end":20,"token_start":2,"token_end":2,"label":"DRUG"},{"start":25,"end":41,"token_start":4,"token_end":4,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30033639/","_input_hash":1876764133,"_task_hash":-612169712,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":2,"child":4,"head_span":{"start":12,"end":20,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":25,"end":41,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Posttransplant immunosuppression to prevent graft-versus-host disease ( GVHD ) consisted of cyclosporine and prednisone ( CSA/PSE ) .","paragraph":"<h3><u>A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study.</u></h3>Two novel preparatory regimens for conditioning of patients with leukemia for allogeneic bone marrow transplantation (BMT) from histocompatible sibling donors have been tested in a phase III trial under the auspices of the Southwest Oncology Group (SWOG 8612). These two regimens consisted either of fractionated total body irradiation and <b style='color:Tomato;'><i>etoposide</i></b> (FTBI/VP-16) or high-dose <b style='color:Tomato;'><i>busulfan</i></b> with <b style='color:Tomato;'><i>cyclophosphamide</i></b> (BU/CY). Only patients who had failed prior conventional management at least once were study eligible, ie, no patients with acute leukemia in first remission (CR) or in first chronic phase (CP) of chronic myelogenous leukemia (CML) participated. Patients were stratified according to the following risk criteria: \"good-risk\" patients were those who were in second CR of their acute leukemia or in accelerated phase (AP) of CML; \"poor-risk\" patients had further advanced stages of leukemia. During a 52-month period, 131 patients were registered of whom 122 (93%) were study eligible. Sixty-one eligible patients were randomized to the FTBI/VP-16 arm and 61 to the BU/CY regimen. Of these 122 patients, 114 (93%) proceeded to BMT according to protocol. <b style='color:DodgerBlue;'><i>Posttransplant</i></b> <b style='color:DodgerBlue;'><i>immunosuppression</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>prevent</i></b> <b style='color:DodgerBlue;'><i>graft-versus-host</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>GVHD</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>consisted</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclosporine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CSA/PSE</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Neither overall survival nor disease-free survival (DFS) differed significantly between the two treatment groups (P = .89 and .69, respectively). Estimated DFS for \"good-risk\" patients who had been prepared with the FTBI/VP-16 regimen was 55% +/- 11%, as compared with patients treated with BU/CY whose DFS figure was 34% +/- 10% (P = .30). For \"poor-risk\" candidates, the DFS rates at 24 months were 17% +/- 6% (for FTBI/VP-16) and 24% +/- 8% (for BU/CY), respectively (P = .81). These figures do not differ significantly, especially in view of the fact that the \"good-risk\" patients prepared with the FTBI/VP-16 regimen were younger than those treated with BU/CY. Both regimens were well tolerated with no regimen-related deaths encountered during the 6-week period after BMT. This study also confirmed the efficacy of the CSA/PSE combination in the prevention of GVHD with 23 of 113 (20%) of BMT recipients developing moderate to severe acute GVHD. The leading cause for treatment failure was leukemic relapse (45 of the 114 BMT recipients suffered a recurrence of their leukemia), whereas 38 patients died without evidence of relapse. Thirty-one patients are alive and in continued CR after marrow transplantation; four are alive in relapse.(ABSTRACT TRUNCATED AT 400 WORDS)","tokens":[{"text":"Posttransplant","start":0,"end":14,"id":0,"ws":true},{"text":"immunosuppression","start":15,"end":32,"id":1,"ws":true},{"text":"to","start":33,"end":35,"id":2,"ws":true},{"text":"prevent","start":36,"end":43,"id":3,"ws":true},{"text":"graft-versus-host","start":44,"end":61,"id":4,"ws":true},{"text":"disease","start":62,"end":69,"id":5,"ws":true},{"text":"(","start":70,"end":71,"id":6,"ws":true},{"text":"GVHD","start":72,"end":76,"id":7,"ws":true},{"text":")","start":77,"end":78,"id":8,"ws":true},{"text":"consisted","start":79,"end":88,"id":9,"ws":true},{"text":"of","start":89,"end":91,"id":10,"ws":true},{"text":"cyclosporine","start":92,"end":104,"id":11,"ws":true},{"text":"and","start":105,"end":108,"id":12,"ws":true},{"text":"prednisone","start":109,"end":119,"id":13,"ws":true},{"text":"(","start":120,"end":121,"id":14,"ws":true},{"text":"CSA/PSE","start":122,"end":129,"id":15,"ws":true},{"text":")","start":130,"end":131,"id":16,"ws":true},{"text":".","start":132,"end":133,"id":17,"ws":false}],"spans":[{"start":92,"end":104,"token_start":11,"token_end":11,"label":"DRUG"},{"start":109,"end":119,"token_start":13,"token_end":13,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8471778/","_input_hash":429142376,"_task_hash":-658872070,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":11,"child":13,"head_span":{"start":92,"end":104,"token_start":11,"token_end":11,"label":"DRUG"},"child_span":{"start":109,"end":119,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Tadalafil 20 mg was preferred to sildenafil 50 mg for the initiation of ED therapy in this study population .","paragraph":"<h3><u>A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction.</u></h3><b style='color:Tomato;'><i>tadalafil</i></b> is a phosphodiesterase 5 (PDE5) inhibitor approved in >30 countries for the treatment of erectile dysfunction (ED). It has been shown to improve erectile function compared with placebo in Phase III studies, but clinical experience comparing <b style='color:Tomato;'><i>tadalafil</i></b> with the PDE5 inhibitor <b style='color:Tomato;'><i>sildenafil</i></b> citrate is lacking. ### objective This study compared patient preference for <b style='color:Tomato;'><i>tadalafil</i></b> 20 mg or <b style='color:Tomato;'><i>sildenafil</i></b> 50 mg during initial treatment for ED. It also compared the tolerability of the 2 agents at these doses. ### methods This randomized, double-blind, fixed-dose, 2-period crossover trial took place at 13 sites in the United States and Germany. Patients were randomized 1:1 to receive 4 weeks of treatment with <b style='color:Tomato;'><i>tadalafil</i></b> 20 mg or <b style='color:Tomato;'><i>sildenafil</i></b> 50 mg, followed by the alternative treatment, to be taken as needed up to once daily before sexual activity. ### results The study enrolled 215 men with ED, 109 randomized to the <b style='color:Tomato;'><i>tadalafil</i></b>-<b style='color:Tomato;'><i>sildenafil</i></b> sequence and 106 to the <b style='color:Tomato;'><i>sildenafil</i></b>-<b style='color:Tomato;'><i>tadalafil</i></b> sequence. Their mean age was 49.8 years; 84.7% were <b style='color:Tomato;'><i>sildenafil</i></b> naive and 15.3% had undergone a previous inadequate trial of <b style='color:Tomato;'><i>sildenafil</i></b>. Most patients had moderate ED (60.5%) of >or=1 year's duration (74.9%). Of 190 evaluable patients, 126 (66.3%) preferred to initiate treatment with <b style='color:Tomato;'><i>tadalafil</i></b>, compared with 64 (33.7%) with <b style='color:Tomato;'><i>sildenafil</i></b> (P < 0.001). Patients' preference did not differ by age, duration of ED, treatment sequence, or previous <b style='color:Tomato;'><i>sildenafil</i></b> exposure. Both medications were well tolerated, with no significant differences in the incidence of treatment-emergent adverse events. Headache (11.2% <b style='color:Tomato;'><i>tadalafil</i></b>, 8.8% <b style='color:Tomato;'><i>sildenafil</i></b>), dyspepsia (6.0% and 4.2%, respectively), nasopharyngitis (4.7% and 2.8%), and flushing (2.8% and 4.7%) were the most common adverse events. The rate of ocular disturbances was low: 1 patient experienced intermittent bilateral reduction in visual acuity with <b style='color:Tomato;'><i>tadalafil</i></b>, and 2 exhibited conjunctival hyperemia or eyelid edema with <b style='color:Tomato;'><i>sildenafil</i></b>. ### conclusions <b style='color:MediumOrchid;'><i>Tadalafil</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>preferred</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>sildenafil</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>initiation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>ED</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>population</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Both medications were well tolerated.","tokens":[{"text":"Tadalafil","start":0,"end":9,"id":0,"ws":true},{"text":"20","start":10,"end":12,"id":1,"ws":true},{"text":"mg","start":13,"end":15,"id":2,"ws":true},{"text":"was","start":16,"end":19,"id":3,"ws":true},{"text":"preferred","start":20,"end":29,"id":4,"ws":true},{"text":"to","start":30,"end":32,"id":5,"ws":true},{"text":"sildenafil","start":33,"end":43,"id":6,"ws":true},{"text":"50","start":44,"end":46,"id":7,"ws":true},{"text":"mg","start":47,"end":49,"id":8,"ws":true},{"text":"for","start":50,"end":53,"id":9,"ws":true},{"text":"the","start":54,"end":57,"id":10,"ws":true},{"text":"initiation","start":58,"end":68,"id":11,"ws":true},{"text":"of","start":69,"end":71,"id":12,"ws":true},{"text":"ED","start":72,"end":74,"id":13,"ws":true},{"text":"therapy","start":75,"end":82,"id":14,"ws":true},{"text":"in","start":83,"end":85,"id":15,"ws":true},{"text":"this","start":86,"end":90,"id":16,"ws":true},{"text":"study","start":91,"end":96,"id":17,"ws":true},{"text":"population","start":97,"end":107,"id":18,"ws":true},{"text":".","start":108,"end":109,"id":19,"ws":false}],"spans":[{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},{"start":33,"end":43,"token_start":6,"token_end":6,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/14693299/","_input_hash":1795396788,"_task_hash":1898892622,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Reactivity of factor IXa with basic pancreatic trypsin inhibitor is enhanced by low molecular weight heparin ( enoxaparin ) .","paragraph":"<h3><u>Heparin modulates the 99-loop of factor IXa: effects on reactivity with isolated Kunitz-type inhibitor domains.</u></h3> <b style='color:DodgerBlue;'><i>Reactivity</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>factor</i></b> <b style='color:DodgerBlue;'><i>IXa</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>basic</i></b> <b style='color:DodgerBlue;'><i>pancreatic</i></b> <b style='color:DodgerBlue;'><i>trypsin</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>enhanced</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>low</i></b> <b style='color:DodgerBlue;'><i>molecular</i></b> <b style='color:DodgerBlue;'><i>weight</i></b> <b style='color:MediumOrchid;'><i>heparin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>enoxaparin</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Previous studies by us have suggested that this effect involves allosteric modulation of factor IXa. We examined the reactivity of factor IXa with several isolated Kunitz-type inhibitor domains: basic pancreatic trypsin inhibitor, the Kunitz inhibitor domain of protease Nexin-2, and the first two inhibitor domains of tissue factor pathway inhibitor. We find that enhancement of factor IXa reactivity by <b style='color:Tomato;'><i>enoxaparin</i></b> is greatest for basic pancreatic trypsin inhibitor (>10-fold), followed by the second tissue factor pathway inhibitor domain (1.7-fold) and the Kunitz inhibitor domain of protease Nexin-2 (1.4-fold). Modeling studies of factor IXa with basic pancreatic trypsin inhibitor suggest that binding of this inhibitor is sterically hindered by the 99-loop of factor IXa, specifically residue Lys(98). Slow-binding kinetic studies support the formation of a weak initial enzyme-inhibitor complex between factor IXa and basic pancreatic trypsin inhibitor that is facilitated by <b style='color:Tomato;'><i>enoxaparin</i></b> binding. Mutation of Lys(98) to Ala in factor IXa results in enhanced reactivity with all inhibitors examined, whereas almost completely abrogating the enhancing effects of <b style='color:Tomato;'><i>enoxaparin</i></b>. The results implicate Lys(98) and the 99-loop of factor IXa in defining enzyme inhibitor specificity. More importantly, these results demonstrate the ability of factor IXa to be allosterically modulated by occupation of the <b style='color:Tomato;'><i>heparin</i></b>-binding exosite.","tokens":[{"text":"Reactivity","start":0,"end":10,"id":0,"ws":true},{"text":"of","start":11,"end":13,"id":1,"ws":true},{"text":"factor","start":14,"end":20,"id":2,"ws":true},{"text":"IXa","start":21,"end":24,"id":3,"ws":true},{"text":"with","start":25,"end":29,"id":4,"ws":true},{"text":"basic","start":30,"end":35,"id":5,"ws":true},{"text":"pancreatic","start":36,"end":46,"id":6,"ws":true},{"text":"trypsin","start":47,"end":54,"id":7,"ws":true},{"text":"inhibitor","start":55,"end":64,"id":8,"ws":true},{"text":"is","start":65,"end":67,"id":9,"ws":true},{"text":"enhanced","start":68,"end":76,"id":10,"ws":true},{"text":"by","start":77,"end":79,"id":11,"ws":true},{"text":"low","start":80,"end":83,"id":12,"ws":true},{"text":"molecular","start":84,"end":93,"id":13,"ws":true},{"text":"weight","start":94,"end":100,"id":14,"ws":true},{"text":"heparin","start":101,"end":108,"id":15,"ws":true},{"text":"(","start":109,"end":110,"id":16,"ws":true},{"text":"enoxaparin","start":111,"end":121,"id":17,"ws":true},{"text":")","start":122,"end":123,"id":18,"ws":true},{"text":".","start":124,"end":125,"id":19,"ws":false}],"spans":[{"start":101,"end":108,"token_start":15,"token_end":15,"label":"DRUG"},{"start":111,"end":121,"token_start":17,"token_end":17,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16766524/","_input_hash":1757287926,"_task_hash":1025618689,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Either 5-fluorouracil ( 5-FU ) and leucovorin for 6 months or 5-FU and levamisole for 12 months are currently considered standard adjuvant treatment for stage III colorectal cancer .","paragraph":"<h3><u>National Cancer Institute Clinical Trials Program in Colorectal Cancer.</u></h3>Colorectal cancer will be diagnosed in approximately 150,000 patients in the USA this year. Chemotherapy has recently been shown to improve survival when given as adjuvant therapy to surgery in patients with stage III colorectal cancer. Demonstration of this benefit required large, randomized controlled trials. <b style='color:DodgerBlue;'><i>Either</i></b> <b style='color:DodgerBlue;'><i>5-fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5-FU</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>leucovorin</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>5-FU</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>levamisole</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>12</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>currently</i></b> <b style='color:DodgerBlue;'><i>considered</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>adjuvant</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>colorectal</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, current adjuvant trials are comparing continuous infusion and intravenous bolus 5-FU regimens and oral uracil/Ftorafur with intravenous 5-FU and <b style='color:Tomato;'><i>leucovorin</i></b>, as well as studying the timing of chemotherapy in the adjuvant setting. Subsequent adjuvant trials will examine newer regimens with activity in advanced colorectal cancer, as well as the efficacy of monoclonal antibodies. Other trials will study which type of surgery is optimal and whether adjuvant therapy is helpful in stage II colon cancer. Trials in metastatic disease will focus on combinations of newer agents which may improve survival in this patient group. Studies in rectal cancer will focus on determining which agents are optimal in combination with radiation therapy in the adjuvant setting. Molecular characteristics of tumor cells are being defined, which may guide therapy in the future. Careful, logically designed clinical trials will hopefully provide more efficacious therapy for this common cancer.","tokens":[{"text":"Either","start":0,"end":6,"id":0,"ws":true},{"text":"5-fluorouracil","start":7,"end":21,"id":1,"ws":true},{"text":"(","start":22,"end":23,"id":2,"ws":true},{"text":"5-FU","start":24,"end":28,"id":3,"ws":true},{"text":")","start":29,"end":30,"id":4,"ws":true},{"text":"and","start":31,"end":34,"id":5,"ws":true},{"text":"leucovorin","start":35,"end":45,"id":6,"ws":true},{"text":"for","start":46,"end":49,"id":7,"ws":true},{"text":"6","start":50,"end":51,"id":8,"ws":true},{"text":"months","start":52,"end":58,"id":9,"ws":true},{"text":"or","start":59,"end":61,"id":10,"ws":true},{"text":"5-FU","start":62,"end":66,"id":11,"ws":true},{"text":"and","start":67,"end":70,"id":12,"ws":true},{"text":"levamisole","start":71,"end":81,"id":13,"ws":true},{"text":"for","start":82,"end":85,"id":14,"ws":true},{"text":"12","start":86,"end":88,"id":15,"ws":true},{"text":"months","start":89,"end":95,"id":16,"ws":true},{"text":"are","start":96,"end":99,"id":17,"ws":true},{"text":"currently","start":100,"end":109,"id":18,"ws":true},{"text":"considered","start":110,"end":120,"id":19,"ws":true},{"text":"standard","start":121,"end":129,"id":20,"ws":true},{"text":"adjuvant","start":130,"end":138,"id":21,"ws":true},{"text":"treatment","start":139,"end":148,"id":22,"ws":true},{"text":"for","start":149,"end":152,"id":23,"ws":true},{"text":"stage","start":153,"end":158,"id":24,"ws":true},{"text":"III","start":159,"end":162,"id":25,"ws":true},{"text":"colorectal","start":163,"end":173,"id":26,"ws":true},{"text":"cancer","start":174,"end":180,"id":27,"ws":true},{"text":".","start":181,"end":182,"id":28,"ws":false}],"spans":[{"start":35,"end":45,"token_start":6,"token_end":6,"label":"DRUG"},{"start":71,"end":81,"token_start":13,"token_end":13,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9750034/","_input_hash":-1591298255,"_task_hash":-348111942,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":3,"child":6,"head_span":{"start":24,"end":28,"token_start":3,"token_end":3,"label":null},"child_span":{"start":35,"end":45,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":11,"child":13,"head_span":{"start":62,"end":66,"token_start":11,"token_end":11,"label":null},"child_span":{"start":71,"end":81,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS10","POS20"],"answer":"accept"}
{"text":"Postmenopausal women with stage I-IIIA hormone receptor-positive breast cancer , who were disease-free after about 5 years of treatment with an aromatase inhibitor or tamoxifen followed by an aromatase inhibitor , were randomly assigned ( 1:1 ) to receive 5 years of letrozole ( 2\u00b75 mg orally per day ) or placebo .","paragraph":"<h3><u>Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.</u></h3>The optimal duration of extended therapy with aromatase inhibitors in patients with postmenopausal breast cancer is unknown. In the NSABP B-42 study, we aimed to determine whether extended <b style='color:Tomato;'><i>letrozole</i></b> treatment improves disease-free survival after 5 years of aromatase inhibitor-based therapy in women with postmenopausal breast cancer. ### methods This randomised, double-blind, placebo-controlled, phase 3 trial was done in 158 centres in the USA, Canada, and Ireland. <b style='color:DodgerBlue;'><i>Postmenopausal</i></b> <b style='color:DodgerBlue;'><i>women</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>I-IIIA</i></b> <b style='color:DodgerBlue;'><i>hormone</i></b> <b style='color:DodgerBlue;'><i>receptor-positive</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>disease-free</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>about</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>years</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>aromatase</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>aromatase</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>randomly</i></b> <b style='color:DodgerBlue;'><i>assigned</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>1:1</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>years</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>letrozole</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>2\u00b75</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>orally</i></b> <b style='color:DodgerBlue;'><i>per</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>placebo</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Randomisation was stratified by pathological node status, previous <b style='color:Tomato;'><i>tamoxifen</i></b> use, and lowest bone mineral density T score in the lumbosacral spine, total hip, or femoral neck. The primary endpoint was disease-free survival, defined as time from randomisation to breast cancer recurrence, second primary malignancy, or death, and was analysed by intention to treat. To adjust for previous interim analyses, the two-sided statistical significance level for disease-free survival was set at 0\u00b70418. This study is registered with ClinicalTrials.gov, number NCT00382070, is active, and is no longer enrolling patients. ### findings Between Sept 28, 2006, and Jan 6, 2010, 3966 patients were randomly assigned to receive <b style='color:Tomato;'><i>letrozole</i></b> (n=1983) or placebo (n=1983). Follow-up information was available for 3903 patients for the analyses of disease-free survival. Median follow-up was 6\u00b79 years (IQR 6\u00b71-7\u00b75). <b style='color:Tomato;'><i>letrozole</i></b> treatment did not significantly improve disease-free survival (339 disease-free survival events were reported in the placebo group and 292 disease-free survival events were reported in the <b style='color:Tomato;'><i>letrozole</i></b> group; hazard ratio 0\u00b785, 95% CI 0\u00b773-0\u00b7999; p=0\u00b7048). 7-year disease-free survival estimate was 81\u00b73% (95% CI 79\u00b73-83\u00b71) in the placebo group and 84\u00b77% (82\u00b79-86\u00b74) in the <b style='color:Tomato;'><i>letrozole</i></b> group. The most common grade 3 adverse events were arthralgia (47 [2%] of 1933 patients in the placebo group vs 50 [3%] of 1941 patients in the <b style='color:Tomato;'><i>letrozole</i></b> group) and back pain (44 [2%] vs 38 [2%]). The most common grade 4 adverse event in the placebo group was thromboembolic event (eight [<1%]) and the most common grade 4 adverse events in the <b style='color:Tomato;'><i>letrozole</i></b> group were urinary tract infection, hypokalaemia, and left ventricular systolic dysfunction (four [<1%] each). ### interpretation After 5 years of aromatase inhibitor-based therapy, 5 years of <b style='color:Tomato;'><i>letrozole</i></b> therapy did not significantly prolong disease-free survival compared with placebo. Careful assessment of potential risks and benefits is required before recommending extended <b style='color:Tomato;'><i>letrozole</i></b> therapy to patients with early-stage breast cancer. ### funding National Cancer Institute, Korea Health Technology R&D Project, Novartis.","tokens":[{"text":"Postmenopausal","start":0,"end":14,"id":0,"ws":true},{"text":"women","start":15,"end":20,"id":1,"ws":true},{"text":"with","start":21,"end":25,"id":2,"ws":true},{"text":"stage","start":26,"end":31,"id":3,"ws":true},{"text":"I-IIIA","start":32,"end":38,"id":4,"ws":true},{"text":"hormone","start":39,"end":46,"id":5,"ws":true},{"text":"receptor-positive","start":47,"end":64,"id":6,"ws":true},{"text":"breast","start":65,"end":71,"id":7,"ws":true},{"text":"cancer","start":72,"end":78,"id":8,"ws":true},{"text":",","start":79,"end":80,"id":9,"ws":true},{"text":"who","start":81,"end":84,"id":10,"ws":true},{"text":"were","start":85,"end":89,"id":11,"ws":true},{"text":"disease-free","start":90,"end":102,"id":12,"ws":true},{"text":"after","start":103,"end":108,"id":13,"ws":true},{"text":"about","start":109,"end":114,"id":14,"ws":true},{"text":"5","start":115,"end":116,"id":15,"ws":true},{"text":"years","start":117,"end":122,"id":16,"ws":true},{"text":"of","start":123,"end":125,"id":17,"ws":true},{"text":"treatment","start":126,"end":135,"id":18,"ws":true},{"text":"with","start":136,"end":140,"id":19,"ws":true},{"text":"an","start":141,"end":143,"id":20,"ws":true},{"text":"aromatase","start":144,"end":153,"id":21,"ws":true},{"text":"inhibitor","start":154,"end":163,"id":22,"ws":true},{"text":"or","start":164,"end":166,"id":23,"ws":true},{"text":"tamoxifen","start":167,"end":176,"id":24,"ws":true},{"text":"followed","start":177,"end":185,"id":25,"ws":true},{"text":"by","start":186,"end":188,"id":26,"ws":true},{"text":"an","start":189,"end":191,"id":27,"ws":true},{"text":"aromatase","start":192,"end":201,"id":28,"ws":true},{"text":"inhibitor","start":202,"end":211,"id":29,"ws":true},{"text":",","start":212,"end":213,"id":30,"ws":true},{"text":"were","start":214,"end":218,"id":31,"ws":true},{"text":"randomly","start":219,"end":227,"id":32,"ws":true},{"text":"assigned","start":228,"end":236,"id":33,"ws":true},{"text":"(","start":237,"end":238,"id":34,"ws":true},{"text":"1:1","start":239,"end":242,"id":35,"ws":true},{"text":")","start":243,"end":244,"id":36,"ws":true},{"text":"to","start":245,"end":247,"id":37,"ws":true},{"text":"receive","start":248,"end":255,"id":38,"ws":true},{"text":"5","start":256,"end":257,"id":39,"ws":true},{"text":"years","start":258,"end":263,"id":40,"ws":true},{"text":"of","start":264,"end":266,"id":41,"ws":true},{"text":"letrozole","start":267,"end":276,"id":42,"ws":true},{"text":"(","start":277,"end":278,"id":43,"ws":true},{"text":"2\u00b75","start":279,"end":282,"id":44,"ws":true},{"text":"mg","start":283,"end":285,"id":45,"ws":true},{"text":"orally","start":286,"end":292,"id":46,"ws":true},{"text":"per","start":293,"end":296,"id":47,"ws":true},{"text":"day","start":297,"end":300,"id":48,"ws":true},{"text":")","start":301,"end":302,"id":49,"ws":true},{"text":"or","start":303,"end":305,"id":50,"ws":true},{"text":"placebo","start":306,"end":313,"id":51,"ws":true},{"text":".","start":314,"end":315,"id":52,"ws":false}],"spans":[{"start":167,"end":176,"token_start":24,"token_end":24,"label":"DRUG"},{"start":267,"end":276,"token_start":42,"token_end":42,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30509771/","_input_hash":-1556521820,"_task_hash":-663735523,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Efficacy of sorafenib combined with the pan-CDK inhibitor flavopiridol was tested both in vitro and in xenograft experiments .","paragraph":"<h3><u>Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.</u></h3>To clarify the effects of cyclin E1 suppression on antitumor efficacy of <b style='color:Tomato;'><i>sorafenib</i></b> in hepatocellular carcinoma cells and to explore the potential of combining <b style='color:Tomato;'><i>sorafenib</i></b> with cyclin-dependent kinase (CDK) inhibition in therapy. ### Experimental Design The effects of cyclin E1 suppression on <b style='color:Tomato;'><i>sorafenib</i></b>-induced apoptosis were tested in both <b style='color:Tomato;'><i>sorafenib</i></b>-sensitive (Huh-7 and HepG2, IC50 5-6 \u03bcmol/L) and <b style='color:Tomato;'><i>sorafenib</i></b>-resistant (Huh-7R and HepG2R, IC50 14-15 \u03bcmol/L) hepatocellular carcinoma cells. The activity of pertinent signaling pathways and the expression of cell cycle and apoptosis-related proteins were measured using Western blotting. <b style='color:DodgerBlue;'><i>Efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>sorafenib</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>pan-CDK</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:MediumOrchid;'><i>flavopiridol</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>tested</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>xenograft</i></b> <b style='color:DodgerBlue;'><i>experiments</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The pertinent downstream mediators of antitumor efficacy were tested in transient transfection and RNA interference experiments. ### results Cyclin E1 mRNA and protein expressions were suppressed after <b style='color:Tomato;'><i>sorafenib</i></b> treatment in <b style='color:Tomato;'><i>sorafenib</i></b>-sensitive but not in <b style='color:Tomato;'><i>sorafenib</i></b>-resistant hepatocellular carcinoma cells. Changes in cyclin E2 or D1 were not correlated with <b style='color:Tomato;'><i>sorafenib</i></b> sensitivity. The knockdown of cyclin E1 expression reversed the resistance of hepatocellular carcinoma cells to <b style='color:Tomato;'><i>sorafenib</i></b> in terms of cell growth and apoptosis induction, whereas the overexpression of cyclin E1 increased the resistance to <b style='color:Tomato;'><i>sorafenib</i></b>. The growth-inhibitory and apoptosis-inducing effects of <b style='color:Tomato;'><i>sorafenib</i></b> were enhanced by <b style='color:Tomato;'><i>flavopiridol</i></b>, and Mcl-1 suppression was determined to play a critical role in mediating this enhancing effect. ### conclusions The cyclin E1 suppression in hepatocellular carcinoma cells may serve as a pharmacodynamic biomarker for predicting <b style='color:Tomato;'><i>sorafenib</i></b> efficacy. The combination of <b style='color:Tomato;'><i>sorafenib</i></b> and CDK inhibitors may improve the efficacy of <b style='color:Tomato;'><i>sorafenib</i></b> in hepatocellular carcinoma. Clin Cancer Res; 22(10); 2555-64. \u00a92015 AACR.","tokens":[{"text":"Efficacy","start":0,"end":8,"id":0,"ws":true},{"text":"of","start":9,"end":11,"id":1,"ws":true},{"text":"sorafenib","start":12,"end":21,"id":2,"ws":true},{"text":"combined","start":22,"end":30,"id":3,"ws":true},{"text":"with","start":31,"end":35,"id":4,"ws":true},{"text":"the","start":36,"end":39,"id":5,"ws":true},{"text":"pan-CDK","start":40,"end":47,"id":6,"ws":true},{"text":"inhibitor","start":48,"end":57,"id":7,"ws":true},{"text":"flavopiridol","start":58,"end":70,"id":8,"ws":true},{"text":"was","start":71,"end":74,"id":9,"ws":true},{"text":"tested","start":75,"end":81,"id":10,"ws":true},{"text":"both","start":82,"end":86,"id":11,"ws":true},{"text":"in","start":87,"end":89,"id":12,"ws":true},{"text":"vitro","start":90,"end":95,"id":13,"ws":true},{"text":"and","start":96,"end":99,"id":14,"ws":true},{"text":"in","start":100,"end":102,"id":15,"ws":true},{"text":"xenograft","start":103,"end":112,"id":16,"ws":true},{"text":"experiments","start":113,"end":124,"id":17,"ws":true},{"text":".","start":125,"end":126,"id":18,"ws":false}],"spans":[{"start":12,"end":21,"token_start":2,"token_end":2,"label":"DRUG"},{"start":58,"end":70,"token_start":8,"token_end":8,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26603262/","_input_hash":1581641631,"_task_hash":1918393341,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":2,"child":8,"head_span":{"start":12,"end":21,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":58,"end":70,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Codelivery of sorafenib and curcumin by directed self-assembled nanoparticles enhances therapeutic effect on hepatocellular carcinoma .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Codelivery</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>sorafenib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>curcumin</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>directed</i></b> <b style='color:DodgerBlue;'><i>self-assembled</i></b> <b style='color:DodgerBlue;'><i>nanoparticles</i></b> <b style='color:DodgerBlue;'><i>enhances</i></b> <b style='color:DodgerBlue;'><i>therapeutic</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>hepatocellular</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related mortality worldwide. Herein, we first reported the codelivery of <b style='color:Tomato;'><i>sorafenib</i></b> and <b style='color:Tomato;'><i>curcumin</i></b> by directed self-assembled nanoparticles (SCN) to enhance the therapeutic effect on HCC. SCN was formed by employing the hydrophobic interactions among the lipophilic structure in <b style='color:Tomato;'><i>sorafenib</i></b>, <b style='color:Tomato;'><i>curcumin</i></b>, and similar hydrophobic segments of polyethylene glycol derivative of vitamin E succinate (PEG-VES), which comprised uniform spherical particles with particle size of 84.97 \u00b1 6.03 nm. SCN presented superior effects over <b style='color:Tomato;'><i>sorafenib</i></b>, <b style='color:Tomato;'><i>curcumin</i></b>, and their physical mixture (Sora + Cur) on enhancing in vitro cytotoxicity and cell apoptosis in BEL-7402 cells and Hep G2 cells, and antiangiogenesis activities in tube formation and microvessel formation from aortic rings. Moreover, the tissue concentration of <b style='color:Tomato;'><i>sorafenib</i></b> and <b style='color:Tomato;'><i>curcumin</i></b> in gastrointestinal tract and major organs were significantly improved after their coassembly into SCN. In particular, in BEL-7402 cells induced tumor xenograft, SCN treatment displayed the obviously enhanced inhibitory effect on tumor progression over free drug monotherapy or their physical mixture, with significantly increased antiproliferation and antiangiogenesis capability. Thereby, the codelivered nanoassemblies of <b style='color:Tomato;'><i>sorafenib</i></b> and <b style='color:Tomato;'><i>curcumin</i></b> provided a promising strategy to enhance the combinational therapy of HCC.","tokens":[{"text":"Codelivery","start":0,"end":10,"id":0,"ws":true},{"text":"of","start":11,"end":13,"id":1,"ws":true},{"text":"sorafenib","start":14,"end":23,"id":2,"ws":true},{"text":"and","start":24,"end":27,"id":3,"ws":true},{"text":"curcumin","start":28,"end":36,"id":4,"ws":true},{"text":"by","start":37,"end":39,"id":5,"ws":true},{"text":"directed","start":40,"end":48,"id":6,"ws":true},{"text":"self-assembled","start":49,"end":63,"id":7,"ws":true},{"text":"nanoparticles","start":64,"end":77,"id":8,"ws":true},{"text":"enhances","start":78,"end":86,"id":9,"ws":true},{"text":"therapeutic","start":87,"end":98,"id":10,"ws":true},{"text":"effect","start":99,"end":105,"id":11,"ws":true},{"text":"on","start":106,"end":108,"id":12,"ws":true},{"text":"hepatocellular","start":109,"end":123,"id":13,"ws":true},{"text":"carcinoma","start":124,"end":133,"id":14,"ws":true},{"text":".","start":134,"end":135,"id":15,"ws":false}],"spans":[{"start":14,"end":23,"token_start":2,"token_end":2,"label":"DRUG"},{"start":28,"end":36,"token_start":4,"token_end":4,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25622075/","_input_hash":1279427679,"_task_hash":-1203458466,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":2,"child":4,"head_span":{"start":14,"end":23,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":28,"end":36,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Single treatment of closantel plus albendazole mixture reduced egg counts in camels by 100 % , 100 % , 98 % and 77 % for Haemonchus longistipes , Ascaris spp . , Monezia expansa and Fasciola hepatica , respectively .","paragraph":"<h3><u>Efficacy of closantel plus albendazole liquid suspension against natural infection of gastrointestinal parasites in camels.</u></h3>Oral administration of <b style='color:Tomato;'><i>closantel</i></b> in a dose of 10 mg/kg plus <b style='color:Tomato;'><i>albendazole</i></b> in a dose of 5 mg/kg liquid suspension was studied in 75 camels naturally infected with various types of gastrointestinal parasites. The camels involved were 15 pregnant she-camels, 20 non-pregnant she-camels and 40 male camels of various ages. Each camel received a single oral dose of <b style='color:Tomato;'><i>closantel</i></b> (10 mg/kg) plus <b style='color:Tomato;'><i>albendazole</i></b> (5 mg/kg) orally. Two weeks later, 20 camels of this group were re-dosed again with the same dose of the anthelmintic. Fecal samples were collected per rectum from all camels at the time of treatment and again 14 and 42 days post treatment. Fecal egg counts and generic determination of third stage larvae was performed. Results indicated that six different species of gastrointestinal tract parasites were identified in camels. <b style='color:DodgerBlue;'><i>Single</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>closantel</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>albendazole</i></b> <b style='color:DodgerBlue;'><i>mixture</i></b> <b style='color:DodgerBlue;'><i>reduced</i></b> <b style='color:DodgerBlue;'><i>egg</i></b> <b style='color:DodgerBlue;'><i>counts</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>camels</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>98</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>77</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>Haemonchus</i></b> <b style='color:DodgerBlue;'><i>longistipes</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Ascaris</i></b> <b style='color:DodgerBlue;'><i>spp</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Monezia</i></b> <b style='color:DodgerBlue;'><i>expansa</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Fasciola</i></b> <b style='color:DodgerBlue;'><i>hepatica</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, administration of the drug twice on the base of 2 weeks apart significantly raised the efficacy of the drug for clearance of the parasites from 92.5% to 100% in camels infected with various parasites. Camels were not adversely affected by treatment.","tokens":[{"text":"Single","start":0,"end":6,"id":0,"ws":true},{"text":"treatment","start":7,"end":16,"id":1,"ws":true},{"text":"of","start":17,"end":19,"id":2,"ws":true},{"text":"closantel","start":20,"end":29,"id":3,"ws":true},{"text":"plus","start":30,"end":34,"id":4,"ws":true},{"text":"albendazole","start":35,"end":46,"id":5,"ws":true},{"text":"mixture","start":47,"end":54,"id":6,"ws":true},{"text":"reduced","start":55,"end":62,"id":7,"ws":true},{"text":"egg","start":63,"end":66,"id":8,"ws":true},{"text":"counts","start":67,"end":73,"id":9,"ws":true},{"text":"in","start":74,"end":76,"id":10,"ws":true},{"text":"camels","start":77,"end":83,"id":11,"ws":true},{"text":"by","start":84,"end":86,"id":12,"ws":true},{"text":"100","start":87,"end":90,"id":13,"ws":true},{"text":"%","start":91,"end":92,"id":14,"ws":true},{"text":",","start":93,"end":94,"id":15,"ws":true},{"text":"100","start":95,"end":98,"id":16,"ws":true},{"text":"%","start":99,"end":100,"id":17,"ws":true},{"text":",","start":101,"end":102,"id":18,"ws":true},{"text":"98","start":103,"end":105,"id":19,"ws":true},{"text":"%","start":106,"end":107,"id":20,"ws":true},{"text":"and","start":108,"end":111,"id":21,"ws":true},{"text":"77","start":112,"end":114,"id":22,"ws":true},{"text":"%","start":115,"end":116,"id":23,"ws":true},{"text":"for","start":117,"end":120,"id":24,"ws":true},{"text":"Haemonchus","start":121,"end":131,"id":25,"ws":true},{"text":"longistipes","start":132,"end":143,"id":26,"ws":true},{"text":",","start":144,"end":145,"id":27,"ws":true},{"text":"Ascaris","start":146,"end":153,"id":28,"ws":true},{"text":"spp","start":154,"end":157,"id":29,"ws":true},{"text":".","start":158,"end":159,"id":30,"ws":true},{"text":",","start":160,"end":161,"id":31,"ws":true},{"text":"Monezia","start":162,"end":169,"id":32,"ws":true},{"text":"expansa","start":170,"end":177,"id":33,"ws":true},{"text":"and","start":178,"end":181,"id":34,"ws":true},{"text":"Fasciola","start":182,"end":190,"id":35,"ws":true},{"text":"hepatica","start":191,"end":199,"id":36,"ws":true},{"text":",","start":200,"end":201,"id":37,"ws":true},{"text":"respectively","start":202,"end":214,"id":38,"ws":true},{"text":".","start":215,"end":216,"id":39,"ws":false}],"spans":[{"start":20,"end":29,"token_start":3,"token_end":3,"label":"DRUG"},{"start":35,"end":46,"token_start":5,"token_end":5,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/10321589/","_input_hash":265346597,"_task_hash":-1009482935,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":3,"child":5,"head_span":{"start":20,"end":29,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":35,"end":46,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"In contrast to patients receiving lidocaine , older patients receiving tetracaine experienced significantly less overall pain and discomfort , unpleasant taste , and dyspnea .","paragraph":"<h3><u>A prospective, randomized, double-blind study comparing the efficacy of topical anesthetics in nasal endoscopy.</u></h3>Transnasal endoscopy is commonly performed in an outpatient otolaryngology setting. Patients are typically administered a topical anesthetic and decongestant prior to this procedure to alleviate discomfort and improve visualization. There is no consensus on which topical anesthetic is most effective in optimizing patient experience during the procedure. ### objective To determine whether there is a difference in the efficacy between atomized 2% <b style='color:Tomato;'><i>tetracaine</i></b> and 4% <b style='color:Tomato;'><i>lidocaine</i></b> as a topical anesthetic prior to transnasal endoscopy. ### Study Design Prospective, randomized, double-blind study. ### methods A total of 99 patients received oxymetazoline and were randomized to receive either 2% <b style='color:Tomato;'><i>tetracaine</i></b> or 4% <b style='color:Tomato;'><i>lidocaine</i></b> prior to transnasal endoscopy. Immediately following the procedure, participants completed a survey assessing level of discomfort and other adverse symptoms pertaining to the procedure using a 10-point visual analog scale (VAS). ### results There were no significant differences in VAS scores between the <b style='color:Tomato;'><i>lidocaine</i></b> and <b style='color:Tomato;'><i>tetracaine</i></b> groups. There were also no significant differences between genders in overall VAS scores and in the <b style='color:Tomato;'><i>lidocaine</i></b> and <b style='color:Tomato;'><i>tetracaine</i></b> subgroups. Older patients demonstrated significantly less discomfort or a sensation of bad taste overall. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>contrast</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>receiving</i></b> <b style='color:MediumOrchid;'><i>lidocaine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>older</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>receiving</i></b> <b style='color:MediumOrchid;'><i>tetracaine</i></b> <b style='color:DodgerBlue;'><i>experienced</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>less</i></b> <b style='color:DodgerBlue;'><i>overall</i></b> <b style='color:DodgerBlue;'><i>pain</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>discomfort</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>unpleasant</i></b> <b style='color:DodgerBlue;'><i>taste</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>dyspnea</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### conclusion In patients undergoing transnasal endoscopy, use of either 2% <b style='color:Tomato;'><i>tetracaine</i></b> or 4% <b style='color:Tomato;'><i>lidocaine</i></b> has similar effect. <b style='color:Tomato;'><i>tetracaine</i></b> may be a better choice in older patients, however.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"contrast","start":3,"end":11,"id":1,"ws":true},{"text":"to","start":12,"end":14,"id":2,"ws":true},{"text":"patients","start":15,"end":23,"id":3,"ws":true},{"text":"receiving","start":24,"end":33,"id":4,"ws":true},{"text":"lidocaine","start":34,"end":43,"id":5,"ws":true},{"text":",","start":44,"end":45,"id":6,"ws":true},{"text":"older","start":46,"end":51,"id":7,"ws":true},{"text":"patients","start":52,"end":60,"id":8,"ws":true},{"text":"receiving","start":61,"end":70,"id":9,"ws":true},{"text":"tetracaine","start":71,"end":81,"id":10,"ws":true},{"text":"experienced","start":82,"end":93,"id":11,"ws":true},{"text":"significantly","start":94,"end":107,"id":12,"ws":true},{"text":"less","start":108,"end":112,"id":13,"ws":true},{"text":"overall","start":113,"end":120,"id":14,"ws":true},{"text":"pain","start":121,"end":125,"id":15,"ws":true},{"text":"and","start":126,"end":129,"id":16,"ws":true},{"text":"discomfort","start":130,"end":140,"id":17,"ws":true},{"text":",","start":141,"end":142,"id":18,"ws":true},{"text":"unpleasant","start":143,"end":153,"id":19,"ws":true},{"text":"taste","start":154,"end":159,"id":20,"ws":true},{"text":",","start":160,"end":161,"id":21,"ws":true},{"text":"and","start":162,"end":165,"id":22,"ws":true},{"text":"dyspnea","start":166,"end":173,"id":23,"ws":true},{"text":".","start":174,"end":175,"id":24,"ws":false}],"spans":[{"start":34,"end":43,"token_start":5,"token_end":5,"label":"DRUG"},{"start":71,"end":81,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/23404424/","_input_hash":290732435,"_task_hash":204247466,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Second-line chemotherapy was also ineffective ; therefore , the bevacizumab and irinotecan were given after a third gross-total resection of the tumor .","paragraph":"<h3><u>Long-term efficacy of bevacizumab and irinotecan in recurrent pediatric glioblastoma.</u></h3>A 5-year-old boy with glioblastoma relapsed soon after postoperative irradiation in combination with <b style='color:Tomato;'><i>temozolomide</i></b>. <b style='color:DodgerBlue;'><i>Second-line</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>ineffective</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>therefore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>third</i></b> <b style='color:DodgerBlue;'><i>gross-total</i></b> <b style='color:DodgerBlue;'><i>resection</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Treatment was interrupted for 1 month due to development of posterior reversible encephalopathy syndrome, but was re-initiated at a lower dose of <b style='color:Tomato;'><i>bevacizumab</i></b> with prolonged intervals between treatments. The patient was alive and disease free 2 years after initial diagnosis. <b style='color:Tomato;'><i>bevacizumab</i></b> and <b style='color:Tomato;'><i>irinotecan</i></b> are a promising regimen for pediatric cases of recurrent glioblastoma after gross-total resection, although the optimal treatment schedule must be determined on a patient-by-patient basis.","tokens":[{"text":"Second-line","start":0,"end":11,"id":0,"ws":true},{"text":"chemotherapy","start":12,"end":24,"id":1,"ws":true},{"text":"was","start":25,"end":28,"id":2,"ws":true},{"text":"also","start":29,"end":33,"id":3,"ws":true},{"text":"ineffective","start":34,"end":45,"id":4,"ws":true},{"text":";","start":46,"end":47,"id":5,"ws":true},{"text":"therefore","start":48,"end":57,"id":6,"ws":true},{"text":",","start":58,"end":59,"id":7,"ws":true},{"text":"the","start":60,"end":63,"id":8,"ws":true},{"text":"bevacizumab","start":64,"end":75,"id":9,"ws":true},{"text":"and","start":76,"end":79,"id":10,"ws":true},{"text":"irinotecan","start":80,"end":90,"id":11,"ws":true},{"text":"were","start":91,"end":95,"id":12,"ws":true},{"text":"given","start":96,"end":101,"id":13,"ws":true},{"text":"after","start":102,"end":107,"id":14,"ws":true},{"text":"a","start":108,"end":109,"id":15,"ws":true},{"text":"third","start":110,"end":115,"id":16,"ws":true},{"text":"gross-total","start":116,"end":127,"id":17,"ws":true},{"text":"resection","start":128,"end":137,"id":18,"ws":true},{"text":"of","start":138,"end":140,"id":19,"ws":true},{"text":"the","start":141,"end":144,"id":20,"ws":true},{"text":"tumor","start":145,"end":150,"id":21,"ws":true},{"text":".","start":151,"end":152,"id":22,"ws":false}],"spans":[{"start":64,"end":75,"token_start":9,"token_end":9,"label":"DRUG"},{"start":80,"end":90,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25711258/","_input_hash":-1340233831,"_task_hash":-1917079631,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":9,"child":11,"head_span":{"start":64,"end":75,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":80,"end":90,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"In unselected patients with advanced HCC immunotherapeutics , namely the programmed cell death-1 ( PD-1 ) antibodies , nivolumab and pembrolizumab have shown promising efficacy in therapy-na\u00efve , as well as pre-treated patients with advanced HCC .","paragraph":"<h3><u>Recent developments with immunotherapy for hepatocellular carcinoma.</u></h3>Immunotherapy is on the way to become the new standard of care for advanced hepatocellular carcinoma (HCC) worldwide. With higher rates of objective responses, and overall less side effects compared to tyrosine-kinase inhibitors (TKIs) immunotherapeutics will probably replace <b style='color:Tomato;'><i>sorafenib</i></b> from standard first-line treatment. ### Areas Covered This review covers recent clinical data on systemic agents and ongoing trials in patients with advanced HCC focusing on immunotherapy. ### Expert Opinion <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>unselected</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>HCC</i></b> <b style='color:DodgerBlue;'><i>immunotherapeutics</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>namely</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>programmed</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>death-1</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>PD-1</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>antibodies</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>nivolumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>pembrolizumab</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>shown</i></b> <b style='color:DodgerBlue;'><i>promising</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>therapy-na\u00efve</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>pre-treated</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>HCC</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, only 10-20 percent of treated patients show an objective and durable response to the indicated therapeutics. Therefore, combination therapies including different immunotherapeutics, e.g. PD-1/programmed cell death 1 ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibodies, or combinations of immunotherapeutics and small molecules, or bifunctional antibodies will be needed to improve response rates. ### abbreviations HCC: hepatocellular carcinoma; TKI: tyrosine-kinase inhibitors; PD-1: programmed death receptor-1; PD-L1: programmed cell death 1 ligand 1; CTLA-4: cytotoxic T-lymphocyte-associated Protein 4; CAR-T: chimeric T cell receptors; TACE: transarterial chemoembolization; SIRT: selective internal radiation therapy; SBRT: stereotactic body radiation therapy; VEGF: vascular endothelial growth factor; MEK: mitogen-activated protein kinase kinase; NK cell: natural killer cell; TGF\u03b2: transforming growth factor-\u03b2; OV: Oncolytic viruses; PFU: plaque-forming unit.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"unselected","start":3,"end":13,"id":1,"ws":true},{"text":"patients","start":14,"end":22,"id":2,"ws":true},{"text":"with","start":23,"end":27,"id":3,"ws":true},{"text":"advanced","start":28,"end":36,"id":4,"ws":true},{"text":"HCC","start":37,"end":40,"id":5,"ws":true},{"text":"immunotherapeutics","start":41,"end":59,"id":6,"ws":true},{"text":",","start":60,"end":61,"id":7,"ws":true},{"text":"namely","start":62,"end":68,"id":8,"ws":true},{"text":"the","start":69,"end":72,"id":9,"ws":true},{"text":"programmed","start":73,"end":83,"id":10,"ws":true},{"text":"cell","start":84,"end":88,"id":11,"ws":true},{"text":"death-1","start":89,"end":96,"id":12,"ws":true},{"text":"(","start":97,"end":98,"id":13,"ws":true},{"text":"PD-1","start":99,"end":103,"id":14,"ws":true},{"text":")","start":104,"end":105,"id":15,"ws":true},{"text":"antibodies","start":106,"end":116,"id":16,"ws":true},{"text":",","start":117,"end":118,"id":17,"ws":true},{"text":"nivolumab","start":119,"end":128,"id":18,"ws":true},{"text":"and","start":129,"end":132,"id":19,"ws":true},{"text":"pembrolizumab","start":133,"end":146,"id":20,"ws":true},{"text":"have","start":147,"end":151,"id":21,"ws":true},{"text":"shown","start":152,"end":157,"id":22,"ws":true},{"text":"promising","start":158,"end":167,"id":23,"ws":true},{"text":"efficacy","start":168,"end":176,"id":24,"ws":true},{"text":"in","start":177,"end":179,"id":25,"ws":true},{"text":"therapy-na\u00efve","start":180,"end":193,"id":26,"ws":true},{"text":",","start":194,"end":195,"id":27,"ws":true},{"text":"as","start":196,"end":198,"id":28,"ws":true},{"text":"well","start":199,"end":203,"id":29,"ws":true},{"text":"as","start":204,"end":206,"id":30,"ws":true},{"text":"pre-treated","start":207,"end":218,"id":31,"ws":true},{"text":"patients","start":219,"end":227,"id":32,"ws":true},{"text":"with","start":228,"end":232,"id":33,"ws":true},{"text":"advanced","start":233,"end":241,"id":34,"ws":true},{"text":"HCC","start":242,"end":245,"id":35,"ws":true},{"text":".","start":246,"end":247,"id":36,"ws":false}],"spans":[{"start":119,"end":128,"token_start":18,"token_end":18,"label":"DRUG"},{"start":133,"end":146,"token_start":20,"token_end":20,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29995439/","_input_hash":1975216327,"_task_hash":1461705986,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Treatment with rapamycin and paclitaxel resulted in decreased phosphorylation of S6 and 4E-BP1 , two critical downstream targets of the mTOR pathway .","paragraph":"<h3><u>Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis.</u></h3>Mammalian target of <b style='color:Tomato;'><i>rapamycin</i></b> (mTOR) inhibitors modulate signaling pathways involved in cell cycle progression, and recent phase II trials demonstrate activity in patients with endometrial cancer. Our objective was to examine the effects of combination therapy with <b style='color:Tomato;'><i>rapamycin</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b> in endometrial cancer cell lines. <b style='color:Tomato;'><i>paclitaxel</i></b> inhibited proliferation in a dose-dependent manner in both cell lines with IC(50) values of 0.1-0.5 nM and 1-5 nM for Ishikawa and ECC-1 cells, respectively. To assess synergy of <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>rapamycin</i></b>, the combination index (CI) was calculated by the method of Chou and Talalay. Simultaneous exposure of cells to various doses of <b style='color:Tomato;'><i>paclitaxel</i></b> in combination with <b style='color:Tomato;'><i>rapamycin</i></b> (1 nM) resulted in a significant synergistic anti-proliferative effect (CI <1, range 0.131-0.920). <b style='color:Tomato;'><i>rapamycin</i></b> alone did not induce apoptosis, but combined treatment with <b style='color:Tomato;'><i>paclitaxel</i></b> increased apoptosis over that of <b style='color:Tomato;'><i>paclitaxel</i></b> alone. <b style='color:DodgerBlue;'><i>Treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>rapamycin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>resulted</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>decreased</i></b> <b style='color:DodgerBlue;'><i>phosphorylation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>S6</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>4E-BP1</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>critical</i></b> <b style='color:DodgerBlue;'><i>downstream</i></b> <b style='color:DodgerBlue;'><i>targets</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>mTOR</i></b> <b style='color:DodgerBlue;'><i>pathway</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>rapamycin</i></b> decreased hTERT mRNA expression by real-time RT-PCR while <b style='color:Tomato;'><i>paclitaxel</i></b> alone had no effect on telomerase activity. <b style='color:Tomato;'><i>paclitaxel</i></b> increased polymerization and acetylation of tubulin, and <b style='color:Tomato;'><i>rapamycin</i></b> appeared to enhance this effect. Thus, in conclusion, we demonstrate that <b style='color:Tomato;'><i>rapamycin</i></b> potentiates the effects of <b style='color:Tomato;'><i>paclitaxel</i></b> in endometrial cancer cells through inhibition of cell proliferation, induction of apoptosis and potentially increased polymerization and acetylation of tubulin. This suggests that the combination of <b style='color:Tomato;'><i>rapamycin</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b> may be a promising effective targeted therapy for endometrial cancer.","tokens":[{"text":"Treatment","start":0,"end":9,"id":0,"ws":true},{"text":"with","start":10,"end":14,"id":1,"ws":true},{"text":"rapamycin","start":15,"end":24,"id":2,"ws":true},{"text":"and","start":25,"end":28,"id":3,"ws":true},{"text":"paclitaxel","start":29,"end":39,"id":4,"ws":true},{"text":"resulted","start":40,"end":48,"id":5,"ws":true},{"text":"in","start":49,"end":51,"id":6,"ws":true},{"text":"decreased","start":52,"end":61,"id":7,"ws":true},{"text":"phosphorylation","start":62,"end":77,"id":8,"ws":true},{"text":"of","start":78,"end":80,"id":9,"ws":true},{"text":"S6","start":81,"end":83,"id":10,"ws":true},{"text":"and","start":84,"end":87,"id":11,"ws":true},{"text":"4E-BP1","start":88,"end":94,"id":12,"ws":true},{"text":",","start":95,"end":96,"id":13,"ws":true},{"text":"two","start":97,"end":100,"id":14,"ws":true},{"text":"critical","start":101,"end":109,"id":15,"ws":true},{"text":"downstream","start":110,"end":120,"id":16,"ws":true},{"text":"targets","start":121,"end":128,"id":17,"ws":true},{"text":"of","start":129,"end":131,"id":18,"ws":true},{"text":"the","start":132,"end":135,"id":19,"ws":true},{"text":"mTOR","start":136,"end":140,"id":20,"ws":true},{"text":"pathway","start":141,"end":148,"id":21,"ws":true},{"text":".","start":149,"end":150,"id":22,"ws":false}],"spans":[{"start":15,"end":24,"token_start":2,"token_end":2,"label":"DRUG"},{"start":29,"end":39,"token_start":4,"token_end":4,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/19688827/","_input_hash":-1539248830,"_task_hash":-2048830506,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":4,"child":2,"head_span":{"start":29,"end":39,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":15,"end":24,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Conversely , the IMbrave150 trial recently showed that , among patients with previously untreated unresectable HCC , treatment with atezolizumab plus bevacizumab resulted in significantly longer overall survival and progression-free survival compared to sorafenib monotherapy .","paragraph":"<h3><u>Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma.</u></h3>Hepatocellular carcinoma (HCC) represents the most commonly diagnosed liver cancer worldwide, and the overall survival of patients with unresectable disease is poor. In the last five years, immune checkpoint inhibitors (ICIs) have revolutionized the treatment scenario of several hematological and solid tumors, and these agents have been actively explored in unresectable HCC. Firstly, promising findings of phase I and II clinical studies reporting durable responses and a tolerable safety profile have led to the assessment of ICIs as single agents in phase III clinical studies; however, the latter have provided controversial results, and the activity of ICI monotherapy seems limited to a small subgroup of patients. <b style='color:DodgerBlue;'><i>Conversely</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>IMbrave150</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>recently</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>among</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>previously</i></b> <b style='color:DodgerBlue;'><i>untreated</i></b> <b style='color:DodgerBlue;'><i>unresectable</i></b> <b style='color:DodgerBlue;'><i>HCC</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>atezolizumab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>resulted</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>longer</i></b> <b style='color:DodgerBlue;'><i>overall</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>progression-free</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>sorafenib</i></b> <b style='color:DodgerBlue;'><i>monotherapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In addition, the activity of several other ICIs is under investigation, as combination immunotherapy as well as combinations of immunotherapy with antiangiogenic agents. Nonetheless, there are currently no validated predictive biomarkers able to guide treatment choice in this setting, where the identification of specific predictors of response to ICIs represents a major challenge. In this review, we aim to provide a critical overview of recent evidence on biochemical predictors of response to ICIs in patients with unresectable HCC, especially focusing on PD-L1, TMB, MSI, and other emerging biomarkers.","tokens":[{"text":"Conversely","start":0,"end":10,"id":0,"ws":true},{"text":",","start":11,"end":12,"id":1,"ws":true},{"text":"the","start":13,"end":16,"id":2,"ws":true},{"text":"IMbrave150","start":17,"end":27,"id":3,"ws":true},{"text":"trial","start":28,"end":33,"id":4,"ws":true},{"text":"recently","start":34,"end":42,"id":5,"ws":true},{"text":"showed","start":43,"end":49,"id":6,"ws":true},{"text":"that","start":50,"end":54,"id":7,"ws":true},{"text":",","start":55,"end":56,"id":8,"ws":true},{"text":"among","start":57,"end":62,"id":9,"ws":true},{"text":"patients","start":63,"end":71,"id":10,"ws":true},{"text":"with","start":72,"end":76,"id":11,"ws":true},{"text":"previously","start":77,"end":87,"id":12,"ws":true},{"text":"untreated","start":88,"end":97,"id":13,"ws":true},{"text":"unresectable","start":98,"end":110,"id":14,"ws":true},{"text":"HCC","start":111,"end":114,"id":15,"ws":true},{"text":",","start":115,"end":116,"id":16,"ws":true},{"text":"treatment","start":117,"end":126,"id":17,"ws":true},{"text":"with","start":127,"end":131,"id":18,"ws":true},{"text":"atezolizumab","start":132,"end":144,"id":19,"ws":true},{"text":"plus","start":145,"end":149,"id":20,"ws":true},{"text":"bevacizumab","start":150,"end":161,"id":21,"ws":true},{"text":"resulted","start":162,"end":170,"id":22,"ws":true},{"text":"in","start":171,"end":173,"id":23,"ws":true},{"text":"significantly","start":174,"end":187,"id":24,"ws":true},{"text":"longer","start":188,"end":194,"id":25,"ws":true},{"text":"overall","start":195,"end":202,"id":26,"ws":true},{"text":"survival","start":203,"end":211,"id":27,"ws":true},{"text":"and","start":212,"end":215,"id":28,"ws":true},{"text":"progression-free","start":216,"end":232,"id":29,"ws":true},{"text":"survival","start":233,"end":241,"id":30,"ws":true},{"text":"compared","start":242,"end":250,"id":31,"ws":true},{"text":"to","start":251,"end":253,"id":32,"ws":true},{"text":"sorafenib","start":254,"end":263,"id":33,"ws":true},{"text":"monotherapy","start":264,"end":275,"id":34,"ws":true},{"text":".","start":276,"end":277,"id":35,"ws":false}],"spans":[{"start":132,"end":144,"token_start":19,"token_end":19,"label":"DRUG"},{"start":150,"end":161,"token_start":21,"token_end":21,"label":"DRUG"},{"start":254,"end":263,"token_start":33,"token_end":33,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33549983/","_input_hash":1227576386,"_task_hash":92750848,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":19,"child":21,"head_span":{"start":132,"end":144,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":150,"end":161,"token_start":21,"token_end":21,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Evaluation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>letrozole</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>assessment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>pharmacokinetic</i></b> <b style='color:DodgerBlue;'><i>interaction</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>postmenopausal</i></b> <b style='color:DodgerBlue;'><i>women</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>The goals of this clinical trial involving postmenopausal women with metastatic breast cancer were to: (a) examine the effects of <b style='color:Tomato;'><i>letrozole</i></b> on <b style='color:Tomato;'><i>tamoxifen</i></b> (TAM) pharmacokinetics; (b) examine estrogen suppression in patients receiving TAM plus <b style='color:Tomato;'><i>letrozole</i></b>; and (c) evaluate tolerability, toxicity, objective response, and time to progression for the combination. Postmenopausal women with measurable or evaluable metastatic breast cancer received TAM (20 mg daily) for 6 weeks, and then <b style='color:Tomato;'><i>letrozole</i></b> (2.5 mg daily) was added. To examine for any effect of <b style='color:Tomato;'><i>letrozole</i></b> on the levels of TAM and two metabolites [N-desmethyl-TAM and 4-hydroxy-TAM], serum samples were obtained at 6, 12, 18, and 24 weeks. To examine for aromatase inhibition, serum samples were obtained before treatment and at 6, 12, 18, and 24 weeks for estradiol, <b style='color:Tomato;'><i>estrone</i></b> (E1) E1 sulfate, and sex hormone-binding globulin. A total of 34 patients were entered on this trial, and 23 patients were still on study at week 24, 18 of whom had blood samples available at both week 6 and week 24. The 95% confidence interval for the mean difference between levels at week 24 and levels at week 6 was -34 to 15 ng/ml for TAM, -35 to 45 ng/ml for N-desmethyl-TAM, and -1 to 2 for 4-hydroxy-TAM. For estradiol, a significant decrease (median, 88.5%; range, 73.7-95.2%) was identified after 6 weeks of <b style='color:Tomato;'><i>letrozole</i></b>, which was maintained for an additional 12 weeks. Similar significant reductions were identified for E1. E1 sulfate levels increased after 6 weeks of TAM alone but then decreased significantly after the addition of <b style='color:Tomato;'><i>letrozole</i></b>. Sex hormone-binding globulin levels were significantly elevated after 6 weeks of TAM alone and remained elevated after the addition of <b style='color:Tomato;'><i>letrozole</i></b>. Six of the 34 patients (17.6%) achieved an objective response (95% confidence interval, 6.8-34.5%), with a median time to disease progression of 7.6 months. There was no indication of a systematic decrease in TAM, N-desmethyl-TAM, or 4-hydroxy-TAM after the additional of <b style='color:Tomato;'><i>letrozole</i></b>. Estrogen suppression induced by <b style='color:Tomato;'><i>letrozole</i></b> was substantial despite the concomitant administration of TAM. The antitumor effect of TAM plus <b style='color:Tomato;'><i>letrozole</i></b> was less than expected.","tokens":[{"text":"Evaluation","start":0,"end":10,"id":0,"ws":true},{"text":"of","start":11,"end":13,"id":1,"ws":true},{"text":"tamoxifen","start":14,"end":23,"id":2,"ws":true},{"text":"plus","start":24,"end":28,"id":3,"ws":true},{"text":"letrozole","start":29,"end":38,"id":4,"ws":true},{"text":"with","start":39,"end":43,"id":5,"ws":true},{"text":"assessment","start":44,"end":54,"id":6,"ws":true},{"text":"of","start":55,"end":57,"id":7,"ws":true},{"text":"pharmacokinetic","start":58,"end":73,"id":8,"ws":true},{"text":"interaction","start":74,"end":85,"id":9,"ws":true},{"text":"in","start":86,"end":88,"id":10,"ws":true},{"text":"postmenopausal","start":89,"end":103,"id":11,"ws":true},{"text":"women","start":104,"end":109,"id":12,"ws":true},{"text":"with","start":110,"end":114,"id":13,"ws":true},{"text":"metastatic","start":115,"end":125,"id":14,"ws":true},{"text":"breast","start":126,"end":132,"id":15,"ws":true},{"text":"cancer","start":133,"end":139,"id":16,"ws":true},{"text":".","start":140,"end":141,"id":17,"ws":false}],"spans":[{"start":14,"end":23,"token_start":2,"token_end":2,"label":"DRUG"},{"start":29,"end":38,"token_start":4,"token_end":4,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/10430063/","_input_hash":-750578039,"_task_hash":-1911141189,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":2,"child":4,"head_span":{"start":14,"end":23,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":29,"end":38,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Moreover , the BCR/ABL1 inhibitors nilotinib and ponatinib were found to decrease STAT5 activity and CD25 expression in KU812 cells and primary CML LSCs .","paragraph":"<h3><u>Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.</u></h3>In chronic myelogenous leukemia (CML), leukemic stem cells (LSC) represent a critical target of therapy. However, little is known about markers and targets expressed by LSCs. The aim of this project was to identify novel relevant markers of CML LSCs. ### Experimental Design CML LSCs were examined by flow cytometry, qPCR, and various bioassays. In addition, we examined the multipotent CD25(+)CML cell line KU812. ### results In contrast to normal hematopoietic stem cells, CD34(+)/CD38(-)CML LSCs expressed the IL-2 receptor alpha chain, IL-2RA (CD25). STAT5 was found to induce expression of CD25 in Lin(-)/Sca-1(+)/Kit(+)stem cells in C57Bl/6 mice. Correspondingly, shRNA-induced STAT5 depletion resulted in decreased CD25 expression in KU812 cells. <b style='color:DodgerBlue;'><i>Moreover</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>BCR/ABL1</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:MediumOrchid;'><i>nilotinib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ponatinib</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>found</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>decrease</i></b> <b style='color:DodgerBlue;'><i>STAT5</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>CD25</i></b> <b style='color:DodgerBlue;'><i>expression</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>KU812</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>primary</i></b> <b style='color:DodgerBlue;'><i>CML</i></b> <b style='color:DodgerBlue;'><i>LSCs</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A CD25-targeting shRNA was found to augment proliferation of KU812 cellsin vitroand their engraftmentin vivoin NOD/SCID-IL-2R\u03b3(-/-)mice. In drug-screening experiments, the PI3K/mTOR blocker BEZ235 promoted the expression of STAT5 and CD25 in CML cells. Finally, we found that BEZ235 produces synergistic antineoplastic effects on CML cells when applied in combination with <b style='color:Tomato;'><i>nilotinib</i></b> or <b style='color:Tomato;'><i>ponatinib</i></b>. ### conclusions CD25 is a novel STAT5-dependent marker of CML LSCs and may be useful for LSC detection and LSC isolation in clinical practice and basic science. Moreover, CD25 serves as a growth regulator of CML LSCs, which may have biologic and clinical implications and may pave the way for the development of new more effective LSC-eradicating treatment strategies in CML.","tokens":[{"text":"Moreover","start":0,"end":8,"id":0,"ws":true},{"text":",","start":9,"end":10,"id":1,"ws":true},{"text":"the","start":11,"end":14,"id":2,"ws":true},{"text":"BCR/ABL1","start":15,"end":23,"id":3,"ws":true},{"text":"inhibitors","start":24,"end":34,"id":4,"ws":true},{"text":"nilotinib","start":35,"end":44,"id":5,"ws":true},{"text":"and","start":45,"end":48,"id":6,"ws":true},{"text":"ponatinib","start":49,"end":58,"id":7,"ws":true},{"text":"were","start":59,"end":63,"id":8,"ws":true},{"text":"found","start":64,"end":69,"id":9,"ws":true},{"text":"to","start":70,"end":72,"id":10,"ws":true},{"text":"decrease","start":73,"end":81,"id":11,"ws":true},{"text":"STAT5","start":82,"end":87,"id":12,"ws":true},{"text":"activity","start":88,"end":96,"id":13,"ws":true},{"text":"and","start":97,"end":100,"id":14,"ws":true},{"text":"CD25","start":101,"end":105,"id":15,"ws":true},{"text":"expression","start":106,"end":116,"id":16,"ws":true},{"text":"in","start":117,"end":119,"id":17,"ws":true},{"text":"KU812","start":120,"end":125,"id":18,"ws":true},{"text":"cells","start":126,"end":131,"id":19,"ws":true},{"text":"and","start":132,"end":135,"id":20,"ws":true},{"text":"primary","start":136,"end":143,"id":21,"ws":true},{"text":"CML","start":144,"end":147,"id":22,"ws":true},{"text":"LSCs","start":148,"end":152,"id":23,"ws":true},{"text":".","start":153,"end":154,"id":24,"ws":false}],"spans":[{"start":35,"end":44,"token_start":5,"token_end":5,"label":"DRUG"},{"start":49,"end":58,"token_start":7,"token_end":7,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26607600/","_input_hash":-1776148781,"_task_hash":-538181250,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The EVERLAR study reports prospective data of somatostatin analogue in combination with everolimus in nonfunctioning gastrointestinal neuroendocrine tumors suggesting meaningful activity and favorable toxicity profile that supports drug combination in this setting .","paragraph":"<h3><u>Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study.</u></h3>Antitumor activity of the combination of <b style='color:Tomato;'><i>somatostatin</i></b> analogues (SSAs) and the mammalian target of <b style='color:Tomato;'><i>rapamycin</i></b> (mTOR) inhibitor <b style='color:Tomato;'><i>everolimus</i></b> in patients with neuroendocrine tumors (NETs) has been reported but not confirmed in prospective trials. ### Materials And Methods This prospective, multicenter, single-arm phase II EVERLAR study evaluated <b style='color:Tomato;'><i>everolimus</i></b> 10 mg/day and the SSA <b style='color:Tomato;'><i>octreotide</i></b> 30 mg every 28 days in patients with advanced nonfunctioning well-differentiated gastrointestinal NETs (GI-NETs) that progressed in the last 12 months (ClinicalTrials.gov NCT01567488). Prior treatment with SSAs and any systemic or locoregional therapy was allowed except for mTOR inhibitors. Patients continued treatment until disease progression or unacceptable adverse events (AEs). The primary endpoint was progression-free survival (PFS) at 12 months; secondary endpoints included early biochemical response, objective response rate (ORR) by RECIST v1.0, overall survival (OS), AEs, activation of mTOR pathway (insulin-like growth factor 1 receptor [IGF1R] and phosphoS6 [pS6] expression). ### results Forty-three patients were included in the intent-to-treat analyses. After 12 months of treatment, 62.3% (95% confidence interval [CI] 48%-77%) of patients had not progressed or died. The 24-month PFS rate was 43.6% (95% CI 29%-58%). The confirmed ORR was 2.3%, and stable disease was 58.1%. Median OS was not reached after 24 months of median follow-up. Dose reductions and temporary interruptions due to AEs were required in 14 (33%) and 33 (77%) patients, respectively. The most frequent AEs were diarrhea, asthenia, mucositis, rash, and hyperglycemia. No correlation was observed between IGFR1 and pS6 expression and PFS/OS. ### conclusion The <b style='color:Tomato;'><i>everolimus</i></b>-<b style='color:Tomato;'><i>octreotide</i></b> combination provided clinically relevant efficacy in nonfunctioning GI-NETs, similar to the results of RADIANT-2 in functioning setting. ### Implications For Practice <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>EVERLAR</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>reports</i></b> <b style='color:DodgerBlue;'><i>prospective</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>somatostatin</i></b> <b style='color:DodgerBlue;'><i>analogue</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>everolimus</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>nonfunctioning</i></b> <b style='color:DodgerBlue;'><i>gastrointestinal</i></b> <b style='color:DodgerBlue;'><i>neuroendocrine</i></b> <b style='color:DodgerBlue;'><i>tumors</i></b> <b style='color:DodgerBlue;'><i>suggesting</i></b> <b style='color:DodgerBlue;'><i>meaningful</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>favorable</i></b> <b style='color:DodgerBlue;'><i>toxicity</i></b> <b style='color:DodgerBlue;'><i>profile</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>supports</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>setting</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"EVERLAR","start":4,"end":11,"id":1,"ws":true},{"text":"study","start":12,"end":17,"id":2,"ws":true},{"text":"reports","start":18,"end":25,"id":3,"ws":true},{"text":"prospective","start":26,"end":37,"id":4,"ws":true},{"text":"data","start":38,"end":42,"id":5,"ws":true},{"text":"of","start":43,"end":45,"id":6,"ws":true},{"text":"somatostatin","start":46,"end":58,"id":7,"ws":true},{"text":"analogue","start":59,"end":67,"id":8,"ws":true},{"text":"in","start":68,"end":70,"id":9,"ws":true},{"text":"combination","start":71,"end":82,"id":10,"ws":true},{"text":"with","start":83,"end":87,"id":11,"ws":true},{"text":"everolimus","start":88,"end":98,"id":12,"ws":true},{"text":"in","start":99,"end":101,"id":13,"ws":true},{"text":"nonfunctioning","start":102,"end":116,"id":14,"ws":true},{"text":"gastrointestinal","start":117,"end":133,"id":15,"ws":true},{"text":"neuroendocrine","start":134,"end":148,"id":16,"ws":true},{"text":"tumors","start":149,"end":155,"id":17,"ws":true},{"text":"suggesting","start":156,"end":166,"id":18,"ws":true},{"text":"meaningful","start":167,"end":177,"id":19,"ws":true},{"text":"activity","start":178,"end":186,"id":20,"ws":true},{"text":"and","start":187,"end":190,"id":21,"ws":true},{"text":"favorable","start":191,"end":200,"id":22,"ws":true},{"text":"toxicity","start":201,"end":209,"id":23,"ws":true},{"text":"profile","start":210,"end":217,"id":24,"ws":true},{"text":"that","start":218,"end":222,"id":25,"ws":true},{"text":"supports","start":223,"end":231,"id":26,"ws":true},{"text":"drug","start":232,"end":236,"id":27,"ws":true},{"text":"combination","start":237,"end":248,"id":28,"ws":true},{"text":"in","start":249,"end":251,"id":29,"ws":true},{"text":"this","start":252,"end":256,"id":30,"ws":true},{"text":"setting","start":257,"end":264,"id":31,"ws":true},{"text":".","start":265,"end":266,"id":32,"ws":false}],"spans":[{"start":46,"end":58,"token_start":7,"token_end":7,"label":"DRUG"},{"start":88,"end":98,"token_start":12,"token_end":12,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29794066/","_input_hash":-793143143,"_task_hash":-208776702,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":7,"child":12,"head_span":{"start":46,"end":58,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":88,"end":98,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Synergism between anti-HER2 monoclonal antibody ( trastuzumab ) and paclitaxel has been shown in vitro and in vivo .","paragraph":"<h3><u>Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer.</u></h3> <b style='color:DodgerBlue;'><i>Synergism</i></b> <b style='color:DodgerBlue;'><i>between</i></b> <b style='color:DodgerBlue;'><i>anti-HER2</i></b> <b style='color:DodgerBlue;'><i>monoclonal</i></b> <b style='color:DodgerBlue;'><i>antibody</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>shown</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vivo</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In previous experiences, weekly administration of <b style='color:Tomato;'><i>trastuzumab</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b> has shown significant activity in metastatic breast cancer. In this phase II study, we evaluated the activity and the toxicity of this weekly regimen in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. Between November 1999 and July 2001, 25 patients were treated with <b style='color:Tomato;'><i>trastuzumab</i></b> (4 mg kg(-1) i.v. loading dose followed by 2 mg kg(-1) i.v. week(-1)) and <b style='color:Tomato;'><i>paclitaxel</i></b> (60-90 mg m(-2) h(-1) i.v. infusion week(-1)). The treatment was planned to continue until disease progression or prohibitive toxicity; in patients with responsive or stable disease, after 6 months of therapy, the decision to stop <b style='color:Tomato;'><i>paclitaxel</i></b> while continuing weekly <b style='color:Tomato;'><i>trastuzumab</i></b> was left to the physicians' judgement. At the median follow-up of 19.6 months (range 9.2-38.1), all patients are evaluable for response and toxicity. We obtained four (16%) complete responses (CR), 10 (40%) partial responses (PR), four (16%) stable diseases and seven (28%) disease progressions. The response rate (CR+PR) was 56% (95% CI, 36.5-75.5%). The median duration of response was 10.4 months (range 4.1-24.2+). Median time to progression was 8.6 months (range 2.5-24.2+). The toxicity was mild; five patients experienced fever and chills during the first infusion of <b style='color:Tomato;'><i>trastuzumab</i></b> (20%); leukopenia grade 2 was recorded in one patient (4%). Two patients (8%) came off study for grade 3 cardiotoxicity (after 9 and 17 weeks of treatment, respectively): both had already received anthracyclines and taxanes. Onycholysis grade 2 was observed in five patients (20%). These results confirm that weekly administration of <b style='color:Tomato;'><i>trastuzumab</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b> is active in anthracycline- and taxane-pretreated metastatic breast cancer patients HER2-overexpressing. Since cardiac disfunctions grade 3 were observed (8%), we recommend that cardiac function should be monitored in these patients.","tokens":[{"text":"Synergism","start":0,"end":9,"id":0,"ws":true},{"text":"between","start":10,"end":17,"id":1,"ws":true},{"text":"anti-HER2","start":18,"end":27,"id":2,"ws":true},{"text":"monoclonal","start":28,"end":38,"id":3,"ws":true},{"text":"antibody","start":39,"end":47,"id":4,"ws":true},{"text":"(","start":48,"end":49,"id":5,"ws":true},{"text":"trastuzumab","start":50,"end":61,"id":6,"ws":true},{"text":")","start":62,"end":63,"id":7,"ws":true},{"text":"and","start":64,"end":67,"id":8,"ws":true},{"text":"paclitaxel","start":68,"end":78,"id":9,"ws":true},{"text":"has","start":79,"end":82,"id":10,"ws":true},{"text":"been","start":83,"end":87,"id":11,"ws":true},{"text":"shown","start":88,"end":93,"id":12,"ws":true},{"text":"in","start":94,"end":96,"id":13,"ws":true},{"text":"vitro","start":97,"end":102,"id":14,"ws":true},{"text":"and","start":103,"end":106,"id":15,"ws":true},{"text":"in","start":107,"end":109,"id":16,"ws":true},{"text":"vivo","start":110,"end":114,"id":17,"ws":true},{"text":".","start":115,"end":116,"id":18,"ws":false}],"spans":[{"start":50,"end":61,"token_start":6,"token_end":6,"label":"DRUG"},{"start":68,"end":78,"token_start":9,"token_end":9,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/14710203/","_input_hash":-1410452084,"_task_hash":-440081934,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[{"head":6,"child":9,"head_span":{"start":50,"end":61,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":68,"end":78,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Between September 1998 and December 1999 , we treated 25 patients at risk for post-operative renal dysfunction ( high-risk basiliximab group ) with the new induction regimen and another 33 patients not at risk ( low-risk CsA group ) for renal dysfunction with our standard cyclosporine protocol .","paragraph":"<h3><u>Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation.</u></h3><b style='color:Tomato;'><i>cyclosporin</i></b>e (CsA) is frequently initiated as induction therapy in patients undergoing orthotopic heart transplantation, but our experience has identified a significant rate of post-operative renal dysfunction. We therefore devised a renal-sparing <b style='color:Tomato;'><i>cyclosporin</i></b>e-free induction regimen consisting of the early administration <b style='color:Tomato;'><i>basiliximab</i></b>, an interleukin-2 receptor monoclonal antibody, followed by the late initiation of <b style='color:Tomato;'><i>cyclosporin</i></b>e on post-operative Day 4. ### methods <b style='color:DodgerBlue;'><i>Between</i></b> <b style='color:DodgerBlue;'><i>September</i></b> <b style='color:DodgerBlue;'><i>1998</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>December</i></b> <b style='color:DodgerBlue;'><i>1999</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>25</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>risk</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>post-operative</i></b> <b style='color:DodgerBlue;'><i>renal</i></b> <b style='color:DodgerBlue;'><i>dysfunction</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>high-risk</i></b> <b style='color:MediumOrchid;'><i>basiliximab</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>new</i></b> <b style='color:DodgerBlue;'><i>induction</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>another</i></b> <b style='color:DodgerBlue;'><i>33</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>risk</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>low-risk</i></b> <b style='color:DodgerBlue;'><i>CsA</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>renal</i></b> <b style='color:DodgerBlue;'><i>dysfunction</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>our</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:MediumOrchid;'><i>cyclosporine</i></b> <b style='color:DodgerBlue;'><i>protocol</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We identified a historical control group (1996 through 1998) of 32 patients at risk for renal dysfunction (high-risk CsA group) who had received our standard <b style='color:Tomato;'><i>cyclosporin</i></b>e protocol. ### results The increase in serum creatinine levels after transplantation was less in the high-risk <b style='color:Tomato;'><i>basiliximab</i></b> group (-0.1 +/- 0.7) than in the high-risk CsA group (0.5 +/- 1.0, p < 0.02) and comparable to the low-risk CsA group (0.03 +/- 0.6). The <b style='color:Tomato;'><i>basiliximab</i></b> protocol did not increase rejection; the percentage of rejection episodes was high-risk <b style='color:Tomato;'><i>basiliximab</i></b>, 0; high-risk CsA, 13; and low-risk CsA, 3 (p = .13). ### conclusion <b style='color:Tomato;'><i>basiliximab</i></b> induction therapy allows delayed initiation of <b style='color:Tomato;'><i>cyclosporin</i></b>e after cardiac transplantation without an increase in rejection and reduces the risk of post-operative renal dysfunction.","tokens":[{"text":"Between","start":0,"end":7,"id":0,"ws":true},{"text":"September","start":8,"end":17,"id":1,"ws":true},{"text":"1998","start":18,"end":22,"id":2,"ws":true},{"text":"and","start":23,"end":26,"id":3,"ws":true},{"text":"December","start":27,"end":35,"id":4,"ws":true},{"text":"1999","start":36,"end":40,"id":5,"ws":true},{"text":",","start":41,"end":42,"id":6,"ws":true},{"text":"we","start":43,"end":45,"id":7,"ws":true},{"text":"treated","start":46,"end":53,"id":8,"ws":true},{"text":"25","start":54,"end":56,"id":9,"ws":true},{"text":"patients","start":57,"end":65,"id":10,"ws":true},{"text":"at","start":66,"end":68,"id":11,"ws":true},{"text":"risk","start":69,"end":73,"id":12,"ws":true},{"text":"for","start":74,"end":77,"id":13,"ws":true},{"text":"post-operative","start":78,"end":92,"id":14,"ws":true},{"text":"renal","start":93,"end":98,"id":15,"ws":true},{"text":"dysfunction","start":99,"end":110,"id":16,"ws":true},{"text":"(","start":111,"end":112,"id":17,"ws":true},{"text":"high-risk","start":113,"end":122,"id":18,"ws":true},{"text":"basiliximab","start":123,"end":134,"id":19,"ws":true},{"text":"group","start":135,"end":140,"id":20,"ws":true},{"text":")","start":141,"end":142,"id":21,"ws":true},{"text":"with","start":143,"end":147,"id":22,"ws":true},{"text":"the","start":148,"end":151,"id":23,"ws":true},{"text":"new","start":152,"end":155,"id":24,"ws":true},{"text":"induction","start":156,"end":165,"id":25,"ws":true},{"text":"regimen","start":166,"end":173,"id":26,"ws":true},{"text":"and","start":174,"end":177,"id":27,"ws":true},{"text":"another","start":178,"end":185,"id":28,"ws":true},{"text":"33","start":186,"end":188,"id":29,"ws":true},{"text":"patients","start":189,"end":197,"id":30,"ws":true},{"text":"not","start":198,"end":201,"id":31,"ws":true},{"text":"at","start":202,"end":204,"id":32,"ws":true},{"text":"risk","start":205,"end":209,"id":33,"ws":true},{"text":"(","start":210,"end":211,"id":34,"ws":true},{"text":"low-risk","start":212,"end":220,"id":35,"ws":true},{"text":"CsA","start":221,"end":224,"id":36,"ws":true},{"text":"group","start":225,"end":230,"id":37,"ws":true},{"text":")","start":231,"end":232,"id":38,"ws":true},{"text":"for","start":233,"end":236,"id":39,"ws":true},{"text":"renal","start":237,"end":242,"id":40,"ws":true},{"text":"dysfunction","start":243,"end":254,"id":41,"ws":true},{"text":"with","start":255,"end":259,"id":42,"ws":true},{"text":"our","start":260,"end":263,"id":43,"ws":true},{"text":"standard","start":264,"end":272,"id":44,"ws":true},{"text":"cyclosporine","start":273,"end":285,"id":45,"ws":true},{"text":"protocol","start":286,"end":294,"id":46,"ws":true},{"text":".","start":295,"end":296,"id":47,"ws":false}],"spans":[{"start":123,"end":134,"token_start":19,"token_end":19,"label":"DRUG"},{"start":273,"end":285,"token_start":45,"token_end":45,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16143252/","_input_hash":-842226561,"_task_hash":-651892887,"_session_id":"drug_drug_test_set_1-yakir","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Cardiac events occurred after posaconazole administration , incriminating posaconazole use , alone or in combination with voriconazole , as the culpable agent .","paragraph":"<h3><u>Long QT Syndrome Leading to Multiple Cardiac Arrests After Posaconazole Administration in an Immune-Compromised Patient with Sepsis: An Unusual Case Report.</u></h3>We present the case of a septic patient with severe immunodeficiency, who developed QT interval prolongation followed by episodes of lethal cardiac arrhythmia. <b style='color:DodgerBlue;'><i>Cardiac</i></b> <b style='color:DodgerBlue;'><i>events</i></b> <b style='color:DodgerBlue;'><i>occurred</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:MediumOrchid;'><i>posaconazole</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>incriminating</i></b> <b style='color:MediumOrchid;'><i>posaconazole</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>voriconazole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>culpable</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### Case Report A 26-year-old female patient underwent orthopedic surgery to remove ectopic calcifications in her left hip joint. On the first post-operative day she became septic due to a surgical wound infection. Despite being treated according to the therapeutic protocols for sepsis, no clinical improvement was noticed and further assessment revealed an underlying immunodeficiency. Considering the underlying immunodeficiency and to that point poor clinical response, an antifungal agent was added to the antibiotic regiment. Following discontinuation of multiple antifungal agents due to adverse effects, <b style='color:Tomato;'><i>posaconazole</i></b> was administered. <b style='color:Tomato;'><i>posaconazole</i></b> oral intake was followed by episodes of bradycardia and QT interval prolongation. The patient suffered continuous incidents of cardiac arrest due to polymorphic ventricular tachycardia (torsades des pointes) that degenerated to lethal ventricular fibrillation. <b style='color:Tomato;'><i>posaconazole</i></b> was immediately discontinued and a temporary pacemaker was installed. The patient finally recovered without any neurological deficit, and was discharged in a good clinical status. ### conclusions Close cardiac monitoring is recommended in cases where <b style='color:Tomato;'><i>posaconazole</i></b> administration is combined with coexisting risk factors, as they may lead to severe ECG abnormalities and cardiac arrhythmias such as long QT interval syndrome and torsades de pointes. <b style='color:Tomato;'><i>posaconazole</i></b> interactions with medications metabolized via the CYP3A4 pathway should be considered an additional risk factor for lethal cardiac incidents.","tokens":[{"text":"Cardiac","start":0,"end":7,"id":0,"ws":true},{"text":"events","start":8,"end":14,"id":1,"ws":true},{"text":"occurred","start":15,"end":23,"id":2,"ws":true},{"text":"after","start":24,"end":29,"id":3,"ws":true},{"text":"posaconazole","start":30,"end":42,"id":4,"ws":true},{"text":"administration","start":43,"end":57,"id":5,"ws":true},{"text":",","start":58,"end":59,"id":6,"ws":true},{"text":"incriminating","start":60,"end":73,"id":7,"ws":true},{"text":"posaconazole","start":74,"end":86,"id":8,"ws":true},{"text":"use","start":87,"end":90,"id":9,"ws":true},{"text":",","start":91,"end":92,"id":10,"ws":true},{"text":"alone","start":93,"end":98,"id":11,"ws":true},{"text":"or","start":99,"end":101,"id":12,"ws":true},{"text":"in","start":102,"end":104,"id":13,"ws":true},{"text":"combination","start":105,"end":116,"id":14,"ws":true},{"text":"with","start":117,"end":121,"id":15,"ws":true},{"text":"voriconazole","start":122,"end":134,"id":16,"ws":true},{"text":",","start":135,"end":136,"id":17,"ws":true},{"text":"as","start":137,"end":139,"id":18,"ws":true},{"text":"the","start":140,"end":143,"id":19,"ws":true},{"text":"culpable","start":144,"end":152,"id":20,"ws":true},{"text":"agent","start":153,"end":158,"id":21,"ws":true},{"text":".","start":159,"end":160,"id":22,"ws":false}],"spans":[{"start":30,"end":42,"token_start":4,"token_end":4,"label":"DRUG"},{"start":74,"end":86,"token_start":8,"token_end":8,"label":"DRUG"},{"start":122,"end":134,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/27125217/","_input_hash":-9132301,"_task_hash":-1195455115,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":8,"child":16,"head_span":{"start":74,"end":86,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":122,"end":134,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG10"],"answer":"accept"}
{"text":"Prognostic value of expression of Kit67 , p53 , TopoIIa and GSTP1 for curatively resected advanced gastric cancer patients receiving adjuvant paclitaxel plus capecitabine chemotherapy .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Prognostic</i></b> <b style='color:DodgerBlue;'><i>value</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>expression</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Kit67</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>p53</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>TopoIIa</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>GSTP1</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>curatively</i></b> <b style='color:DodgerBlue;'><i>resected</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>gastric</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>receiving</i></b> <b style='color:DodgerBlue;'><i>adjuvant</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>To investigate the role of Kit67, p53, topoisomerase II (TopoII) and glutathione S-transferase P1 (GSTP1) in predicting clinical outcome of advanced gastric cancer patients receiving <b style='color:Tomato;'><i>capecitabine</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b> chemotherapy. ### methodology The clinical data and tissue samples from 136 curatively resected advanced gastric cancer patients receiving <b style='color:Tomato;'><i>capecitabine</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b> in the third affiliated hospital of Kunming medical university from January 2005 to December 2007 were retrospectively collected and analyzed for Kit67, p53, TopoIIa and GSTP1 expressions by immunohistochemistry. The relationships between expressions of the biomarkers and survival were analyzed. ### results p53 expression were associated with the significantly shorter disease-free survival (DFS) (p<0.001) and overall survival (OS) (p=0.012) in the curatively resected advanced gastric cancer patients receiving <b style='color:Tomato;'><i>capecitabine</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b>. Kit67, TopoIIa and GSTP1 expressions were not related to DFS and OS. ### conclusions p53 expression positive might predict prognosis in gastric cancer patients who underwent curative surgery followed by adjuvant <b style='color:Tomato;'><i>capecitabine</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b> chemotherapy. A favorable effect of <b style='color:Tomato;'><i>capecitabine</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b> might therefore be expected in patients that do not express p53.","tokens":[{"text":"Prognostic","start":0,"end":10,"id":0,"ws":true},{"text":"value","start":11,"end":16,"id":1,"ws":true},{"text":"of","start":17,"end":19,"id":2,"ws":true},{"text":"expression","start":20,"end":30,"id":3,"ws":true},{"text":"of","start":31,"end":33,"id":4,"ws":true},{"text":"Kit67","start":34,"end":39,"id":5,"ws":true},{"text":",","start":40,"end":41,"id":6,"ws":true},{"text":"p53","start":42,"end":45,"id":7,"ws":true},{"text":",","start":46,"end":47,"id":8,"ws":true},{"text":"TopoIIa","start":48,"end":55,"id":9,"ws":true},{"text":"and","start":56,"end":59,"id":10,"ws":true},{"text":"GSTP1","start":60,"end":65,"id":11,"ws":true},{"text":"for","start":66,"end":69,"id":12,"ws":true},{"text":"curatively","start":70,"end":80,"id":13,"ws":true},{"text":"resected","start":81,"end":89,"id":14,"ws":true},{"text":"advanced","start":90,"end":98,"id":15,"ws":true},{"text":"gastric","start":99,"end":106,"id":16,"ws":true},{"text":"cancer","start":107,"end":113,"id":17,"ws":true},{"text":"patients","start":114,"end":122,"id":18,"ws":true},{"text":"receiving","start":123,"end":132,"id":19,"ws":true},{"text":"adjuvant","start":133,"end":141,"id":20,"ws":true},{"text":"paclitaxel","start":142,"end":152,"id":21,"ws":true},{"text":"plus","start":153,"end":157,"id":22,"ws":true},{"text":"capecitabine","start":158,"end":170,"id":23,"ws":true},{"text":"chemotherapy","start":171,"end":183,"id":24,"ws":true},{"text":".","start":184,"end":185,"id":25,"ws":false}],"spans":[{"start":142,"end":152,"token_start":21,"token_end":21,"label":"DRUG"},{"start":158,"end":170,"token_start":23,"token_end":23,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22534478/","_input_hash":-1836483379,"_task_hash":-417698877,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":21,"child":23,"head_span":{"start":142,"end":152,"token_start":21,"token_end":21,"label":"DRUG"},"child_span":{"start":158,"end":170,"token_start":23,"token_end":23,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"The standard adjuvant treatment of colon cancer is fluorouracil plus leucovorin ( FL ) .","paragraph":"<h3><u>Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>adjuvant</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>colon</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>leucovorin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>FL</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>oxaliplatin</i></b> improves the efficacy of this combination in patients with metastatic colorectal cancer. We evaluated the efficacy of treatment with FL plus <b style='color:Tomato;'><i>oxaliplatin</i></b> in the postoperative adjuvant setting. ### methods We randomly assigned 2246 patients who had undergone curative resection for stage II or III colon cancer to receive FL alone or with <b style='color:Tomato;'><i>oxaliplatin</i></b> for six months. The primary end point was disease-free survival. ### results A total of 1123 patients were randomly assigned to each group. After a median follow-up of 37.9 months, 237 patients in the group given FL plus <b style='color:Tomato;'><i>oxaliplatin</i></b> had had a cancer-related event, as compared with 293 patients in the FL group (21.1 percent vs. 26.1 percent; hazard ratio for recurrence, 0.77; P=0.002). The rate of disease-free survival at three years was 78.2 percent (95 percent confidence interval, 75.6 to 80.7) in the group given FL plus <b style='color:Tomato;'><i>oxaliplatin</i></b> and 72.9 percent (95 percent confidence interval, 70.2 to 75.7) in the FL group (P=0.002 by the stratified log-rank test). In the group given FL plus <b style='color:Tomato;'><i>oxaliplatin</i></b>, the incidence of febrile neutropenia was 1.8 percent, the incidence of gastrointestinal adverse effects was low, and the incidence of grade 3 sensory neuropathy was 12.4 percent during treatment, decreasing to 1.1 percent at one year of follow-up. Six patients in each group died during treatment (death rate, 0.5 percent). ### conclusions Adding <b style='color:Tomato;'><i>oxaliplatin</i></b> to a regimen of <b style='color:Tomato;'><i>fluorouracil</i></b> and <b style='color:Tomato;'><i>leucovorin</i></b> improves the adjuvant treatment of colon cancer.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"standard","start":4,"end":12,"id":1,"ws":true},{"text":"adjuvant","start":13,"end":21,"id":2,"ws":true},{"text":"treatment","start":22,"end":31,"id":3,"ws":true},{"text":"of","start":32,"end":34,"id":4,"ws":true},{"text":"colon","start":35,"end":40,"id":5,"ws":true},{"text":"cancer","start":41,"end":47,"id":6,"ws":true},{"text":"is","start":48,"end":50,"id":7,"ws":true},{"text":"fluorouracil","start":51,"end":63,"id":8,"ws":true},{"text":"plus","start":64,"end":68,"id":9,"ws":true},{"text":"leucovorin","start":69,"end":79,"id":10,"ws":true},{"text":"(","start":80,"end":81,"id":11,"ws":true},{"text":"FL","start":82,"end":84,"id":12,"ws":true},{"text":")","start":85,"end":86,"id":13,"ws":true},{"text":".","start":87,"end":88,"id":14,"ws":false}],"spans":[{"start":51,"end":63,"token_start":8,"token_end":8,"label":"DRUG"},{"start":69,"end":79,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/15175436/","_input_hash":312360282,"_task_hash":409765963,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":8,"child":10,"head_span":{"start":51,"end":63,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":69,"end":79,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Effects of ultrasound were similar at baseline and after propranolol but increased after phenylephrine .","paragraph":"<h3><u>Alteration of left ventricular endocardial function by intracavitary high-power ultrasound interacts with volume, inotropic state, and alpha 1-adrenergic stimulation.</u></h3>High-power intracavitary ultrasound abbreviates left ventricular (LV) ejection duration, thereby decreasing mechanical LV performance, presumably by selective impairment of endocardial endothelial function. ### Methods And Results Effects of ultrasound were evaluated in the ejecting LV of anesthetized, open-chest dogs under different conditions of LV volume and contractile state and after mild selective alpha 1-adrenergic stimulation. LV pressures, left atrial pressures, and regional segment lengths were measured in anterior and posterior midwall. A cylindrical ultrasound probe (0.9 MHz, 25 W) mounted on a catheter was inserted into the LV cavity through the apex and was activated for 4 minutes in each condition. In protocol A (n = 7), LV volume was altered with caval vein occlusion and intravenous dextran infusion. The ultrasound probe was activated at low (4.1 +/- 0.9 mm Hg), mid (10.6 +/- 1.5 mm Hg), and high (17.9 +/- 1.8 mm Hg) LV end-diastolic pressure (EDP). Effects of ultrasound were less pronounced at higher EDP. For example, the time interval from end-diastole to peak (-)dP/dt decreased by 7.5 +/- 2.3% at low, 4.4 +/- 2.2% at mid, and 1.9 +/- 1.6% at high LVEDP (p < 0.001). In protocol B (n = 7), LV inotropic state was altered by slow intravenous infusion of low-dose calcium. The ultrasound probe was activated before and after calcium. Effects of ultrasound were less pronounced after calcium. Time from end-diastole to peak (-)dP/dt decreased by 8.4 +/- 3.1% at baseline and by 3.5 +/- 2.1% after calcium (p < 0.001). In protocol C (n = 7), activation of the ultrasound probe was performed at baseline and after mild selective alpha 1-adrenergic stimulation (<b style='color:Tomato;'><i>propranolol</i></b> plus <b style='color:Tomato;'><i>phenylephrine</i></b>). <b style='color:DodgerBlue;'><i>Effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>ultrasound</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>similar</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>baseline</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:MediumOrchid;'><i>propranolol</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:MediumOrchid;'><i>phenylephrine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Time from end-diastole to peak (-)dP/dt decreased by 5.2 +/- 2.4% at baseline, by 5.3 +/- 1.9% after <b style='color:Tomato;'><i>propranolol</i></b>, and by 8.9 +/- 3.2% after <b style='color:Tomato;'><i>phenylephrine</i></b> (p < 0.05). ### conclusions Effects of intracavitary ultrasound, which are presumably mediated through modulation of endocardial endothelial function, were more important at low volume, lower calcium, and under mild selective alpha 1-adrenergic stimulation.","tokens":[{"text":"Effects","start":0,"end":7,"id":0,"ws":true},{"text":"of","start":8,"end":10,"id":1,"ws":true},{"text":"ultrasound","start":11,"end":21,"id":2,"ws":true},{"text":"were","start":22,"end":26,"id":3,"ws":true},{"text":"similar","start":27,"end":34,"id":4,"ws":true},{"text":"at","start":35,"end":37,"id":5,"ws":true},{"text":"baseline","start":38,"end":46,"id":6,"ws":true},{"text":"and","start":47,"end":50,"id":7,"ws":true},{"text":"after","start":51,"end":56,"id":8,"ws":true},{"text":"propranolol","start":57,"end":68,"id":9,"ws":true},{"text":"but","start":69,"end":72,"id":10,"ws":true},{"text":"increased","start":73,"end":82,"id":11,"ws":true},{"text":"after","start":83,"end":88,"id":12,"ws":true},{"text":"phenylephrine","start":89,"end":102,"id":13,"ws":true},{"text":".","start":103,"end":104,"id":14,"ws":false}],"spans":[{"start":57,"end":68,"token_start":9,"token_end":9,"label":"DRUG"},{"start":89,"end":102,"token_start":13,"token_end":13,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/7681734/","_input_hash":-1194206629,"_task_hash":325387940,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Thirty-four patients ( 4 patients with stage IIIb , 30 patients in stage IV ) , with median age 66 and performance status 0 - 1 , were administered paclitaxel , 175 mg/m(2 ) in a 3-h infusion rate on day 1 and vinorelbine , 25 mg/m(2 ) in a 10-min infusion rate on days 1 , and 8 with G-CSF and EPO support .","paragraph":"<h3><u>A phase II study of non-platinum based chemotherapy with paclitaxel and vinorelbine in non-small cell lung cancer.</u></h3><b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>vinorelbine</i></b> combination in previous untreated patients with stage IIIb-IV non-small cell lung cancer (NSCLC) as a phase II study. ### Patients And Methods <b style='color:DodgerBlue;'><i>Thirty-four</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>IIIb</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>30</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>IV</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>median</i></b> <b style='color:DodgerBlue;'><i>age</i></b> <b style='color:DodgerBlue;'><i>66</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>performance</i></b> <b style='color:DodgerBlue;'><i>status</i></b> <b style='color:DodgerBlue;'><i>0</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>175</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>3-h</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>rate</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>vinorelbine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>25</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>10-min</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>rate</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>8</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>G-CSF</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>EPO</i></b> <b style='color:DodgerBlue;'><i>support</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results Among our 33 evaluable patients for toxicity 16 patients (48.4%) presented leukopenia and 15 patients (45.4%) presented anemia despite G-CSF and EPO administration. Two patients (6%) presented Grade III-IV peripheral neuropathy. The overall response rate was 67.7%; 5 patients (16.1%) showed complete response (2 patients stage IIIb) and 16 patients (51.6%) showed partial response (1 patient stage IIIb). The overall median survival time was 10 months (range 3-18 months) and the median disease-free survival was 9 months (range 3-15 months) with an 1-year survival time of 45.1% (14 patients). ### conclusion The results of the combination as 1st line treatment for patients with non-operable NSCLC are promising and should be further investigated.","tokens":[{"text":"Thirty-four","start":0,"end":11,"id":0,"ws":true},{"text":"patients","start":12,"end":20,"id":1,"ws":true},{"text":"(","start":21,"end":22,"id":2,"ws":true},{"text":"4","start":23,"end":24,"id":3,"ws":true},{"text":"patients","start":25,"end":33,"id":4,"ws":true},{"text":"with","start":34,"end":38,"id":5,"ws":true},{"text":"stage","start":39,"end":44,"id":6,"ws":true},{"text":"IIIb","start":45,"end":49,"id":7,"ws":true},{"text":",","start":50,"end":51,"id":8,"ws":true},{"text":"30","start":52,"end":54,"id":9,"ws":true},{"text":"patients","start":55,"end":63,"id":10,"ws":true},{"text":"in","start":64,"end":66,"id":11,"ws":true},{"text":"stage","start":67,"end":72,"id":12,"ws":true},{"text":"IV","start":73,"end":75,"id":13,"ws":true},{"text":")","start":76,"end":77,"id":14,"ws":true},{"text":",","start":78,"end":79,"id":15,"ws":true},{"text":"with","start":80,"end":84,"id":16,"ws":true},{"text":"median","start":85,"end":91,"id":17,"ws":true},{"text":"age","start":92,"end":95,"id":18,"ws":true},{"text":"66","start":96,"end":98,"id":19,"ws":true},{"text":"and","start":99,"end":102,"id":20,"ws":true},{"text":"performance","start":103,"end":114,"id":21,"ws":true},{"text":"status","start":115,"end":121,"id":22,"ws":true},{"text":"0","start":122,"end":123,"id":23,"ws":true},{"text":"-","start":124,"end":125,"id":24,"ws":true},{"text":"1","start":126,"end":127,"id":25,"ws":true},{"text":",","start":128,"end":129,"id":26,"ws":true},{"text":"were","start":130,"end":134,"id":27,"ws":true},{"text":"administered","start":135,"end":147,"id":28,"ws":true},{"text":"paclitaxel","start":148,"end":158,"id":29,"ws":true},{"text":",","start":159,"end":160,"id":30,"ws":true},{"text":"175","start":161,"end":164,"id":31,"ws":true},{"text":"mg/m(2","start":165,"end":171,"id":32,"ws":true},{"text":")","start":172,"end":173,"id":33,"ws":true},{"text":"in","start":174,"end":176,"id":34,"ws":true},{"text":"a","start":177,"end":178,"id":35,"ws":true},{"text":"3-h","start":179,"end":182,"id":36,"ws":true},{"text":"infusion","start":183,"end":191,"id":37,"ws":true},{"text":"rate","start":192,"end":196,"id":38,"ws":true},{"text":"on","start":197,"end":199,"id":39,"ws":true},{"text":"day","start":200,"end":203,"id":40,"ws":true},{"text":"1","start":204,"end":205,"id":41,"ws":true},{"text":"and","start":206,"end":209,"id":42,"ws":true},{"text":"vinorelbine","start":210,"end":221,"id":43,"ws":true},{"text":",","start":222,"end":223,"id":44,"ws":true},{"text":"25","start":224,"end":226,"id":45,"ws":true},{"text":"mg/m(2","start":227,"end":233,"id":46,"ws":true},{"text":")","start":234,"end":235,"id":47,"ws":true},{"text":"in","start":236,"end":238,"id":48,"ws":true},{"text":"a","start":239,"end":240,"id":49,"ws":true},{"text":"10-min","start":241,"end":247,"id":50,"ws":true},{"text":"infusion","start":248,"end":256,"id":51,"ws":true},{"text":"rate","start":257,"end":261,"id":52,"ws":true},{"text":"on","start":262,"end":264,"id":53,"ws":true},{"text":"days","start":265,"end":269,"id":54,"ws":true},{"text":"1","start":270,"end":271,"id":55,"ws":true},{"text":",","start":272,"end":273,"id":56,"ws":true},{"text":"and","start":274,"end":277,"id":57,"ws":true},{"text":"8","start":278,"end":279,"id":58,"ws":true},{"text":"with","start":280,"end":284,"id":59,"ws":true},{"text":"G-CSF","start":285,"end":290,"id":60,"ws":true},{"text":"and","start":291,"end":294,"id":61,"ws":true},{"text":"EPO","start":295,"end":298,"id":62,"ws":true},{"text":"support","start":299,"end":306,"id":63,"ws":true},{"text":".","start":307,"end":308,"id":64,"ws":false}],"spans":[{"start":148,"end":158,"token_start":29,"token_end":29,"label":"DRUG"},{"start":210,"end":221,"token_start":43,"token_end":43,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/12399133/","_input_hash":1446922198,"_task_hash":1350048234,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":29,"child":43,"head_span":{"start":148,"end":158,"token_start":29,"token_end":29,"label":"DRUG"},"child_span":{"start":210,"end":221,"token_start":43,"token_end":43,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Phase</i></b> <b style='color:DodgerBlue;'><i>I</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>decitabine</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>valproic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>myeloid</i></b> <b style='color:DodgerBlue;'><i>leukemia</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>To determine an optimal biologic dose (OBD) of <b style='color:Tomato;'><i>decitabine</i></b> as a single agent and then the maximum-tolerated dose (MTD) of <b style='color:Tomato;'><i>valproic</i></b> acid (VA) combined with <b style='color:Tomato;'><i>decitabine</i></b> in acute myeloid leukemia (AML). ### Patients And Methods Twenty-five patients (median age, 70 years) were enrolled; 12 were untreated and 13 had relapsed AML. To determine an OBD (based on a gene re-expression end point), 14 patients received <b style='color:Tomato;'><i>decitabine</i></b> alone for 10 days. To determine the MTD, 11 patients received <b style='color:Tomato;'><i>decitabine</i></b> (at OBD, days 1 through 10) plus dose-escalating VA (days 5 through 21). ### results The OBD of <b style='color:Tomato;'><i>decitabine</i></b> was 20 mg/m(2)/d intravenously, with limited nonhematologic toxicity. In patients treated with <b style='color:Tomato;'><i>decitabine</i></b> plus VA, dose-limiting encephalopathy occurred in two of two patients at VA 25 mg/kg/d and one of six patients at VA 20 mg/kg/d. Drug-induced re-expression of estrogen receptor (ER) was associated with clinical response (P < or = .05). ER promoter demethylation, global DNA hypomethylation, depletion of DNA methyltransferase enzyme, and histone hyperacetylation were also observed. In an intent-to-treat analysis, the response rate was 44% (11 of 25). Of 21 assessable patients, 11 (52%) responded: four with morphologic and cytogenetic complete remission (CR; each had complex karyotype), four with incomplete CR, and three with partial remission. In untreated AML, four of nine assessable patients achieved CR. Clinical responses appeared similar for <b style='color:Tomato;'><i>decitabine</i></b> alone or with VA. ### conclusion Low-dose <b style='color:Tomato;'><i>decitabine</i></b> was safe and showed encouraging clinical and biologic activity in AML, but the addition of VA led to encephalopathy at relatively low doses. On the basis of these results, additional studies of <b style='color:Tomato;'><i>decitabine</i></b> (20 mg/m(2)/d for 10 days) alone or with an alternative deacetylating agent are warranted.","tokens":[{"text":"Phase","start":0,"end":5,"id":0,"ws":true},{"text":"I","start":6,"end":7,"id":1,"ws":true},{"text":"study","start":8,"end":13,"id":2,"ws":true},{"text":"of","start":14,"end":16,"id":3,"ws":true},{"text":"decitabine","start":17,"end":27,"id":4,"ws":true},{"text":"alone","start":28,"end":33,"id":5,"ws":true},{"text":"or","start":34,"end":36,"id":6,"ws":true},{"text":"in","start":37,"end":39,"id":7,"ws":true},{"text":"combination","start":40,"end":51,"id":8,"ws":true},{"text":"with","start":52,"end":56,"id":9,"ws":true},{"text":"valproic","start":57,"end":65,"id":10,"ws":true},{"text":"acid","start":66,"end":70,"id":11,"ws":true},{"text":"in","start":71,"end":73,"id":12,"ws":true},{"text":"acute","start":74,"end":79,"id":13,"ws":true},{"text":"myeloid","start":80,"end":87,"id":14,"ws":true},{"text":"leukemia","start":88,"end":96,"id":15,"ws":true},{"text":".","start":97,"end":98,"id":16,"ws":false}],"spans":[{"start":17,"end":27,"token_start":4,"token_end":4,"label":"DRUG"},{"start":57,"end":65,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/17679729/","_input_hash":741112160,"_task_hash":-528000752,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":4,"child":10,"head_span":{"start":17,"end":27,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":57,"end":65,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG11"],"answer":"accept"}
{"text":"Early discontinuation of clopidogrel results in a transient rebound increase in risk of recurrence in acute coronary syndromes , but there are no published data on any similar rebound effect in patients with TIA or stroke that might inform the design of clinical trials of aspirin and clopidogrel in the acute phase .","paragraph":"<h3><u>Low risk of rebound events after a short course of clopidogrel in acute TIA or minor stroke.</u></h3>The combination of <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>clopidogrel</i></b> is indicated after acute coronary events and possibly for a short period after TIA or minor ischemic stroke. <b style='color:DodgerBlue;'><i>Early</i></b> <b style='color:DodgerBlue;'><i>discontinuation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>clopidogrel</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>transient</i></b> <b style='color:DodgerBlue;'><i>rebound</i></b> <b style='color:DodgerBlue;'><i>increase</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>risk</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>recurrence</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>coronary</i></b> <b style='color:DodgerBlue;'><i>syndromes</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>there</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>published</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>any</i></b> <b style='color:DodgerBlue;'><i>similar</i></b> <b style='color:DodgerBlue;'><i>rebound</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>TIA</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>stroke</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>might</i></b> <b style='color:DodgerBlue;'><i>inform</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>design</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>aspirin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>clopidogrel</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods A 30-day course of <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>clopidogrel</i></b> (both 75 mg daily) was given to high-risk patients with TIA or minor ischemic stroke seen acutely in the EXPRESS study clinic from April 1, 2002, to March 31, 2009. <b style='color:Tomato;'><i>clopidogrel</i></b> was stopped after 30 days and <b style='color:Tomato;'><i>aspirin</i></b> continued. Recurrent events were ascertained at face-to-face follow-up. ### results A total of 320 patients were prescribed a 30-day course of <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>clopidogrel</i></b> acutely after TIA or minor stroke. There were 5 recurrent ischemic strokes and 7 TIAs during the <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>clopidogrel</i></b> treatment period, but no strokes and 4 TIAs during the 30 days after stopping <b style='color:Tomato;'><i>clopidogrel</i></b>. A similar temporal trend in stroke risk was seen in the 487 patients prescribed <b style='color:Tomato;'><i>aspirin</i></b> alone in the acute phase, with 12 and 5 strokes in the equivalent time periods. The upper 95% confidence intervals of the observed 0% risk of stroke during the 30 days after stopping <b style='color:Tomato;'><i>clopidogrel</i></b> was 1.15% overall. ### conclusion Although larger studies are required, our findings suggest there is unlikely to be a large rebound effect after discontinuation of a 30-day course of <b style='color:Tomato;'><i>clopidogrel</i></b> in acute TIA and minor ischemic stroke. However, planned trials of <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>clopidogrel</i></b> in the acute phase after TIA or stroke should still follow-up beyond the cessation of <b style='color:Tomato;'><i>clopidogrel</i></b> treatment.","tokens":[{"text":"Early","start":0,"end":5,"id":0,"ws":true},{"text":"discontinuation","start":6,"end":21,"id":1,"ws":true},{"text":"of","start":22,"end":24,"id":2,"ws":true},{"text":"clopidogrel","start":25,"end":36,"id":3,"ws":true},{"text":"results","start":37,"end":44,"id":4,"ws":true},{"text":"in","start":45,"end":47,"id":5,"ws":true},{"text":"a","start":48,"end":49,"id":6,"ws":true},{"text":"transient","start":50,"end":59,"id":7,"ws":true},{"text":"rebound","start":60,"end":67,"id":8,"ws":true},{"text":"increase","start":68,"end":76,"id":9,"ws":true},{"text":"in","start":77,"end":79,"id":10,"ws":true},{"text":"risk","start":80,"end":84,"id":11,"ws":true},{"text":"of","start":85,"end":87,"id":12,"ws":true},{"text":"recurrence","start":88,"end":98,"id":13,"ws":true},{"text":"in","start":99,"end":101,"id":14,"ws":true},{"text":"acute","start":102,"end":107,"id":15,"ws":true},{"text":"coronary","start":108,"end":116,"id":16,"ws":true},{"text":"syndromes","start":117,"end":126,"id":17,"ws":true},{"text":",","start":127,"end":128,"id":18,"ws":true},{"text":"but","start":129,"end":132,"id":19,"ws":true},{"text":"there","start":133,"end":138,"id":20,"ws":true},{"text":"are","start":139,"end":142,"id":21,"ws":true},{"text":"no","start":143,"end":145,"id":22,"ws":true},{"text":"published","start":146,"end":155,"id":23,"ws":true},{"text":"data","start":156,"end":160,"id":24,"ws":true},{"text":"on","start":161,"end":163,"id":25,"ws":true},{"text":"any","start":164,"end":167,"id":26,"ws":true},{"text":"similar","start":168,"end":175,"id":27,"ws":true},{"text":"rebound","start":176,"end":183,"id":28,"ws":true},{"text":"effect","start":184,"end":190,"id":29,"ws":true},{"text":"in","start":191,"end":193,"id":30,"ws":true},{"text":"patients","start":194,"end":202,"id":31,"ws":true},{"text":"with","start":203,"end":207,"id":32,"ws":true},{"text":"TIA","start":208,"end":211,"id":33,"ws":true},{"text":"or","start":212,"end":214,"id":34,"ws":true},{"text":"stroke","start":215,"end":221,"id":35,"ws":true},{"text":"that","start":222,"end":226,"id":36,"ws":true},{"text":"might","start":227,"end":232,"id":37,"ws":true},{"text":"inform","start":233,"end":239,"id":38,"ws":true},{"text":"the","start":240,"end":243,"id":39,"ws":true},{"text":"design","start":244,"end":250,"id":40,"ws":true},{"text":"of","start":251,"end":253,"id":41,"ws":true},{"text":"clinical","start":254,"end":262,"id":42,"ws":true},{"text":"trials","start":263,"end":269,"id":43,"ws":true},{"text":"of","start":270,"end":272,"id":44,"ws":true},{"text":"aspirin","start":273,"end":280,"id":45,"ws":true},{"text":"and","start":281,"end":284,"id":46,"ws":true},{"text":"clopidogrel","start":285,"end":296,"id":47,"ws":true},{"text":"in","start":297,"end":299,"id":48,"ws":true},{"text":"the","start":300,"end":303,"id":49,"ws":true},{"text":"acute","start":304,"end":309,"id":50,"ws":true},{"text":"phase","start":310,"end":315,"id":51,"ws":true},{"text":".","start":316,"end":317,"id":52,"ws":false}],"spans":[{"start":25,"end":36,"token_start":3,"token_end":3,"label":"DRUG"},{"start":273,"end":280,"token_start":45,"token_end":45,"label":"DRUG"},{"start":285,"end":296,"token_start":47,"token_end":47,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/20530325/","_input_hash":779656601,"_task_hash":1542041114,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Patients received docetaxel 35 mg/m(2 ) and irinotecan 60 mg/m(2 ) , intravenously , on Days 1 and 8 , every 21 days , until disease progression .","paragraph":"<h3><u>Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group.</u></h3><b style='color:Tomato;'><i>docetaxel</i></b> and <b style='color:Tomato;'><i>irinotecan</i></b> have single-agent antitumor activity in squamous cell carcinoma of the head and neck (SCCHN). The authors sought to evaluate their combination in the treatment of patients with recurrent or metastatic SCCHN. ### methods Eligibility criteria included recurrent or metastatic SCCHN with measurable disease, good performance status, and adequate laboratory parameters. <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>35</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>60</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>intravenously</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>Days</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>8</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>until</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>progression</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The authors assessed UGT1A1 genotype, vascular endothelial growth factor (VEGF) in serum, and cyclooxygenase-2 and VEGF in baseline tumor tissue. ### results Fifty-two patients were analyzable: 20 chemotherapy naive (Group A) and 32 previously treated with 1 chemotherapy regimen (Group B); 73% of patients had distant metastasis, and 60% were <b style='color:Tomato;'><i>paclitaxel</i></b>-exposed. In Group A, 3 (15%) patients achieved a partial response; in Group B, 1 (3%) patient achieved a partial response. Median progression-free survival (PFS) and overall survival were 3.3 and 8.2 months in Group A and 1.9 and 5.0 months in Group B, respectively. Common serious toxicities were diarrhea, fatigue, and anorexia. Patients with high serum VEGF had a median PFS of 2.8 months versus 1.7 months for patients with low VEGF (P = .085). ### conclusions <b style='color:Tomato;'><i>docetaxel</i></b> and <b style='color:Tomato;'><i>irinotecan</i></b> had acceptable toxicities, but efficacy results in unselected patients with recurrent or metastatic SCCHN did not suggest an advantage over <b style='color:Tomato;'><i>docetaxel</i></b> alone or platinum-based regimens.","tokens":[{"text":"Patients","start":0,"end":8,"id":0,"ws":true},{"text":"received","start":9,"end":17,"id":1,"ws":true},{"text":"docetaxel","start":18,"end":27,"id":2,"ws":true},{"text":"35","start":28,"end":30,"id":3,"ws":true},{"text":"mg/m(2","start":31,"end":37,"id":4,"ws":true},{"text":")","start":38,"end":39,"id":5,"ws":true},{"text":"and","start":40,"end":43,"id":6,"ws":true},{"text":"irinotecan","start":44,"end":54,"id":7,"ws":true},{"text":"60","start":55,"end":57,"id":8,"ws":true},{"text":"mg/m(2","start":58,"end":64,"id":9,"ws":true},{"text":")","start":65,"end":66,"id":10,"ws":true},{"text":",","start":67,"end":68,"id":11,"ws":true},{"text":"intravenously","start":69,"end":82,"id":12,"ws":true},{"text":",","start":83,"end":84,"id":13,"ws":true},{"text":"on","start":85,"end":87,"id":14,"ws":true},{"text":"Days","start":88,"end":92,"id":15,"ws":true},{"text":"1","start":93,"end":94,"id":16,"ws":true},{"text":"and","start":95,"end":98,"id":17,"ws":true},{"text":"8","start":99,"end":100,"id":18,"ws":true},{"text":",","start":101,"end":102,"id":19,"ws":true},{"text":"every","start":103,"end":108,"id":20,"ws":true},{"text":"21","start":109,"end":111,"id":21,"ws":true},{"text":"days","start":112,"end":116,"id":22,"ws":true},{"text":",","start":117,"end":118,"id":23,"ws":true},{"text":"until","start":119,"end":124,"id":24,"ws":true},{"text":"disease","start":125,"end":132,"id":25,"ws":true},{"text":"progression","start":133,"end":144,"id":26,"ws":true},{"text":".","start":145,"end":146,"id":27,"ws":false}],"spans":[{"start":18,"end":27,"token_start":2,"token_end":2,"label":"DRUG"},{"start":44,"end":54,"token_start":7,"token_end":7,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/19634157/","_input_hash":-1994564215,"_task_hash":-1898193515,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":2,"child":7,"head_span":{"start":18,"end":27,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":44,"end":54,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG11"],"answer":"accept"}
{"text":"Most patients with advanced ovarian cancer achieve a clinical complete remission following cytoreductive surgery and chemotherapy with paclitaxel plus carboplatin .","paragraph":"<h3><u>Gemcitabine and carboplatin in second-line ovarian cancer.</u></h3> <b style='color:DodgerBlue;'><i>Most</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>achieve</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>complete</i></b> <b style='color:DodgerBlue;'><i>remission</i></b> <b style='color:DodgerBlue;'><i>following</i></b> <b style='color:DodgerBlue;'><i>cytoreductive</i></b> <b style='color:DodgerBlue;'><i>surgery</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, a majority of these patients will ultimately recur, and second-line treatment for this group of patients is an important aspect of management of this disease as well as an area of active clinical investigation. Until recently, for patients with platinum-sensitive ovarian cancer (more than 6-month disease-free interval), chemotherapy with single-agent <b style='color:Tomato;'><i>carboplatin</i></b> was frequently recommended. However, two recent prospective randomized trials have shown that combination chemotherapy produces higher response rates and improvement in progression-free survival compared with treatment with single-agent <b style='color:Tomato;'><i>carboplatin</i></b>. One trial compared treatment with <b style='color:Tomato;'><i>paclitaxel</i></b> plus a platinum compound with re-treatment with platinum, and a second trial compared <b style='color:Tomato;'><i>carboplatin</i></b> plus <b style='color:Tomato;'><i>gemcitabine</i></b> re-treatment against <b style='color:Tomato;'><i>carboplatin</i></b> in patients with platinum-sensitive recurrent ovarian cancer. Both trials showed a 3-month improvement in progression-free survival in patients treated with the combination, as well as acceptable toxicity. In the absence of a prospective randomized trial comparing these two regimens in patients with platinum-sensitive recurrent ovarian cancer, the choice of which combination to use may depend on toxicity considerations.","tokens":[{"text":"Most","start":0,"end":4,"id":0,"ws":true},{"text":"patients","start":5,"end":13,"id":1,"ws":true},{"text":"with","start":14,"end":18,"id":2,"ws":true},{"text":"advanced","start":19,"end":27,"id":3,"ws":true},{"text":"ovarian","start":28,"end":35,"id":4,"ws":true},{"text":"cancer","start":36,"end":42,"id":5,"ws":true},{"text":"achieve","start":43,"end":50,"id":6,"ws":true},{"text":"a","start":51,"end":52,"id":7,"ws":true},{"text":"clinical","start":53,"end":61,"id":8,"ws":true},{"text":"complete","start":62,"end":70,"id":9,"ws":true},{"text":"remission","start":71,"end":80,"id":10,"ws":true},{"text":"following","start":81,"end":90,"id":11,"ws":true},{"text":"cytoreductive","start":91,"end":104,"id":12,"ws":true},{"text":"surgery","start":105,"end":112,"id":13,"ws":true},{"text":"and","start":113,"end":116,"id":14,"ws":true},{"text":"chemotherapy","start":117,"end":129,"id":15,"ws":true},{"text":"with","start":130,"end":134,"id":16,"ws":true},{"text":"paclitaxel","start":135,"end":145,"id":17,"ws":true},{"text":"plus","start":146,"end":150,"id":18,"ws":true},{"text":"carboplatin","start":151,"end":162,"id":19,"ws":true},{"text":".","start":163,"end":164,"id":20,"ws":false}],"spans":[{"start":135,"end":145,"token_start":17,"token_end":17,"label":"DRUG"},{"start":151,"end":162,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16143161/","_input_hash":-848463825,"_task_hash":1187260872,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":17,"child":19,"head_span":{"start":135,"end":145,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":151,"end":162,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Patients were assigned to receive either oxaliplatin ( 100 mg/m(2 ) ) in the SOX arm or docetaxel ( 40 mg/m(2 ) ) in the mDS arm on day 1 of every 3-week cycle .","paragraph":"<h3><u>Low-dosed docetaxel showed equivalent efficacy but improved tolerability compared with oxaliplatin in the S-1-based first-line chemotherapy regimen for metastatic or recurrent gastric adenocarcinoma.</u></h3>Platinum-fluoropyrimidine combinations are the preferred first-line options for advanced gastric cancer (AGC) in East Asia. On the other hand, <b style='color:Tomato;'><i>docetaxel</i></b>-containing regimens without platinum have demonstrated promising activity in AGC. However, dose-related toxicity of <b style='color:Tomato;'><i>docetaxel</i></b> has limited its clinical adoption. This study compared the efficacy and safety of a modified low-dosed <b style='color:Tomato;'><i>docetaxel</i></b> plus S-1 (mDS) with <b style='color:Tomato;'><i>oxaliplatin</i></b> plus S-1 (SOX) in Chinese patients with AGC. <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>assigned</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>SOX</i></b> <b style='color:DodgerBlue;'><i>arm</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>40</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>mDS</i></b> <b style='color:DodgerBlue;'><i>arm</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3-week</i></b> <b style='color:DodgerBlue;'><i>cycle</i></b> <b style='color:DodgerBlue;'><i>.</i></b> S-1 80-120 mg/day was administered orally on days 1-14 in the 3-week cycle in both groups. One hundred and eighty-eight patients (mDS regimen 101; SOX 87) showed similar overall survival (OS; 13.1 vs 12.8 months, P = 0.878), progression-free survival (PFS; 5.8 vs 5.5 months, P = 0.924), and overall response rate (39.7 vs 44.2%, P = 0.569) in the mDS and SOX arms, respectively. mDS was associated with significantly less grade 3/4 toxicities in thrombocytopenia (5.9 vs 16.1%) and gastrointestinal disturbances (1.0 vs 8.0%). Furthermore, in patients who had ever received <b style='color:Tomato;'><i>oxaliplatin</i></b>-based adjuvant chemotherapy (N = 40), mDS resulted in significantly superior OS (17.8 vs 9.5 months, P = 0.015) and PFS (7.0 vs 4.2 months, P = 0.008) compared with SOX. In conclusion, mDS was as effective as SOX in Chinese patients with AGC, but it resulted in a significantly improved tolerability. In patients who received <b style='color:Tomato;'><i>oxaliplatin</i></b>-based adjuvant chemotherapy before, mDS was associated with improved efficacy in the first-line setting.","tokens":[{"text":"Patients","start":0,"end":8,"id":0,"ws":true},{"text":"were","start":9,"end":13,"id":1,"ws":true},{"text":"assigned","start":14,"end":22,"id":2,"ws":true},{"text":"to","start":23,"end":25,"id":3,"ws":true},{"text":"receive","start":26,"end":33,"id":4,"ws":true},{"text":"either","start":34,"end":40,"id":5,"ws":true},{"text":"oxaliplatin","start":41,"end":52,"id":6,"ws":true},{"text":"(","start":53,"end":54,"id":7,"ws":true},{"text":"100","start":55,"end":58,"id":8,"ws":true},{"text":"mg/m(2","start":59,"end":65,"id":9,"ws":true},{"text":")","start":66,"end":67,"id":10,"ws":true},{"text":")","start":68,"end":69,"id":11,"ws":true},{"text":"in","start":70,"end":72,"id":12,"ws":true},{"text":"the","start":73,"end":76,"id":13,"ws":true},{"text":"SOX","start":77,"end":80,"id":14,"ws":true},{"text":"arm","start":81,"end":84,"id":15,"ws":true},{"text":"or","start":85,"end":87,"id":16,"ws":true},{"text":"docetaxel","start":88,"end":97,"id":17,"ws":true},{"text":"(","start":98,"end":99,"id":18,"ws":true},{"text":"40","start":100,"end":102,"id":19,"ws":true},{"text":"mg/m(2","start":103,"end":109,"id":20,"ws":true},{"text":")","start":110,"end":111,"id":21,"ws":true},{"text":")","start":112,"end":113,"id":22,"ws":true},{"text":"in","start":114,"end":116,"id":23,"ws":true},{"text":"the","start":117,"end":120,"id":24,"ws":true},{"text":"mDS","start":121,"end":124,"id":25,"ws":true},{"text":"arm","start":125,"end":128,"id":26,"ws":true},{"text":"on","start":129,"end":131,"id":27,"ws":true},{"text":"day","start":132,"end":135,"id":28,"ws":true},{"text":"1","start":136,"end":137,"id":29,"ws":true},{"text":"of","start":138,"end":140,"id":30,"ws":true},{"text":"every","start":141,"end":146,"id":31,"ws":true},{"text":"3-week","start":147,"end":153,"id":32,"ws":true},{"text":"cycle","start":154,"end":159,"id":33,"ws":true},{"text":".","start":160,"end":161,"id":34,"ws":false}],"spans":[{"start":41,"end":52,"token_start":6,"token_end":6,"label":"DRUG"},{"start":88,"end":97,"token_start":17,"token_end":17,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26268397/","_input_hash":258919544,"_task_hash":389632687,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Agents in clinical trials for subsets of MDS include luspatercept , antibodies targeting CD33 , isocitrate dehydrogenase inhibitors , deacetylase inhibitors , venetoclax , and immunotherapies designed to overcome immune checkpoint inhibition .","paragraph":"<h3><u>Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approaches.</u></h3>It has been more than 10 years since any new disease-modifying therapies have received regulatory approval for indications related to myelodysplastic syndromes (MDS). Advances in our collective biological understanding of MDS in the last decade, however, have made it possible to hope that effective therapeutics can be designed to improve MDS-associated cytopenias and patients' quality of life, and perhaps even delay clonal progression and extend survival. Classes of MDS-associated mutations and disordered biological pathways targeted by developmental therapeutics include the following: aberrant messenger RNA splicing, neomorphic enzymes in the citric acid cycle with oncogenic activity, overactivated tyrosine and serine-threonine kinases, epigenetic and chromatin remodeling alterations, abnormal telomere dynamics, and failed protection of DNA integrity. At present, treatments for MDS are usually administered as sequential monotherapy, but there is a trend toward clinical trials of combination therapies-in which new agents are added to a DNA hypomethylating agent backbone-for both upfront treatment and the treatment of relapsed/refractory disease. <b style='color:DodgerBlue;'><i>Agents</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>subsets</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>MDS</i></b> <b style='color:DodgerBlue;'><i>include</i></b> <b style='color:MediumOrchid;'><i>luspatercept</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>antibodies</i></b> <b style='color:DodgerBlue;'><i>targeting</i></b> <b style='color:DodgerBlue;'><i>CD33</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>isocitrate</i></b> <b style='color:DodgerBlue;'><i>dehydrogenase</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>deacetylase</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>venetoclax</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>immunotherapies</i></b> <b style='color:DodgerBlue;'><i>designed</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>overcome</i></b> <b style='color:DodgerBlue;'><i>immune</i></b> <b style='color:DodgerBlue;'><i>checkpoint</i></b> <b style='color:DodgerBlue;'><i>inhibition</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These biologically based therapeutics, as well as the encouraging precedent of 7 new approvals by the US Food and Drug Administration in 2017 for the treatment of acute leukemia, offer the prospect that 10 more years will not elapse before another new therapy is approved for MDS.","tokens":[{"text":"Agents","start":0,"end":6,"id":0,"ws":true},{"text":"in","start":7,"end":9,"id":1,"ws":true},{"text":"clinical","start":10,"end":18,"id":2,"ws":true},{"text":"trials","start":19,"end":25,"id":3,"ws":true},{"text":"for","start":26,"end":29,"id":4,"ws":true},{"text":"subsets","start":30,"end":37,"id":5,"ws":true},{"text":"of","start":38,"end":40,"id":6,"ws":true},{"text":"MDS","start":41,"end":44,"id":7,"ws":true},{"text":"include","start":45,"end":52,"id":8,"ws":true},{"text":"luspatercept","start":53,"end":65,"id":9,"ws":true},{"text":",","start":66,"end":67,"id":10,"ws":true},{"text":"antibodies","start":68,"end":78,"id":11,"ws":true},{"text":"targeting","start":79,"end":88,"id":12,"ws":true},{"text":"CD33","start":89,"end":93,"id":13,"ws":true},{"text":",","start":94,"end":95,"id":14,"ws":true},{"text":"isocitrate","start":96,"end":106,"id":15,"ws":true},{"text":"dehydrogenase","start":107,"end":120,"id":16,"ws":true},{"text":"inhibitors","start":121,"end":131,"id":17,"ws":true},{"text":",","start":132,"end":133,"id":18,"ws":true},{"text":"deacetylase","start":134,"end":145,"id":19,"ws":true},{"text":"inhibitors","start":146,"end":156,"id":20,"ws":true},{"text":",","start":157,"end":158,"id":21,"ws":true},{"text":"venetoclax","start":159,"end":169,"id":22,"ws":true},{"text":",","start":170,"end":171,"id":23,"ws":true},{"text":"and","start":172,"end":175,"id":24,"ws":true},{"text":"immunotherapies","start":176,"end":191,"id":25,"ws":true},{"text":"designed","start":192,"end":200,"id":26,"ws":true},{"text":"to","start":201,"end":203,"id":27,"ws":true},{"text":"overcome","start":204,"end":212,"id":28,"ws":true},{"text":"immune","start":213,"end":219,"id":29,"ws":true},{"text":"checkpoint","start":220,"end":230,"id":30,"ws":true},{"text":"inhibition","start":231,"end":241,"id":31,"ws":true},{"text":".","start":242,"end":243,"id":32,"ws":false}],"spans":[{"start":53,"end":65,"token_start":9,"token_end":9,"label":"DRUG"},{"start":159,"end":169,"token_start":22,"token_end":22,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29741506/","_input_hash":85053744,"_task_hash":1768436942,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Possible differences between enalapril and captopril .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Possible</i></b> <b style='color:DodgerBlue;'><i>differences</i></b> <b style='color:DodgerBlue;'><i>between</i></b> <b style='color:MediumOrchid;'><i>enalapril</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>captopril</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Inhibitors of angiotensin converting enzyme block the conversion of angiotensin I to angiotensin II, the active hormone of the renin-angiotensin system. This inhibition leads to a reduction in angiotensin-mediated vasoconstriction and aldosterone production. Although converting enzyme inhibitors have other potential metabolic effects, their beneficial effects in hypertension and congestive heart failure appear to be, in large part, related to their ability to reduce angiotensin II. This causes an increase in plasma renin levels and a fall in plasma and urine aldosterone, which can be sustained for many years. As a consequence, converting enzyme inhibitors produce mild natriuresis and positive potassium balance. At conventionally used doses, <b style='color:Tomato;'><i>enalapril</i></b> more completely prevents posture-induced increases in aldosterone than does <b style='color:Tomato;'><i>captopril</i></b>, probably reflecting more complete inhibition of angiotensin II formation in vivo.","tokens":[{"text":"Possible","start":0,"end":8,"id":0,"ws":true},{"text":"differences","start":9,"end":20,"id":1,"ws":true},{"text":"between","start":21,"end":28,"id":2,"ws":true},{"text":"enalapril","start":29,"end":38,"id":3,"ws":true},{"text":"and","start":39,"end":42,"id":4,"ws":true},{"text":"captopril","start":43,"end":52,"id":5,"ws":true},{"text":".","start":53,"end":54,"id":6,"ws":false}],"spans":[{"start":29,"end":38,"token_start":3,"token_end":3,"label":"DRUG"},{"start":43,"end":52,"token_start":5,"token_end":5,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/6089554/","_input_hash":-1441819874,"_task_hash":198220139,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Exposure of the saphenous veins to imipenem or imipenem combined with amphotericin B had no adverse effects on the viability of the endothelial cells with 12 h exposure .","paragraph":"<h3><u>Effects of antibiotics on the endothelium of fresh and cryopreserved canine saphenous veins.</u></h3>To determine if antibiotic solutions for potential use in antimicrobial treatment of tissues were detrimental to cell viability, canine saphenous veins were exposed to three different antibiotic solutions at 37 degrees C for 12 h. Viability was determined by tissue culture, utilizing a limiting dilution assay. The antibiotic series included two formulations currently used for the preservation of heart valves and a new formulation containing <b style='color:Tomato;'><i>imipenem</i></b>, a broad spectrum beta-lactam. Currently used antibiotic regimes and <b style='color:Tomato;'><i>imipenem</i></b> with <b style='color:Tomato;'><i>gentamicin</i></b> resulted in a decrease of 30 to 50% of the viable endothelial cells within 12 h. <b style='color:DodgerBlue;'><i>Exposure</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>saphenous</i></b> <b style='color:DodgerBlue;'><i>veins</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>imipenem</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>imipenem</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>amphotericin</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>adverse</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>viability</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>endothelial</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>12</i></b> <b style='color:DodgerBlue;'><i>h</i></b> <b style='color:DodgerBlue;'><i>exposure</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, veins exposed to <b style='color:Tomato;'><i>amphotericin</i></b> B were more susceptible to subsequent damage during freezing and thawing than veins frozen after incubation with either <b style='color:Tomato;'><i>imipenem</i></b> alone or <b style='color:Tomato;'><i>imipenem</i></b> combined with <b style='color:Tomato;'><i>flucytosine</i></b>. These studies indicate that <b style='color:Tomato;'><i>imipenem</i></b> combined with <b style='color:Tomato;'><i>flucytosine</i></b> is suitable for use with vein grafts.","tokens":[{"text":"Exposure","start":0,"end":8,"id":0,"ws":true},{"text":"of","start":9,"end":11,"id":1,"ws":true},{"text":"the","start":12,"end":15,"id":2,"ws":true},{"text":"saphenous","start":16,"end":25,"id":3,"ws":true},{"text":"veins","start":26,"end":31,"id":4,"ws":true},{"text":"to","start":32,"end":34,"id":5,"ws":true},{"text":"imipenem","start":35,"end":43,"id":6,"ws":true},{"text":"or","start":44,"end":46,"id":7,"ws":true},{"text":"imipenem","start":47,"end":55,"id":8,"ws":true},{"text":"combined","start":56,"end":64,"id":9,"ws":true},{"text":"with","start":65,"end":69,"id":10,"ws":true},{"text":"amphotericin","start":70,"end":82,"id":11,"ws":true},{"text":"B","start":83,"end":84,"id":12,"ws":true},{"text":"had","start":85,"end":88,"id":13,"ws":true},{"text":"no","start":89,"end":91,"id":14,"ws":true},{"text":"adverse","start":92,"end":99,"id":15,"ws":true},{"text":"effects","start":100,"end":107,"id":16,"ws":true},{"text":"on","start":108,"end":110,"id":17,"ws":true},{"text":"the","start":111,"end":114,"id":18,"ws":true},{"text":"viability","start":115,"end":124,"id":19,"ws":true},{"text":"of","start":125,"end":127,"id":20,"ws":true},{"text":"the","start":128,"end":131,"id":21,"ws":true},{"text":"endothelial","start":132,"end":143,"id":22,"ws":true},{"text":"cells","start":144,"end":149,"id":23,"ws":true},{"text":"with","start":150,"end":154,"id":24,"ws":true},{"text":"12","start":155,"end":157,"id":25,"ws":true},{"text":"h","start":158,"end":159,"id":26,"ws":true},{"text":"exposure","start":160,"end":168,"id":27,"ws":true},{"text":".","start":169,"end":170,"id":28,"ws":false}],"spans":[{"start":35,"end":43,"token_start":6,"token_end":6,"label":"DRUG"},{"start":47,"end":55,"token_start":8,"token_end":8,"label":"DRUG"},{"start":70,"end":82,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8319486/","_input_hash":-1861796111,"_task_hash":1320881043,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"First-line chemotherapy was either R-CHOP ( rituximab , cyclophosphamide , doxorubicin , vincristine and prednisolone ) or CHOP-like-based regimen .","paragraph":"<h3><u>[Primary testicular non-Hodgkin's lymphoma: clinical analysis of 21 cases].</u></h3>To explore the clinical characteristics and prognosis of patients with primary testicular non-Hodgkin's lymphoma. ### methods The clinical profiles and prognostic factors of 21 cases newly diagnosed as primary testicular non-Hodgkin's lymphoma at Peking University Cancer Hospital from January 2005 to December 2012 were retrospectively analyzed. ### results Their median age was 59 (34-86) years. And they were classified as Ann Arbor stage I (n = 8), stage II (n = 2) and stage IV (n = 11). There were B symptoms (n = 4), extranodal involvement outside testis (n = 12) and elevated lactate dehydrogenase (LDH) at diagnosis (n = 6). The scores of international prognostic index (IPI) were 0-1 point (n = 10), 3 points (n = 10) and 4 points (n = 1). The regimens included orchidectomy as the initial treatment (n = 15), chemotherapy followed by radiotherapy (n = 7) and CNS prophylaxis during treatment (n = 15). All patients were pathologically diagnosed as diffuse large B-cell lymphoma. And 11 cases belonged to the non-germinal center B cell-like subgroup. <b style='color:DodgerBlue;'><i>First-line</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:DodgerBlue;'><i>R-CHOP</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisolone</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>CHOP-like-based</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Complete response was achieved in 85.7% of patients. The median follow-up period was 18 (6-58) months. The 1, 2 and 3-year survival rates were 100%, 80% and 60% respectively. Statistical analysis showed that the first-line chemotherapy with <b style='color:Tomato;'><i>rituximab</i></b> was a prognostic factor (P = 0.038).Other factors included stage (P = 0.275), LDH level (P = 0.179) , \u03b22-microglobulin level (P = 0.229) and IPI (P = 0.275) . ### conclusions The prognosis of primary testicular non-Hodgkin's lymphoma is usually poor. The first-line chemotherapy with <b style='color:Tomato;'><i>rituximab</i></b> is a prognostic factor.","tokens":[{"text":"First-line","start":0,"end":10,"id":0,"ws":true},{"text":"chemotherapy","start":11,"end":23,"id":1,"ws":true},{"text":"was","start":24,"end":27,"id":2,"ws":true},{"text":"either","start":28,"end":34,"id":3,"ws":true},{"text":"R-CHOP","start":35,"end":41,"id":4,"ws":true},{"text":"(","start":42,"end":43,"id":5,"ws":true},{"text":"rituximab","start":44,"end":53,"id":6,"ws":true},{"text":",","start":54,"end":55,"id":7,"ws":true},{"text":"cyclophosphamide","start":56,"end":72,"id":8,"ws":true},{"text":",","start":73,"end":74,"id":9,"ws":true},{"text":"doxorubicin","start":75,"end":86,"id":10,"ws":true},{"text":",","start":87,"end":88,"id":11,"ws":true},{"text":"vincristine","start":89,"end":100,"id":12,"ws":true},{"text":"and","start":101,"end":104,"id":13,"ws":true},{"text":"prednisolone","start":105,"end":117,"id":14,"ws":true},{"text":")","start":118,"end":119,"id":15,"ws":true},{"text":"or","start":120,"end":122,"id":16,"ws":true},{"text":"CHOP-like-based","start":123,"end":138,"id":17,"ws":true},{"text":"regimen","start":139,"end":146,"id":18,"ws":true},{"text":".","start":147,"end":148,"id":19,"ws":false}],"spans":[{"start":44,"end":53,"token_start":6,"token_end":6,"label":"DRUG"},{"start":56,"end":72,"token_start":8,"token_end":8,"label":"DRUG"},{"start":75,"end":86,"token_start":10,"token_end":10,"label":"DRUG"},{"start":89,"end":100,"token_start":12,"token_end":12,"label":"DRUG"},{"start":105,"end":117,"token_start":14,"token_end":14,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/24169330/","_input_hash":1227589076,"_task_hash":-754511544,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":6,"child":8,"head_span":{"start":44,"end":53,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":56,"end":72,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":8,"child":10,"head_span":{"start":56,"end":72,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":75,"end":86,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":10,"child":12,"head_span":{"start":75,"end":86,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":89,"end":100,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":12,"child":14,"head_span":{"start":89,"end":100,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":105,"end":117,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The combination of rituximab with vincristine and 5-day cyclophosphamide is able to produce CR in patients with advanced follicular lymphoma , even in patients resistant to third-generation regimens .","paragraph":"<h3><u>Immunochemotherapy with rituximab, vincristine and 5-day cyclophosphamide for heavily pretreated follicular lymphoma.</u></h3>Therapeutic options for relapsed or refractory follicular lymphoma include combination chemotherapy, immunotherapy and, for selected patients, autotransplant. Because of the different mechanisms of action and non-overlapping toxicities, combination of <b style='color:Tomato;'><i>rituximab</i></b> with chemotherapy is a rational approach. ### methods 30 patients with follicular non-Hodgkin's lymphoma with advanced-stage disease were treated with four cycles of immunochemotherapy with <b style='color:Tomato;'><i>rituximab</i></b> 375 mg/m2 on day 1, <b style='color:Tomato;'><i>vincristine</i></b> 2 mg i.v. on day 2 and <b style='color:Tomato;'><i>cyclophosphamide</i></b> 400 mg/m2 i.v. from days 2 to 6, repeated at 3-week intervals. All patients had received multiple lines of therapy (median 3); 9 (30%) had relapses (2 after high-dose therapy with autologous transplant), and 21 (70%) were in relapse and refractory to salvage treatment (with an anthracycline-containing regimen in 19). ### results Of 29 patients evaluable for response, 16 (55 %) obtained a complete response (CR) and 3 (10%) a partial response (PR), with an overall response rate of 65% (19/29); 10 patients (35%) achieved less than PR. The median event-free survival was 16.1 months for all patients, being 22.8 months for responders. After a median follow-up of 2 years from the start of therapy (range 6 months to 3.8 years), of 16 patients who achieved CR, 10 remain free of disease. ### conclusion <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>5-day</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>able</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>produce</i></b> <b style='color:DodgerBlue;'><i>CR</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>follicular</i></b> <b style='color:DodgerBlue;'><i>lymphoma</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>even</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>third-generation</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The regimen designed on the basis of pharmacokinetics of the chimeric antibody seemed important for the clinical efficacy of the combination.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"combination","start":4,"end":15,"id":1,"ws":true},{"text":"of","start":16,"end":18,"id":2,"ws":true},{"text":"rituximab","start":19,"end":28,"id":3,"ws":true},{"text":"with","start":29,"end":33,"id":4,"ws":true},{"text":"vincristine","start":34,"end":45,"id":5,"ws":true},{"text":"and","start":46,"end":49,"id":6,"ws":true},{"text":"5-day","start":50,"end":55,"id":7,"ws":true},{"text":"cyclophosphamide","start":56,"end":72,"id":8,"ws":true},{"text":"is","start":73,"end":75,"id":9,"ws":true},{"text":"able","start":76,"end":80,"id":10,"ws":true},{"text":"to","start":81,"end":83,"id":11,"ws":true},{"text":"produce","start":84,"end":91,"id":12,"ws":true},{"text":"CR","start":92,"end":94,"id":13,"ws":true},{"text":"in","start":95,"end":97,"id":14,"ws":true},{"text":"patients","start":98,"end":106,"id":15,"ws":true},{"text":"with","start":107,"end":111,"id":16,"ws":true},{"text":"advanced","start":112,"end":120,"id":17,"ws":true},{"text":"follicular","start":121,"end":131,"id":18,"ws":true},{"text":"lymphoma","start":132,"end":140,"id":19,"ws":true},{"text":",","start":141,"end":142,"id":20,"ws":true},{"text":"even","start":143,"end":147,"id":21,"ws":true},{"text":"in","start":148,"end":150,"id":22,"ws":true},{"text":"patients","start":151,"end":159,"id":23,"ws":true},{"text":"resistant","start":160,"end":169,"id":24,"ws":true},{"text":"to","start":170,"end":172,"id":25,"ws":true},{"text":"third-generation","start":173,"end":189,"id":26,"ws":true},{"text":"regimens","start":190,"end":198,"id":27,"ws":true},{"text":".","start":199,"end":200,"id":28,"ws":false}],"spans":[{"start":19,"end":28,"token_start":3,"token_end":3,"label":"DRUG"},{"start":34,"end":45,"token_start":5,"token_end":5,"label":"DRUG"},{"start":56,"end":72,"token_start":8,"token_end":8,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16006752/","_input_hash":-1125996466,"_task_hash":-1111940363,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":3,"child":5,"head_span":{"start":19,"end":28,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":34,"end":45,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":5,"child":8,"head_span":{"start":34,"end":45,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":56,"end":72,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"The results showed that lamotrigine did not produce any change in cognitive function , while carbamazepine produced cognitive dysfunction .","paragraph":"<h3><u>Effect of carbamazepine and lamotrigine on cognitive function and oxidative stress in brain during chemical epileptogenesis in rats.</u></h3>The present study assessed the effect of <b style='color:Tomato;'><i>carbamazepine</i></b> and <b style='color:Tomato;'><i>lamotrigine</i></b> on cognitive function and oxidative stress in brain during chemically induced epileptogenesis in rats. Epileptogenesis was induced by administration of pentylenetetrazole (30 mg/kg, s.c.) on alternate days (three times/week) for 9-11 weeks or until stage 4 of seizure score was achieved. The neurobehavioural parameters used for cognitive assessment were step-down latency in continuous avoidance apparatus and transfer latency in elevated plus maze test paradigm. <b style='color:Tomato;'><i>carbamazepine</i></b> and <b style='color:Tomato;'><i>lamotrigine</i></b> were administered intraperitoneally in doses of 60 mg/kg and 25 mg/kg, respectively, according to the groups, once a day for 11 weeks. Oxidative stress was assessed in isolated homogenized whole brain samples and estimated for the levels of malondialdehyde, reduced glutathione, catalase and superoxide dismutase. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:MediumOrchid;'><i>lamotrigine</i></b> <b style='color:DodgerBlue;'><i>did</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>produce</i></b> <b style='color:DodgerBlue;'><i>any</i></b> <b style='color:DodgerBlue;'><i>change</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>cognitive</i></b> <b style='color:DodgerBlue;'><i>function</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>while</i></b> <b style='color:MediumOrchid;'><i>carbamazepine</i></b> <b style='color:DodgerBlue;'><i>produced</i></b> <b style='color:DodgerBlue;'><i>cognitive</i></b> <b style='color:DodgerBlue;'><i>dysfunction</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Cognitive decline seen in the <b style='color:Tomato;'><i>carbamazepine</i></b>-treated pentylenetetrazole-kindled group was also associated with increased oxidative stress. <b style='color:Tomato;'><i>lamotrigine</i></b> treatment had no effect on oxidative stress parameters alone, while it significantly decreased oxidative stress in the pentylenetetrazole-kindled group as compared to the pentylenetetrazole-kindled <b style='color:Tomato;'><i>carbamazepine</i></b>-treated group.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"results","start":4,"end":11,"id":1,"ws":true},{"text":"showed","start":12,"end":18,"id":2,"ws":true},{"text":"that","start":19,"end":23,"id":3,"ws":true},{"text":"lamotrigine","start":24,"end":35,"id":4,"ws":true},{"text":"did","start":36,"end":39,"id":5,"ws":true},{"text":"not","start":40,"end":43,"id":6,"ws":true},{"text":"produce","start":44,"end":51,"id":7,"ws":true},{"text":"any","start":52,"end":55,"id":8,"ws":true},{"text":"change","start":56,"end":62,"id":9,"ws":true},{"text":"in","start":63,"end":65,"id":10,"ws":true},{"text":"cognitive","start":66,"end":75,"id":11,"ws":true},{"text":"function","start":76,"end":84,"id":12,"ws":true},{"text":",","start":85,"end":86,"id":13,"ws":true},{"text":"while","start":87,"end":92,"id":14,"ws":true},{"text":"carbamazepine","start":93,"end":106,"id":15,"ws":true},{"text":"produced","start":107,"end":115,"id":16,"ws":true},{"text":"cognitive","start":116,"end":125,"id":17,"ws":true},{"text":"dysfunction","start":126,"end":137,"id":18,"ws":true},{"text":".","start":138,"end":139,"id":19,"ws":false}],"spans":[{"start":24,"end":35,"token_start":4,"token_end":4,"label":"DRUG"},{"start":93,"end":106,"token_start":15,"token_end":15,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/20002063/","_input_hash":1266528498,"_task_hash":-276814944,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"These results confirm that sequential decitabine and carboplatin requires further investigation as a combination treatment for melanoma .","paragraph":"<h3><u>Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma.</u></h3>Melanoma has two key features, an over-representation of UV-induced mutations and resistance to DNA damaging chemotherapy agents. Both of these features may result from dysfunction of the nucleotide excision repair pathway, in particular the DNA damage detection branch, global genome repair (GGR). The key GGR component XPC does not respond to DNA damage in melanoma, the cause of this lack of response has not been investigated. In this study, we investigated the role of methylation in reduced XPC in melanoma. ### methods To reduce methylation and induce DNA-damage, melanoma cell lines were treated with <b style='color:Tomato;'><i>decitabine</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b>, individually and sequentially. Global DNA methylation levels, XPC mRNA and protein expression and methylation of the XPC promoter were examined. Apoptosis, cell proliferation and senescence were also quantified. XPC siRNA was used to determine that the responses seen were reliant on XPC induction. ### results Treatment with high-dose <b style='color:Tomato;'><i>decitabine</i></b> resulted in global demethylation, including the the shores of the XPC CpG island and significantly increased XPC mRNA expression. Lower, clinically relevant dose of <b style='color:Tomato;'><i>decitabine</i></b> also resulted in global demethylation including the CpG island shores and induced XPC in 50% of cell lines. <b style='color:Tomato;'><i>decitabine</i></b> followed by DNA-damaging <b style='color:Tomato;'><i>carboplatin</i></b> treatment led to significantly higher XPC expression in 75% of melanoma cell lines tested. Combined sequential treatment also resulted in a greater apoptotic response in 75% of cell lines compared to <b style='color:Tomato;'><i>carboplatin</i></b> alone, and significantly slowed cell proliferation, with some melanoma cell lines going into senescence. Inhibiting the increased XPC using siRNA had a small but significant negative effect, indicating that XPC plays a partial role in the response to sequential <b style='color:Tomato;'><i>decitabine</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b>. ### conclusions Demethylation using <b style='color:Tomato;'><i>decitabine</i></b> increased XPC and apoptosis after sequential <b style='color:Tomato;'><i>carboplatin</i></b>. <b style='color:DodgerBlue;'><i>These</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>confirm</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>sequential</i></b> <b style='color:MediumOrchid;'><i>decitabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>requires</i></b> <b style='color:DodgerBlue;'><i>further</i></b> <b style='color:DodgerBlue;'><i>investigation</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>melanoma</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"These","start":0,"end":5,"id":0,"ws":true},{"text":"results","start":6,"end":13,"id":1,"ws":true},{"text":"confirm","start":14,"end":21,"id":2,"ws":true},{"text":"that","start":22,"end":26,"id":3,"ws":true},{"text":"sequential","start":27,"end":37,"id":4,"ws":true},{"text":"decitabine","start":38,"end":48,"id":5,"ws":true},{"text":"and","start":49,"end":52,"id":6,"ws":true},{"text":"carboplatin","start":53,"end":64,"id":7,"ws":true},{"text":"requires","start":65,"end":73,"id":8,"ws":true},{"text":"further","start":74,"end":81,"id":9,"ws":true},{"text":"investigation","start":82,"end":95,"id":10,"ws":true},{"text":"as","start":96,"end":98,"id":11,"ws":true},{"text":"a","start":99,"end":100,"id":12,"ws":true},{"text":"combination","start":101,"end":112,"id":13,"ws":true},{"text":"treatment","start":113,"end":122,"id":14,"ws":true},{"text":"for","start":123,"end":126,"id":15,"ws":true},{"text":"melanoma","start":127,"end":135,"id":16,"ws":true},{"text":".","start":136,"end":137,"id":17,"ws":false}],"spans":[{"start":38,"end":48,"token_start":5,"token_end":5,"label":"DRUG"},{"start":53,"end":64,"token_start":7,"token_end":7,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29373959/","_input_hash":329451074,"_task_hash":947957786,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":5,"child":7,"head_span":{"start":38,"end":48,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":53,"end":64,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"[ Rhabdomyosarcoma of the urinary bladder : complete remission induced by vinblastine , cis-platinum , and bleomycin ] .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>Rhabdomyosarcoma</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>urinary</i></b> <b style='color:DodgerBlue;'><i>bladder</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>complete</i></b> <b style='color:DodgerBlue;'><i>remission</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>vinblastine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>cis-platinum</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bleomycin</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Combination therapy consisting of <b style='color:Tomato;'><i>vincristine</i></b>, actinomycin-D, and <b style='color:Tomato;'><i>cyclophosphamide</i></b> with or without adriamycin is the most common chemotherapy for rhabdomyosarcoma in childhood. But the effective chemotherapy for rhabdomyosarcoma resistant to these four drugs has not been established. We report a case with rhabdomyosarcoma, which was resistant to these four drugs but responded completely to three drug combination chemotherapy consisting of <b style='color:Tomato;'><i>vinblastine</i></b>, cis-platinum, and <b style='color:Tomato;'><i>bleomycin</i></b> (VPB therapy). A 11-months-old boy was referred to us because of giant abdominal tumor. Postoperative diagnosis was Group III embryonal rhabdomyosarcoma of the urinary bladder. Partial resection was followed by <b style='color:Tomato;'><i>vincristine</i></b>, actinomycin-D, <b style='color:Tomato;'><i>cyclophosphamide</i></b>, and adriamycin, but his residual tumor was growing. Then VPB therapy was administered and the first course of the chemotherapy reduced the size of tumor. After three courses of VPB therapy the second-look operation was performed. At operation no residual tumor was found and a complete remission was confirmed. During the course of VPB therapy no severe adverse effect was detectable.","tokens":[{"text":"[","start":0,"end":1,"id":0,"ws":true},{"text":"Rhabdomyosarcoma","start":2,"end":18,"id":1,"ws":true},{"text":"of","start":19,"end":21,"id":2,"ws":true},{"text":"the","start":22,"end":25,"id":3,"ws":true},{"text":"urinary","start":26,"end":33,"id":4,"ws":true},{"text":"bladder","start":34,"end":41,"id":5,"ws":true},{"text":":","start":42,"end":43,"id":6,"ws":true},{"text":"complete","start":44,"end":52,"id":7,"ws":true},{"text":"remission","start":53,"end":62,"id":8,"ws":true},{"text":"induced","start":63,"end":70,"id":9,"ws":true},{"text":"by","start":71,"end":73,"id":10,"ws":true},{"text":"vinblastine","start":74,"end":85,"id":11,"ws":true},{"text":",","start":86,"end":87,"id":12,"ws":true},{"text":"cis-platinum","start":88,"end":100,"id":13,"ws":true},{"text":",","start":101,"end":102,"id":14,"ws":true},{"text":"and","start":103,"end":106,"id":15,"ws":true},{"text":"bleomycin","start":107,"end":116,"id":16,"ws":true},{"text":"]","start":117,"end":118,"id":17,"ws":true},{"text":".","start":119,"end":120,"id":18,"ws":false}],"spans":[{"start":74,"end":85,"token_start":11,"token_end":11,"label":"DRUG"},{"start":107,"end":116,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/6191695/","_input_hash":1763146291,"_task_hash":228955403,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":11,"child":13,"head_span":{"start":74,"end":85,"token_start":11,"token_end":11,"label":"DRUG"},"child_span":{"start":88,"end":100,"token_start":13,"token_end":13,"label":null},"color":"#c5bdf4","label":"POS1"},{"head":13,"child":16,"head_span":{"start":88,"end":100,"token_start":13,"token_end":13,"label":null},"child_span":{"start":107,"end":116,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Recent comparative studies suggest that atenolol ( 200 mg daily ) , metoprolol ( 200 mg daily ) ; acebutolol ( 400 mg daily ) , oxprenolol ( 160 mg daily ) , nadolol ( 80 mg daily ) and timolol ( 20 mg daily ) produce a beneficial clinical response equal to that seen with propranolol ( 160 mg daily ) .","paragraph":"<h3><u>Use of beta-adrenoceptor blocking drugs in hyperthyroidism.</u></h3>There is an increasing use and variety of beta-adrenoceptor blocking agents (beta-blockers) available for the treatment of hyperthyroidism. <b style='color:DodgerBlue;'><i>Recent</i></b> <b style='color:DodgerBlue;'><i>comparative</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>suggest</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:MediumOrchid;'><i>atenolol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>200</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>metoprolol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>200</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:MediumOrchid;'><i>acebutolol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>400</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>oxprenolol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>160</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>nadolol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>80</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>timolol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>produce</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>beneficial</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>equal</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>seen</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>propranolol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>160</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Most beta-blockers reduce resting heart rate by approximately 25 to 30 beats/min, although a lesser reduction is seen with those possessing intrinsic sympathomimetic activity such as <b style='color:Tomato;'><i>oxprenolol</i></b> and <b style='color:Tomato;'><i>pindolol</i></b>. While earlier studies employing large doses of intravenous <b style='color:Tomato;'><i>propranolol</i></b> concluded that beta-blockade reduced myocardial contractility, more recent non-invasive studies suggest that the predominant cardiac effect is on heart rate. In patients with cardiac failure, beta-blockers may, however, produce a profound fall in cardiac output. Nevertheless, in combination with <b style='color:Tomato;'><i>digoxin</i></b> they may be useful in controlling the atrial fibrillation of thyrocardiac disease. beta-Blockers improve nervousness and tremor (although to a lesser extent with cardioselective agents) and severe myopathy, and they also reduce the frequency of paralysis in patients with thyrotoxic periodic paralysis. There is often subjective improvement in sweating but usually no major effect on eye signs. Recent studies show a 10% reduction in oxygen consumption/basal metabolic rate with long term oral use of selective or nonselective beta-blockers. In addition, many agents (<b style='color:Tomato;'><i>propranolol</i></b>, <b style='color:Tomato;'><i>metoprolol</i></b>, <b style='color:Tomato;'><i>nadolol</i></b> and <b style='color:Tomato;'><i>sotalol</i></b> but not <b style='color:Tomato;'><i>acebutolol</i></b>, <b style='color:Tomato;'><i>atenolol</i></b> or <b style='color:Tomato;'><i>oxprenolol</i></b>) reduce circulating tri-iodothyronine (T3) concentration by between 10 and 40%, although the clinical significance of this effect (if any) is not established. beta-Blockers may also have endocrinological effects on gastrin, cyclic AMP, catecholamines and other hormone levels. Given in adequate dosage, <b style='color:Tomato;'><i>propranolol</i></b> has been shown to control thyrotoxic hypercalcaemia. Minor side effects (nausea, headaches, tiredness, etc.) are quite common but overall beta-blockers are well tolerated by the thyrotoxic patient. The major use of these drugs is in symptomatic control while awaiting definitive diagnosis or treatment. As an adjunct to antithyroid drugs or radioactive iodine, beta-blockers will produce a satisfactory clinical response in the weeks to months before these forms of therapy produce a euthyroid state. beta-Blockers are more convenient than antithyroid drugs in the control of patients receiving therapeutic radioiodine, in that continuous therapy and assessment of biochemical response is possible.(ABSTRACT TRUNCATED AT 400 WORDS)","tokens":[{"text":"Recent","start":0,"end":6,"id":0,"ws":true},{"text":"comparative","start":7,"end":18,"id":1,"ws":true},{"text":"studies","start":19,"end":26,"id":2,"ws":true},{"text":"suggest","start":27,"end":34,"id":3,"ws":true},{"text":"that","start":35,"end":39,"id":4,"ws":true},{"text":"atenolol","start":40,"end":48,"id":5,"ws":true},{"text":"(","start":49,"end":50,"id":6,"ws":true},{"text":"200","start":51,"end":54,"id":7,"ws":true},{"text":"mg","start":55,"end":57,"id":8,"ws":true},{"text":"daily","start":58,"end":63,"id":9,"ws":true},{"text":")","start":64,"end":65,"id":10,"ws":true},{"text":",","start":66,"end":67,"id":11,"ws":true},{"text":"metoprolol","start":68,"end":78,"id":12,"ws":true},{"text":"(","start":79,"end":80,"id":13,"ws":true},{"text":"200","start":81,"end":84,"id":14,"ws":true},{"text":"mg","start":85,"end":87,"id":15,"ws":true},{"text":"daily","start":88,"end":93,"id":16,"ws":true},{"text":")","start":94,"end":95,"id":17,"ws":true},{"text":";","start":96,"end":97,"id":18,"ws":true},{"text":"acebutolol","start":98,"end":108,"id":19,"ws":true},{"text":"(","start":109,"end":110,"id":20,"ws":true},{"text":"400","start":111,"end":114,"id":21,"ws":true},{"text":"mg","start":115,"end":117,"id":22,"ws":true},{"text":"daily","start":118,"end":123,"id":23,"ws":true},{"text":")","start":124,"end":125,"id":24,"ws":true},{"text":",","start":126,"end":127,"id":25,"ws":true},{"text":"oxprenolol","start":128,"end":138,"id":26,"ws":true},{"text":"(","start":139,"end":140,"id":27,"ws":true},{"text":"160","start":141,"end":144,"id":28,"ws":true},{"text":"mg","start":145,"end":147,"id":29,"ws":true},{"text":"daily","start":148,"end":153,"id":30,"ws":true},{"text":")","start":154,"end":155,"id":31,"ws":true},{"text":",","start":156,"end":157,"id":32,"ws":true},{"text":"nadolol","start":158,"end":165,"id":33,"ws":true},{"text":"(","start":166,"end":167,"id":34,"ws":true},{"text":"80","start":168,"end":170,"id":35,"ws":true},{"text":"mg","start":171,"end":173,"id":36,"ws":true},{"text":"daily","start":174,"end":179,"id":37,"ws":true},{"text":")","start":180,"end":181,"id":38,"ws":true},{"text":"and","start":182,"end":185,"id":39,"ws":true},{"text":"timolol","start":186,"end":193,"id":40,"ws":true},{"text":"(","start":194,"end":195,"id":41,"ws":true},{"text":"20","start":196,"end":198,"id":42,"ws":true},{"text":"mg","start":199,"end":201,"id":43,"ws":true},{"text":"daily","start":202,"end":207,"id":44,"ws":true},{"text":")","start":208,"end":209,"id":45,"ws":true},{"text":"produce","start":210,"end":217,"id":46,"ws":true},{"text":"a","start":218,"end":219,"id":47,"ws":true},{"text":"beneficial","start":220,"end":230,"id":48,"ws":true},{"text":"clinical","start":231,"end":239,"id":49,"ws":true},{"text":"response","start":240,"end":248,"id":50,"ws":true},{"text":"equal","start":249,"end":254,"id":51,"ws":true},{"text":"to","start":255,"end":257,"id":52,"ws":true},{"text":"that","start":258,"end":262,"id":53,"ws":true},{"text":"seen","start":263,"end":267,"id":54,"ws":true},{"text":"with","start":268,"end":272,"id":55,"ws":true},{"text":"propranolol","start":273,"end":284,"id":56,"ws":true},{"text":"(","start":285,"end":286,"id":57,"ws":true},{"text":"160","start":287,"end":290,"id":58,"ws":true},{"text":"mg","start":291,"end":293,"id":59,"ws":true},{"text":"daily","start":294,"end":299,"id":60,"ws":true},{"text":")","start":300,"end":301,"id":61,"ws":true},{"text":".","start":302,"end":303,"id":62,"ws":false}],"spans":[{"start":40,"end":48,"token_start":5,"token_end":5,"label":"DRUG"},{"start":68,"end":78,"token_start":12,"token_end":12,"label":"DRUG"},{"start":98,"end":108,"token_start":19,"token_end":19,"label":"DRUG"},{"start":128,"end":138,"token_start":26,"token_end":26,"label":"DRUG"},{"start":158,"end":165,"token_start":33,"token_end":33,"label":"DRUG"},{"start":186,"end":193,"token_start":40,"token_end":40,"label":"DRUG"},{"start":273,"end":284,"token_start":56,"token_end":56,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/6144501/","_input_hash":990193972,"_task_hash":-9132630,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":5,"child":12,"head_span":{"start":40,"end":48,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":68,"end":78,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":12,"child":19,"head_span":{"start":68,"end":78,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":98,"end":108,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":19,"child":26,"head_span":{"start":98,"end":108,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":128,"end":138,"token_start":26,"token_end":26,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":26,"child":33,"head_span":{"start":128,"end":138,"token_start":26,"token_end":26,"label":"DRUG"},"child_span":{"start":158,"end":165,"token_start":33,"token_end":33,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":33,"child":40,"head_span":{"start":158,"end":165,"token_start":33,"token_end":33,"label":"DRUG"},"child_span":{"start":186,"end":193,"token_start":40,"token_end":40,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"All the animals in the placebo group had tumors in each lobe compared with only 43 % each in the dorsolateral ( DLP ) and anterior prostate ( AP ) of the animals treated with raloxifene ( 10 mg/kg/day ) plus nimesulide .","paragraph":"<h3><u>Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by raloxifene, an antiestrogen with anti-androgen action, but not nimesulide, a selective cyclooxygenase-2 inhibitor.</u></h3>The chemopreventive efficacies of <b style='color:Tomato;'><i>raloxifene</i></b> and <b style='color:Tomato;'><i>nimesulide</i></b>, an anti-estrogen but with anti-androgen action and a cyclooxygenase-2 (COX-2) selective inhibitor, respectively, were evaluated in probasin/SV40 T antigen (Tag) transgenic (TG) rats. The treatment groups were placebo, <b style='color:Tomato;'><i>nimesulide</i></b> (400 p.p.m. in basal diet p.o.), <b style='color:Tomato;'><i>raloxifene</i></b> (slow-release pellets implanted s.c., 5 mg/kg/day), <b style='color:Tomato;'><i>raloxifene</i></b> (5 mg/kg/day) plus <b style='color:Tomato;'><i>nimesulide</i></b> (400 p.p.m.), and <b style='color:Tomato;'><i>raloxifene</i></b> (10 mg/kg/day) plus <b style='color:Tomato;'><i>nimesulide</i></b> (400 p.p.m.). Animals were killed at 17 weeks of age, and prostate tissues were harvested and weighed by lobes. Tissues were evaluated by histology, immunohistochemistry, and western blot analyses and blood was collected to measure the testosterone levels. <b style='color:DodgerBlue;'><i>All</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>animals</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>placebo</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>tumors</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>each</i></b> <b style='color:DodgerBlue;'><i>lobe</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>43</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>each</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>dorsolateral</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>DLP</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>anterior</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AP</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>animals</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>raloxifene</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>mg/kg/day</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>nimesulide</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The total prostate weights and adenocarcinoma portions were significantly reduced in the three <b style='color:Tomato;'><i>raloxifene</i></b>-treated groups, whereas atrophic glands were increased. There were no significant differences between the <b style='color:Tomato;'><i>nimesulide</i></b> alone and placebo groups or between the <b style='color:Tomato;'><i>raloxifene</i></b> (5 mg/kg/day) alone and <b style='color:Tomato;'><i>raloxifene</i></b> (5 mg/kg/day) plus <b style='color:Tomato;'><i>nimesulide</i></b> group, suggesting a lack of cancer preventive effects of the COX-2 inhibitor in this animal model. PCNA positive rates in ventral prostate (VP) and DLP, and androgen receptor (AR) levels in VP were significantly reduced in the three <b style='color:Tomato;'><i>raloxifene</i></b>-treated groups. Furthermore, circulating testosterone was decreased after <b style='color:Tomato;'><i>raloxifene</i></b> (10 mg/kg/day) plus <b style='color:Tomato;'><i>nimesulide</i></b> treatment. These results demonstrate that <b style='color:Tomato;'><i>raloxifene</i></b>, but not <b style='color:Tomato;'><i>nimesulide</i></b>, inhibits prostate carcinogenesis in SV40 Tag TG rats associated with a decline in circulating testosterone levels and a loss of AR expression, as well as an inhibition of cell proliferation.","tokens":[{"text":"All","start":0,"end":3,"id":0,"ws":true},{"text":"the","start":4,"end":7,"id":1,"ws":true},{"text":"animals","start":8,"end":15,"id":2,"ws":true},{"text":"in","start":16,"end":18,"id":3,"ws":true},{"text":"the","start":19,"end":22,"id":4,"ws":true},{"text":"placebo","start":23,"end":30,"id":5,"ws":true},{"text":"group","start":31,"end":36,"id":6,"ws":true},{"text":"had","start":37,"end":40,"id":7,"ws":true},{"text":"tumors","start":41,"end":47,"id":8,"ws":true},{"text":"in","start":48,"end":50,"id":9,"ws":true},{"text":"each","start":51,"end":55,"id":10,"ws":true},{"text":"lobe","start":56,"end":60,"id":11,"ws":true},{"text":"compared","start":61,"end":69,"id":12,"ws":true},{"text":"with","start":70,"end":74,"id":13,"ws":true},{"text":"only","start":75,"end":79,"id":14,"ws":true},{"text":"43","start":80,"end":82,"id":15,"ws":true},{"text":"%","start":83,"end":84,"id":16,"ws":true},{"text":"each","start":85,"end":89,"id":17,"ws":true},{"text":"in","start":90,"end":92,"id":18,"ws":true},{"text":"the","start":93,"end":96,"id":19,"ws":true},{"text":"dorsolateral","start":97,"end":109,"id":20,"ws":true},{"text":"(","start":110,"end":111,"id":21,"ws":true},{"text":"DLP","start":112,"end":115,"id":22,"ws":true},{"text":")","start":116,"end":117,"id":23,"ws":true},{"text":"and","start":118,"end":121,"id":24,"ws":true},{"text":"anterior","start":122,"end":130,"id":25,"ws":true},{"text":"prostate","start":131,"end":139,"id":26,"ws":true},{"text":"(","start":140,"end":141,"id":27,"ws":true},{"text":"AP","start":142,"end":144,"id":28,"ws":true},{"text":")","start":145,"end":146,"id":29,"ws":true},{"text":"of","start":147,"end":149,"id":30,"ws":true},{"text":"the","start":150,"end":153,"id":31,"ws":true},{"text":"animals","start":154,"end":161,"id":32,"ws":true},{"text":"treated","start":162,"end":169,"id":33,"ws":true},{"text":"with","start":170,"end":174,"id":34,"ws":true},{"text":"raloxifene","start":175,"end":185,"id":35,"ws":true},{"text":"(","start":186,"end":187,"id":36,"ws":true},{"text":"10","start":188,"end":190,"id":37,"ws":true},{"text":"mg/kg/day","start":191,"end":200,"id":38,"ws":true},{"text":")","start":201,"end":202,"id":39,"ws":true},{"text":"plus","start":203,"end":207,"id":40,"ws":true},{"text":"nimesulide","start":208,"end":218,"id":41,"ws":true},{"text":".","start":219,"end":220,"id":42,"ws":false}],"spans":[{"start":175,"end":185,"token_start":35,"token_end":35,"label":"DRUG"},{"start":208,"end":218,"token_start":41,"token_end":41,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/15731164/","_input_hash":-1074706345,"_task_hash":911107500,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":35,"child":41,"head_span":{"start":175,"end":185,"token_start":35,"token_end":35,"label":"DRUG"},"child_span":{"start":208,"end":218,"token_start":41,"token_end":41,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Overdose of dolutegravir in combination with tenofovir disaproxil fumarate/emtricitabine in suicide attempt in a 21-year old patient .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Overdose</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>dolutegravir</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>tenofovir</i></b> <b style='color:DodgerBlue;'><i>disaproxil</i></b> <b style='color:DodgerBlue;'><i>fumarate/emtricitabine</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>suicide</i></b> <b style='color:DodgerBlue;'><i>attempt</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>21-year</i></b> <b style='color:DodgerBlue;'><i>old</i></b> <b style='color:DodgerBlue;'><i>patient</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>A 21\u00a0year old MSM patient with newly diagnosed HIV infection was hospitalized in our department after ingestion of an overdose of his antiretroviral therapy (ART) comprising <b style='color:Tomato;'><i>dolutegravir</i></b> (DTG - Tivicay\u00ae) and <b style='color:Tomato;'><i>tenofovir</i></b> disaproxil fumarate/<b style='color:Tomato;'><i>emtricitabine</i></b> (Truvada\u00ae) in suicidal intention. On admission, the patient did not show any clinical signs of intoxication and laboratory findings were unremarkable. After 6\u00a0hours of intensive care monitoring, the patient was referred to a psychiatric clinic. 5\u00a0days after the day of intoxication, serum creatinine levels increased to high normal values (1.2\u00a0mg/dl). However, levels never exceeded the upper threshold. 8 and 12\u00a0weeks later, serum creatinine normalized to levels measured prior to the intoxication. No other adverse events occurred, and the patient does not suffer from permanent impairments.","tokens":[{"text":"Overdose","start":0,"end":8,"id":0,"ws":true},{"text":"of","start":9,"end":11,"id":1,"ws":true},{"text":"dolutegravir","start":12,"end":24,"id":2,"ws":true},{"text":"in","start":25,"end":27,"id":3,"ws":true},{"text":"combination","start":28,"end":39,"id":4,"ws":true},{"text":"with","start":40,"end":44,"id":5,"ws":true},{"text":"tenofovir","start":45,"end":54,"id":6,"ws":true},{"text":"disaproxil","start":55,"end":65,"id":7,"ws":true},{"text":"fumarate/emtricitabine","start":66,"end":88,"id":8,"ws":true},{"text":"in","start":89,"end":91,"id":9,"ws":true},{"text":"suicide","start":92,"end":99,"id":10,"ws":true},{"text":"attempt","start":100,"end":107,"id":11,"ws":true},{"text":"in","start":108,"end":110,"id":12,"ws":true},{"text":"a","start":111,"end":112,"id":13,"ws":true},{"text":"21-year","start":113,"end":120,"id":14,"ws":true},{"text":"old","start":121,"end":124,"id":15,"ws":true},{"text":"patient","start":125,"end":132,"id":16,"ws":true},{"text":".","start":133,"end":134,"id":17,"ws":false}],"spans":[{"start":12,"end":24,"token_start":2,"token_end":2,"label":"DRUG"},{"start":45,"end":54,"token_start":6,"token_end":6,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26045712/","_input_hash":-247737991,"_task_hash":-854886939,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer : a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes .","paragraph":"<h3><u><b style='color:MediumOrchid;'><i>Abiraterone</i></b> <b style='color:DodgerBlue;'><i>acetate</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>pre-</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>post-docetaxel</i></b> <b style='color:DodgerBlue;'><i>setting</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>castration-resistant</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>mono-institutional</i></b> <b style='color:DodgerBlue;'><i>experience</i></b> <b style='color:DodgerBlue;'><i>focused</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>cardiovascular</i></b> <b style='color:DodgerBlue;'><i>events</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>impact</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>outcomes</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>The aim of this work was to to evaluate the incidence and risk factors of adverse events (AEs), focusing on cardiovascular events (CVEs) and hypokalemia, in patients treated with <b style='color:Tomato;'><i>abiraterone</i></b> acetate (AA) and <b style='color:Tomato;'><i>prednisone</i></b> (PDN) outside clinical trials, and their association with survival outcomes. ### methods This was a retrospective cohort study of 105 patients treated from 2011 to 2016. Incidence of AEs was descriptively summarized in the whole cohort and by subgroup (pre- ### results Overall, median PFS and OS were 14.9 and 24.6 months, respectively. Prostate-specific antigen (PSA) \u2a7e 10 ng/ml ( ### conclusions Median PFS and OS estimates and incidence of CVEs and hypokalemia in our series are consistent with those of pivotal trials of AA plus PDN, confirming the efficacy and safety of this regimen also in the real-world setting. Elderly patients have higher odds of developing/worsening CVEs. However, regardless of age, CVEs were not associated with worse outcomes. Treatment-related hypokalemia seemed to be associated with longer OS, albeit this finding needs confirmation within larger, prospective series.","tokens":[{"text":"Abiraterone","start":0,"end":11,"id":0,"ws":true},{"text":"acetate","start":12,"end":19,"id":1,"ws":true},{"text":"and","start":20,"end":23,"id":2,"ws":true},{"text":"prednisone","start":24,"end":34,"id":3,"ws":true},{"text":"in","start":35,"end":37,"id":4,"ws":true},{"text":"the","start":38,"end":41,"id":5,"ws":true},{"text":"pre-","start":42,"end":46,"id":6,"ws":true},{"text":"and","start":47,"end":50,"id":7,"ws":true},{"text":"post-docetaxel","start":51,"end":65,"id":8,"ws":true},{"text":"setting","start":66,"end":73,"id":9,"ws":true},{"text":"for","start":74,"end":77,"id":10,"ws":true},{"text":"metastatic","start":78,"end":88,"id":11,"ws":true},{"text":"castration-resistant","start":89,"end":109,"id":12,"ws":true},{"text":"prostate","start":110,"end":118,"id":13,"ws":true},{"text":"cancer","start":119,"end":125,"id":14,"ws":true},{"text":":","start":126,"end":127,"id":15,"ws":true},{"text":"a","start":128,"end":129,"id":16,"ws":true},{"text":"mono-institutional","start":130,"end":148,"id":17,"ws":true},{"text":"experience","start":149,"end":159,"id":18,"ws":true},{"text":"focused","start":160,"end":167,"id":19,"ws":true},{"text":"on","start":168,"end":170,"id":20,"ws":true},{"text":"cardiovascular","start":171,"end":185,"id":21,"ws":true},{"text":"events","start":186,"end":192,"id":22,"ws":true},{"text":"and","start":193,"end":196,"id":23,"ws":true},{"text":"their","start":197,"end":202,"id":24,"ws":true},{"text":"impact","start":203,"end":209,"id":25,"ws":true},{"text":"on","start":210,"end":212,"id":26,"ws":true},{"text":"clinical","start":213,"end":221,"id":27,"ws":true},{"text":"outcomes","start":222,"end":230,"id":28,"ws":true},{"text":".","start":231,"end":232,"id":29,"ws":false}],"spans":[{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},{"start":24,"end":34,"token_start":3,"token_end":3,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29383035/","_input_hash":-1606804744,"_task_hash":761335342,"_session_id":"drug_drug_pilot_split2c-dana_a","_view_id":"blocks","relations":[{"head":0,"child":3,"head_span":{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":24,"end":34,"token_start":3,"token_end":3,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Nivolumab plus ipilimumab combined therapy is among the most effective therapies for advanced melanoma .","paragraph":"<h3><u>Increased serum CCL26 level is a potential biomarker for the effectiveness of anti-PD1 antibodies in patients with advanced melanoma.</u></h3> <b style='color:MediumOrchid;'><i>Nivolumab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>ipilimumab</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>among</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>most</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>melanoma</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, this therapy is also associated with a high frequency of immune-related adverse events (irAEs). To avoid such severe irAEs caused by additional administration of anti-CTLA4 antibodies, biomarkers to distinguish responders from non-responders among patients treated with anti-PD1 antibodies are important. The purpose of this study is to evaluate the increased serum levels of CCL11, CCL24, and CCL26 as a predictive biomarker for the efficacy of anti-PD1 antibodies in advanced cutaneous melanoma patients. This study analyzed increased serum levels of CCL11, CCL24, and CCL26 in 46 cases of advanced cutaneous melanoma treated with anti-PD1 antibodies. Serum levels on day 42 were compared to baseline (day 0) and analyzed statistically. Receiver operating characteristic curves were established to evaluate the correlation between serum levels of CCL11, CCL24, and CCL26 and efficacy of anti-PD1 antibodies. Increased serum levels of CCL26 correlated significantly with the efficacy of anti-PD1 antibodies. In contrast, no significant correlations were seen between increased serum levels of CCL11 and CCL24 and efficacy of anti-PD1 antibodies. Increased serum levels of CCL26 may be a useful biomarker for identifying those patients with advanced cutaneous melanoma most likely to benefit from anti-melanoma immunotherapy.","tokens":[{"text":"Nivolumab","start":0,"end":9,"id":0,"ws":true},{"text":"plus","start":10,"end":14,"id":1,"ws":true},{"text":"ipilimumab","start":15,"end":25,"id":2,"ws":true},{"text":"combined","start":26,"end":34,"id":3,"ws":true},{"text":"therapy","start":35,"end":42,"id":4,"ws":true},{"text":"is","start":43,"end":45,"id":5,"ws":true},{"text":"among","start":46,"end":51,"id":6,"ws":true},{"text":"the","start":52,"end":55,"id":7,"ws":true},{"text":"most","start":56,"end":60,"id":8,"ws":true},{"text":"effective","start":61,"end":70,"id":9,"ws":true},{"text":"therapies","start":71,"end":80,"id":10,"ws":true},{"text":"for","start":81,"end":84,"id":11,"ws":true},{"text":"advanced","start":85,"end":93,"id":12,"ws":true},{"text":"melanoma","start":94,"end":102,"id":13,"ws":true},{"text":".","start":103,"end":104,"id":14,"ws":false}],"spans":[{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},{"start":15,"end":25,"token_start":2,"token_end":2,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/32658051/","_input_hash":238886149,"_task_hash":2049657732,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":0,"child":2,"head_span":{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":15,"end":25,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Cells that were sequentially exposed to rapamycin and topotecan had significantly higher levels of cleaved caspase-8 , -3 , and PARP compared to those treated with topotecan alone .","paragraph":"<h3><u>Rapamycin-topotecan combination exhibited enhanced antitumor efficacy compared to topotecan used alone in cisplatin-resistant ovarian cancer cells.</u></h3>The present study aimed to investigate the antitumor efficacy of combination of <b style='color:Tomato;'><i>topotecan</i></b> with <b style='color:Tomato;'><i>rapamycin</i></b>, a\u00a0mTOR inhibitor, in <b style='color:Tomato;'><i>cisplatin</i></b>-resistant ovarian cancer cells A2780cis and COC1/DDP. Expressions of mTOR and its target molecules p70S6K and 4E-BP1 were determined in A2780cis and COC1/DDP and the parental cells A2780 and COC1 that are sensitive to <b style='color:Tomato;'><i>cisplatin</i></b> using Western blotting. Cell proliferation was examined using MTT assay in vitro and a\u00a0nude mouse model in vivo, respectively. Cell apoptosis and the relevant proteins were determined by flow cytometry and Western blotting. We found that the levels of phosphorylated mTOR, p70S6K, and 4E-BP1 were obviously higher in A2780cis and COC1/DDP cells than that in A2780 and COC1 cells. Pretreatment with <b style='color:Tomato;'><i>rapamycin</i></b> significantly enhanced the effects of <b style='color:Tomato;'><i>topotecan</i></b> in suppressing cell proliferation and soliciting cell apoptosis in A2780cis and COC1/DDP cells. <b style='color:DodgerBlue;'><i>Cells</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>sequentially</i></b> <b style='color:DodgerBlue;'><i>exposed</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>rapamycin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>higher</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cleaved</i></b> <b style='color:DodgerBlue;'><i>caspase-8</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>-3</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>PARP</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Mice co-administered <b style='color:Tomato;'><i>rapamycin</i></b> and <b style='color:Tomato;'><i>topotecan</i></b> had significantly decreased terminal tumor burden without additional loss of bodyweight compared to the mice received <b style='color:Tomato;'><i>topotecan</i></b> alone. The results suggested that <b style='color:Tomato;'><i>rapamycin</i></b> sensitized A2780cis and COC1/DDP cells to <b style='color:Tomato;'><i>topotecan</i></b>-induced apoptosis and <b style='color:Tomato;'><i>rapamycin</i></b>-<b style='color:Tomato;'><i>topotecan</i></b> combination might have a\u00a0value in treatment of <b style='color:Tomato;'><i>cisplatin</i></b>-resistant ovarian cancer.","tokens":[{"text":"Cells","start":0,"end":5,"id":0,"ws":true},{"text":"that","start":6,"end":10,"id":1,"ws":true},{"text":"were","start":11,"end":15,"id":2,"ws":true},{"text":"sequentially","start":16,"end":28,"id":3,"ws":true},{"text":"exposed","start":29,"end":36,"id":4,"ws":true},{"text":"to","start":37,"end":39,"id":5,"ws":true},{"text":"rapamycin","start":40,"end":49,"id":6,"ws":true},{"text":"and","start":50,"end":53,"id":7,"ws":true},{"text":"topotecan","start":54,"end":63,"id":8,"ws":true},{"text":"had","start":64,"end":67,"id":9,"ws":true},{"text":"significantly","start":68,"end":81,"id":10,"ws":true},{"text":"higher","start":82,"end":88,"id":11,"ws":true},{"text":"levels","start":89,"end":95,"id":12,"ws":true},{"text":"of","start":96,"end":98,"id":13,"ws":true},{"text":"cleaved","start":99,"end":106,"id":14,"ws":true},{"text":"caspase-8","start":107,"end":116,"id":15,"ws":true},{"text":",","start":117,"end":118,"id":16,"ws":true},{"text":"-3","start":119,"end":121,"id":17,"ws":true},{"text":",","start":122,"end":123,"id":18,"ws":true},{"text":"and","start":124,"end":127,"id":19,"ws":true},{"text":"PARP","start":128,"end":132,"id":20,"ws":true},{"text":"compared","start":133,"end":141,"id":21,"ws":true},{"text":"to","start":142,"end":144,"id":22,"ws":true},{"text":"those","start":145,"end":150,"id":23,"ws":true},{"text":"treated","start":151,"end":158,"id":24,"ws":true},{"text":"with","start":159,"end":163,"id":25,"ws":true},{"text":"topotecan","start":164,"end":173,"id":26,"ws":true},{"text":"alone","start":174,"end":179,"id":27,"ws":true},{"text":".","start":180,"end":181,"id":28,"ws":false}],"spans":[{"start":40,"end":49,"token_start":6,"token_end":6,"label":"DRUG"},{"start":54,"end":63,"token_start":8,"token_end":8,"label":"DRUG"},{"start":164,"end":173,"token_start":26,"token_end":26,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26278147/","_input_hash":1375843614,"_task_hash":-289441407,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":6,"child":8,"head_span":{"start":40,"end":49,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":54,"end":63,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"No cross-resistance was found with conventional drugs , being PNU-159548 active also in cells resistant to doxorubicin and with a multidrug resistance phenotype ( associated with MDR1 gene/P-glycoprotein overexpression ) , as well as in cells resistant to methotrexate or to cisplatin .","paragraph":"<h3><u>4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a promising new candidate for chemotherapeutic treatment of osteosarcoma patients.</u></h3>The effectiveness of the alkycycline 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-<b style='color:Tomato;'><i>daunorubicin</i></b> (PNU-159548, ladirubicin), a new drug with high antitumour activity against a broad range of neoplasms, was evaluated by using a panel of 32 human osteosarcoma cell lines, including cell lines resistant to <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>methotrexate</i></b>, or <b style='color:Tomato;'><i>cisplatin</i></b>. PNU-159548 resulted to be highly active in all cell lines. <b style='color:DodgerBlue;'><i>No</i></b> <b style='color:DodgerBlue;'><i>cross-resistance</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>found</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>conventional</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>being</i></b> <b style='color:DodgerBlue;'><i>PNU-159548</i></b> <b style='color:DodgerBlue;'><i>active</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>multidrug</i></b> <b style='color:DodgerBlue;'><i>resistance</i></b> <b style='color:DodgerBlue;'><i>phenotype</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>MDR1</i></b> <b style='color:DodgerBlue;'><i>gene/P-glycoprotein</i></b> <b style='color:DodgerBlue;'><i>overexpression</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Analysis of drug-drug interactions showed that PNU-159548 could be successfully used in combination with all the most important drugs currently used in OS chemotherapy. In fact, the simultaneous administration of PNU-159548 and <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>methotrexate</i></b>, or <b style='color:Tomato;'><i>cisplatin</i></b> produced mostly additive or synergistic effects. Sequential exposure to PNU-159548 followed immediately by <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>methotrexate</i></b>, or <b style='color:Tomato;'><i>cisplatin</i></b> was the most effective sequence of administration, invariably resulting in additive or synergistic effects in both drug-sensitive and drug-resistant osteosarcoma cell lines. In conclusion, the high in vitro effectiveness, the absence of cross-resistance with <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>methotrexate</i></b>, or <b style='color:Tomato;'><i>cisplatin</i></b> and the possibility to be successfully used in combination with these drugs indicate PNU-159548 as a promising candidate to be considered for planning new therapeutic regimens for osteosarcoma patients, who show a decreased response to conventional chemotherapy.","tokens":[{"text":"No","start":0,"end":2,"id":0,"ws":true},{"text":"cross-resistance","start":3,"end":19,"id":1,"ws":true},{"text":"was","start":20,"end":23,"id":2,"ws":true},{"text":"found","start":24,"end":29,"id":3,"ws":true},{"text":"with","start":30,"end":34,"id":4,"ws":true},{"text":"conventional","start":35,"end":47,"id":5,"ws":true},{"text":"drugs","start":48,"end":53,"id":6,"ws":true},{"text":",","start":54,"end":55,"id":7,"ws":true},{"text":"being","start":56,"end":61,"id":8,"ws":true},{"text":"PNU-159548","start":62,"end":72,"id":9,"ws":true},{"text":"active","start":73,"end":79,"id":10,"ws":true},{"text":"also","start":80,"end":84,"id":11,"ws":true},{"text":"in","start":85,"end":87,"id":12,"ws":true},{"text":"cells","start":88,"end":93,"id":13,"ws":true},{"text":"resistant","start":94,"end":103,"id":14,"ws":true},{"text":"to","start":104,"end":106,"id":15,"ws":true},{"text":"doxorubicin","start":107,"end":118,"id":16,"ws":true},{"text":"and","start":119,"end":122,"id":17,"ws":true},{"text":"with","start":123,"end":127,"id":18,"ws":true},{"text":"a","start":128,"end":129,"id":19,"ws":true},{"text":"multidrug","start":130,"end":139,"id":20,"ws":true},{"text":"resistance","start":140,"end":150,"id":21,"ws":true},{"text":"phenotype","start":151,"end":160,"id":22,"ws":true},{"text":"(","start":161,"end":162,"id":23,"ws":true},{"text":"associated","start":163,"end":173,"id":24,"ws":true},{"text":"with","start":174,"end":178,"id":25,"ws":true},{"text":"MDR1","start":179,"end":183,"id":26,"ws":true},{"text":"gene/P-glycoprotein","start":184,"end":203,"id":27,"ws":true},{"text":"overexpression","start":204,"end":218,"id":28,"ws":true},{"text":")","start":219,"end":220,"id":29,"ws":true},{"text":",","start":221,"end":222,"id":30,"ws":true},{"text":"as","start":223,"end":225,"id":31,"ws":true},{"text":"well","start":226,"end":230,"id":32,"ws":true},{"text":"as","start":231,"end":233,"id":33,"ws":true},{"text":"in","start":234,"end":236,"id":34,"ws":true},{"text":"cells","start":237,"end":242,"id":35,"ws":true},{"text":"resistant","start":243,"end":252,"id":36,"ws":true},{"text":"to","start":253,"end":255,"id":37,"ws":true},{"text":"methotrexate","start":256,"end":268,"id":38,"ws":true},{"text":"or","start":269,"end":271,"id":39,"ws":true},{"text":"to","start":272,"end":274,"id":40,"ws":true},{"text":"cisplatin","start":275,"end":284,"id":41,"ws":true},{"text":".","start":285,"end":286,"id":42,"ws":false}],"spans":[{"start":62,"end":72,"token_start":9,"token_end":9,"label":"DRUG"},{"start":107,"end":118,"token_start":16,"token_end":16,"label":"DRUG"},{"start":256,"end":268,"token_start":38,"token_end":38,"label":"DRUG"},{"start":275,"end":284,"token_start":41,"token_end":41,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16140527/","_input_hash":-1391381095,"_task_hash":-2089933908,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Synergistic cytotoxic effects of recombinant human tumor necrosis factor and Etoposide ( VP16 ) or Doxorubicin on A2774 human epithelial ovarian cancer cell line .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Synergistic</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>recombinant</i></b> <b style='color:DodgerBlue;'><i>human</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>necrosis</i></b> <b style='color:DodgerBlue;'><i>factor</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Etoposide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>VP16</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>Doxorubicin</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>A2774</i></b> <b style='color:DodgerBlue;'><i>human</i></b> <b style='color:DodgerBlue;'><i>epithelial</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>line</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Recombinant human tumor necrosis factor (rHuTNF) is a cytokine, with some antitumor activity, released by stimulated monocytes-macrophages. In vivo and in vitro cytotoxicity studies testing the effectiveness of rHuTNF alone or in combination with chemotherapeutic agents have been carried out. We have evaluated the direct cytotoxic effect of rHuTNF on a human epithelial ovarian cancer cell line in vitro (A2774), alone or in combination with <b style='color:Tomato;'><i>etoposide</i></b> (VP16) or <b style='color:Tomato;'><i>doxorubicin</i></b> (Doxo), some topoisomerase II (Topo II) targeted drugs, or in combination with <b style='color:Tomato;'><i>cisplatin</i></b> (CDDP), a not Topo II interactive drug. Our results suggest that rHuTNF is directly cytotoxic and that it is also able to induce a potentiation of VP16- or Doxo-cytotoxicity, but it is unable to potentiate CDDP-cytotoxicity. These data represent a reasonable basis for combining rHuTNF with Topo II inhibitors within phase I studies. The combination regimen could be tested in ovarian cancer patients.","tokens":[{"text":"Synergistic","start":0,"end":11,"id":0,"ws":true},{"text":"cytotoxic","start":12,"end":21,"id":1,"ws":true},{"text":"effects","start":22,"end":29,"id":2,"ws":true},{"text":"of","start":30,"end":32,"id":3,"ws":true},{"text":"recombinant","start":33,"end":44,"id":4,"ws":true},{"text":"human","start":45,"end":50,"id":5,"ws":true},{"text":"tumor","start":51,"end":56,"id":6,"ws":true},{"text":"necrosis","start":57,"end":65,"id":7,"ws":true},{"text":"factor","start":66,"end":72,"id":8,"ws":true},{"text":"and","start":73,"end":76,"id":9,"ws":true},{"text":"Etoposide","start":77,"end":86,"id":10,"ws":true},{"text":"(","start":87,"end":88,"id":11,"ws":true},{"text":"VP16","start":89,"end":93,"id":12,"ws":true},{"text":")","start":94,"end":95,"id":13,"ws":true},{"text":"or","start":96,"end":98,"id":14,"ws":true},{"text":"Doxorubicin","start":99,"end":110,"id":15,"ws":true},{"text":"on","start":111,"end":113,"id":16,"ws":true},{"text":"A2774","start":114,"end":119,"id":17,"ws":true},{"text":"human","start":120,"end":125,"id":18,"ws":true},{"text":"epithelial","start":126,"end":136,"id":19,"ws":true},{"text":"ovarian","start":137,"end":144,"id":20,"ws":true},{"text":"cancer","start":145,"end":151,"id":21,"ws":true},{"text":"cell","start":152,"end":156,"id":22,"ws":true},{"text":"line","start":157,"end":161,"id":23,"ws":true},{"text":".","start":162,"end":163,"id":24,"ws":false}],"spans":[{"start":45,"end":72,"token_start":5,"token_end":8,"label":"DRUG"},{"start":77,"end":86,"token_start":10,"token_end":10,"label":"DRUG"},{"start":99,"end":110,"token_start":15,"token_end":15,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/11576250/","_input_hash":464556084,"_task_hash":-284315972,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":8,"child":10,"head_span":{"start":45,"end":72,"token_start":5,"token_end":8,"label":"DRUG"},"child_span":{"start":77,"end":86,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":8,"child":15,"head_span":{"start":45,"end":72,"token_start":5,"token_end":8,"label":"DRUG"},"child_span":{"start":99,"end":110,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS10","POS20"],"answer":"accept"}
{"text":"Many ESBL-producing E. coli had significantly lower susceptibility to gentamicin ( p \uff1c 0.0001 ) and the quinolones nalidixic acid ( p\uff1d0.004 ) and ciprofloxacin ( p \uff1c 0.0001 ) than non-producers .","paragraph":"<h3><u>Antibiotic Susceptibilities and Genetic Characteristics of Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Isolates from Stools of Pediatric Diarrhea Patients in Surabaya, Indonesia.</u></h3>The purpose of this study was to investigate extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli isolates from pediatric (aged 0 to 3 years) diarrhea patients in Surabaya, Indonesia, where this kind of survey is rare; our study included assessment of their antibiotic susceptibilities, as well as ESBL typing, multilocus sequence typing (MLST), and diarrheagenic E. coli (DEC)-typing. ESBL-producing E. coli were detected in 18.8% of all the samples. <b style='color:DodgerBlue;'><i>Many</i></b> <b style='color:DodgerBlue;'><i>ESBL-producing</i></b> <b style='color:DodgerBlue;'><i>E.</i></b> <b style='color:DodgerBlue;'><i>coli</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>lower</i></b> <b style='color:DodgerBlue;'><i>susceptibility</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>gentamicin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>p</i></b> <b style='color:DodgerBlue;'><i>\uff1c</i></b> <b style='color:DodgerBlue;'><i>0.0001</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>quinolones</i></b> <b style='color:MediumOrchid;'><i>nalidixic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>p\uff1d0.004</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ciprofloxacin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>p</i></b> <b style='color:DodgerBlue;'><i>\uff1c</i></b> <b style='color:DodgerBlue;'><i>0.0001</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>non-producers</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In ESBL-producing E. coli, 84.0% of strains expressed CTX-M-15 alone or in combination with other ESBL types. MLST revealed that 24.0% of ESBL-producers had sequence type 617, all of which expressed the CTX-M-15 gene; we also detected expression of 3 DEC-related genes: 2 enteroaggregative E. coli genes and 1 enteropathogenic E. coli gene. In conclusion, CTX-M-15-type ESBL-producing E. coli ST617 appear to have spread to Indonesia.","tokens":[{"text":"Many","start":0,"end":4,"id":0,"ws":true},{"text":"ESBL-producing","start":5,"end":19,"id":1,"ws":true},{"text":"E.","start":20,"end":22,"id":2,"ws":true},{"text":"coli","start":23,"end":27,"id":3,"ws":true},{"text":"had","start":28,"end":31,"id":4,"ws":true},{"text":"significantly","start":32,"end":45,"id":5,"ws":true},{"text":"lower","start":46,"end":51,"id":6,"ws":true},{"text":"susceptibility","start":52,"end":66,"id":7,"ws":true},{"text":"to","start":67,"end":69,"id":8,"ws":true},{"text":"gentamicin","start":70,"end":80,"id":9,"ws":true},{"text":"(","start":81,"end":82,"id":10,"ws":true},{"text":"p","start":83,"end":84,"id":11,"ws":true},{"text":"\uff1c","start":85,"end":86,"id":12,"ws":true},{"text":"0.0001","start":87,"end":93,"id":13,"ws":true},{"text":")","start":94,"end":95,"id":14,"ws":true},{"text":"and","start":96,"end":99,"id":15,"ws":true},{"text":"the","start":100,"end":103,"id":16,"ws":true},{"text":"quinolones","start":104,"end":114,"id":17,"ws":true},{"text":"nalidixic","start":115,"end":124,"id":18,"ws":true},{"text":"acid","start":125,"end":129,"id":19,"ws":true},{"text":"(","start":130,"end":131,"id":20,"ws":true},{"text":"p\uff1d0.004","start":132,"end":139,"id":21,"ws":true},{"text":")","start":140,"end":141,"id":22,"ws":true},{"text":"and","start":142,"end":145,"id":23,"ws":true},{"text":"ciprofloxacin","start":146,"end":159,"id":24,"ws":true},{"text":"(","start":160,"end":161,"id":25,"ws":true},{"text":"p","start":162,"end":163,"id":26,"ws":true},{"text":"\uff1c","start":164,"end":165,"id":27,"ws":true},{"text":"0.0001","start":166,"end":172,"id":28,"ws":true},{"text":")","start":173,"end":174,"id":29,"ws":true},{"text":"than","start":175,"end":179,"id":30,"ws":true},{"text":"non-producers","start":180,"end":193,"id":31,"ws":true},{"text":".","start":194,"end":195,"id":32,"ws":false}],"spans":[{"start":70,"end":80,"token_start":9,"token_end":9,"label":"DRUG"},{"start":115,"end":124,"token_start":18,"token_end":18,"label":"DRUG"},{"start":146,"end":159,"token_start":24,"token_end":24,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/28003592/","_input_hash":-959830506,"_task_hash":1562370820,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The resistance of topotecan in MDR HL-60 cells was potently reversed by the addition of amlodipine .","paragraph":"<h3><u>Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice.</u></h3>Multidrug resistance (MDR) is a major obstacle to successful cancer chemotherapy as the over-expressed MDR protein acts as an efflux pump, which leads to a reduction in the uptake of the anticancer agent by tumour cells. We combined <b style='color:Tomato;'><i>topotecan</i></b> and <b style='color:Tomato;'><i>amlodipine</i></b> together into the stealthy liposomes, in which <b style='color:Tomato;'><i>amlodipine</i></b> was applied as a MDR reversing agent to overcome the resistance. ### Materials And Methods Cytotoxicity, apoptosis and the signalling pathway assays were performed on human chronic myelogenous leukaemia K562, promyelocytic leukaemia HL-60 and MDR HL-60 cells, respectively. Pharmacokinetics and antitumour activity studies were performed on normal Kunming mice and female BALB/c nude mice with MDR HL-60 xenografts, respectively. ### results <b style='color:Tomato;'><i>topotecan</i></b> alone was effective in inhibiting the growth of non-resistant leukaemia cells, K562 and HL-60 cells but not the growth of MDR HL-60 cells. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>resistance</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>MDR</i></b> <b style='color:DodgerBlue;'><i>HL-60</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>potently</i></b> <b style='color:DodgerBlue;'><i>reversed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>amlodipine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Moreover, <b style='color:Tomato;'><i>amlodipine</i></b> enhanced the apoptosis-inducing effect of <b style='color:Tomato;'><i>topotecan</i></b> synergistically. Apoptosis was through activating caspases in a cascade: first, the initiator caspase 8 and then effectors caspase 3/7 (total activity of caspases 3 and 7) were activated. Being encapsulated into the stealthy liposomes with an acidic internal medium, <b style='color:Tomato;'><i>topotecan</i></b> existed dominantly in an active lactone species, which was reversibly changed from an inactive carboxylate form via a pH-dependent reaction. After administration of stealthy liposomes to mice, the blood exposure of the lactone form was evidently increased and extended. The antitumour effects in the MDR HL-60 xenografted tumour were stealthy liposomal <b style='color:Tomato;'><i>topotecan</i></b> (SLT) plus <b style='color:Tomato;'><i>amlodipine</i></b> > SLT > un-encapsulated <b style='color:Tomato;'><i>topotecan</i></b> > blank control. ### conclusions The enhanced antitumour activity in the MDR HL-60 cells by the SLT plus <b style='color:Tomato;'><i>amlodipine</i></b> could be owing to multiple reasons: (a) synergistic apoptosis inducing effect, (b) reversing MDR by <b style='color:Tomato;'><i>amlodipine</i></b> and (c) increasing the availability of active lactone of <b style='color:Tomato;'><i>topotecan</i></b> by the stealthy liposomes. The apoptosis induced by <b style='color:Tomato;'><i>amlodipine</i></b> is through caspase 8 and then the 3/7 signalling pathway.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"resistance","start":4,"end":14,"id":1,"ws":true},{"text":"of","start":15,"end":17,"id":2,"ws":true},{"text":"topotecan","start":18,"end":27,"id":3,"ws":true},{"text":"in","start":28,"end":30,"id":4,"ws":true},{"text":"MDR","start":31,"end":34,"id":5,"ws":true},{"text":"HL-60","start":35,"end":40,"id":6,"ws":true},{"text":"cells","start":41,"end":46,"id":7,"ws":true},{"text":"was","start":47,"end":50,"id":8,"ws":true},{"text":"potently","start":51,"end":59,"id":9,"ws":true},{"text":"reversed","start":60,"end":68,"id":10,"ws":true},{"text":"by","start":69,"end":71,"id":11,"ws":true},{"text":"the","start":72,"end":75,"id":12,"ws":true},{"text":"addition","start":76,"end":84,"id":13,"ws":true},{"text":"of","start":85,"end":87,"id":14,"ws":true},{"text":"amlodipine","start":88,"end":98,"id":15,"ws":true},{"text":".","start":99,"end":100,"id":16,"ws":false}],"spans":[{"start":18,"end":27,"token_start":3,"token_end":3,"label":"DRUG"},{"start":88,"end":98,"token_start":15,"token_end":15,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16684125/","_input_hash":920981054,"_task_hash":947211331,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":3,"child":15,"head_span":{"start":18,"end":27,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":88,"end":98,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"In separate studies , the electrocardiogram ( ECG ) and cardiovascular effects of loratadine ( 30 and 100 mg/kg , i.v . ) , terfenadine ( 10 mg/kg , i.v . ) , promethazine ( 5 mg/kg , i.v . ) and diphenhydramine ( 20 mg/kg , i.v . ) were evaluated .","paragraph":"<h3><u>Antihistamine activity, central nervous system and cardiovascular profiles of histamine H1 antagonists: comparative studies with loratadine, terfenadine and sedating antihistamines in guinea-pigs.</u></h3>Sedation limits the clinical utility of classical H1 antihistamines, while newer antihistamines such as <b style='color:Tomato;'><i>loratadine</i></b> and <b style='color:Tomato;'><i>terfenadine</i></b> are non-sedating. However, clinical use of the <b style='color:Tomato;'><i>terfenadine</i></b> has been associated with rare but severe cardiac arrhythmias, in particular torsades de pointes. ### objective To establish a quantitative experimental model for assessing the sedating and cardiotoxicity potential of non-sedating and sedating antihistamines. ### methods Drugs were administered intravenously and the integrated amplitude of the cortical electroencephalogram (EEG) signal was recorded. The threshold dose that depressed EEG activity was compared with the dose required to inhibit by 50% the peripheral bronchospasm elicited by 10 micrograms/kg i.v., of histamine. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>separate</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>electrocardiogram</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ECG</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>cardiovascular</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>loratadine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>30</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>terfenadine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>promethazine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>diphenhydramine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>evaluated</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results The sedating antihistamines, <b style='color:Tomato;'><i>diphenhydramine</i></b> and <b style='color:Tomato;'><i>promethazine</i></b>, depressed the integrated EEG at doses between 0.6 and 2.0 times their peripheral antihistamine doses. <b style='color:Tomato;'><i>loratadine</i></b> had no EEG depressant activity at 100 mg/kg, i.v., a dose more than 170 times its ED50 (0.58 mg/kg, i.v.) against histamine bronchospasm. We were unable to evaluate the EEG effects of <b style='color:Tomato;'><i>terfenadine</i></b>, because it produced cardiovascular collapse at 10 mg/kg, i.v. <b style='color:Tomato;'><i>loratadine</i></b> and <b style='color:Tomato;'><i>promethazine</i></b> did not produce adverse cardiovascular effects, nor did they alter normal ECG activity. <b style='color:Tomato;'><i>diphenhydramine</i></b> produced bradycardia followed by a transient hypertensive phase without affecting the QTc interval. In contrast, <b style='color:Tomato;'><i>terfenadine</i></b> elicited hypotension, bradycardia and significant arrhythmogenic activity, causing a prolongation of the QTc interval and a torsades de pointes--like ventricular arrhythmia. Pharmacokinetic studies after i.v. administration of <b style='color:Tomato;'><i>loratadine</i></b> (30 and 100 mg/kg) demonstrated plasma levels of <b style='color:Tomato;'><i>loratadine</i></b> and its major metabolite descarboethoxy<b style='color:Tomato;'><i>loratadine</i></b> to be several orders of magnitude greater than levels found in humans at the clinical dose of 10 mg. ### conclusion The CNS depressant effects of H1 antihistamines are <b style='color:Tomato;'><i>promethazine</i></b> approximately <b style='color:Tomato;'><i>diphenhydramine</i></b> >> <b style='color:Tomato;'><i>loratadine</i></b> = placebo. Of the non-sedating antihistamines, <b style='color:Tomato;'><i>loratadine</i></b> was devoid of adverse cardiovascular effects whereas <b style='color:Tomato;'><i>terfenadine</i></b> caused a pronounced disruption of the normal ECG, characterized by a torsades de pointes-like effect.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"separate","start":3,"end":11,"id":1,"ws":true},{"text":"studies","start":12,"end":19,"id":2,"ws":true},{"text":",","start":20,"end":21,"id":3,"ws":true},{"text":"the","start":22,"end":25,"id":4,"ws":true},{"text":"electrocardiogram","start":26,"end":43,"id":5,"ws":true},{"text":"(","start":44,"end":45,"id":6,"ws":true},{"text":"ECG","start":46,"end":49,"id":7,"ws":true},{"text":")","start":50,"end":51,"id":8,"ws":true},{"text":"and","start":52,"end":55,"id":9,"ws":true},{"text":"cardiovascular","start":56,"end":70,"id":10,"ws":true},{"text":"effects","start":71,"end":78,"id":11,"ws":true},{"text":"of","start":79,"end":81,"id":12,"ws":true},{"text":"loratadine","start":82,"end":92,"id":13,"ws":true},{"text":"(","start":93,"end":94,"id":14,"ws":true},{"text":"30","start":95,"end":97,"id":15,"ws":true},{"text":"and","start":98,"end":101,"id":16,"ws":true},{"text":"100","start":102,"end":105,"id":17,"ws":true},{"text":"mg/kg","start":106,"end":111,"id":18,"ws":true},{"text":",","start":112,"end":113,"id":19,"ws":true},{"text":"i.v","start":114,"end":117,"id":20,"ws":true},{"text":".","start":118,"end":119,"id":21,"ws":true},{"text":")","start":120,"end":121,"id":22,"ws":true},{"text":",","start":122,"end":123,"id":23,"ws":true},{"text":"terfenadine","start":124,"end":135,"id":24,"ws":true},{"text":"(","start":136,"end":137,"id":25,"ws":true},{"text":"10","start":138,"end":140,"id":26,"ws":true},{"text":"mg/kg","start":141,"end":146,"id":27,"ws":true},{"text":",","start":147,"end":148,"id":28,"ws":true},{"text":"i.v","start":149,"end":152,"id":29,"ws":true},{"text":".","start":153,"end":154,"id":30,"ws":true},{"text":")","start":155,"end":156,"id":31,"ws":true},{"text":",","start":157,"end":158,"id":32,"ws":true},{"text":"promethazine","start":159,"end":171,"id":33,"ws":true},{"text":"(","start":172,"end":173,"id":34,"ws":true},{"text":"5","start":174,"end":175,"id":35,"ws":true},{"text":"mg/kg","start":176,"end":181,"id":36,"ws":true},{"text":",","start":182,"end":183,"id":37,"ws":true},{"text":"i.v","start":184,"end":187,"id":38,"ws":true},{"text":".","start":188,"end":189,"id":39,"ws":true},{"text":")","start":190,"end":191,"id":40,"ws":true},{"text":"and","start":192,"end":195,"id":41,"ws":true},{"text":"diphenhydramine","start":196,"end":211,"id":42,"ws":true},{"text":"(","start":212,"end":213,"id":43,"ws":true},{"text":"20","start":214,"end":216,"id":44,"ws":true},{"text":"mg/kg","start":217,"end":222,"id":45,"ws":true},{"text":",","start":223,"end":224,"id":46,"ws":true},{"text":"i.v","start":225,"end":228,"id":47,"ws":true},{"text":".","start":229,"end":230,"id":48,"ws":true},{"text":")","start":231,"end":232,"id":49,"ws":true},{"text":"were","start":233,"end":237,"id":50,"ws":true},{"text":"evaluated","start":238,"end":247,"id":51,"ws":true},{"text":".","start":248,"end":249,"id":52,"ws":false}],"spans":[{"start":82,"end":92,"token_start":13,"token_end":13,"label":"DRUG"},{"start":124,"end":135,"token_start":24,"token_end":24,"label":"DRUG"},{"start":159,"end":171,"token_start":33,"token_end":33,"label":"DRUG"},{"start":196,"end":211,"token_start":42,"token_end":42,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8556569/","_input_hash":1378418684,"_task_hash":-1885246676,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"[ Clinical evaluation of effects from neoadjuvant chemotherapy with epirubicin plus paclitaxel in cases of locally advanced breast cancer -- comparative study of treatment with 2 and 4 cycles ] .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>Clinical</i></b> <b style='color:DodgerBlue;'><i>evaluation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>neoadjuvant</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>epirubicin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>cases</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>locally</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>--</i></b> <b style='color:DodgerBlue;'><i>comparative</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Neoadjuvant chemotherapy of <b style='color:Tomato;'><i>epirubicin</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b> was administered to 75 patients (including a 2-cycle group of 39 patients and a 4-cycle group of 36 patients) with locally advanced breast cancer (35 cases of stage IIb, 28 of stage IIIa, 12 of stage IIIb) to compare efficacy and toxicity of 2 cycle and 4 cycle regimens. All patients were female. They were treated with <b style='color:Tomato;'><i>epirubicin</i></b> 60 mg/m2, on day 1, by i.v., followed by <b style='color:Tomato;'><i>paclitaxel</i></b> 150 mg/m2, by 3 hour continuous infusion on day 2 repeated every 3 weeks. Premedication with <b style='color:Tomato;'><i>dexamethasone</i></b>, <b style='color:Tomato;'><i>ondansetron</i></b>, <b style='color:Tomato;'><i>diphenhydramine</i></b> and <b style='color:Tomato;'><i>cimetidine</i></b> were administered to prevent gastroenteritic and allergic reactions before chemotherapy. Thirty-nine patients were given 2 cycles and thirty-six were given 4 cycles of this regimen. One of 39 patients had complete response, 28 had partial response and 10 had no change in the 2-cycle group. In addition, 21 of 36 patients had complete response (including 9 who had pathologic complete response), 13 had partial response and 2 had no change. The response rates were 74% (29/39) in the 2-cycle group and 94% (34/36) in the 4-cycle group. There were no progressive disease in these 2 groups. However a higher proportion of PR was observed in stage II patients than in stage III patients. Twelve of 36 patients underwent breast conserving surgery, as tumor size had become smaller and down-staging was realized after neoadjuvant chemotherapy. In addition, axillary lymph nodes were palpable in all 75 patients before neoadjuvant chemotherapy with the ET regimen. But 46% (18/39) in the 2-cycle group and 75% (27/36) in the 4-cycle group became impalpable. Conversely, major toxicities (including leukopenia and gastroenteric reactions) were similar in both groups, but myalgia, arthralgia, neurotoxicity and alopecia were more severe in the 4-cycle group than in the 2-cycle group. In the present study, neoadjuvant chemotherapy with a 4-cycle ET regimen was more effective than with a 2-cycle regimen in down staging locally advanced breast cancer. Although major toxicities were more severe in the 4-cycle group than in the 2-cycle group, the regimen was tolerable and safe.","tokens":[{"text":"[","start":0,"end":1,"id":0,"ws":true},{"text":"Clinical","start":2,"end":10,"id":1,"ws":true},{"text":"evaluation","start":11,"end":21,"id":2,"ws":true},{"text":"of","start":22,"end":24,"id":3,"ws":true},{"text":"effects","start":25,"end":32,"id":4,"ws":true},{"text":"from","start":33,"end":37,"id":5,"ws":true},{"text":"neoadjuvant","start":38,"end":49,"id":6,"ws":true},{"text":"chemotherapy","start":50,"end":62,"id":7,"ws":true},{"text":"with","start":63,"end":67,"id":8,"ws":true},{"text":"epirubicin","start":68,"end":78,"id":9,"ws":true},{"text":"plus","start":79,"end":83,"id":10,"ws":true},{"text":"paclitaxel","start":84,"end":94,"id":11,"ws":true},{"text":"in","start":95,"end":97,"id":12,"ws":true},{"text":"cases","start":98,"end":103,"id":13,"ws":true},{"text":"of","start":104,"end":106,"id":14,"ws":true},{"text":"locally","start":107,"end":114,"id":15,"ws":true},{"text":"advanced","start":115,"end":123,"id":16,"ws":true},{"text":"breast","start":124,"end":130,"id":17,"ws":true},{"text":"cancer","start":131,"end":137,"id":18,"ws":true},{"text":"--","start":138,"end":140,"id":19,"ws":true},{"text":"comparative","start":141,"end":152,"id":20,"ws":true},{"text":"study","start":153,"end":158,"id":21,"ws":true},{"text":"of","start":159,"end":161,"id":22,"ws":true},{"text":"treatment","start":162,"end":171,"id":23,"ws":true},{"text":"with","start":172,"end":176,"id":24,"ws":true},{"text":"2","start":177,"end":178,"id":25,"ws":true},{"text":"and","start":179,"end":182,"id":26,"ws":true},{"text":"4","start":183,"end":184,"id":27,"ws":true},{"text":"cycles","start":185,"end":191,"id":28,"ws":true},{"text":"]","start":192,"end":193,"id":29,"ws":true},{"text":".","start":194,"end":195,"id":30,"ws":false}],"spans":[{"start":68,"end":78,"token_start":9,"token_end":9,"label":"DRUG"},{"start":84,"end":94,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/14997752/","_input_hash":-2122849102,"_task_hash":1304982906,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":9,"child":11,"head_span":{"start":68,"end":78,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":84,"end":94,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"When systemically active chemotherapy doses were reached , further dose escalation was discontinued , and a phase II dose-range was established ( pemetrexed 500 mg/m(2 ) and carboplatin AUC = 5 - 6 ) .","paragraph":"<h3><u>A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.</u></h3>The primary objective of this phase I study was to determine the maximum tolerated dose for <b style='color:Tomato;'><i>pemetrexed</i></b>, alone and in combination with <b style='color:Tomato;'><i>carboplatin</i></b>, with concurrent radiotherapy. ### Experimental Design Patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) or esophageal cancer were treated every 21 days for two cycles. Regimen 1 was <b style='color:Tomato;'><i>pemetrexed</i></b> (200-600 mg/m(2)); regimen 2 was <b style='color:Tomato;'><i>pemetrexed</i></b> (500 mg/m(2)) with escalating <b style='color:Tomato;'><i>carboplatin</i></b> doses (AUC = 4-6). Both regimens included concurrent radiation (40-66 Gy; palliative-intent doses were lower). ### results Thirty patients (18 locally advanced and 12 metastatic with dominant local symptoms) were enrolled, with an Eastern Cooperative Oncology Group performance status of 0/1/2 (n = 8/21/1). All dose levels were tolerable for regimen 1 (n = 18: 15 NSCLC and 3 esophageal cancers) and regimen 2 (n = 12: all NSCLC). In regimen 1, one dose-limiting toxicity (grade 4 esophagitis/anorexia) occurred (500 mg/m(2)). Grade 3 neutropenia (3 of 18 patients) was the main hematologic toxicity. In regimen 2, one dose-limiting toxicity (grade 3 esophagitis) occurred (500 mg/m(2); AUC = 6); grade 3/4 leukopenia (4 of 12 patients) was the main hematologic toxicity. Four complete responses (2 pathology proven) and eight partial responses were observed. <b style='color:DodgerBlue;'><i>When</i></b> <b style='color:DodgerBlue;'><i>systemically</i></b> <b style='color:DodgerBlue;'><i>active</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>reached</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>further</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>escalation</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>discontinued</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>dose-range</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>established</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>pemetrexed</i></b> <b style='color:DodgerBlue;'><i>500</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>AUC</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### conclusions The combination of <b style='color:Tomato;'><i>pemetrexed</i></b> (500 mg/m(2)) and <b style='color:Tomato;'><i>carboplatin</i></b> (AUC = 5 or 6) with concurrent radiation is well tolerated, allows for the administration of systemically active chemotherapy doses, and shows signs of activity. To further determine efficacy, safety profile, and optimal dosing, the Cancer and Leukemia Group B study 30407 is currently evaluating this regimen in patients with unresectable stage III NSCLC.","tokens":[{"text":"When","start":0,"end":4,"id":0,"ws":true},{"text":"systemically","start":5,"end":17,"id":1,"ws":true},{"text":"active","start":18,"end":24,"id":2,"ws":true},{"text":"chemotherapy","start":25,"end":37,"id":3,"ws":true},{"text":"doses","start":38,"end":43,"id":4,"ws":true},{"text":"were","start":44,"end":48,"id":5,"ws":true},{"text":"reached","start":49,"end":56,"id":6,"ws":true},{"text":",","start":57,"end":58,"id":7,"ws":true},{"text":"further","start":59,"end":66,"id":8,"ws":true},{"text":"dose","start":67,"end":71,"id":9,"ws":true},{"text":"escalation","start":72,"end":82,"id":10,"ws":true},{"text":"was","start":83,"end":86,"id":11,"ws":true},{"text":"discontinued","start":87,"end":99,"id":12,"ws":true},{"text":",","start":100,"end":101,"id":13,"ws":true},{"text":"and","start":102,"end":105,"id":14,"ws":true},{"text":"a","start":106,"end":107,"id":15,"ws":true},{"text":"phase","start":108,"end":113,"id":16,"ws":true},{"text":"II","start":114,"end":116,"id":17,"ws":true},{"text":"dose-range","start":117,"end":127,"id":18,"ws":true},{"text":"was","start":128,"end":131,"id":19,"ws":true},{"text":"established","start":132,"end":143,"id":20,"ws":true},{"text":"(","start":144,"end":145,"id":21,"ws":true},{"text":"pemetrexed","start":146,"end":156,"id":22,"ws":true},{"text":"500","start":157,"end":160,"id":23,"ws":true},{"text":"mg/m(2","start":161,"end":167,"id":24,"ws":true},{"text":")","start":168,"end":169,"id":25,"ws":true},{"text":"and","start":170,"end":173,"id":26,"ws":true},{"text":"carboplatin","start":174,"end":185,"id":27,"ws":true},{"text":"AUC","start":186,"end":189,"id":28,"ws":true},{"text":"=","start":190,"end":191,"id":29,"ws":true},{"text":"5","start":192,"end":193,"id":30,"ws":true},{"text":"-","start":194,"end":195,"id":31,"ws":true},{"text":"6","start":196,"end":197,"id":32,"ws":true},{"text":")","start":198,"end":199,"id":33,"ws":true},{"text":".","start":200,"end":201,"id":34,"ws":false}],"spans":[{"start":146,"end":156,"token_start":22,"token_end":22,"label":"DRUG"},{"start":174,"end":185,"token_start":27,"token_end":27,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/17255273/","_input_hash":1071410750,"_task_hash":1537762818,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":22,"child":27,"head_span":{"start":146,"end":156,"token_start":22,"token_end":22,"label":"DRUG"},"child_span":{"start":174,"end":185,"token_start":27,"token_end":27,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Increased dose density is feasible : a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel , at 10- or 11-day intervals with filgrastim support in women with breast cancer .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Increased</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>density</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>feasible</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>pilot</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>adjuvant</i></b> <b style='color:MediumOrchid;'><i>epirubicin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>10-</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>11-day</i></b> <b style='color:DodgerBlue;'><i>intervals</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>filgrastim</i></b> <b style='color:DodgerBlue;'><i>support</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>women</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Because Cancer and Leukemia Group B 9741 trial showed a benefit for every 14-day administration of chemotherapy compared with every 21-day treatment, we hypothesized that even greater dose density would be more effective. We conducted a pilot trial to assess the feasibility of dose-dense chemotherapy consisting of a standard regime at 10- to 11-day intervals in the adjuvant/neoadjuvant setting. A 2-day window was allowed for scheduling logistics. ### Experimental Design Thirty-nine women with early-stage breast carcinoma were accrued from April 2004 to October 2004. Median age was 47 years (range, 26-67 years). Patients received therapy with 100 mg/m(2) <b style='color:Tomato;'><i>epirubicin</i></b> and 600 mg/m(2) <b style='color:Tomato;'><i>cyclophosphamide</i></b> (EC) q 10 to 11 days for four cycles followed by 175 mg/m(2) <b style='color:Tomato;'><i>paclitaxel</i></b> q 10 to 11 days for four cycles, all with <b style='color:Tomato;'><i>filgrastim</i></b> support (300 microg s.c. daily) from day 2 to 24 h before the next treatment. ### results Thirty-five (90%) patients completed all planned therapy. The median intertreatment interval was 10 days (range, 8-28 days). Cycles (80.7%) were delivered at no more than 10- to 11-day intervals. There were five dose reductions of 25% for grade 3 nonhematologic toxicity in five patients. Six (16%) patients developed febrile neutropenia defined as temperature >38 degrees C with absolute neutrophil count <1,000/microL. All febrile neutropenia was during therapy with EC. Other grade 3 toxicities included bone pain, hand and foot syndrome, neuropathy, mucositis, nausea, and vomiting. ### conclusions Therapy with EC for four cycles followed by <b style='color:Tomato;'><i>paclitaxel</i></b> for four cycles at 10- to 11-day intervals is feasible. The approximately 30% reduction in intertreatment interval compared with every 14-day treatment could increase the efficacy of adjuvant chemotherapy.","tokens":[{"text":"Increased","start":0,"end":9,"id":0,"ws":true},{"text":"dose","start":10,"end":14,"id":1,"ws":true},{"text":"density","start":15,"end":22,"id":2,"ws":true},{"text":"is","start":23,"end":25,"id":3,"ws":true},{"text":"feasible","start":26,"end":34,"id":4,"ws":true},{"text":":","start":35,"end":36,"id":5,"ws":true},{"text":"a","start":37,"end":38,"id":6,"ws":true},{"text":"pilot","start":39,"end":44,"id":7,"ws":true},{"text":"study","start":45,"end":50,"id":8,"ws":true},{"text":"of","start":51,"end":53,"id":9,"ws":true},{"text":"adjuvant","start":54,"end":62,"id":10,"ws":true},{"text":"epirubicin","start":63,"end":73,"id":11,"ws":true},{"text":"and","start":74,"end":77,"id":12,"ws":true},{"text":"cyclophosphamide","start":78,"end":94,"id":13,"ws":true},{"text":"followed","start":95,"end":103,"id":14,"ws":true},{"text":"by","start":104,"end":106,"id":15,"ws":true},{"text":"paclitaxel","start":107,"end":117,"id":16,"ws":true},{"text":",","start":118,"end":119,"id":17,"ws":true},{"text":"at","start":120,"end":122,"id":18,"ws":true},{"text":"10-","start":123,"end":126,"id":19,"ws":true},{"text":"or","start":127,"end":129,"id":20,"ws":true},{"text":"11-day","start":130,"end":136,"id":21,"ws":true},{"text":"intervals","start":137,"end":146,"id":22,"ws":true},{"text":"with","start":147,"end":151,"id":23,"ws":true},{"text":"filgrastim","start":152,"end":162,"id":24,"ws":true},{"text":"support","start":163,"end":170,"id":25,"ws":true},{"text":"in","start":171,"end":173,"id":26,"ws":true},{"text":"women","start":174,"end":179,"id":27,"ws":true},{"text":"with","start":180,"end":184,"id":28,"ws":true},{"text":"breast","start":185,"end":191,"id":29,"ws":true},{"text":"cancer","start":192,"end":198,"id":30,"ws":true},{"text":".","start":199,"end":200,"id":31,"ws":false}],"spans":[{"start":63,"end":73,"token_start":11,"token_end":11,"label":"DRUG"},{"start":78,"end":94,"token_start":13,"token_end":13,"label":"DRUG"},{"start":107,"end":117,"token_start":16,"token_end":16,"label":"DRUG"},{"start":152,"end":162,"token_start":24,"token_end":24,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/17200358/","_input_hash":939881528,"_task_hash":2125935323,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":13,"child":11,"head_span":{"start":78,"end":94,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":63,"end":73,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":13,"child":16,"head_span":{"start":78,"end":94,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":107,"end":117,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":16,"child":24,"head_span":{"start":107,"end":117,"token_start":16,"token_end":16,"label":"DRUG"},"child_span":{"start":152,"end":162,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Those who test positive are treated with combinations of the following agents : omeprazole , clarithromycin , amoxicillin , tetracycline , and metronidazole .","paragraph":"<h3><u>Pharmacist-managed Helicobacter pylori clinic.</u></h3>A pharmacist-managed Helicobacter pylori assessment clinic for ambulatory patients is described. The pharmacy service at a 400-bed Veterans Affairs Medical Center established a pharmacist-managed clinic to assess patients who were receiving long-term acid-suppressive medications (histamine H2-receptor antagonists, <b style='color:Tomato;'><i>sucralfate</i></b>, or <b style='color:Tomato;'><i>omeprazole</i></b>). Patients with active ulcer disease and those receiving ulcer prophylaxis are screened for the presence of H. pylori. <b style='color:DodgerBlue;'><i>Those</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>test</i></b> <b style='color:DodgerBlue;'><i>positive</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>combinations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>following</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>clarithromycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>amoxicillin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>tetracycline</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>metronidazole</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The pharmacist also may adjust or discontinue acid-suppressive drug regimens. The pharmacist is responsible for ordering all appropriate laboratory tests, monitoring patients for adverse effects, collecting data on patient outcomes, and providing patient education. The clinic provides opportunities for pharmacists to study the clinical effectiveness and pharmacoeconomics of various regimens for treating H. pylori-associated disease and for pharmacy students and residents to interact with patients. As of fall 1994, 20 patients had been evaluated at the clinic: 12 tested positive for H. pylori and were treated with antimicrobials and all were pain-free without medication at the end of treatment. An H. pylori assessment clinic enabled pharmacists to assume a primary care role, document improvement in patient outcomes, and study the effectiveness of various antimicrobial regimens.","tokens":[{"text":"Those","start":0,"end":5,"id":0,"ws":true},{"text":"who","start":6,"end":9,"id":1,"ws":true},{"text":"test","start":10,"end":14,"id":2,"ws":true},{"text":"positive","start":15,"end":23,"id":3,"ws":true},{"text":"are","start":24,"end":27,"id":4,"ws":true},{"text":"treated","start":28,"end":35,"id":5,"ws":true},{"text":"with","start":36,"end":40,"id":6,"ws":true},{"text":"combinations","start":41,"end":53,"id":7,"ws":true},{"text":"of","start":54,"end":56,"id":8,"ws":true},{"text":"the","start":57,"end":60,"id":9,"ws":true},{"text":"following","start":61,"end":70,"id":10,"ws":true},{"text":"agents","start":71,"end":77,"id":11,"ws":true},{"text":":","start":78,"end":79,"id":12,"ws":true},{"text":"omeprazole","start":80,"end":90,"id":13,"ws":true},{"text":",","start":91,"end":92,"id":14,"ws":true},{"text":"clarithromycin","start":93,"end":107,"id":15,"ws":true},{"text":",","start":108,"end":109,"id":16,"ws":true},{"text":"amoxicillin","start":110,"end":121,"id":17,"ws":true},{"text":",","start":122,"end":123,"id":18,"ws":true},{"text":"tetracycline","start":124,"end":136,"id":19,"ws":true},{"text":",","start":137,"end":138,"id":20,"ws":true},{"text":"and","start":139,"end":142,"id":21,"ws":true},{"text":"metronidazole","start":143,"end":156,"id":22,"ws":true},{"text":".","start":157,"end":158,"id":23,"ws":false}],"spans":[{"start":80,"end":90,"token_start":13,"token_end":13,"label":"DRUG"},{"start":93,"end":107,"token_start":15,"token_end":15,"label":"DRUG"},{"start":110,"end":121,"token_start":17,"token_end":17,"label":"DRUG"},{"start":124,"end":136,"token_start":19,"token_end":19,"label":"DRUG"},{"start":143,"end":156,"token_start":22,"token_end":22,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/12879545/","_input_hash":-1629384935,"_task_hash":-792898755,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":13,"child":15,"head_span":{"start":80,"end":90,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":93,"end":107,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":15,"child":17,"head_span":{"start":93,"end":107,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":110,"end":121,"token_start":17,"token_end":17,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":17,"child":19,"head_span":{"start":110,"end":121,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":124,"end":136,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":19,"child":22,"head_span":{"start":124,"end":136,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":143,"end":156,"token_start":22,"token_end":22,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Patients can be treatment-na\u00efve for mCRPC or on first-line androgen receptor-targeted therapy for mCRPC ( ie , abiraterone or enzalutamide ) without evidence of progression at enrolment , and with no prior chemotherapy for mCRPC .","paragraph":"<h3><u>Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol.</u></h3>Preliminary evidence supports the beneficial role of physical activity on prostate cancer outcomes. This phase III randomised controlled trial (RCT) is designed to determine if supervised high-intensity aerobic and resistance exercise increases overall survival (OS) in patients with metastatic castrate-resistant prostate cancer (mCRPC). ### Methods And Analysis Participants (n=866) must have histologically documented metastatic prostate cancer with evidence of progressive disease on androgen deprivation therapy (defined as mCRPC). <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>can</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>treatment-na\u00efve</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>mCRPC</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>androgen</i></b> <b style='color:DodgerBlue;'><i>receptor-targeted</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>mCRPC</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ie</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>abiraterone</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>enzalutamide</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>without</i></b> <b style='color:DodgerBlue;'><i>evidence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>progression</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>enrolment</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>prior</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>mCRPC</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Patients will receive psychosocial support and will be randomly assigned (1:1) to either supervised exercise (high-intensity aerobic and resistance training) or self-directed exercise (provision of guidelines), stratified by treatment status and site. Exercise prescriptions will be tailored to each participant's fitness and morbidities. The primary endpoint is OS. Secondary endpoints include time to disease progression, occurrence of a skeletal-related event or progression of pain, and degree of pain, opiate use, physical and emotional quality of life, and changes in metabolic biomarkers. An assessment of whether immune function, inflammation, dysregulation of insulin and energy metabolism, and androgen biomarkers are associated with OS will be performed, and whether they mediate the primary association between exercise and OS will also be investigated. This study will also establish a biobank for future biomarker discovery or validation. ### Ethics And Dissemination Validation of exercise as medicine and its mechanisms of action will create evidence to change clinical practice. Accordingly, outcomes of this RCT will be published in international, peer-reviewed journals, and presented at national and international conferences. Ethics approval was first obtained at Edith Cowan University (ID: 13236 NEWTON), with a further 10 investigator sites since receiving ethics approval, prior to activation. ### Trial Registration Number NCT02730338.","tokens":[{"text":"Patients","start":0,"end":8,"id":0,"ws":true},{"text":"can","start":9,"end":12,"id":1,"ws":true},{"text":"be","start":13,"end":15,"id":2,"ws":true},{"text":"treatment-na\u00efve","start":16,"end":31,"id":3,"ws":true},{"text":"for","start":32,"end":35,"id":4,"ws":true},{"text":"mCRPC","start":36,"end":41,"id":5,"ws":true},{"text":"or","start":42,"end":44,"id":6,"ws":true},{"text":"on","start":45,"end":47,"id":7,"ws":true},{"text":"first-line","start":48,"end":58,"id":8,"ws":true},{"text":"androgen","start":59,"end":67,"id":9,"ws":true},{"text":"receptor-targeted","start":68,"end":85,"id":10,"ws":true},{"text":"therapy","start":86,"end":93,"id":11,"ws":true},{"text":"for","start":94,"end":97,"id":12,"ws":true},{"text":"mCRPC","start":98,"end":103,"id":13,"ws":true},{"text":"(","start":104,"end":105,"id":14,"ws":true},{"text":"ie","start":106,"end":108,"id":15,"ws":true},{"text":",","start":109,"end":110,"id":16,"ws":true},{"text":"abiraterone","start":111,"end":122,"id":17,"ws":true},{"text":"or","start":123,"end":125,"id":18,"ws":true},{"text":"enzalutamide","start":126,"end":138,"id":19,"ws":true},{"text":")","start":139,"end":140,"id":20,"ws":true},{"text":"without","start":141,"end":148,"id":21,"ws":true},{"text":"evidence","start":149,"end":157,"id":22,"ws":true},{"text":"of","start":158,"end":160,"id":23,"ws":true},{"text":"progression","start":161,"end":172,"id":24,"ws":true},{"text":"at","start":173,"end":175,"id":25,"ws":true},{"text":"enrolment","start":176,"end":185,"id":26,"ws":true},{"text":",","start":186,"end":187,"id":27,"ws":true},{"text":"and","start":188,"end":191,"id":28,"ws":true},{"text":"with","start":192,"end":196,"id":29,"ws":true},{"text":"no","start":197,"end":199,"id":30,"ws":true},{"text":"prior","start":200,"end":205,"id":31,"ws":true},{"text":"chemotherapy","start":206,"end":218,"id":32,"ws":true},{"text":"for","start":219,"end":222,"id":33,"ws":true},{"text":"mCRPC","start":223,"end":228,"id":34,"ws":true},{"text":".","start":229,"end":230,"id":35,"ws":false}],"spans":[{"start":111,"end":122,"token_start":17,"token_end":17,"label":"DRUG"},{"start":126,"end":138,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29764892/","_input_hash":-196170261,"_task_hash":1174955668,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"CYP2D6 metabolizes other opioid analgesics , including tramadol , dihydrocodeine , oxycodone and hydrocodone , although they have been less systematically studied .","paragraph":"<h3><u>Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer.</u></h3><b style='color:Tomato;'><i>codeine</i></b> is metabolized by the cytochrome P450 2D6 (CYP2D6) to morphine. <b style='color:Tomato;'><i>codeine</i></b> is a much weaker agonist at mu opioid receptors than morphine. Therefore, <b style='color:Tomato;'><i>codeine</i></b> analgesia is highly dependent on CYP2D6 activity. Large prospective studies in the clinical environment do not exist, but it appears reasonable to avoid <b style='color:Tomato;'><i>codeine</i></b> use in CYP2D6 poor metabolizers (PMs). <b style='color:DodgerBlue;'><i>CYP2D6</i></b> <b style='color:DodgerBlue;'><i>metabolizes</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>opioid</i></b> <b style='color:DodgerBlue;'><i>analgesics</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:MediumOrchid;'><i>tramadol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>dihydrocodeine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>oxycodone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>hydrocodone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>although</i></b> <b style='color:DodgerBlue;'><i>they</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>less</i></b> <b style='color:DodgerBlue;'><i>systematically</i></b> <b style='color:DodgerBlue;'><i>studied</i></b> <b style='color:DodgerBlue;'><i>.</i></b> It is unclear whether these other pro-drugs may be as completely dependent on CYP2D6 for their analgesia as <b style='color:Tomato;'><i>codeine</i></b>. We describe a patient identified as a CYP2D6 PM with a history of problems with opioid analgesics. The patient was an 85-year-old female Caucasian who had hip surgery. The patient had a long-standing intolerance to <b style='color:Tomato;'><i>codeine</i></b>. In her first admission, she couldn't tolerate the regimen of oxycodone combined with <b style='color:Tomato;'><i>tramadol</i></b> prns (as needed). She was genotyped as a CYP2D6 PM and after the information was provided to the treating physician in her second admission, she seemed to have a better response to <b style='color:Tomato;'><i>hydrocodone</i></b>. Large case-control naturalistic studies followed by randomized trials in patients taking opioid analgesics may be needed to definitively establish that CYP2D6 genotyping has clinical relevance in the use of several opioid analgesics.","tokens":[{"text":"CYP2D6","start":0,"end":6,"id":0,"ws":true},{"text":"metabolizes","start":7,"end":18,"id":1,"ws":true},{"text":"other","start":19,"end":24,"id":2,"ws":true},{"text":"opioid","start":25,"end":31,"id":3,"ws":true},{"text":"analgesics","start":32,"end":42,"id":4,"ws":true},{"text":",","start":43,"end":44,"id":5,"ws":true},{"text":"including","start":45,"end":54,"id":6,"ws":true},{"text":"tramadol","start":55,"end":63,"id":7,"ws":true},{"text":",","start":64,"end":65,"id":8,"ws":true},{"text":"dihydrocodeine","start":66,"end":80,"id":9,"ws":true},{"text":",","start":81,"end":82,"id":10,"ws":true},{"text":"oxycodone","start":83,"end":92,"id":11,"ws":true},{"text":"and","start":93,"end":96,"id":12,"ws":true},{"text":"hydrocodone","start":97,"end":108,"id":13,"ws":true},{"text":",","start":109,"end":110,"id":14,"ws":true},{"text":"although","start":111,"end":119,"id":15,"ws":true},{"text":"they","start":120,"end":124,"id":16,"ws":true},{"text":"have","start":125,"end":129,"id":17,"ws":true},{"text":"been","start":130,"end":134,"id":18,"ws":true},{"text":"less","start":135,"end":139,"id":19,"ws":true},{"text":"systematically","start":140,"end":154,"id":20,"ws":true},{"text":"studied","start":155,"end":162,"id":21,"ws":true},{"text":".","start":163,"end":164,"id":22,"ws":false}],"spans":[{"start":55,"end":63,"token_start":7,"token_end":7,"label":"DRUG"},{"start":97,"end":108,"token_start":13,"token_end":13,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16631290/","_input_hash":180518504,"_task_hash":386885726,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Atracurium or vecuronium was given for intubation .","paragraph":"<h3><u>Prediction of oculocardiac reflex in strabismus surgery using neural networks.</u></h3>Successfully predicting an oculocardiac reflex (OCR) is difficult to achieve despite various proposed maneuvers. The aim of this study was to test the models built up by neural networks to predict the occurrence of OCR during strabismus surgery in children. Premedication was not given. <b style='color:Tomato;'><i>atropine</i></b> 0.01 mg/kg was medicated just before induction. Induction was performed with fentanyl or <b style='color:Tomato;'><i>ketorolac</i></b>, followed by <b style='color:Tomato;'><i>propofol</i></b>. <b style='color:MediumOrchid;'><i>Atracurium</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>vecuronium</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>intubation</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Anesthesia was maintained with O2-N2O with continuous <b style='color:Tomato;'><i>propofol</i></b> infusion. Chi-square test was performed for induction agents, gender, weight, muscle blockade, repaired muscle, number of repaired muscles, duration of operation to detect any association between the occurrence of OCR and to develop the model of neural networks. The multi-layer perceptron, radial basis function and Bayesian backpropagation network were tested. The occurrence of OCR was significantly associated with gender and repaired muscle (p < 0.05). Gender, repaired muscle and age were considered as input for the multi-layer perceptron, radial basis function and Bayesian backpropagation network. Three neural networks had predicted the same correction rate in the occurrence of OCR as being 87.5% overall among 16 patients' records tested. These models are conceptually different in predicting compared to conventional maneuvers, and have the advantage of testing individually and foretelling the propensity. By comparison neural networks use grouped experiential data and predict OCR by the learning rule. Neural networks require a relatively abundant number of experienced and homogenous patients' records to establish an accurate model. The multi-layer perceptron, radial basis function and Bayesian backpropagation modeling network may be an alternative way, and preferable to vagal tone maneuvers if the associated relationships to the occurrence of OCR are more clearly defined.","tokens":[{"text":"Atracurium","start":0,"end":10,"id":0,"ws":true},{"text":"or","start":11,"end":13,"id":1,"ws":true},{"text":"vecuronium","start":14,"end":24,"id":2,"ws":true},{"text":"was","start":25,"end":28,"id":3,"ws":true},{"text":"given","start":29,"end":34,"id":4,"ws":true},{"text":"for","start":35,"end":38,"id":5,"ws":true},{"text":"intubation","start":39,"end":49,"id":6,"ws":true},{"text":".","start":50,"end":51,"id":7,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":14,"end":24,"token_start":2,"token_end":2,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/10412336/","_input_hash":1481785694,"_task_hash":868944343,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The data show that knockdown of Rad51 or BRCA2 greatly sensitizes cells to DSBs and the induction of cell death following temozolomide and nimustine ( ACNU ) .","paragraph":"<h3><u>Rad51 and BRCA2--New molecular targets for sensitizing glioma cells to alkylating anticancer drugs.</u></h3>First line chemotherapeutics for brain tumors (malignant gliomas) are alkylating agents such as <b style='color:Tomato;'><i>temozolomide</i></b> and <b style='color:Tomato;'><i>nimustine</i></b>. Despite growing knowledge of how these agents work, patients suffering from this malignancy still face a dismal prognosis. Alkylating agents target DNA, forming the killing lesion O(6)-alkylguanine, which is converted into DNA double-strand breaks (DSBs) that trigger apoptosis. Here we assessed whether inhibiting repair of DSBs by homologous recombination (HR) or non-homologous end joining (NHEJ) is a reasonable strategy for sensitizing glioma cells to alkylating agents. For down-regulation of HR in glioma cells, we used an interference RNA (iRNA) approach targeting Rad51 and BRCA2, and for NHEJ we employed the DNA-PK inhibitor NU7026. We also assessed whether inhibition of poly(ADP)ribosyltransferase (PARP) by <b style='color:Tomato;'><i>olaparib</i></b> would enhance the killing effect. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>show</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>knockdown</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Rad51</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>BRCA2</i></b> <b style='color:DodgerBlue;'><i>greatly</i></b> <b style='color:DodgerBlue;'><i>sensitizes</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>DSBs</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>induction</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>death</i></b> <b style='color:DodgerBlue;'><i>following</i></b> <b style='color:MediumOrchid;'><i>temozolomide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>nimustine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ACNU</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> It did not sensitize to ionizing radiation (IR). The expression of O(6)-methylguanine-DNA methyltransferase (MGMT) abolished all these effects, indicating that O(6)-alkylguanine induced by these drugs is the primary lesion responsible for the formation of DSBs and increased sensitivity of glioma cells following knockdown of Rad51 and BRCA2. Inhibition of DNA-PK only slightly sensitized to <b style='color:Tomato;'><i>temozolomide</i></b> whereas a significant effect was observed with IR. A triple strategy including siRNA and the PARP inhibitor <b style='color:Tomato;'><i>olaparib</i></b> further improved the killing effect of <b style='color:Tomato;'><i>temozolomide</i></b>. The data provides evidence that down-regulation of Rad51 or BRCA2 is a reasonable strategy for sensitizing glioma cells to killing by O(6)-alkylating anti-cancer drugs. The data also provide proof of principle that a triple strategy involving down-regulation of HR, PARP inhibition and MGMT depletion may greatly enhance the therapeutic effect of <b style='color:Tomato;'><i>temozolomide</i></b>.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"data","start":4,"end":8,"id":1,"ws":true},{"text":"show","start":9,"end":13,"id":2,"ws":true},{"text":"that","start":14,"end":18,"id":3,"ws":true},{"text":"knockdown","start":19,"end":28,"id":4,"ws":true},{"text":"of","start":29,"end":31,"id":5,"ws":true},{"text":"Rad51","start":32,"end":37,"id":6,"ws":true},{"text":"or","start":38,"end":40,"id":7,"ws":true},{"text":"BRCA2","start":41,"end":46,"id":8,"ws":true},{"text":"greatly","start":47,"end":54,"id":9,"ws":true},{"text":"sensitizes","start":55,"end":65,"id":10,"ws":true},{"text":"cells","start":66,"end":71,"id":11,"ws":true},{"text":"to","start":72,"end":74,"id":12,"ws":true},{"text":"DSBs","start":75,"end":79,"id":13,"ws":true},{"text":"and","start":80,"end":83,"id":14,"ws":true},{"text":"the","start":84,"end":87,"id":15,"ws":true},{"text":"induction","start":88,"end":97,"id":16,"ws":true},{"text":"of","start":98,"end":100,"id":17,"ws":true},{"text":"cell","start":101,"end":105,"id":18,"ws":true},{"text":"death","start":106,"end":111,"id":19,"ws":true},{"text":"following","start":112,"end":121,"id":20,"ws":true},{"text":"temozolomide","start":122,"end":134,"id":21,"ws":true},{"text":"and","start":135,"end":138,"id":22,"ws":true},{"text":"nimustine","start":139,"end":148,"id":23,"ws":true},{"text":"(","start":149,"end":150,"id":24,"ws":true},{"text":"ACNU","start":151,"end":155,"id":25,"ws":true},{"text":")","start":156,"end":157,"id":26,"ws":true},{"text":".","start":158,"end":159,"id":27,"ws":false}],"spans":[{"start":122,"end":134,"token_start":21,"token_end":21,"label":"DRUG"},{"start":139,"end":148,"token_start":23,"token_end":23,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22073281/","_input_hash":-1385267655,"_task_hash":1362201328,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The systemic treatment in both studies consisted of a four-drug-regimen ( VACA = vincristine , actinomycin D , cyclophosphamide , and adriamycin ; or VAIA = vincristine , actinomycin D , ifosfamide , and adriamycin ) and a total number of four courses , each lasting nine weeks , was recommended by the protocol .","paragraph":"<h3><u>Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies.</u></h3>During recent years, more intensified systemic and local treatment regimens have increased the 5-year survival figures in localized Ewing's sarcoma to more than 60%. There is, however, concern about the risk of second malignancies (SM) in long-term survivors. We have analyzed the second malignancies in patients treated in the German Ewing's Sarcoma Studies CESS 81 and CESS 86. ### Materials And Methods From January 1981 through June 1991, 674 patients were registered in the two sequential multicentric Ewing's sarcoma trials CESS 81 (recruitment period 1981-1985) and CESS 86 (1986-1991). <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>systemic</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>consisted</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>four-drug-regimen</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>VACA</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>actinomycin</i></b> <b style='color:DodgerBlue;'><i>D</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>adriamycin</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>VAIA</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>actinomycin</i></b> <b style='color:DodgerBlue;'><i>D</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>adriamycin</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>total</i></b> <b style='color:DodgerBlue;'><i>number</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>four</i></b> <b style='color:DodgerBlue;'><i>courses</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>each</i></b> <b style='color:DodgerBlue;'><i>lasting</i></b> <b style='color:DodgerBlue;'><i>nine</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>protocol</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Local therapy in curative patients was either complete surgery (n = 162), surgery plus postoperative radiotherapy with 36-46Gy (n = 274), or definitive radiotherapy with 46-60Gy (n = 212). The median follow-up at the time of this analysis was 5.1 years, the maximum follow-up 16.5 years. ### results The overall survival of all patients including metastatic patients was 55% after 5 years, 48% after 10 years, and 37% after 15 years. Eight out of 674 patients (1.2%) developed a SM. Five of these were acute myelogenic leukemias (n = 4) or MDS (n = 1), and three were sarcomas. The interval between diagnosis of Ewing's sarcoma and the diagnosis of the SM was 17-78 months for the four AMLs, 96 months for the MDS and 82-136 months for the three sarcomas. The cumulative risk of an SM was 0.7% after 5 years, 2.9% after 10 years, and 4.7% after 15 years. Out of five patients with AML/MDS, three died of rapid AML-progression, and two are living with disease. Local therapy (surgery vs. surgery plus postoperative irradiation vs. definitive radiotherapy) had no impact on the frequency of AML/MDS, but local therapy did influence the risk of secondary sarcomas. All three patients with secondary sarcomas had received radiotherapy; however, all three sarcomas were salvaged by subsequent treatment and are in clinical remission with a follow-up of 1 month, 4.3 years, and 7.5 years after the diagnosis of the secondary sarcoma. Thus far, SM contributed to less than 1 % (3/328) of all deaths in the CESS-studies. ### conclusions The risk of leukemia after treatment for Ewing's sarcoma is probably in the range of 2%. The risk of solid tumors also seems to be low within the first 10 years after treatment and remains in the range of 5 % after 15 years. In the CESS-studies, less than 1% of all deaths within the first 10 years after diagnosis were caused by SM. Effective salvage therapy for secondary sarcomas is feasible.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"systemic","start":4,"end":12,"id":1,"ws":true},{"text":"treatment","start":13,"end":22,"id":2,"ws":true},{"text":"in","start":23,"end":25,"id":3,"ws":true},{"text":"both","start":26,"end":30,"id":4,"ws":true},{"text":"studies","start":31,"end":38,"id":5,"ws":true},{"text":"consisted","start":39,"end":48,"id":6,"ws":true},{"text":"of","start":49,"end":51,"id":7,"ws":true},{"text":"a","start":52,"end":53,"id":8,"ws":true},{"text":"four-drug-regimen","start":54,"end":71,"id":9,"ws":true},{"text":"(","start":72,"end":73,"id":10,"ws":true},{"text":"VACA","start":74,"end":78,"id":11,"ws":true},{"text":"=","start":79,"end":80,"id":12,"ws":true},{"text":"vincristine","start":81,"end":92,"id":13,"ws":true},{"text":",","start":93,"end":94,"id":14,"ws":true},{"text":"actinomycin","start":95,"end":106,"id":15,"ws":true},{"text":"D","start":107,"end":108,"id":16,"ws":true},{"text":",","start":109,"end":110,"id":17,"ws":true},{"text":"cyclophosphamide","start":111,"end":127,"id":18,"ws":true},{"text":",","start":128,"end":129,"id":19,"ws":true},{"text":"and","start":130,"end":133,"id":20,"ws":true},{"text":"adriamycin","start":134,"end":144,"id":21,"ws":true},{"text":";","start":145,"end":146,"id":22,"ws":true},{"text":"or","start":147,"end":149,"id":23,"ws":true},{"text":"VAIA","start":150,"end":154,"id":24,"ws":true},{"text":"=","start":155,"end":156,"id":25,"ws":true},{"text":"vincristine","start":157,"end":168,"id":26,"ws":true},{"text":",","start":169,"end":170,"id":27,"ws":true},{"text":"actinomycin","start":171,"end":182,"id":28,"ws":true},{"text":"D","start":183,"end":184,"id":29,"ws":true},{"text":",","start":185,"end":186,"id":30,"ws":true},{"text":"ifosfamide","start":187,"end":197,"id":31,"ws":true},{"text":",","start":198,"end":199,"id":32,"ws":true},{"text":"and","start":200,"end":203,"id":33,"ws":true},{"text":"adriamycin","start":204,"end":214,"id":34,"ws":true},{"text":")","start":215,"end":216,"id":35,"ws":true},{"text":"and","start":217,"end":220,"id":36,"ws":true},{"text":"a","start":221,"end":222,"id":37,"ws":true},{"text":"total","start":223,"end":228,"id":38,"ws":true},{"text":"number","start":229,"end":235,"id":39,"ws":true},{"text":"of","start":236,"end":238,"id":40,"ws":true},{"text":"four","start":239,"end":243,"id":41,"ws":true},{"text":"courses","start":244,"end":251,"id":42,"ws":true},{"text":",","start":252,"end":253,"id":43,"ws":true},{"text":"each","start":254,"end":258,"id":44,"ws":true},{"text":"lasting","start":259,"end":266,"id":45,"ws":true},{"text":"nine","start":267,"end":271,"id":46,"ws":true},{"text":"weeks","start":272,"end":277,"id":47,"ws":true},{"text":",","start":278,"end":279,"id":48,"ws":true},{"text":"was","start":280,"end":283,"id":49,"ws":true},{"text":"recommended","start":284,"end":295,"id":50,"ws":true},{"text":"by","start":296,"end":298,"id":51,"ws":true},{"text":"the","start":299,"end":302,"id":52,"ws":true},{"text":"protocol","start":303,"end":311,"id":53,"ws":true},{"text":".","start":312,"end":313,"id":54,"ws":false}],"spans":[{"start":81,"end":92,"token_start":13,"token_end":13,"label":"DRUG"},{"start":95,"end":106,"token_start":15,"token_end":15,"label":"DRUG"},{"start":111,"end":127,"token_start":18,"token_end":18,"label":"DRUG"},{"start":134,"end":144,"token_start":21,"token_end":21,"label":"DRUG"},{"start":157,"end":168,"token_start":26,"token_end":26,"label":"DRUG"},{"start":171,"end":182,"token_start":28,"token_end":28,"label":"DRUG"},{"start":187,"end":197,"token_start":31,"token_end":31,"label":"DRUG"},{"start":204,"end":214,"token_start":34,"token_end":34,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9788419/","_input_hash":261521970,"_task_hash":456606957,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":13,"child":15,"head_span":{"start":81,"end":92,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":95,"end":106,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":15,"child":18,"head_span":{"start":95,"end":106,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":111,"end":127,"token_start":18,"token_end":18,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":18,"child":21,"head_span":{"start":111,"end":127,"token_start":18,"token_end":18,"label":"DRUG"},"child_span":{"start":134,"end":144,"token_start":21,"token_end":21,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":26,"child":28,"head_span":{"start":157,"end":168,"token_start":26,"token_end":26,"label":"DRUG"},"child_span":{"start":171,"end":182,"token_start":28,"token_end":28,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"},{"head":28,"child":31,"head_span":{"start":171,"end":182,"token_start":28,"token_end":28,"label":"DRUG"},"child_span":{"start":187,"end":197,"token_start":31,"token_end":31,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"},{"head":31,"child":34,"head_span":{"start":187,"end":197,"token_start":31,"token_end":31,"label":"DRUG"},"child_span":{"start":204,"end":214,"token_start":34,"token_end":34,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"}],"radio":[],"answer":"accept"}
{"text":"Rationale , design , and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive , nonhypercholesterolemic subjects with microalbuminuria ( the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [ PREVEND IT ] ) .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Rationale</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>design</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>baseline</i></b> <b style='color:DodgerBlue;'><i>characteristics</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>prevention</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cardiovascular</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>renal</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>fosinopril</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>pravastatin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>nonhypertensive</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>nonhypercholesterolemic</i></b> <b style='color:DodgerBlue;'><i>subjects</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>microalbuminuria</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Prevention</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>REnal</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Vascular</i></b> <b style='color:DodgerBlue;'><i>ENdstage</i></b> <b style='color:DodgerBlue;'><i>Disease</i></b> <b style='color:DodgerBlue;'><i>Intervention</i></b> <b style='color:DodgerBlue;'><i>Trial</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>PREVEND</i></b> <b style='color:DodgerBlue;'><i>IT</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>This study describes the rationale, design, and baseline characteristics of a trial to determine whether treatment with <b style='color:Tomato;'><i>fosinopril</i></b> 20 mg/day and/or <b style='color:Tomato;'><i>pravastatin</i></b> 40 mg/ day will prevent cardiovascular and renal disease in nonhypertensive (RR <160/100 mm Hg and not using antihypertensive medication) and nonhypercholesterolemic (total cholesterol <8.0 or <5.0 mmol/L in case of previous myocardial infarction and not using lipid lowering medication) men and women with persistent microalbuminuria (urinary albumin excretion >10 mg/L once in an early morning spot urine and 15 to 300 mg/24-hour at least once in two 24-hour urine collections). The Prevention of REnal and Vascular ENdstage Disease Intervention Trial is a single-center, double-blind, randomized, placebo-controlled trial with a 2 x 2 factorial design. The 864 randomized subjects will be monitored for a minimum of 4 years and a maximum of 5 years. The primary efficacy parameter is defined as the combined incidence of all-cause mortality or hospital admission for documented (1) nonfatal myocardial infarction, (2) myocardial ischemia, (3) heart failure, (4) peripheral vascular disease, (5) cerebrovascular accident and/or (6) end-stage renal disease.","tokens":[{"text":"Rationale","start":0,"end":9,"id":0,"ws":true},{"text":",","start":10,"end":11,"id":1,"ws":true},{"text":"design","start":12,"end":18,"id":2,"ws":true},{"text":",","start":19,"end":20,"id":3,"ws":true},{"text":"and","start":21,"end":24,"id":4,"ws":true},{"text":"baseline","start":25,"end":33,"id":5,"ws":true},{"text":"characteristics","start":34,"end":49,"id":6,"ws":true},{"text":"of","start":50,"end":52,"id":7,"ws":true},{"text":"a","start":53,"end":54,"id":8,"ws":true},{"text":"trial","start":55,"end":60,"id":9,"ws":true},{"text":"of","start":61,"end":63,"id":10,"ws":true},{"text":"prevention","start":64,"end":74,"id":11,"ws":true},{"text":"of","start":75,"end":77,"id":12,"ws":true},{"text":"cardiovascular","start":78,"end":92,"id":13,"ws":true},{"text":"and","start":93,"end":96,"id":14,"ws":true},{"text":"renal","start":97,"end":102,"id":15,"ws":true},{"text":"disease","start":103,"end":110,"id":16,"ws":true},{"text":"with","start":111,"end":115,"id":17,"ws":true},{"text":"fosinopril","start":116,"end":126,"id":18,"ws":true},{"text":"and","start":127,"end":130,"id":19,"ws":true},{"text":"pravastatin","start":131,"end":142,"id":20,"ws":true},{"text":"in","start":143,"end":145,"id":21,"ws":true},{"text":"nonhypertensive","start":146,"end":161,"id":22,"ws":true},{"text":",","start":162,"end":163,"id":23,"ws":true},{"text":"nonhypercholesterolemic","start":164,"end":187,"id":24,"ws":true},{"text":"subjects","start":188,"end":196,"id":25,"ws":true},{"text":"with","start":197,"end":201,"id":26,"ws":true},{"text":"microalbuminuria","start":202,"end":218,"id":27,"ws":true},{"text":"(","start":219,"end":220,"id":28,"ws":true},{"text":"the","start":221,"end":224,"id":29,"ws":true},{"text":"Prevention","start":225,"end":235,"id":30,"ws":true},{"text":"of","start":236,"end":238,"id":31,"ws":true},{"text":"REnal","start":239,"end":244,"id":32,"ws":true},{"text":"and","start":245,"end":248,"id":33,"ws":true},{"text":"Vascular","start":249,"end":257,"id":34,"ws":true},{"text":"ENdstage","start":258,"end":266,"id":35,"ws":true},{"text":"Disease","start":267,"end":274,"id":36,"ws":true},{"text":"Intervention","start":275,"end":287,"id":37,"ws":true},{"text":"Trial","start":288,"end":293,"id":38,"ws":true},{"text":"[","start":294,"end":295,"id":39,"ws":true},{"text":"PREVEND","start":296,"end":303,"id":40,"ws":true},{"text":"IT","start":304,"end":306,"id":41,"ws":true},{"text":"]","start":307,"end":308,"id":42,"ws":true},{"text":")","start":309,"end":310,"id":43,"ws":true},{"text":".","start":311,"end":312,"id":44,"ws":false}],"spans":[{"start":116,"end":126,"token_start":18,"token_end":18,"label":"DRUG"},{"start":131,"end":142,"token_start":20,"token_end":20,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/10980214/","_input_hash":-1982290624,"_task_hash":1322187593,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"In the present study , rabbits prepared with chronic vascular cannulae were used to study the effects of nicotine administration on plasma corticosterone , catecholamine ( epinephrine , norepinephrine and dopamine ) and glucose responses to physical restraint stress .","paragraph":"<h3><u>Neuroendocrine responses to nicotine and stress: enhancement of peripheral stress responses by the administration of nicotine.</u></h3>Habitual smokers frequently report that when they are stressed smoking helps them to relax. One potential explanation for the reported stress ameliorating effect of smoking is that cigarette consumption (<b style='color:Tomato;'><i>nicotine</i></b> self-administration) may decrease the sympathetic autonomic nervous system activity which is associated with the stress response. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>rabbits</i></b> <b style='color:DodgerBlue;'><i>prepared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>chronic</i></b> <b style='color:DodgerBlue;'><i>vascular</i></b> <b style='color:DodgerBlue;'><i>cannulae</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>nicotine</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>plasma</i></b> <b style='color:DodgerBlue;'><i>corticosterone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>catecholamine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>epinephrine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>norepinephrine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>dopamine</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>glucose</i></b> <b style='color:DodgerBlue;'><i>responses</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>physical</i></b> <b style='color:DodgerBlue;'><i>restraint</i></b> <b style='color:DodgerBlue;'><i>stress</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>nicotine</i></b> (0.025, 0.05 or 0.10 mg <b style='color:Tomato;'><i>nicotine</i></b> base/kg body weight) was administered for 10 days prior to the \"stress test\" to allow for the development of habituation/tolerance to its acute toxic effects. Independent administration of <b style='color:Tomato;'><i>nicotine</i></b>, or the application of the physical restraint stressor, resulted in increases in the plasma concentrations of corticosterone, <b style='color:Tomato;'><i>epinephrine</i></b>, nor<b style='color:Tomato;'><i>epinephrine</i></b>, and glucose. <b style='color:Tomato;'><i>nicotine</i></b> administration during restraint stress enhanced the increase in plasma corticosterone and <b style='color:Tomato;'><i>epinephrine</i></b>, as compared to the responses induced by either factor alone. The results suggest that the stress ameliorating effect of continued cigarette smoking, as reported by habitual smokers, is not due to a reduction in the activity of the peripheral sympathetic autonomic nervous system.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"the","start":3,"end":6,"id":1,"ws":true},{"text":"present","start":7,"end":14,"id":2,"ws":true},{"text":"study","start":15,"end":20,"id":3,"ws":true},{"text":",","start":21,"end":22,"id":4,"ws":true},{"text":"rabbits","start":23,"end":30,"id":5,"ws":true},{"text":"prepared","start":31,"end":39,"id":6,"ws":true},{"text":"with","start":40,"end":44,"id":7,"ws":true},{"text":"chronic","start":45,"end":52,"id":8,"ws":true},{"text":"vascular","start":53,"end":61,"id":9,"ws":true},{"text":"cannulae","start":62,"end":70,"id":10,"ws":true},{"text":"were","start":71,"end":75,"id":11,"ws":true},{"text":"used","start":76,"end":80,"id":12,"ws":true},{"text":"to","start":81,"end":83,"id":13,"ws":true},{"text":"study","start":84,"end":89,"id":14,"ws":true},{"text":"the","start":90,"end":93,"id":15,"ws":true},{"text":"effects","start":94,"end":101,"id":16,"ws":true},{"text":"of","start":102,"end":104,"id":17,"ws":true},{"text":"nicotine","start":105,"end":113,"id":18,"ws":true},{"text":"administration","start":114,"end":128,"id":19,"ws":true},{"text":"on","start":129,"end":131,"id":20,"ws":true},{"text":"plasma","start":132,"end":138,"id":21,"ws":true},{"text":"corticosterone","start":139,"end":153,"id":22,"ws":true},{"text":",","start":154,"end":155,"id":23,"ws":true},{"text":"catecholamine","start":156,"end":169,"id":24,"ws":true},{"text":"(","start":170,"end":171,"id":25,"ws":true},{"text":"epinephrine","start":172,"end":183,"id":26,"ws":true},{"text":",","start":184,"end":185,"id":27,"ws":true},{"text":"norepinephrine","start":186,"end":200,"id":28,"ws":true},{"text":"and","start":201,"end":204,"id":29,"ws":true},{"text":"dopamine","start":205,"end":213,"id":30,"ws":true},{"text":")","start":214,"end":215,"id":31,"ws":true},{"text":"and","start":216,"end":219,"id":32,"ws":true},{"text":"glucose","start":220,"end":227,"id":33,"ws":true},{"text":"responses","start":228,"end":237,"id":34,"ws":true},{"text":"to","start":238,"end":240,"id":35,"ws":true},{"text":"physical","start":241,"end":249,"id":36,"ws":true},{"text":"restraint","start":250,"end":259,"id":37,"ws":true},{"text":"stress","start":260,"end":266,"id":38,"ws":true},{"text":".","start":267,"end":268,"id":39,"ws":false}],"spans":[{"start":105,"end":113,"token_start":18,"token_end":18,"label":"DRUG"},{"start":172,"end":183,"token_start":26,"token_end":26,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/2505296/","_input_hash":-1406796643,"_task_hash":386005025,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Phase III , randomized , double-blind , multicenter trial comparing orteronel ( TAK-700 ) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy : ELM-PC 5 .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Phase</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>double-blind</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>multicenter</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>comparing</i></b> <b style='color:DodgerBlue;'><i>orteronel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>TAK-700</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>placebo</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>castration-resistant</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>progressed</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>docetaxel-based</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>ELM-PC</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Orteronel (<b style='color:Tomato;'><i>tak-700</i></b>) is an investigational, nonsteroidal, reversible, selective 17,20-lyase inhibitor. This study examined orteronel in patients with metastatic castration-resistant prostate cancer that progressed after <b style='color:Tomato;'><i>docetaxel</i></b> therapy. ### Patients And Methods In our study, 1,099 men were randomly assigned in a 2:1 schedule to receive orteronel 400 mg plus <b style='color:Tomato;'><i>prednisone</i></b> 5 mg twice daily or placebo plus <b style='color:Tomato;'><i>prednisone</i></b> 5 mg twice daily, stratified by region (Europe, North America [NA], and non-Europe/NA) and Brief Pain Inventory-Short Form worst pain score. Primary end point was overall survival (OS). Key secondary end points (radiographic progression-free survival [rPFS], \u2265 50% decrease of prostate-specific antigen [PSA50], and pain response at 12 weeks) were to undergo statistical testing only if the primary end point analysis was significant. ### results The study was unblinded after crossing a prespecified OS futility boundary. The median OS was 17.0 months versus 15.2 months with orteronel-<b style='color:Tomato;'><i>prednisone</i></b> versus placebo-<b style='color:Tomato;'><i>prednisone</i></b> (hazard ratio [HR], 0.886; 95% CI, 0.739 to 1.062; P = .190). Improved rPFS was observed with orteronel-<b style='color:Tomato;'><i>prednisone</i></b> (median, 8.3 v 5.7 months; HR, 0.760; 95% CI, 0.653 to 0.885; P < .001). Orteronel-<b style='color:Tomato;'><i>prednisone</i></b> showed advantages over placebo-<b style='color:Tomato;'><i>prednisone</i></b> in PSA50 rate (25% v 10%, P < .001) and time to PSA progression (median, 5.5 v 2.9 months, P < .001) but not pain response rate (12% v 9%; P = .128). Adverse events (all grades) were generally more frequent with orteronel-<b style='color:Tomato;'><i>prednisone</i></b>, including nausea (42% v 26%), vomiting (36% v 17%), fatigue (29% v 23%), and increased amylase (14% v 2%). ### conclusion Our study did not meet the primary end point of OS. Longer rPFS and a higher PSA50 rate with orteronel-<b style='color:Tomato;'><i>prednisone</i></b> indicate antitumor activity.","tokens":[{"text":"Phase","start":0,"end":5,"id":0,"ws":true},{"text":"III","start":6,"end":9,"id":1,"ws":true},{"text":",","start":10,"end":11,"id":2,"ws":true},{"text":"randomized","start":12,"end":22,"id":3,"ws":true},{"text":",","start":23,"end":24,"id":4,"ws":true},{"text":"double-blind","start":25,"end":37,"id":5,"ws":true},{"text":",","start":38,"end":39,"id":6,"ws":true},{"text":"multicenter","start":40,"end":51,"id":7,"ws":true},{"text":"trial","start":52,"end":57,"id":8,"ws":true},{"text":"comparing","start":58,"end":67,"id":9,"ws":true},{"text":"orteronel","start":68,"end":77,"id":10,"ws":true},{"text":"(","start":78,"end":79,"id":11,"ws":true},{"text":"TAK-700","start":80,"end":87,"id":12,"ws":true},{"text":")","start":88,"end":89,"id":13,"ws":true},{"text":"plus","start":90,"end":94,"id":14,"ws":true},{"text":"prednisone","start":95,"end":105,"id":15,"ws":true},{"text":"with","start":106,"end":110,"id":16,"ws":true},{"text":"placebo","start":111,"end":118,"id":17,"ws":true},{"text":"plus","start":119,"end":123,"id":18,"ws":true},{"text":"prednisone","start":124,"end":134,"id":19,"ws":true},{"text":"in","start":135,"end":137,"id":20,"ws":true},{"text":"patients","start":138,"end":146,"id":21,"ws":true},{"text":"with","start":147,"end":151,"id":22,"ws":true},{"text":"metastatic","start":152,"end":162,"id":23,"ws":true},{"text":"castration-resistant","start":163,"end":183,"id":24,"ws":true},{"text":"prostate","start":184,"end":192,"id":25,"ws":true},{"text":"cancer","start":193,"end":199,"id":26,"ws":true},{"text":"that","start":200,"end":204,"id":27,"ws":true},{"text":"has","start":205,"end":208,"id":28,"ws":true},{"text":"progressed","start":209,"end":219,"id":29,"ws":true},{"text":"during","start":220,"end":226,"id":30,"ws":true},{"text":"or","start":227,"end":229,"id":31,"ws":true},{"text":"after","start":230,"end":235,"id":32,"ws":true},{"text":"docetaxel-based","start":236,"end":251,"id":33,"ws":true},{"text":"therapy","start":252,"end":259,"id":34,"ws":true},{"text":":","start":260,"end":261,"id":35,"ws":true},{"text":"ELM-PC","start":262,"end":268,"id":36,"ws":true},{"text":"5","start":269,"end":270,"id":37,"ws":true},{"text":".","start":271,"end":272,"id":38,"ws":false}],"spans":[{"start":80,"end":87,"token_start":12,"token_end":12,"label":"DRUG"},{"start":95,"end":105,"token_start":15,"token_end":15,"label":"DRUG"},{"start":124,"end":134,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25624429/","_input_hash":-1244978902,"_task_hash":632074452,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Five clinical trials with temozolomide or dacarbazine have been performed in metastatic colorectal cancer ( mCRC ) with selection based on methyl-specific PCR ( MSP ) testing with modest results .","paragraph":"<h3><u>Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in\u00a0metastatic colorectal cancer patients.</u></h3>O(6)-methylguanine-DNA-methyltransferase (MGMT) is a repair protein, and its deficiency makes tumours more susceptible to the cytotoxic effect of alkylating agents. <b style='color:DodgerBlue;'><i>Five</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>temozolomide</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>dacarbazine</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>performed</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>colorectal</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>mCRC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>selection</i></b> <b style='color:DodgerBlue;'><i>based</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>methyl-specific</i></b> <b style='color:DodgerBlue;'><i>PCR</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MSP</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>testing</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>modest</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We hypothesised that mitigated results are consequences of unspecific patient selection and that alternative methodologies for MGMT testing such as immunohistochemistry (IHC) and digital polymerase chain reaction (PCR) could enhance patient enrolment. ### Patients And Methods Formalin-fixed paraffin embedded archival tumour tissue samples from four phase II studies of <b style='color:Tomato;'><i>temozolomide</i></b> or <b style='color:Tomato;'><i>dacarbazine</i></b> in MGMT MSP-positive mCRCs were analysed by IHC for MGMT protein expression and by methyl-BEAMing (MB) for percentage of promoter methylation. Pooled data were then retrospectively analysed according to objective response rate, progression-free survival (PFS) and overall survival (OS). ### results One hundred and five patients were included in the study. Twelve had achieved partial response (PR) (11.4%), 24 stable disease (SD; 22.9%) and 69 progressive disease (PD; 65.7%). Patients with PR/SD had lower IHC scores and higher MB levels than those with PD. MGMT expression by IHC was negatively and MB levels positively associated with PFS (p\u00a0<\u00a00.001 and 0.004, respectively), but not with OS. By combining both assays, IHC low/MB high patients displayed an 87% reduction in the hazard of progression (p\u00a0<\u00a00.001) and a 77% in the hazard for death (p\u00a0=\u00a00.001). ### conclusion In mCRC selected for MGMT deficiency by MSP, IHC and MB testing improve clinical outcome to alkylating agents. Their combination could enhance patient selection in this setting.","tokens":[{"text":"Five","start":0,"end":4,"id":0,"ws":true},{"text":"clinical","start":5,"end":13,"id":1,"ws":true},{"text":"trials","start":14,"end":20,"id":2,"ws":true},{"text":"with","start":21,"end":25,"id":3,"ws":true},{"text":"temozolomide","start":26,"end":38,"id":4,"ws":true},{"text":"or","start":39,"end":41,"id":5,"ws":true},{"text":"dacarbazine","start":42,"end":53,"id":6,"ws":true},{"text":"have","start":54,"end":58,"id":7,"ws":true},{"text":"been","start":59,"end":63,"id":8,"ws":true},{"text":"performed","start":64,"end":73,"id":9,"ws":true},{"text":"in","start":74,"end":76,"id":10,"ws":true},{"text":"metastatic","start":77,"end":87,"id":11,"ws":true},{"text":"colorectal","start":88,"end":98,"id":12,"ws":true},{"text":"cancer","start":99,"end":105,"id":13,"ws":true},{"text":"(","start":106,"end":107,"id":14,"ws":true},{"text":"mCRC","start":108,"end":112,"id":15,"ws":true},{"text":")","start":113,"end":114,"id":16,"ws":true},{"text":"with","start":115,"end":119,"id":17,"ws":true},{"text":"selection","start":120,"end":129,"id":18,"ws":true},{"text":"based","start":130,"end":135,"id":19,"ws":true},{"text":"on","start":136,"end":138,"id":20,"ws":true},{"text":"methyl-specific","start":139,"end":154,"id":21,"ws":true},{"text":"PCR","start":155,"end":158,"id":22,"ws":true},{"text":"(","start":159,"end":160,"id":23,"ws":true},{"text":"MSP","start":161,"end":164,"id":24,"ws":true},{"text":")","start":165,"end":166,"id":25,"ws":true},{"text":"testing","start":167,"end":174,"id":26,"ws":true},{"text":"with","start":175,"end":179,"id":27,"ws":true},{"text":"modest","start":180,"end":186,"id":28,"ws":true},{"text":"results","start":187,"end":194,"id":29,"ws":true},{"text":".","start":195,"end":196,"id":30,"ws":false}],"spans":[{"start":26,"end":38,"token_start":4,"token_end":4,"label":"DRUG"},{"start":42,"end":53,"token_start":6,"token_end":6,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/27997874/","_input_hash":-261435108,"_task_hash":-743889492,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Heparin infusion , followed by oral warfarin , is indicated for symptomatic thromboembolic disease as well as for asymptomatic patients with substantial proximal deep venous thrombosis or large pulmonary emboli .","paragraph":"<h3><u>Therapy for postoperative thromboembolic disease:  indications and treatment.</u></h3>Postarthroplasty patients develop venous thromboembolic disease because of venous stasis, hypercoaguability, and vessel wall injury.  However, most venous thrombi are nonocclusive or small and elicit few symptoms; pulmonary emboli also tend to be asymptomatic.  Noninvasive techniques to detect deep vein thrombosis do not appear to be reliable in this population, so venography may be required.  Postoperative perfusion lung scans, with comparison to preoperative perfusion scans, are the best screen for asymptomatic pulmonary emboli. <b style='color:MediumOrchid;'><i>Heparin</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>warfarin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>indicated</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>symptomatic</i></b> <b style='color:DodgerBlue;'><i>thromboembolic</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>asymptomatic</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>substantial</i></b> <b style='color:DodgerBlue;'><i>proximal</i></b> <b style='color:DodgerBlue;'><i>deep</i></b> <b style='color:DodgerBlue;'><i>venous</i></b> <b style='color:DodgerBlue;'><i>thrombosis</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>large</i></b> <b style='color:DodgerBlue;'><i>pulmonary</i></b> <b style='color:DodgerBlue;'><i>emboli</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"Heparin","start":0,"end":7,"id":0,"ws":true},{"text":"infusion","start":8,"end":16,"id":1,"ws":true},{"text":",","start":17,"end":18,"id":2,"ws":true},{"text":"followed","start":19,"end":27,"id":3,"ws":true},{"text":"by","start":28,"end":30,"id":4,"ws":true},{"text":"oral","start":31,"end":35,"id":5,"ws":true},{"text":"warfarin","start":36,"end":44,"id":6,"ws":true},{"text":",","start":45,"end":46,"id":7,"ws":true},{"text":"is","start":47,"end":49,"id":8,"ws":true},{"text":"indicated","start":50,"end":59,"id":9,"ws":true},{"text":"for","start":60,"end":63,"id":10,"ws":true},{"text":"symptomatic","start":64,"end":75,"id":11,"ws":true},{"text":"thromboembolic","start":76,"end":90,"id":12,"ws":true},{"text":"disease","start":91,"end":98,"id":13,"ws":true},{"text":"as","start":99,"end":101,"id":14,"ws":true},{"text":"well","start":102,"end":106,"id":15,"ws":true},{"text":"as","start":107,"end":109,"id":16,"ws":true},{"text":"for","start":110,"end":113,"id":17,"ws":true},{"text":"asymptomatic","start":114,"end":126,"id":18,"ws":true},{"text":"patients","start":127,"end":135,"id":19,"ws":true},{"text":"with","start":136,"end":140,"id":20,"ws":true},{"text":"substantial","start":141,"end":152,"id":21,"ws":true},{"text":"proximal","start":153,"end":161,"id":22,"ws":true},{"text":"deep","start":162,"end":166,"id":23,"ws":true},{"text":"venous","start":167,"end":173,"id":24,"ws":true},{"text":"thrombosis","start":174,"end":184,"id":25,"ws":true},{"text":"or","start":185,"end":187,"id":26,"ws":true},{"text":"large","start":188,"end":193,"id":27,"ws":true},{"text":"pulmonary","start":194,"end":203,"id":28,"ws":true},{"text":"emboli","start":204,"end":210,"id":29,"ws":true},{"text":".","start":211,"end":212,"id":30,"ws":false}],"spans":[{"start":0,"end":7,"token_start":0,"token_end":0,"label":"DRUG"},{"start":36,"end":44,"token_start":6,"token_end":6,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/10147578/","_input_hash":630344348,"_task_hash":-1639191693,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":0,"child":6,"head_span":{"start":0,"end":7,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":36,"end":44,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Fluoxetine and paroxetine are potent inhibitors of CYP2D6 and administration of these SSRIs reduces the clinical benefit of an anticancer drug , such as tamoxifen , by decreasing the formation of active metabolites of this drug .","paragraph":"<h3><u>Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract.</u></h3>Different antidepressant drugs are currently used for the treatment of depression in cancer patients, such as second-generation antidepressants and, recently, the extracts of Hypericum perforatum. These agents are susceptible to metabolically-based drug interactions with anticancer drugs. The aim of the present article is to provide an updated review of clinically relevant metabolic drug interactions between selected anticancer drugs and antidepressants, focusing on selective serotonin reuptake inhibitors (SSRIs) and Hypericum extract. SSRIs can cause pharmacokinetic interactions through their in vitro ability to inhibit one or more cytochrome P450 isoenzymes (CYPs). SSRIs differ in their potential for metabolic drug interactions with anticancer drugs. <b style='color:MediumOrchid;'><i>Fluoxetine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>paroxetine</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>potent</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>CYP2D6</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>SSRIs</i></b> <b style='color:DodgerBlue;'><i>reduces</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>benefit</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>anticancer</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>decreasing</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>formation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>active</i></b> <b style='color:DodgerBlue;'><i>metabolites</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Women with breast cancer who receive <b style='color:Tomato;'><i>paroxetine</i></b> in combination with <b style='color:Tomato;'><i>tamoxifen</i></b> are at increased risk for death. Other SSRIs, including <b style='color:Tomato;'><i>citalopram</i></b>, es<b style='color:Tomato;'><i>citalopram</i></b>, are weak or negligible inhibitors of CYP2D6 and are less likely to interact with anticancer drugs, while <b style='color:Tomato;'><i>sertraline</i></b> causes significant inhibition of this isoform only at high doses. Hypericum extract, by inducing both the CYP3A4 and the P-glycoprotein (P-gp), can reduce the plasma concentrations of different antineoplastic agents such as <b style='color:Tomato;'><i>imatinib</i></b>, <b style='color:Tomato;'><i>irinotecan</i></b> and <b style='color:Tomato;'><i>docetaxel</i></b>, thus reducing the clinical efficacy of these drugs. Although these interactions are often predictable, the use of <b style='color:Tomato;'><i>fluoxetine</i></b>, <b style='color:Tomato;'><i>paroxetine</i></b> and Hypericum extract should be avoided in cancer patients.","tokens":[{"text":"Fluoxetine","start":0,"end":10,"id":0,"ws":true},{"text":"and","start":11,"end":14,"id":1,"ws":true},{"text":"paroxetine","start":15,"end":25,"id":2,"ws":true},{"text":"are","start":26,"end":29,"id":3,"ws":true},{"text":"potent","start":30,"end":36,"id":4,"ws":true},{"text":"inhibitors","start":37,"end":47,"id":5,"ws":true},{"text":"of","start":48,"end":50,"id":6,"ws":true},{"text":"CYP2D6","start":51,"end":57,"id":7,"ws":true},{"text":"and","start":58,"end":61,"id":8,"ws":true},{"text":"administration","start":62,"end":76,"id":9,"ws":true},{"text":"of","start":77,"end":79,"id":10,"ws":true},{"text":"these","start":80,"end":85,"id":11,"ws":true},{"text":"SSRIs","start":86,"end":91,"id":12,"ws":true},{"text":"reduces","start":92,"end":99,"id":13,"ws":true},{"text":"the","start":100,"end":103,"id":14,"ws":true},{"text":"clinical","start":104,"end":112,"id":15,"ws":true},{"text":"benefit","start":113,"end":120,"id":16,"ws":true},{"text":"of","start":121,"end":123,"id":17,"ws":true},{"text":"an","start":124,"end":126,"id":18,"ws":true},{"text":"anticancer","start":127,"end":137,"id":19,"ws":true},{"text":"drug","start":138,"end":142,"id":20,"ws":true},{"text":",","start":143,"end":144,"id":21,"ws":true},{"text":"such","start":145,"end":149,"id":22,"ws":true},{"text":"as","start":150,"end":152,"id":23,"ws":true},{"text":"tamoxifen","start":153,"end":162,"id":24,"ws":true},{"text":",","start":163,"end":164,"id":25,"ws":true},{"text":"by","start":165,"end":167,"id":26,"ws":true},{"text":"decreasing","start":168,"end":178,"id":27,"ws":true},{"text":"the","start":179,"end":182,"id":28,"ws":true},{"text":"formation","start":183,"end":192,"id":29,"ws":true},{"text":"of","start":193,"end":195,"id":30,"ws":true},{"text":"active","start":196,"end":202,"id":31,"ws":true},{"text":"metabolites","start":203,"end":214,"id":32,"ws":true},{"text":"of","start":215,"end":217,"id":33,"ws":true},{"text":"this","start":218,"end":222,"id":34,"ws":true},{"text":"drug","start":223,"end":227,"id":35,"ws":true},{"text":".","start":228,"end":229,"id":36,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":15,"end":25,"token_start":2,"token_end":2,"label":"DRUG"},{"start":153,"end":162,"token_start":24,"token_end":24,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/21395523/","_input_hash":-1272081112,"_task_hash":-110484064,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":2,"child":24,"head_span":{"start":15,"end":25,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":153,"end":162,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":0,"child":24,"head_span":{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":153,"end":162,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#ffdaf9","label":"NEG2"}],"radio":["NEG10","NEG20"],"answer":"accept"}
{"text":"Epirubicin is an anthracyclin , analogous to doxorubicin , with a different toxicologic pattern .","paragraph":"<h3><u>A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma.</u></h3>Few chemotherapeutic agents have demonstrated their efficacy in malignant mesothelioma. The <b style='color:Tomato;'><i>cisplatin</i></b> plus <b style='color:Tomato;'><i>doxorubicin</i></b> combination has one of the highest response rates. <b style='color:MediumOrchid;'><i>Epirubicin</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>anthracyclin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>analogous</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>different</i></b> <b style='color:DodgerBlue;'><i>toxicologic</i></b> <b style='color:DodgerBlue;'><i>pattern</i></b> <b style='color:DodgerBlue;'><i>.</i></b> As there are no data on the activity of the combination <b style='color:Tomato;'><i>cisplatin</i></b> plus <b style='color:Tomato;'><i>epirubicin</i></b> in malignant mesothelioma, the European Lung Cancer Working Party (ELCWP) designed a phase II study with response rate as primary objective. Sixty-nine eligible patients with malignant pleural mesothelioma were centrally registered. The majority of the patients were male (n=59), had a Karnofsky performance status of 80 or more (n=62) and presented with an epithelial histologic subtype (n=43). Median age was 62 years. In nine patients, metastases were documented at the initial work-up, mainly in bone, lung and skin. Three hundred and twenty-four cycles of chemotherapy were administered. The main toxicities were nausea and vomiting, neutropenia and alopecia. Among 63 assessable patients, response rate was 19.0% (95% confidence interval [CI] 9-29%). Median survival was 13.3 months. In multivariate analysis, poor prognostic factors for survival were neutrophil count and CALGB groups 4-6. In conclusion, <b style='color:Tomato;'><i>cisplatin</i></b> plus <b style='color:Tomato;'><i>epirubicin</i></b> appears as an effective regimen in malignant mesothelioma, with a favourable toxicity profile. However, it does not demonstrate superior activity to other active regimens in this disease.","tokens":[{"text":"Epirubicin","start":0,"end":10,"id":0,"ws":true},{"text":"is","start":11,"end":13,"id":1,"ws":true},{"text":"an","start":14,"end":16,"id":2,"ws":true},{"text":"anthracyclin","start":17,"end":29,"id":3,"ws":true},{"text":",","start":30,"end":31,"id":4,"ws":true},{"text":"analogous","start":32,"end":41,"id":5,"ws":true},{"text":"to","start":42,"end":44,"id":6,"ws":true},{"text":"doxorubicin","start":45,"end":56,"id":7,"ws":true},{"text":",","start":57,"end":58,"id":8,"ws":true},{"text":"with","start":59,"end":63,"id":9,"ws":true},{"text":"a","start":64,"end":65,"id":10,"ws":true},{"text":"different","start":66,"end":75,"id":11,"ws":true},{"text":"toxicologic","start":76,"end":87,"id":12,"ws":true},{"text":"pattern","start":88,"end":95,"id":13,"ws":true},{"text":".","start":96,"end":97,"id":14,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":45,"end":56,"token_start":7,"token_end":7,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16005104/","_input_hash":-1375944148,"_task_hash":-1600740243,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"A total of 460 patients were randomized into four 10-day therapeutic schemes ( 115 patients per group ): ( i ) standard OCA , omeprazole , clarithromycin and amoxicillin ; ( ii ) triple OLA , omeprazole , levofloxacin and amoxicillin ; ( iii ) sequential OACM , omeprazole plus amoxicillin for 5 days , followed by omeprazole plus clarithromycin plus metronidazole for 5 days ; and ( iv ) modified sequential OALM , using levofloxacin instead of clarithromycin .","paragraph":"<h3><u>Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication.</u></h3>Helicobacter pylori eradication rates with standard triple therapy have declined to unacceptable levels. ### aim To compare <b style='color:Tomato;'><i>clarithromycin</i></b> and <b style='color:Tomato;'><i>levofloxacin</i></b> in triple and sequential first-line regimens. ### methods <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>total</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>460</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>four</i></b> <b style='color:DodgerBlue;'><i>10-day</i></b> <b style='color:DodgerBlue;'><i>therapeutic</i></b> <b style='color:DodgerBlue;'><i>schemes</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>115</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>per</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>):</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>OCA</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>clarithromycin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>amoxicillin</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ii</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>triple</i></b> <b style='color:DodgerBlue;'><i>OLA</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>levofloxacin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>amoxicillin</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>iii</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>sequential</i></b> <b style='color:DodgerBlue;'><i>OACM</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>amoxicillin</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>clarithromycin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>metronidazole</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>iv</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>modified</i></b> <b style='color:DodgerBlue;'><i>sequential</i></b> <b style='color:DodgerBlue;'><i>OALM</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:MediumOrchid;'><i>levofloxacin</i></b> <b style='color:DodgerBlue;'><i>instead</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>clarithromycin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Eradication was confirmed by 13C-urea breath test. Adverse effects and compliance were assessed by a questionnaire. ### results Per protocol cure rates were: OCA (66%; 95% CI: 57-74%), OLA (82.6%; 75-89%), OACM (80.8%; 73-88%) and OALM (85.2%; 78-91%). Intention-to-treat cure rates were: OCA (64%; 55-73%), OLA (80.8%; 73-88%), OACM (76.5%; 69-85%) and OALM (82.5%; 75-89%). Eradication rates were lower with OCA than with all the other regimens (P < 0.05). No differences in compliance or adverse effects were demonstrated among treatments. ### conclusions <b style='color:Tomato;'><i>levofloxacin</i></b>-based and sequential therapy are superior to standard triple scheme as first-line regimens in a setting with high <b style='color:Tomato;'><i>clarithromycin</i></b> resistance. However, all of these therapies still have a 20% failure rate.","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"total","start":2,"end":7,"id":1,"ws":true},{"text":"of","start":8,"end":10,"id":2,"ws":true},{"text":"460","start":11,"end":14,"id":3,"ws":true},{"text":"patients","start":15,"end":23,"id":4,"ws":true},{"text":"were","start":24,"end":28,"id":5,"ws":true},{"text":"randomized","start":29,"end":39,"id":6,"ws":true},{"text":"into","start":40,"end":44,"id":7,"ws":true},{"text":"four","start":45,"end":49,"id":8,"ws":true},{"text":"10-day","start":50,"end":56,"id":9,"ws":true},{"text":"therapeutic","start":57,"end":68,"id":10,"ws":true},{"text":"schemes","start":69,"end":76,"id":11,"ws":true},{"text":"(","start":77,"end":78,"id":12,"ws":true},{"text":"115","start":79,"end":82,"id":13,"ws":true},{"text":"patients","start":83,"end":91,"id":14,"ws":true},{"text":"per","start":92,"end":95,"id":15,"ws":true},{"text":"group","start":96,"end":101,"id":16,"ws":true},{"text":"):","start":102,"end":104,"id":17,"ws":true},{"text":"(","start":105,"end":106,"id":18,"ws":true},{"text":"i","start":107,"end":108,"id":19,"ws":true},{"text":")","start":109,"end":110,"id":20,"ws":true},{"text":"standard","start":111,"end":119,"id":21,"ws":true},{"text":"OCA","start":120,"end":123,"id":22,"ws":true},{"text":",","start":124,"end":125,"id":23,"ws":true},{"text":"omeprazole","start":126,"end":136,"id":24,"ws":true},{"text":",","start":137,"end":138,"id":25,"ws":true},{"text":"clarithromycin","start":139,"end":153,"id":26,"ws":true},{"text":"and","start":154,"end":157,"id":27,"ws":true},{"text":"amoxicillin","start":158,"end":169,"id":28,"ws":true},{"text":";","start":170,"end":171,"id":29,"ws":true},{"text":"(","start":172,"end":173,"id":30,"ws":true},{"text":"ii","start":174,"end":176,"id":31,"ws":true},{"text":")","start":177,"end":178,"id":32,"ws":true},{"text":"triple","start":179,"end":185,"id":33,"ws":true},{"text":"OLA","start":186,"end":189,"id":34,"ws":true},{"text":",","start":190,"end":191,"id":35,"ws":true},{"text":"omeprazole","start":192,"end":202,"id":36,"ws":true},{"text":",","start":203,"end":204,"id":37,"ws":true},{"text":"levofloxacin","start":205,"end":217,"id":38,"ws":true},{"text":"and","start":218,"end":221,"id":39,"ws":true},{"text":"amoxicillin","start":222,"end":233,"id":40,"ws":true},{"text":";","start":234,"end":235,"id":41,"ws":true},{"text":"(","start":236,"end":237,"id":42,"ws":true},{"text":"iii","start":238,"end":241,"id":43,"ws":true},{"text":")","start":242,"end":243,"id":44,"ws":true},{"text":"sequential","start":244,"end":254,"id":45,"ws":true},{"text":"OACM","start":255,"end":259,"id":46,"ws":true},{"text":",","start":260,"end":261,"id":47,"ws":true},{"text":"omeprazole","start":262,"end":272,"id":48,"ws":true},{"text":"plus","start":273,"end":277,"id":49,"ws":true},{"text":"amoxicillin","start":278,"end":289,"id":50,"ws":true},{"text":"for","start":290,"end":293,"id":51,"ws":true},{"text":"5","start":294,"end":295,"id":52,"ws":true},{"text":"days","start":296,"end":300,"id":53,"ws":true},{"text":",","start":301,"end":302,"id":54,"ws":true},{"text":"followed","start":303,"end":311,"id":55,"ws":true},{"text":"by","start":312,"end":314,"id":56,"ws":true},{"text":"omeprazole","start":315,"end":325,"id":57,"ws":true},{"text":"plus","start":326,"end":330,"id":58,"ws":true},{"text":"clarithromycin","start":331,"end":345,"id":59,"ws":true},{"text":"plus","start":346,"end":350,"id":60,"ws":true},{"text":"metronidazole","start":351,"end":364,"id":61,"ws":true},{"text":"for","start":365,"end":368,"id":62,"ws":true},{"text":"5","start":369,"end":370,"id":63,"ws":true},{"text":"days","start":371,"end":375,"id":64,"ws":true},{"text":";","start":376,"end":377,"id":65,"ws":true},{"text":"and","start":378,"end":381,"id":66,"ws":true},{"text":"(","start":382,"end":383,"id":67,"ws":true},{"text":"iv","start":384,"end":386,"id":68,"ws":true},{"text":")","start":387,"end":388,"id":69,"ws":true},{"text":"modified","start":389,"end":397,"id":70,"ws":true},{"text":"sequential","start":398,"end":408,"id":71,"ws":true},{"text":"OALM","start":409,"end":413,"id":72,"ws":true},{"text":",","start":414,"end":415,"id":73,"ws":true},{"text":"using","start":416,"end":421,"id":74,"ws":true},{"text":"levofloxacin","start":422,"end":434,"id":75,"ws":true},{"text":"instead","start":435,"end":442,"id":76,"ws":true},{"text":"of","start":443,"end":445,"id":77,"ws":true},{"text":"clarithromycin","start":446,"end":460,"id":78,"ws":true},{"text":".","start":461,"end":462,"id":79,"ws":false}],"spans":[{"start":126,"end":136,"token_start":24,"token_end":24,"label":"DRUG"},{"start":139,"end":153,"token_start":26,"token_end":26,"label":"DRUG"},{"start":158,"end":169,"token_start":28,"token_end":28,"label":"DRUG"},{"start":192,"end":202,"token_start":36,"token_end":36,"label":"DRUG"},{"start":205,"end":217,"token_start":38,"token_end":38,"label":"DRUG"},{"start":222,"end":233,"token_start":40,"token_end":40,"label":"DRUG"},{"start":262,"end":272,"token_start":48,"token_end":48,"label":"DRUG"},{"start":278,"end":289,"token_start":50,"token_end":50,"label":"DRUG"},{"start":315,"end":325,"token_start":57,"token_end":57,"label":"DRUG"},{"start":331,"end":345,"token_start":59,"token_end":59,"label":"DRUG"},{"start":351,"end":364,"token_start":61,"token_end":61,"label":"DRUG"},{"start":422,"end":434,"token_start":75,"token_end":75,"label":"DRUG"},{"start":446,"end":460,"token_start":78,"token_end":78,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/20180787/","_input_hash":1528379475,"_task_hash":831950146,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":24,"child":26,"head_span":{"start":126,"end":136,"token_start":24,"token_end":24,"label":"DRUG"},"child_span":{"start":139,"end":153,"token_start":26,"token_end":26,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":26,"child":28,"head_span":{"start":139,"end":153,"token_start":26,"token_end":26,"label":"DRUG"},"child_span":{"start":158,"end":169,"token_start":28,"token_end":28,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":36,"child":38,"head_span":{"start":192,"end":202,"token_start":36,"token_end":36,"label":"DRUG"},"child_span":{"start":205,"end":217,"token_start":38,"token_end":38,"label":"DRUG"},"color":"#ffd882","label":"POS2"},{"head":38,"child":40,"head_span":{"start":205,"end":217,"token_start":38,"token_end":38,"label":"DRUG"},"child_span":{"start":222,"end":233,"token_start":40,"token_end":40,"label":"DRUG"},"color":"#ffd882","label":"POS2"},{"head":48,"child":50,"head_span":{"start":262,"end":272,"token_start":48,"token_end":48,"label":"DRUG"},"child_span":{"start":278,"end":289,"token_start":50,"token_end":50,"label":"DRUG"},"color":"#d9fbad","label":"POS3"},{"head":50,"child":59,"head_span":{"start":278,"end":289,"token_start":50,"token_end":50,"label":"DRUG"},"child_span":{"start":331,"end":345,"token_start":59,"token_end":59,"label":"DRUG"},"color":"#d9fbad","label":"POS3"},{"head":59,"child":61,"head_span":{"start":331,"end":345,"token_start":59,"token_end":59,"label":"DRUG"},"child_span":{"start":351,"end":364,"token_start":61,"token_end":61,"label":"DRUG"},"color":"#d9fbad","label":"POS3"}],"radio":["POS11","POS21","POS31"],"answer":"accept"}
{"text":"Captopril in combination with HYZ significantly reduced BP compared with controls but T replacement increased BP and coronary collagen deposition in spite of HYZ and captopril treatment .","paragraph":"<h3><u>Testosterone increases blood pressure and cardiovascular and renal pathology in spontaneously hypertensive rats.</u></h3>The objective of this paper was to test the hypothesis that testosterone (T) raises blood pressure (BP), which is associated with increased coronary adventitial collagen, whereas the hemodynamic force of BP increases the coronary media:lumen ratio. Five treatment groups of spontaneously hypertensive rat (SHR) were established (n = 8-10 per group): controls; <b style='color:Tomato;'><i>hydralazine</i></b> (HYZ); castration; castration + HYZ; and castration + HYZ + T + <b style='color:Tomato;'><i>captopril</i></b>. At 12 weeks of age, the castrate + HYZ group was divided so that the mean BP was the same in both groups (162 mmHg). Both groups continued to receive HYZ treatment; however one group received T implants. Also, at 12 weeks of age the castrate + HYZ + T + <b style='color:Tomato;'><i>captopril</i></b> group received T implants. BP in the HYZ group was reduced compared with controls (192 mmHg vs 218 mmHg, p < 0.01). Castration lowered BP to 170 mmHg (p < 0.01) compared with controls. However, T implants increased BP by 15 mmHg (p < 0.02) in the castrate + HYZ group and by 44 mmHg in the castrate + HYZ + <b style='color:Tomato;'><i>captopril</i></b> group (p < 0.01). <b style='color:MediumOrchid;'><i>Captopril</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>HYZ</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>reduced</i></b> <b style='color:DodgerBlue;'><i>BP</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>controls</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>T</i></b> <b style='color:DodgerBlue;'><i>replacement</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:DodgerBlue;'><i>BP</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>coronary</i></b> <b style='color:DodgerBlue;'><i>collagen</i></b> <b style='color:DodgerBlue;'><i>deposition</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>spite</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>HYZ</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>captopril</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"Captopril","start":0,"end":9,"id":0,"ws":true},{"text":"in","start":10,"end":12,"id":1,"ws":true},{"text":"combination","start":13,"end":24,"id":2,"ws":true},{"text":"with","start":25,"end":29,"id":3,"ws":true},{"text":"HYZ","start":30,"end":33,"id":4,"ws":true},{"text":"significantly","start":34,"end":47,"id":5,"ws":true},{"text":"reduced","start":48,"end":55,"id":6,"ws":true},{"text":"BP","start":56,"end":58,"id":7,"ws":true},{"text":"compared","start":59,"end":67,"id":8,"ws":true},{"text":"with","start":68,"end":72,"id":9,"ws":true},{"text":"controls","start":73,"end":81,"id":10,"ws":true},{"text":"but","start":82,"end":85,"id":11,"ws":true},{"text":"T","start":86,"end":87,"id":12,"ws":true},{"text":"replacement","start":88,"end":99,"id":13,"ws":true},{"text":"increased","start":100,"end":109,"id":14,"ws":true},{"text":"BP","start":110,"end":112,"id":15,"ws":true},{"text":"and","start":113,"end":116,"id":16,"ws":true},{"text":"coronary","start":117,"end":125,"id":17,"ws":true},{"text":"collagen","start":126,"end":134,"id":18,"ws":true},{"text":"deposition","start":135,"end":145,"id":19,"ws":true},{"text":"in","start":146,"end":148,"id":20,"ws":true},{"text":"spite","start":149,"end":154,"id":21,"ws":true},{"text":"of","start":155,"end":157,"id":22,"ws":true},{"text":"HYZ","start":158,"end":161,"id":23,"ws":true},{"text":"and","start":162,"end":165,"id":24,"ws":true},{"text":"captopril","start":166,"end":175,"id":25,"ws":true},{"text":"treatment","start":176,"end":185,"id":26,"ws":true},{"text":".","start":186,"end":187,"id":27,"ws":false}],"spans":[{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},{"start":30,"end":33,"token_start":4,"token_end":4,"label":"DRUG"},{"start":166,"end":175,"token_start":25,"token_end":25,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/11055476/","_input_hash":-1679930929,"_task_hash":983882790,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":0,"child":4,"head_span":{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":30,"end":33,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Targeted therapy was administered to match the P1K3CA , c-MET , and SPARC and COX2 aberrations with sirolimus+ crizotinib and abraxane+ celecoxib .","paragraph":"<h3><u>Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.</u></h3>Despite advances in molecular medicine over recent decades, there has been little advancement in the treatment of osteosarcoma. We performed comprehensive molecular profiling in two cases of metastatic and chemotherapy-refractory osteosarcoma to guide molecularly targeted therapy. ### Patients And Methods Hybridization capture of >300 cancer-related genes plus introns from 28 genes often rearranged or altered in cancer was applied to >50 ng of DNA extracted from tumor samples from two patients with recurrent, metastatic osteosarcoma. The DNA from each sample was sequenced to high, uniform coverage. Immunohistochemical probes and morphoproteomics analysis were performed, in addition to fluorescence in situ hybridization. All analyses were performed in CLIA-certified laboratories. Molecularly targeted therapy based on the resulting profiles was offered to the patients. Biomedical analytics were performed using QIAGEN's Ingenuity\u00ae Pathway Analysis. ### results In Patient #1, comprehensive next-generation exome sequencing showed MET amplification, PIK3CA mutation, CCNE1 amplification, and PTPRD mutation. Immunohistochemistry-based morphoproteomic analysis revealed c-Met expression [(p)-c-Met (Tyr1234/1235)] and activation of mTOR/AKT pathway [IGF-1R (Tyr1165/1166), p-mTOR [Ser2448], p-Akt (Ser473)] and expression of SPARC and COX2. <b style='color:DodgerBlue;'><i>Targeted</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>match</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>P1K3CA</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>c-MET</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>SPARC</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>COX2</i></b> <b style='color:DodgerBlue;'><i>aberrations</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>sirolimus+</i></b> <b style='color:MediumOrchid;'><i>crizotinib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>abraxane+</i></b> <b style='color:MediumOrchid;'><i>celecoxib</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In Patient #2, aberrations included NF2 loss in exons 2-16, PDGFR\u03b1 amplification, and TP53 mutation. This patient was enrolled on a clinical trial combining targeted agents tem<b style='color:Tomato;'><i>sirolimus</i></b>, <b style='color:Tomato;'><i>sorafenib</i></b> and <b style='color:Tomato;'><i>bevacizumab</i></b>, to match NF2, PDGFR\u03b1 and TP53 aberrations. Both the patients did not benefit from matched therapy. ### conclusions Relapsed osteosarcoma is characterized by complex signaling and drug resistance pathways. Comprehensive molecular profiling holds great promise for tailoring personalized therapies for cancer. Methods for such profiling are evolving and need to be refined to better assist clinicians in making treatment decisions based on the large amount of data that results from this type of testing. Further research in this area is warranted.","tokens":[{"text":"Targeted","start":0,"end":8,"id":0,"ws":true},{"text":"therapy","start":9,"end":16,"id":1,"ws":true},{"text":"was","start":17,"end":20,"id":2,"ws":true},{"text":"administered","start":21,"end":33,"id":3,"ws":true},{"text":"to","start":34,"end":36,"id":4,"ws":true},{"text":"match","start":37,"end":42,"id":5,"ws":true},{"text":"the","start":43,"end":46,"id":6,"ws":true},{"text":"P1K3CA","start":47,"end":53,"id":7,"ws":true},{"text":",","start":54,"end":55,"id":8,"ws":true},{"text":"c-MET","start":56,"end":61,"id":9,"ws":true},{"text":",","start":62,"end":63,"id":10,"ws":true},{"text":"and","start":64,"end":67,"id":11,"ws":true},{"text":"SPARC","start":68,"end":73,"id":12,"ws":true},{"text":"and","start":74,"end":77,"id":13,"ws":true},{"text":"COX2","start":78,"end":82,"id":14,"ws":true},{"text":"aberrations","start":83,"end":94,"id":15,"ws":true},{"text":"with","start":95,"end":99,"id":16,"ws":true},{"text":"sirolimus+","start":100,"end":110,"id":17,"ws":true},{"text":"crizotinib","start":111,"end":121,"id":18,"ws":true},{"text":"and","start":122,"end":125,"id":19,"ws":true},{"text":"abraxane+","start":126,"end":135,"id":20,"ws":true},{"text":"celecoxib","start":136,"end":145,"id":21,"ws":true},{"text":".","start":146,"end":147,"id":22,"ws":false}],"spans":[{"start":100,"end":110,"token_start":17,"token_end":17,"label":"DRUG"},{"start":111,"end":121,"token_start":18,"token_end":18,"label":"DRUG"},{"start":126,"end":135,"token_start":20,"token_end":20,"label":"DRUG"},{"start":136,"end":145,"token_start":21,"token_end":21,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26510912/","_input_hash":84312616,"_task_hash":1485475965,"_session_id":"drug_drug_pilot_split2c-dana_n","_view_id":"blocks","relations":[{"head":17,"child":18,"head_span":{"start":100,"end":110,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":111,"end":121,"token_start":18,"token_end":18,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":20,"child":21,"head_span":{"start":126,"end":135,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":136,"end":145,"token_start":21,"token_end":21,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"}],"radio":[],"answer":"accept"}
{"text":"Aspirin in antiinflammatory doses has been associated with gastrointestinal bleeding , and the bleeding potential of even 75 mg aspirin has been established .","paragraph":"<h3><u>Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events. A critical analysis.</u></h3>Low-dose <b style='color:Tomato;'><i>aspirin</i></b> has been recommended for primary and secondary prevention of myocardial infarction and for the maintenance of aortocoronary bypass patency. Doses as low as 75 mg/day significantly lessen the risk of stroke or death in patients who experience cerebrovascular and ischemic events. <b style='color:MediumOrchid;'><i>Aspirin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>antiinflammatory</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>gastrointestinal</i></b> <b style='color:DodgerBlue;'><i>bleeding</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>bleeding</i></b> <b style='color:DodgerBlue;'><i>potential</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>even</i></b> <b style='color:DodgerBlue;'><i>75</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:MediumOrchid;'><i>aspirin</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>established</i></b> <b style='color:DodgerBlue;'><i>.</i></b> I assessed the role of low-dose <b style='color:Tomato;'><i>aspirin</i></b> in gastrointestinal bleeding by combining the results of nine studies that dealt with the prevention of ischemic, thromboembolic, or cerebrovascular events. The combination of the results showed that the occurrence of bleeding was 1.5 times higher in patients treated with low-dose <b style='color:Tomato;'><i>aspirin</i></b> in doses of 75-325 mg/day as compared with placebo (odds ratio 1.52; 95% CI 1.32-1.75). The monthly probability of gastrointestinal bleeding per 1,000 patients treated with low-dose <b style='color:Tomato;'><i>aspirin</i></b> ranged between 0 and 2.1.","tokens":[{"text":"Aspirin","start":0,"end":7,"id":0,"ws":true},{"text":"in","start":8,"end":10,"id":1,"ws":true},{"text":"antiinflammatory","start":11,"end":27,"id":2,"ws":true},{"text":"doses","start":28,"end":33,"id":3,"ws":true},{"text":"has","start":34,"end":37,"id":4,"ws":true},{"text":"been","start":38,"end":42,"id":5,"ws":true},{"text":"associated","start":43,"end":53,"id":6,"ws":true},{"text":"with","start":54,"end":58,"id":7,"ws":true},{"text":"gastrointestinal","start":59,"end":75,"id":8,"ws":true},{"text":"bleeding","start":76,"end":84,"id":9,"ws":true},{"text":",","start":85,"end":86,"id":10,"ws":true},{"text":"and","start":87,"end":90,"id":11,"ws":true},{"text":"the","start":91,"end":94,"id":12,"ws":true},{"text":"bleeding","start":95,"end":103,"id":13,"ws":true},{"text":"potential","start":104,"end":113,"id":14,"ws":true},{"text":"of","start":114,"end":116,"id":15,"ws":true},{"text":"even","start":117,"end":121,"id":16,"ws":true},{"text":"75","start":122,"end":124,"id":17,"ws":true},{"text":"mg","start":125,"end":127,"id":18,"ws":true},{"text":"aspirin","start":128,"end":135,"id":19,"ws":true},{"text":"has","start":136,"end":139,"id":20,"ws":true},{"text":"been","start":140,"end":144,"id":21,"ws":true},{"text":"established","start":145,"end":156,"id":22,"ws":true},{"text":".","start":157,"end":158,"id":23,"ws":false}],"spans":[{"start":0,"end":7,"token_start":0,"token_end":0,"label":"DRUG"},{"start":128,"end":135,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/7560825/","_input_hash":-1674945343,"_task_hash":1558867634,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"EURAMOS-1 results do not support the addition of ifosfamide and etoposide to postoperative chemotherapy in patients with poorly responding osteosarcoma because its administration was associated with increased toxicity without improving event-free survival .","paragraph":"<h3><u>Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.</u></h3>We designed the EURAMOS-1 trial to investigate whether intensified postoperative chemotherapy for patients whose tumour showed a poor response to preoperative chemotherapy (\u226510% viable tumour) improved event-free survival in patients with high-grade osteosarcoma. ### methods EURAMOS-1 was an open-label, international, phase 3 randomised, controlled trial. Consenting patients with newly diagnosed, resectable, high-grade osteosarcoma aged 40 years or younger were eligible for randomisation. Patients were randomly assigned (1:1) to receive either postoperative <b style='color:Tomato;'><i>cisplatin</i></b>, <b style='color:Tomato;'><i>doxorubicin</i></b>, and <b style='color:Tomato;'><i>methotrexate</i></b> (MAP) or MAP plus <b style='color:Tomato;'><i>ifosfamide</i></b> and <b style='color:Tomato;'><i>etoposide</i></b> (MAPIE) using concealed permuted blocks with three stratification factors: trial group; location of tumour (proximal femur or proximal humerus vs other limb vs axial skeleton); and presence of metastases (no vs yes or possible). The MAP regimen consisted of <b style='color:Tomato;'><i>cisplatin</i></b> 120 mg/m ### findings Between April 14, 2005, and June 30, 2011, 2260 patients were registered from 325 sites in 17 countries. 618 patients with poor response were randomly assigned; 310 to receive MAP and 308 to receive MAPIE. Median follow-up was 62\u00b71 months (IQR 46\u00b76-76\u00b76); 62\u00b73 months (IQR 46\u00b79-77\u00b71) for the MAP group and 61\u00b71 months (IQR 46\u00b75-75\u00b73) for the MAPIE group. 307 event-free survival events were reported (153 in the MAP group vs 154 in the MAPIE group). 193 deaths were reported (101 in the MAP group vs 92 in the MAPIE group). Event-free survival did not differ between treatment groups (hazard ratio [HR] 0\u00b798 [95% CI 0\u00b778-1\u00b723]); hazards were non-proportional (p=0\u00b70003). The most common grade 3-4 adverse events were neutropenia (268 [89%] patients in MAP vs 268 [90%] in MAPIE), thrombocytopenia (231 [78% in MAP vs 248 [83%] in MAPIE), and febrile neutropenia without documented infection (149 [50%] in MAP vs 217 [73%] in MAPIE). MAPIE was associated with more frequent grade 4 non-haematological toxicity than MAP (35 [12%] of 301 in the MAP group vs 71 [24%] of 298 in the MAPIE group). Two patients died during postoperative therapy, one from infection (although their absolute neutrophil count was normal), which was definitely related to their MAP treatment (specifically <b style='color:Tomato;'><i>doxorubicin</i></b> and <b style='color:Tomato;'><i>cisplatin</i></b>), and one from left ventricular systolic dysfunction, which was probably related to MAPIE treatment (specifically <b style='color:Tomato;'><i>doxorubicin</i></b>). One suspected unexpected serious adverse reaction was reported in the MAP group: bone marrow infarction due to <b style='color:Tomato;'><i>methotrexate</i></b>. ### interpretation <b style='color:DodgerBlue;'><i>EURAMOS-1</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>do</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>support</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>postoperative</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>poorly</i></b> <b style='color:DodgerBlue;'><i>responding</i></b> <b style='color:DodgerBlue;'><i>osteosarcoma</i></b> <b style='color:DodgerBlue;'><i>because</i></b> <b style='color:DodgerBlue;'><i>its</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:DodgerBlue;'><i>toxicity</i></b> <b style='color:DodgerBlue;'><i>without</i></b> <b style='color:DodgerBlue;'><i>improving</i></b> <b style='color:DodgerBlue;'><i>event-free</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The results define standard of care for this population. New strategies are required to improve outcomes in this setting. ### funding UK Medical Research Council, National Cancer Institute, European Science Foundation, St Anna Kinderkrebsforschung, Fonds National de la Recherche Scientifique, Fonds voor Wetenschappelijk Onderzoek-Vlaanderen, Parents Organization, Danish Medical Research Council, Academy of Finland, Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe, Federal Ministry of Education and Research, Semmelweis Foundation, ZonMw (Council for Medical Research), Research Council of Norway, Scandinavian Sarcoma Group, Swiss Paediatric Oncology Group, Cancer Research UK, National Institute for Health Research, University College London Hospitals, and Biomedical Research Centre.","tokens":[{"text":"EURAMOS-1","start":0,"end":9,"id":0,"ws":true},{"text":"results","start":10,"end":17,"id":1,"ws":true},{"text":"do","start":18,"end":20,"id":2,"ws":true},{"text":"not","start":21,"end":24,"id":3,"ws":true},{"text":"support","start":25,"end":32,"id":4,"ws":true},{"text":"the","start":33,"end":36,"id":5,"ws":true},{"text":"addition","start":37,"end":45,"id":6,"ws":true},{"text":"of","start":46,"end":48,"id":7,"ws":true},{"text":"ifosfamide","start":49,"end":59,"id":8,"ws":true},{"text":"and","start":60,"end":63,"id":9,"ws":true},{"text":"etoposide","start":64,"end":73,"id":10,"ws":true},{"text":"to","start":74,"end":76,"id":11,"ws":true},{"text":"postoperative","start":77,"end":90,"id":12,"ws":true},{"text":"chemotherapy","start":91,"end":103,"id":13,"ws":true},{"text":"in","start":104,"end":106,"id":14,"ws":true},{"text":"patients","start":107,"end":115,"id":15,"ws":true},{"text":"with","start":116,"end":120,"id":16,"ws":true},{"text":"poorly","start":121,"end":127,"id":17,"ws":true},{"text":"responding","start":128,"end":138,"id":18,"ws":true},{"text":"osteosarcoma","start":139,"end":151,"id":19,"ws":true},{"text":"because","start":152,"end":159,"id":20,"ws":true},{"text":"its","start":160,"end":163,"id":21,"ws":true},{"text":"administration","start":164,"end":178,"id":22,"ws":true},{"text":"was","start":179,"end":182,"id":23,"ws":true},{"text":"associated","start":183,"end":193,"id":24,"ws":true},{"text":"with","start":194,"end":198,"id":25,"ws":true},{"text":"increased","start":199,"end":208,"id":26,"ws":true},{"text":"toxicity","start":209,"end":217,"id":27,"ws":true},{"text":"without","start":218,"end":225,"id":28,"ws":true},{"text":"improving","start":226,"end":235,"id":29,"ws":true},{"text":"event-free","start":236,"end":246,"id":30,"ws":true},{"text":"survival","start":247,"end":255,"id":31,"ws":true},{"text":".","start":256,"end":257,"id":32,"ws":false}],"spans":[{"start":49,"end":59,"token_start":8,"token_end":8,"label":"DRUG"},{"start":64,"end":73,"token_start":10,"token_end":10,"label":"DRUG"},{"start":77,"end":103,"token_start":12,"token_end":13,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/27569442/","_input_hash":1532611365,"_task_hash":-785120694,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":10,"child":13,"head_span":{"start":64,"end":73,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":77,"end":103,"token_start":12,"token_end":13,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":8,"child":13,"head_span":{"start":49,"end":59,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":77,"end":103,"token_start":12,"token_end":13,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG10"],"answer":"accept"}
{"text":"The focus of this study is to investigate , whether altered expression levels of potentially relevant microRNAs ( miRs ) in serum are associated with response to trastuzumab or lapatinib .","paragraph":"<h3><u>Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.</u></h3><b style='color:Tomato;'><i>trastuzumab</i></b> and <b style='color:Tomato;'><i>lapatinib</i></b> are established treatments for patients with HER2 (human epidermal growth factor receptor 2)-positive breast cancer with different mechanisms of action. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>focus</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>investigate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>whether</i></b> <b style='color:DodgerBlue;'><i>altered</i></b> <b style='color:DodgerBlue;'><i>expression</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>potentially</i></b> <b style='color:DodgerBlue;'><i>relevant</i></b> <b style='color:DodgerBlue;'><i>microRNAs</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>miRs</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>lapatinib</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Circulating miR-21, miR-210, and miR-373 were quantified with TaqMan MicroRNA assays in serum of 127 HER2-postive breast cancer patients before and after neoadjuvant therapy and in 19 healthy controls. Patients received chemotherapy combined with either <b style='color:Tomato;'><i>trastuzumab</i></b> or <b style='color:Tomato;'><i>lapatinib</i></b> within the prospectively randomized Geparquinto trial. The association between miR levels and pathological response (pCR) to therapy and type of therapy was examined. Serum levels of miR-21 (p\u00a0=\u00a05.04e-08, p\u00a0=\u00a01.43e-10), miR-210 (p\u00a0=\u00a00.00151, p\u00a0=\u00a01.6e-05), and miR-373 (p\u00a0=\u00a07.87e-06, p\u00a0=\u00a01.75e-07) were significantly higher in patients before and after chemotherapy than in healthy women. Concentrations of miR-21 (p\u00a0=\u00a05.73e-08), miR-210 (p\u00a0=\u00a00.000724), and miR-373 (p\u00a0=\u00a00.00209) increased further after chemotherapy. A significant association of higher serum levels of miR-373 with advanced clinical tumor stage could be detected (p\u00a0<\u00a00.002). An association of miR-21 levels before (p\u00a0=\u00a00.0091) and after (p\u00a0=\u00a00.037) chemotherapy with overall survival of the patients could be detected, independent of type of anti-HER2 therapy. No association of circulating miRs with pCR was found. Our findings demonstrate a specific influence of neoadjuvant therapy on the serum levels of miR-21, miR-210, and miR-373 in breast cancer patients together with a prognostic value of miR-21.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"focus","start":4,"end":9,"id":1,"ws":true},{"text":"of","start":10,"end":12,"id":2,"ws":true},{"text":"this","start":13,"end":17,"id":3,"ws":true},{"text":"study","start":18,"end":23,"id":4,"ws":true},{"text":"is","start":24,"end":26,"id":5,"ws":true},{"text":"to","start":27,"end":29,"id":6,"ws":true},{"text":"investigate","start":30,"end":41,"id":7,"ws":true},{"text":",","start":42,"end":43,"id":8,"ws":true},{"text":"whether","start":44,"end":51,"id":9,"ws":true},{"text":"altered","start":52,"end":59,"id":10,"ws":true},{"text":"expression","start":60,"end":70,"id":11,"ws":true},{"text":"levels","start":71,"end":77,"id":12,"ws":true},{"text":"of","start":78,"end":80,"id":13,"ws":true},{"text":"potentially","start":81,"end":92,"id":14,"ws":true},{"text":"relevant","start":93,"end":101,"id":15,"ws":true},{"text":"microRNAs","start":102,"end":111,"id":16,"ws":true},{"text":"(","start":112,"end":113,"id":17,"ws":true},{"text":"miRs","start":114,"end":118,"id":18,"ws":true},{"text":")","start":119,"end":120,"id":19,"ws":true},{"text":"in","start":121,"end":123,"id":20,"ws":true},{"text":"serum","start":124,"end":129,"id":21,"ws":true},{"text":"are","start":130,"end":133,"id":22,"ws":true},{"text":"associated","start":134,"end":144,"id":23,"ws":true},{"text":"with","start":145,"end":149,"id":24,"ws":true},{"text":"response","start":150,"end":158,"id":25,"ws":true},{"text":"to","start":159,"end":161,"id":26,"ws":true},{"text":"trastuzumab","start":162,"end":173,"id":27,"ws":true},{"text":"or","start":174,"end":176,"id":28,"ws":true},{"text":"lapatinib","start":177,"end":186,"id":29,"ws":true},{"text":".","start":187,"end":188,"id":30,"ws":false}],"spans":[{"start":162,"end":173,"token_start":27,"token_end":27,"label":"DRUG"},{"start":177,"end":186,"token_start":29,"token_end":29,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25086636/","_input_hash":1312052038,"_task_hash":391736444,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"These results suggest that the addition of intravenous ceftriaxone during the first 3 days of hospitalization does not improve the cost-efficacy of oral norfloxacin in the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding and high risk of infection .","paragraph":"<h3><u>Parenteral antibiotic prophylaxis of bacterial infections does not improve cost-efficacy of oral norfloxacin in cirrhotic patients with gastrointestinal bleeding.</u></h3>Selective intestinal decontamination with <b style='color:Tomato;'><i>norfloxacin</i></b> is useful in the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding. However, bleeding cirrhotic patients with ascites, encephalopathy, or shock are at high risk to develop bacterial infections in spite of prophylactic <b style='color:Tomato;'><i>norfloxacin</i></b>. The aim of this study was to assess whether the addition of intravenous <b style='color:Tomato;'><i>ceftriaxone</i></b> could improve the efficacy of prophylaxis with <b style='color:Tomato;'><i>norfloxacin</i></b> in these patients. ### methods Fifty-six cirrhotic patients with gastrointestinal hemorrhage and ascites, encephalopathy, or shock were randomized into two groups: Group 1 (n = 28) received oral <b style='color:Tomato;'><i>norfloxacin</i></b> 400 mg/12 h for 7 days, and group 2 (n = 28) received <b style='color:Tomato;'><i>norfloxacin</i></b> plus intravenous <b style='color:Tomato;'><i>ceftriaxone</i></b> 2 g daily during the first 3 days of admission. ### results Ten patients were excluded because of community-acquired infection, surgery, or death within the first 24 h. The incidence of bacterial infections during hospitalization was 18.1% in group 1 and 12.5% in group 2 (p = NS). The incidence of severe infections (spontaneous bacterial peritonitis, bacteremia, or pneumonia) was also similar in both groups: 9% in group 1 versus 8.3% in group 2 (p = NS). There were no statistical differences between the two groups with respect to duration of hospitalization or mortality. The cost of antibiotic therapy (including prophylaxis and treatment of infections) was significantly higher in group 2. ### conclusion <b style='color:DodgerBlue;'><i>These</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>suggest</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:MediumOrchid;'><i>ceftriaxone</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>hospitalization</i></b> <b style='color:DodgerBlue;'><i>does</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>improve</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>cost-efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>norfloxacin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>prevention</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>bacterial</i></b> <b style='color:DodgerBlue;'><i>infections</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>cirrhotic</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>gastrointestinal</i></b> <b style='color:DodgerBlue;'><i>bleeding</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>high</i></b> <b style='color:DodgerBlue;'><i>risk</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>infection</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"These","start":0,"end":5,"id":0,"ws":true},{"text":"results","start":6,"end":13,"id":1,"ws":true},{"text":"suggest","start":14,"end":21,"id":2,"ws":true},{"text":"that","start":22,"end":26,"id":3,"ws":true},{"text":"the","start":27,"end":30,"id":4,"ws":true},{"text":"addition","start":31,"end":39,"id":5,"ws":true},{"text":"of","start":40,"end":42,"id":6,"ws":true},{"text":"intravenous","start":43,"end":54,"id":7,"ws":true},{"text":"ceftriaxone","start":55,"end":66,"id":8,"ws":true},{"text":"during","start":67,"end":73,"id":9,"ws":true},{"text":"the","start":74,"end":77,"id":10,"ws":true},{"text":"first","start":78,"end":83,"id":11,"ws":true},{"text":"3","start":84,"end":85,"id":12,"ws":true},{"text":"days","start":86,"end":90,"id":13,"ws":true},{"text":"of","start":91,"end":93,"id":14,"ws":true},{"text":"hospitalization","start":94,"end":109,"id":15,"ws":true},{"text":"does","start":110,"end":114,"id":16,"ws":true},{"text":"not","start":115,"end":118,"id":17,"ws":true},{"text":"improve","start":119,"end":126,"id":18,"ws":true},{"text":"the","start":127,"end":130,"id":19,"ws":true},{"text":"cost-efficacy","start":131,"end":144,"id":20,"ws":true},{"text":"of","start":145,"end":147,"id":21,"ws":true},{"text":"oral","start":148,"end":152,"id":22,"ws":true},{"text":"norfloxacin","start":153,"end":164,"id":23,"ws":true},{"text":"in","start":165,"end":167,"id":24,"ws":true},{"text":"the","start":168,"end":171,"id":25,"ws":true},{"text":"prevention","start":172,"end":182,"id":26,"ws":true},{"text":"of","start":183,"end":185,"id":27,"ws":true},{"text":"bacterial","start":186,"end":195,"id":28,"ws":true},{"text":"infections","start":196,"end":206,"id":29,"ws":true},{"text":"in","start":207,"end":209,"id":30,"ws":true},{"text":"cirrhotic","start":210,"end":219,"id":31,"ws":true},{"text":"patients","start":220,"end":228,"id":32,"ws":true},{"text":"with","start":229,"end":233,"id":33,"ws":true},{"text":"gastrointestinal","start":234,"end":250,"id":34,"ws":true},{"text":"bleeding","start":251,"end":259,"id":35,"ws":true},{"text":"and","start":260,"end":263,"id":36,"ws":true},{"text":"high","start":264,"end":268,"id":37,"ws":true},{"text":"risk","start":269,"end":273,"id":38,"ws":true},{"text":"of","start":274,"end":276,"id":39,"ws":true},{"text":"infection","start":277,"end":286,"id":40,"ws":true},{"text":".","start":287,"end":288,"id":41,"ws":false}],"spans":[{"start":55,"end":66,"token_start":8,"token_end":8,"label":"DRUG"},{"start":153,"end":164,"token_start":23,"token_end":23,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9860409/","_input_hash":-1538837134,"_task_hash":-782081798,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":8,"child":23,"head_span":{"start":55,"end":66,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":153,"end":164,"token_start":23,"token_end":23,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG10"],"answer":"accept"}
{"text":"However , clindamycin possesses only one of the two mechanisms of lincomycin action , which is bacteriostatic , against Escherichia coli .","paragraph":"<h3><u>Microbial kinetics of drug action against gram-positive and gram-negative organisms. III: Effect of lincomycin and clindamycin combinations on Staphylococcus aureus and Escherichia coli.</u></h3>The functional dependencies of apparent first-order generation rate constants kapp, of drug-affected cultures on drug concentrations indicate that <b style='color:Tomato;'><i>lincomycin</i></b> and <b style='color:Tomato;'><i>clindamycin</i></b> possess the same mechanism of action, which is bacteriostatic, against Staphylococcus aureus. <b style='color:Tomato;'><i>clindamycin</i></b> also possesses another mechanism of action, which is bactericidal, at high concentration levels. <b style='color:DodgerBlue;'><i>However</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>clindamycin</i></b> <b style='color:DodgerBlue;'><i>possesses</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>one</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>mechanisms</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>lincomycin</i></b> <b style='color:DodgerBlue;'><i>action</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>bacteriostatic</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>Escherichia</i></b> <b style='color:DodgerBlue;'><i>coli</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The relative potency of action of a <b style='color:Tomato;'><i>clindamycin</i></b>-<b style='color:Tomato;'><i>lincomycin</i></b> combination against Staph. aureus is variable, and the effective ratio ranges between 5:1 and 9:1; the effective ratio against E. coli is fixed at 6:1 over a wide concentration range. This difference is attributed to differences in bioavailability and/or binding characteristics of the drugs for bioreceptors, as a consequence of structural modifications in the drug molecules, and to differences in modes of action in the respective organisms. Mixtures containing equipotent fractions of <b style='color:Tomato;'><i>clindamycin</i></b> and <b style='color:Tomato;'><i>lincomycin</i></b> show \"equivalence\" or \"indifference\" of effects on Staph. aureus. The combined action of the mixtures can be quantitatively predicted from the separate dose-response curves of either component drug alone. Therefore, it is concluded that <b style='color:Tomato;'><i>clindamycin</i></b> and <b style='color:Tomato;'><i>lincomycin</i></b> may bind to the same receptor site that is engaged in microbial protein synthesis to inhibit the generation of Staph. aureus. However, combinations of <b style='color:Tomato;'><i>clindamycin</i></b> and <b style='color:Tomato;'><i>lincomycin</i></b> are less active than the a priori equipotent concentration of either drug alone in their action against E. coli, demonstrating unequivocally an antagonism of effects. Furthermore, the degree of antagonism is dependent on the order of addition of the drugs, which is attributed to the possibility that <b style='color:Tomato;'><i>clindamycin</i></b> and <b style='color:Tomato;'><i>lincomycin</i></b> bind differently on active and allosteric loci of the same receptor site functionally engaged in protein synthesis in E. coli. A rational approach to the quantification and prediction of combined antibiotic action must, therefore, be based not only on the kinetics and mechanisms of action as well as on the dose-response relationship over a wide concentration range for the separate antibiotics but also on the strain and species of the test organism.","tokens":[{"text":"However","start":0,"end":7,"id":0,"ws":true},{"text":",","start":8,"end":9,"id":1,"ws":true},{"text":"clindamycin","start":10,"end":21,"id":2,"ws":true},{"text":"possesses","start":22,"end":31,"id":3,"ws":true},{"text":"only","start":32,"end":36,"id":4,"ws":true},{"text":"one","start":37,"end":40,"id":5,"ws":true},{"text":"of","start":41,"end":43,"id":6,"ws":true},{"text":"the","start":44,"end":47,"id":7,"ws":true},{"text":"two","start":48,"end":51,"id":8,"ws":true},{"text":"mechanisms","start":52,"end":62,"id":9,"ws":true},{"text":"of","start":63,"end":65,"id":10,"ws":true},{"text":"lincomycin","start":66,"end":76,"id":11,"ws":true},{"text":"action","start":77,"end":83,"id":12,"ws":true},{"text":",","start":84,"end":85,"id":13,"ws":true},{"text":"which","start":86,"end":91,"id":14,"ws":true},{"text":"is","start":92,"end":94,"id":15,"ws":true},{"text":"bacteriostatic","start":95,"end":109,"id":16,"ws":true},{"text":",","start":110,"end":111,"id":17,"ws":true},{"text":"against","start":112,"end":119,"id":18,"ws":true},{"text":"Escherichia","start":120,"end":131,"id":19,"ws":true},{"text":"coli","start":132,"end":136,"id":20,"ws":true},{"text":".","start":137,"end":138,"id":21,"ws":false}],"spans":[{"start":10,"end":21,"token_start":2,"token_end":2,"label":"DRUG"},{"start":66,"end":76,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/1102659/","_input_hash":1108803543,"_task_hash":557502043,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"We conducted a multicenter , retrospective study to evaluate the efficacy and safety of combination nivolumab plus ipilimumab ( NIVO+IPI ) in 35 patients with advanced or metastatic renal cell carcinoma ( mRCC ) .","paragraph":"<h3><u>Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study.</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>multicenter</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>retrospective</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:MediumOrchid;'><i>nivolumab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>ipilimumab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>NIVO+IPI</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>35</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>renal</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>mRCC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In this study, we focused on patients who received NIVO+IPI and were stratified into intermediate- or poor-risk disease according to the International Metastatic Renal Cell Carcinoma Database Consortium model at five institutions in Japan. The primary endpoint was overall survival (OS). Secondary endpoints were disease control rate (DCR), best overall response (BOR), objective response rate (ORR), and progression-free survival (PFS). In addition, we evaluated the role of inflammatory cell ratios, namely neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), as predictive biomarkers in patients with mRCC. The median follow-up period was 1 year, and the 1-year OS rate was 95.8%. The ORR and DCR were 34.3% and 80.0%, respectively. According to BOR, four patients (11.4%) achieved complete response. According to NLR stratification, the 1-year PFS rates were 82.6% and 23.7% when the NLR was \u22644.6 and >4.6, respectively (","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"conducted","start":3,"end":12,"id":1,"ws":true},{"text":"a","start":13,"end":14,"id":2,"ws":true},{"text":"multicenter","start":15,"end":26,"id":3,"ws":true},{"text":",","start":27,"end":28,"id":4,"ws":true},{"text":"retrospective","start":29,"end":42,"id":5,"ws":true},{"text":"study","start":43,"end":48,"id":6,"ws":true},{"text":"to","start":49,"end":51,"id":7,"ws":true},{"text":"evaluate","start":52,"end":60,"id":8,"ws":true},{"text":"the","start":61,"end":64,"id":9,"ws":true},{"text":"efficacy","start":65,"end":73,"id":10,"ws":true},{"text":"and","start":74,"end":77,"id":11,"ws":true},{"text":"safety","start":78,"end":84,"id":12,"ws":true},{"text":"of","start":85,"end":87,"id":13,"ws":true},{"text":"combination","start":88,"end":99,"id":14,"ws":true},{"text":"nivolumab","start":100,"end":109,"id":15,"ws":true},{"text":"plus","start":110,"end":114,"id":16,"ws":true},{"text":"ipilimumab","start":115,"end":125,"id":17,"ws":true},{"text":"(","start":126,"end":127,"id":18,"ws":true},{"text":"NIVO+IPI","start":128,"end":136,"id":19,"ws":true},{"text":")","start":137,"end":138,"id":20,"ws":true},{"text":"in","start":139,"end":141,"id":21,"ws":true},{"text":"35","start":142,"end":144,"id":22,"ws":true},{"text":"patients","start":145,"end":153,"id":23,"ws":true},{"text":"with","start":154,"end":158,"id":24,"ws":true},{"text":"advanced","start":159,"end":167,"id":25,"ws":true},{"text":"or","start":168,"end":170,"id":26,"ws":true},{"text":"metastatic","start":171,"end":181,"id":27,"ws":true},{"text":"renal","start":182,"end":187,"id":28,"ws":true},{"text":"cell","start":188,"end":192,"id":29,"ws":true},{"text":"carcinoma","start":193,"end":202,"id":30,"ws":true},{"text":"(","start":203,"end":204,"id":31,"ws":true},{"text":"mRCC","start":205,"end":209,"id":32,"ws":true},{"text":")","start":210,"end":211,"id":33,"ws":true},{"text":".","start":212,"end":213,"id":34,"ws":false}],"spans":[{"start":100,"end":109,"token_start":15,"token_end":15,"label":"DRUG"},{"start":115,"end":125,"token_start":17,"token_end":17,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33916792/","_input_hash":-66354120,"_task_hash":-648982159,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":15,"child":17,"head_span":{"start":100,"end":109,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":115,"end":125,"token_start":17,"token_end":17,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"This study evaluated the response rate of the combination therapy of aprinocarsen , gemcitabine , and carboplatin in previously untreated patients with advanced non-small cell lung cancer ( NSCLC ) .","paragraph":"<h3><u>Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer.</u></h3>The antisense oligonucleotide aprinocarsen specifically inhibits the transcription of protein kinase C-alpha. <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>evaluated</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>rate</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>aprinocarsen</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>previously</i></b> <b style='color:DodgerBlue;'><i>untreated</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>non-small</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>NSCLC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Secondary objectives included the measurement of time-to-event efficacy parameters and toxicity. Patients with stage IV or stage IIIB disease (N(3) and/or pleural/pericardial effusion) were treated with <b style='color:Tomato;'><i>gemcitabine</i></b> 1,250 mg/m(2) on days 1 and 8 and <b style='color:Tomato;'><i>carboplatin</i></b> AUC 5 on day 1 every 21 days. Aprinocarsen was administered as 2mg/kg/day continuous iv infusion on the first 14 days of each cycle, following the <b style='color:Tomato;'><i>carboplatin</i></b> treatment. A total of 36 patients received a median of 3 treatment cycles, with 10 patients completing 6 cycles. No complete response was observed, while partial response was seen in 25% of patients. Stable disease and progressive disease was observed in 36.1% and 22.2% of patients. The median overall survival was 8.3 months, and the median duration of progression-free survival was 5.7 months (95% CI, 3.2-7.1 months). Thrombocytopenia (78%) and neutropenia (50%) were the major grade 3/4 toxicities. Enrollment for this study was stopped and the study was terminated in March 2003 due to the results of a large phase III study, which suggested that aprinocarsen did not improve response or add survival benefit to chemotherapy in advanced NSCLC. The addition of aprinocarsen to <b style='color:Tomato;'><i>gemcitabine</i></b>+<b style='color:Tomato;'><i>carboplatin</i></b> therapy in patients with NSCLC showed moderate activity. However, this combination resulted in severe thrombocytopenia in the majority of patients.","tokens":[{"text":"This","start":0,"end":4,"id":0,"ws":true},{"text":"study","start":5,"end":10,"id":1,"ws":true},{"text":"evaluated","start":11,"end":20,"id":2,"ws":true},{"text":"the","start":21,"end":24,"id":3,"ws":true},{"text":"response","start":25,"end":33,"id":4,"ws":true},{"text":"rate","start":34,"end":38,"id":5,"ws":true},{"text":"of","start":39,"end":41,"id":6,"ws":true},{"text":"the","start":42,"end":45,"id":7,"ws":true},{"text":"combination","start":46,"end":57,"id":8,"ws":true},{"text":"therapy","start":58,"end":65,"id":9,"ws":true},{"text":"of","start":66,"end":68,"id":10,"ws":true},{"text":"aprinocarsen","start":69,"end":81,"id":11,"ws":true},{"text":",","start":82,"end":83,"id":12,"ws":true},{"text":"gemcitabine","start":84,"end":95,"id":13,"ws":true},{"text":",","start":96,"end":97,"id":14,"ws":true},{"text":"and","start":98,"end":101,"id":15,"ws":true},{"text":"carboplatin","start":102,"end":113,"id":16,"ws":true},{"text":"in","start":114,"end":116,"id":17,"ws":true},{"text":"previously","start":117,"end":127,"id":18,"ws":true},{"text":"untreated","start":128,"end":137,"id":19,"ws":true},{"text":"patients","start":138,"end":146,"id":20,"ws":true},{"text":"with","start":147,"end":151,"id":21,"ws":true},{"text":"advanced","start":152,"end":160,"id":22,"ws":true},{"text":"non-small","start":161,"end":170,"id":23,"ws":true},{"text":"cell","start":171,"end":175,"id":24,"ws":true},{"text":"lung","start":176,"end":180,"id":25,"ws":true},{"text":"cancer","start":181,"end":187,"id":26,"ws":true},{"text":"(","start":188,"end":189,"id":27,"ws":true},{"text":"NSCLC","start":190,"end":195,"id":28,"ws":true},{"text":")","start":196,"end":197,"id":29,"ws":true},{"text":".","start":198,"end":199,"id":30,"ws":false}],"spans":[{"start":69,"end":81,"token_start":11,"token_end":11,"label":"DRUG"},{"start":84,"end":95,"token_start":13,"token_end":13,"label":"DRUG"},{"start":102,"end":113,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16507327/","_input_hash":-1769105221,"_task_hash":-1161201303,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":11,"child":13,"head_span":{"start":69,"end":81,"token_start":11,"token_end":11,"label":"DRUG"},"child_span":{"start":84,"end":95,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":13,"child":16,"head_span":{"start":84,"end":95,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":102,"end":113,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG11"],"answer":"accept"}
{"text":"All patients were treated by surgical debridement followed by a combination of antibiotics ; ( ceftazidime , amoxy-clavulanic acid , co-trimoxazole and doxycycline ) for six months except for one who died due to fulminant septicemia .","paragraph":"<h3><u>Burkholderia pseudomallei musculoskeletal infections (melioidosis) in India.</u></h3>Melioidosis, an infection due to gram negative Burkholderia pseudomallei, is an important cause of sepsis in east Asia especially Thailand and northern Australia. It usually causes abscesses in lung, liver, spleen, skeletal muscle and parotids especially in patients with diabetes, chronic renal failure and thalassemia. Musculoskeletal melioidosis is not common in India even though sporadic cases have been reported mostly involving soft tissues. During a two-year-period, we had five patients with musculoskeletal melioidosis. All patients presented with multifocal osteomyelitis, recurrent osteomyelitis or septic arthritis. One patient died early because of septicemia and multi-organ failure. All patients were diagnosed on the basis of positive pus culture. <b style='color:DodgerBlue;'><i>All</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>surgical</i></b> <b style='color:DodgerBlue;'><i>debridement</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>antibiotics</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>ceftazidime</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>amoxy-clavulanic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>co-trimoxazole</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>doxycycline</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>six</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>except</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>one</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>died</i></b> <b style='color:DodgerBlue;'><i>due</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>fulminant</i></b> <b style='color:DodgerBlue;'><i>septicemia</i></b> <b style='color:DodgerBlue;'><i>.</i></b> All other patients recovered completely with no recurrences. With increasing awareness and better diagnostic facilities, probably musculoskeletal melioidosis will be increasingly diagnosed in future.","tokens":[{"text":"All","start":0,"end":3,"id":0,"ws":true},{"text":"patients","start":4,"end":12,"id":1,"ws":true},{"text":"were","start":13,"end":17,"id":2,"ws":true},{"text":"treated","start":18,"end":25,"id":3,"ws":true},{"text":"by","start":26,"end":28,"id":4,"ws":true},{"text":"surgical","start":29,"end":37,"id":5,"ws":true},{"text":"debridement","start":38,"end":49,"id":6,"ws":true},{"text":"followed","start":50,"end":58,"id":7,"ws":true},{"text":"by","start":59,"end":61,"id":8,"ws":true},{"text":"a","start":62,"end":63,"id":9,"ws":true},{"text":"combination","start":64,"end":75,"id":10,"ws":true},{"text":"of","start":76,"end":78,"id":11,"ws":true},{"text":"antibiotics","start":79,"end":90,"id":12,"ws":true},{"text":";","start":91,"end":92,"id":13,"ws":true},{"text":"(","start":93,"end":94,"id":14,"ws":true},{"text":"ceftazidime","start":95,"end":106,"id":15,"ws":true},{"text":",","start":107,"end":108,"id":16,"ws":true},{"text":"amoxy-clavulanic","start":109,"end":125,"id":17,"ws":true},{"text":"acid","start":126,"end":130,"id":18,"ws":true},{"text":",","start":131,"end":132,"id":19,"ws":true},{"text":"co-trimoxazole","start":133,"end":147,"id":20,"ws":true},{"text":"and","start":148,"end":151,"id":21,"ws":true},{"text":"doxycycline","start":152,"end":163,"id":22,"ws":true},{"text":")","start":164,"end":165,"id":23,"ws":true},{"text":"for","start":166,"end":169,"id":24,"ws":true},{"text":"six","start":170,"end":173,"id":25,"ws":true},{"text":"months","start":174,"end":180,"id":26,"ws":true},{"text":"except","start":181,"end":187,"id":27,"ws":true},{"text":"for","start":188,"end":191,"id":28,"ws":true},{"text":"one","start":192,"end":195,"id":29,"ws":true},{"text":"who","start":196,"end":199,"id":30,"ws":true},{"text":"died","start":200,"end":204,"id":31,"ws":true},{"text":"due","start":205,"end":208,"id":32,"ws":true},{"text":"to","start":209,"end":211,"id":33,"ws":true},{"text":"fulminant","start":212,"end":221,"id":34,"ws":true},{"text":"septicemia","start":222,"end":232,"id":35,"ws":true},{"text":".","start":233,"end":234,"id":36,"ws":false}],"spans":[{"start":95,"end":106,"token_start":15,"token_end":15,"label":"DRUG"},{"start":109,"end":125,"token_start":17,"token_end":17,"label":"DRUG"},{"start":133,"end":147,"token_start":20,"token_end":20,"label":"DRUG"},{"start":152,"end":163,"token_start":22,"token_end":22,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/20419012/","_input_hash":1130976532,"_task_hash":290964828,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":15,"child":17,"head_span":{"start":95,"end":106,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":109,"end":125,"token_start":17,"token_end":17,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":17,"child":20,"head_span":{"start":109,"end":125,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":133,"end":147,"token_start":20,"token_end":20,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":20,"child":22,"head_span":{"start":133,"end":147,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":152,"end":163,"token_start":22,"token_end":22,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"To evaluate the eradication of Helicobacter pylori by therapy with a combination of 60 mg lansoprazole and 800 mg clarithromycin .","paragraph":"<h3><u>Dual therapy with lansoprazole and clarithromycin for eradication of Helicobacter pylori.</u></h3> <b style='color:DodgerBlue;'><i>To</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>eradication</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Helicobacter</i></b> <b style='color:DodgerBlue;'><i>pylori</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>60</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:MediumOrchid;'><i>lansoprazole</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>800</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:MediumOrchid;'><i>clarithromycin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### Patients And Methods In an open therapeutic trial, 30 H. pylori-positive patients with active ulcer disease took 30 mg <b style='color:Tomato;'><i>lansoprazole</i></b> twice a day and 400 mg <b style='color:Tomato;'><i>clarithromycin</i></b> twice a day for the first 2 weeks, followed by 30 mg <b style='color:Tomato;'><i>lansoprazole</i></b> once a day for 4-6 weeks. Endoscopy was performed both before and at the end of therapy, and 4 weeks after the end of the therapy. H. pylori was detected by using a combination of smear, culture and tissue sections. ### results Complete pain relief occurred within 3 days in all patients and all ulcers were healed by the end of the therapy. The H. pylori clearance rate was 83.3% and the eradication rate was 73.3%. A minor side effect (metallic taste) was reported by only one patient (3.3%). ### conclusions Therapy with a combination of 60 mg <b style='color:Tomato;'><i>lansoprazole</i></b> and 800 mg <b style='color:Tomato;'><i>clarithromycin</i></b> is efficacious in the eradication of H. pylori and has the advantage of a low incidence of side effects and quick pain relief for patients with active ulcers.","tokens":[{"text":"To","start":0,"end":2,"id":0,"ws":true},{"text":"evaluate","start":3,"end":11,"id":1,"ws":true},{"text":"the","start":12,"end":15,"id":2,"ws":true},{"text":"eradication","start":16,"end":27,"id":3,"ws":true},{"text":"of","start":28,"end":30,"id":4,"ws":true},{"text":"Helicobacter","start":31,"end":43,"id":5,"ws":true},{"text":"pylori","start":44,"end":50,"id":6,"ws":true},{"text":"by","start":51,"end":53,"id":7,"ws":true},{"text":"therapy","start":54,"end":61,"id":8,"ws":true},{"text":"with","start":62,"end":66,"id":9,"ws":true},{"text":"a","start":67,"end":68,"id":10,"ws":true},{"text":"combination","start":69,"end":80,"id":11,"ws":true},{"text":"of","start":81,"end":83,"id":12,"ws":true},{"text":"60","start":84,"end":86,"id":13,"ws":true},{"text":"mg","start":87,"end":89,"id":14,"ws":true},{"text":"lansoprazole","start":90,"end":102,"id":15,"ws":true},{"text":"and","start":103,"end":106,"id":16,"ws":true},{"text":"800","start":107,"end":110,"id":17,"ws":true},{"text":"mg","start":111,"end":113,"id":18,"ws":true},{"text":"clarithromycin","start":114,"end":128,"id":19,"ws":true},{"text":".","start":129,"end":130,"id":20,"ws":false}],"spans":[{"start":90,"end":102,"token_start":15,"token_end":15,"label":"DRUG"},{"start":114,"end":128,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8574739/","_input_hash":-1870005838,"_task_hash":2124968462,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":15,"child":19,"head_span":{"start":90,"end":102,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":114,"end":128,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"All patients were treated with vincristine , doxorubicin , cyclophosphamide and actinomycin-D , alternating with ifosfamide and etoposide every 3 weeks .","paragraph":"<h3><u>Extraskeletal Ewing's sarcoma family of tumors in adults: prognostic factors and clinical outcome.</u></h3>The aim of this study was to evaluate prognostic factors, survival rate and the efficacy of the treatment modalities used in patients with extraskeletal Ewing's sarcoma. ### methods Data of patients with extraskeletal Ewing's sarcoma followed up at our center between 1997 and 2010 were retrospectively analyzed. ### results The median age of 27 patients was 24 years (range, 16-54 years). The median follow-up was 31.8 months (range, 6-144 months). Tumor size was between 1.5 and 14 cm (median: 8 cm). Eighty-five percent of patients had localized disease at presentation and 15% had metastatic disease. Local therapy was surgery alone in 16% of patients, surgery combined with radiotherapy in 42% and radiotherapy alone in 27%. <b style='color:DodgerBlue;'><i>All</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>actinomycin-D</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>alternating</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In patients with localized disease at presentation, the 5-year event-free survival and overall survival were 59.7 and 64.5%, respectively. At univariate analysis, patients with tumor size \u2265 8 cm, high serum lactate dehydrogenase, metastasis at presentation, poor histological response to chemotherapy and positive surgical margin had significantly worse event-free survival. The significant predictors of worse overall survival at univariate analysis were tumor size 8 \u2265 cm, high lactate dehydrogenase, metastasis at presentation, poor histological response to chemotherapy, radiotherapy only as local treatment and positive surgical margin. ### conclusions Prognostic factors were similar to primary osseous Ewing's sarcomas. Adequate surgical resection, aggressive chemotherapy (<b style='color:Tomato;'><i>vincristine</i></b>, <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>cyclophosphamide</i></b> and actinomycin-D alternating with <b style='color:Tomato;'><i>ifosfamide</i></b> and <b style='color:Tomato;'><i>etoposide</i></b>) and radiotherapy if indicated are the recommended therapy for patients with extraskeletal Ewing's sarcoma.","tokens":[{"text":"All","start":0,"end":3,"id":0,"ws":true},{"text":"patients","start":4,"end":12,"id":1,"ws":true},{"text":"were","start":13,"end":17,"id":2,"ws":true},{"text":"treated","start":18,"end":25,"id":3,"ws":true},{"text":"with","start":26,"end":30,"id":4,"ws":true},{"text":"vincristine","start":31,"end":42,"id":5,"ws":true},{"text":",","start":43,"end":44,"id":6,"ws":true},{"text":"doxorubicin","start":45,"end":56,"id":7,"ws":true},{"text":",","start":57,"end":58,"id":8,"ws":true},{"text":"cyclophosphamide","start":59,"end":75,"id":9,"ws":true},{"text":"and","start":76,"end":79,"id":10,"ws":true},{"text":"actinomycin-D","start":80,"end":93,"id":11,"ws":true},{"text":",","start":94,"end":95,"id":12,"ws":true},{"text":"alternating","start":96,"end":107,"id":13,"ws":true},{"text":"with","start":108,"end":112,"id":14,"ws":true},{"text":"ifosfamide","start":113,"end":123,"id":15,"ws":true},{"text":"and","start":124,"end":127,"id":16,"ws":true},{"text":"etoposide","start":128,"end":137,"id":17,"ws":true},{"text":"every","start":138,"end":143,"id":18,"ws":true},{"text":"3","start":144,"end":145,"id":19,"ws":true},{"text":"weeks","start":146,"end":151,"id":20,"ws":true},{"text":".","start":152,"end":153,"id":21,"ws":false}],"spans":[{"start":31,"end":42,"token_start":5,"token_end":5,"label":"DRUG"},{"start":45,"end":56,"token_start":7,"token_end":7,"label":"DRUG"},{"start":59,"end":75,"token_start":9,"token_end":9,"label":"DRUG"},{"start":80,"end":93,"token_start":11,"token_end":11,"label":"DRUG"},{"start":113,"end":123,"token_start":15,"token_end":15,"label":"DRUG"},{"start":128,"end":137,"token_start":17,"token_end":17,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22416252/","_input_hash":-1284586151,"_task_hash":-1817856654,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":5,"child":7,"head_span":{"start":31,"end":42,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":45,"end":56,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":7,"child":9,"head_span":{"start":45,"end":56,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":59,"end":75,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":9,"child":11,"head_span":{"start":59,"end":75,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":80,"end":93,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":11,"child":15,"head_span":{"start":80,"end":93,"token_start":11,"token_end":11,"label":"DRUG"},"child_span":{"start":113,"end":123,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":15,"child":17,"head_span":{"start":113,"end":123,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":128,"end":137,"token_start":17,"token_end":17,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"We identified 49 and 220 patients treated with sorafenib and sunitinib , respectively , as first-line therapy in the Asan Medical Centre from April 2005 to March 2011 .","paragraph":"<h3><u>Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.</u></h3>This study investigated the efficacy and toxicity of <b style='color:Tomato;'><i>sorafenib</i></b> and <b style='color:Tomato;'><i>sunitinib</i></b> as primary treatment for patients with metastatic renal cell carcinoma (mRCC). ### methods <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>identified</i></b> <b style='color:DodgerBlue;'><i>49</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>220</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>sorafenib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>sunitinib</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Asan</i></b> <b style='color:DodgerBlue;'><i>Medical</i></b> <b style='color:DodgerBlue;'><i>Centre</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>April</i></b> <b style='color:DodgerBlue;'><i>2005</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>March</i></b> <b style='color:DodgerBlue;'><i>2011</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results Disease control rates of 71 and 74% were achieved with <b style='color:Tomato;'><i>sorafenib</i></b> and <b style='color:Tomato;'><i>sunitinib</i></b>, respectively (p = 0.687). After a median follow-up of 27.6 months, progression-free survival (PFS) and overall survival (OS) were not significantly different between the <b style='color:Tomato;'><i>sorafenib</i></b> and the <b style='color:Tomato;'><i>sunitinib</i></b> group (PFS 8.6 vs. 9.9 months, respectively, p = 0.948, and OS 25.7 vs. 22.6 months, p = 0.774). Patients treated with <b style='color:Tomato;'><i>sorafenib</i></b> required dose reduction due to toxicities less frequently than those treated with <b style='color:Tomato;'><i>sunitinib</i></b> (37 vs. 54%, p = 0.034). Haematological toxicity of grade 3 or 4 was more common in the <b style='color:Tomato;'><i>sunitinib</i></b> group than in the <b style='color:Tomato;'><i>sorafenib</i></b> group (45 vs. 4%, p < 0.001). Multivariate analysis showed old age, Heng's risk group, and bone and liver metastases, but not the type of vascular endothelial growth factor tyrosine kinase inhibitor, were independent prognostic factors affecting OS. ### conclusion The results of this study indicate that <b style='color:Tomato;'><i>sorafenib</i></b> has comparable efficacy to <b style='color:Tomato;'><i>sunitinib</i></b> in the treatment of mRCC patients and fewer and less severe toxicities, but the number of patients included in the study was small.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"identified","start":3,"end":13,"id":1,"ws":true},{"text":"49","start":14,"end":16,"id":2,"ws":true},{"text":"and","start":17,"end":20,"id":3,"ws":true},{"text":"220","start":21,"end":24,"id":4,"ws":true},{"text":"patients","start":25,"end":33,"id":5,"ws":true},{"text":"treated","start":34,"end":41,"id":6,"ws":true},{"text":"with","start":42,"end":46,"id":7,"ws":true},{"text":"sorafenib","start":47,"end":56,"id":8,"ws":true},{"text":"and","start":57,"end":60,"id":9,"ws":true},{"text":"sunitinib","start":61,"end":70,"id":10,"ws":true},{"text":",","start":71,"end":72,"id":11,"ws":true},{"text":"respectively","start":73,"end":85,"id":12,"ws":true},{"text":",","start":86,"end":87,"id":13,"ws":true},{"text":"as","start":88,"end":90,"id":14,"ws":true},{"text":"first-line","start":91,"end":101,"id":15,"ws":true},{"text":"therapy","start":102,"end":109,"id":16,"ws":true},{"text":"in","start":110,"end":112,"id":17,"ws":true},{"text":"the","start":113,"end":116,"id":18,"ws":true},{"text":"Asan","start":117,"end":121,"id":19,"ws":true},{"text":"Medical","start":122,"end":129,"id":20,"ws":true},{"text":"Centre","start":130,"end":136,"id":21,"ws":true},{"text":"from","start":137,"end":141,"id":22,"ws":true},{"text":"April","start":142,"end":147,"id":23,"ws":true},{"text":"2005","start":148,"end":152,"id":24,"ws":true},{"text":"to","start":153,"end":155,"id":25,"ws":true},{"text":"March","start":156,"end":161,"id":26,"ws":true},{"text":"2011","start":162,"end":166,"id":27,"ws":true},{"text":".","start":167,"end":168,"id":28,"ws":false}],"spans":[{"start":47,"end":56,"token_start":8,"token_end":8,"label":"DRUG"},{"start":61,"end":70,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/23548259/","_input_hash":923599862,"_task_hash":-319191677,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"We studied the combination of pemetrexed , a multi-targeted antifolate , and cetuximab , an mAb against the epidermal growth factor receptor , with radiotherapy in poor prognosis head and neck cancer .","paragraph":"<h3><u>Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer.</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>studied</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>pemetrexed</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>multi-targeted</i></b> <b style='color:DodgerBlue;'><i>antifolate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>mAb</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>epidermal</i></b> <b style='color:DodgerBlue;'><i>growth</i></b> <b style='color:DodgerBlue;'><i>factor</i></b> <b style='color:DodgerBlue;'><i>receptor</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>radiotherapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>poor</i></b> <b style='color:DodgerBlue;'><i>prognosis</i></b> <b style='color:DodgerBlue;'><i>head</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>neck</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### Patients And Methods Patients received <b style='color:Tomato;'><i>pemetrexed</i></b> on days 1, 22, and 43 on a dose-escalation scheme with starting level (0) 350 mg/m(2) (level -1, 200 mg/m(2); level +1, 500 mg/m(2)) with concurrent radiotherapy (2 Gy/day) and <b style='color:Tomato;'><i>cetuximab</i></b> in two separate cohorts, not previously irradiated (A) and previously irradiated (B), who received 70 and 60-66 Gy, respectively. Genetic polymorphisms of thymidylate synthase and methylenetetrahydrofolate reductase were evaluated. ### results Thirty-two patients were enrolled. The maximum tolerated dose of <b style='color:Tomato;'><i>pemetrexed</i></b> was 500 mg/m(2) in cohort A and 350 mg/m(2) in cohort B. Prophylactic antibiotics were required. In cohort A, two dose-limiting toxicities (DLTs) occurred (febrile neutropenia), one each at levels 0 and +1. In cohort B, two DLTs occurred at level +1 (febrile neutropenia; death from perforated duodenal ulcer and sepsis). Grade 3 mucositis was common. No association of gene polymorphisms with toxicity or efficacy was evident. ### conclusion The addition of <b style='color:Tomato;'><i>pemetrexed</i></b> 500 mg/m(2) to <b style='color:Tomato;'><i>cetuximab</i></b> and radiotherapy is recommended for further study in not previously irradiated patients.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"studied","start":3,"end":10,"id":1,"ws":true},{"text":"the","start":11,"end":14,"id":2,"ws":true},{"text":"combination","start":15,"end":26,"id":3,"ws":true},{"text":"of","start":27,"end":29,"id":4,"ws":true},{"text":"pemetrexed","start":30,"end":40,"id":5,"ws":true},{"text":",","start":41,"end":42,"id":6,"ws":true},{"text":"a","start":43,"end":44,"id":7,"ws":true},{"text":"multi-targeted","start":45,"end":59,"id":8,"ws":true},{"text":"antifolate","start":60,"end":70,"id":9,"ws":true},{"text":",","start":71,"end":72,"id":10,"ws":true},{"text":"and","start":73,"end":76,"id":11,"ws":true},{"text":"cetuximab","start":77,"end":86,"id":12,"ws":true},{"text":",","start":87,"end":88,"id":13,"ws":true},{"text":"an","start":89,"end":91,"id":14,"ws":true},{"text":"mAb","start":92,"end":95,"id":15,"ws":true},{"text":"against","start":96,"end":103,"id":16,"ws":true},{"text":"the","start":104,"end":107,"id":17,"ws":true},{"text":"epidermal","start":108,"end":117,"id":18,"ws":true},{"text":"growth","start":118,"end":124,"id":19,"ws":true},{"text":"factor","start":125,"end":131,"id":20,"ws":true},{"text":"receptor","start":132,"end":140,"id":21,"ws":true},{"text":",","start":141,"end":142,"id":22,"ws":true},{"text":"with","start":143,"end":147,"id":23,"ws":true},{"text":"radiotherapy","start":148,"end":160,"id":24,"ws":true},{"text":"in","start":161,"end":163,"id":25,"ws":true},{"text":"poor","start":164,"end":168,"id":26,"ws":true},{"text":"prognosis","start":169,"end":178,"id":27,"ws":true},{"text":"head","start":179,"end":183,"id":28,"ws":true},{"text":"and","start":184,"end":187,"id":29,"ws":true},{"text":"neck","start":188,"end":192,"id":30,"ws":true},{"text":"cancer","start":193,"end":199,"id":31,"ws":true},{"text":".","start":200,"end":201,"id":32,"ws":false}],"spans":[{"start":30,"end":40,"token_start":5,"token_end":5,"label":"DRUG"},{"start":77,"end":86,"token_start":12,"token_end":12,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/21363880/","_input_hash":-1439597952,"_task_hash":-2062337790,"_session_id":"drug_drug_pilot_split2c-yosi","_view_id":"blocks","relations":[{"head":5,"child":12,"head_span":{"start":30,"end":40,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":77,"end":86,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Boosting darunavir with ritonavir instead of with cobicistat may be preferred if darunavir is to be combined with etravirine in clinical practice .","paragraph":"<h3><u>Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.</u></h3>To determine the effect of <b style='color:Tomato;'><i>etravirine</i></b> on the pharmacokinetics of <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b> and vice versa. Safety and tolerability of this combination were also evaluated. ### methods Open-label, fixed-sequence trial in two cohorts of HIV-infected patients on therapy with <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b> 800/150\u2009mg once daily (DRV cohort; n\u2009=\u200915) or <b style='color:Tomato;'><i>etravirine</i></b> 400\u2009mg once daily (ETR cohort; n\u2009=\u200915). <b style='color:Tomato;'><i>etravirine</i></b> or <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b> were added on days 1-14 and 1-7 in participants in the DRV or ETR cohort, respectively. Full pharmacokinetic profiles were obtained on days 0 and 14 in the DRV cohort, and on days 0 and 7 in the ETR cohort. <b style='color:Tomato;'><i>darunavir</i></b>, <b style='color:Tomato;'><i>cobicistat</i></b> and <b style='color:Tomato;'><i>etravirine</i></b> pharmacokinetic parameters [AUC0-24, Cmax and trough concentrations in plasma (C24)] were calculated for each individual by non-compartmental analysis and were compared using linear mixed-effects models. Adverse events and HIV-1 RNA in plasma were monitored. ### results <b style='color:Tomato;'><i>etravirine</i></b> co-administration decreased <b style='color:Tomato;'><i>cobicistat</i></b> AUC0-24, Cmax and C24 by 30%, 14% and 66%, respectively. Although <b style='color:Tomato;'><i>darunavir</i></b> AUC0-24 and Cmax were unchanged by <b style='color:Tomato;'><i>etravirine</i></b>, <b style='color:Tomato;'><i>darunavir</i></b> C24 was 56% lower for <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b> co-administered with <b style='color:Tomato;'><i>etravirine</i></b> relative to <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b> alone. <b style='color:Tomato;'><i>etravirine</i></b> pharmacokinetics were unchanged by <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b>. Treatments were well tolerated, and HIV-1 RNA remained undetectable in all participants. ### conclusions Although <b style='color:Tomato;'><i>etravirine</i></b> pharmacokinetics was unchanged by <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b>, there was a significant decrease in <b style='color:Tomato;'><i>cobicistat</i></b> exposure and in <b style='color:Tomato;'><i>darunavir</i></b> C24 when <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b> was co-administered with <b style='color:Tomato;'><i>etravirine</i></b>. <b style='color:DodgerBlue;'><i>Boosting</i></b> <b style='color:MediumOrchid;'><i>darunavir</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>ritonavir</i></b> <b style='color:DodgerBlue;'><i>instead</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>cobicistat</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>preferred</i></b> <b style='color:DodgerBlue;'><i>if</i></b> <b style='color:MediumOrchid;'><i>darunavir</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>etravirine</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>practice</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"Boosting","start":0,"end":8,"id":0,"ws":true},{"text":"darunavir","start":9,"end":18,"id":1,"ws":true},{"text":"with","start":19,"end":23,"id":2,"ws":true},{"text":"ritonavir","start":24,"end":33,"id":3,"ws":true},{"text":"instead","start":34,"end":41,"id":4,"ws":true},{"text":"of","start":42,"end":44,"id":5,"ws":true},{"text":"with","start":45,"end":49,"id":6,"ws":true},{"text":"cobicistat","start":50,"end":60,"id":7,"ws":true},{"text":"may","start":61,"end":64,"id":8,"ws":true},{"text":"be","start":65,"end":67,"id":9,"ws":true},{"text":"preferred","start":68,"end":77,"id":10,"ws":true},{"text":"if","start":78,"end":80,"id":11,"ws":true},{"text":"darunavir","start":81,"end":90,"id":12,"ws":true},{"text":"is","start":91,"end":93,"id":13,"ws":true},{"text":"to","start":94,"end":96,"id":14,"ws":true},{"text":"be","start":97,"end":99,"id":15,"ws":true},{"text":"combined","start":100,"end":108,"id":16,"ws":true},{"text":"with","start":109,"end":113,"id":17,"ws":true},{"text":"etravirine","start":114,"end":124,"id":18,"ws":true},{"text":"in","start":125,"end":127,"id":19,"ws":true},{"text":"clinical","start":128,"end":136,"id":20,"ws":true},{"text":"practice","start":137,"end":145,"id":21,"ws":true},{"text":".","start":146,"end":147,"id":22,"ws":false}],"spans":[{"start":9,"end":18,"token_start":1,"token_end":1,"label":"DRUG"},{"start":24,"end":33,"token_start":3,"token_end":3,"label":"DRUG"},{"start":50,"end":60,"token_start":7,"token_end":7,"label":"DRUG"},{"start":81,"end":90,"token_start":12,"token_end":12,"label":"DRUG"},{"start":114,"end":124,"token_start":18,"token_end":18,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29237008/","_input_hash":-1591603289,"_task_hash":-1954409406,"_session_id":"drug_drug_pilot_split2c-yosi","_view_id":"blocks","relations":[{"head":1,"child":3,"head_span":{"start":9,"end":18,"token_start":1,"token_end":1,"label":"DRUG"},"child_span":{"start":24,"end":33,"token_start":3,"token_end":3,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":12,"child":18,"head_span":{"start":81,"end":90,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":114,"end":124,"token_start":18,"token_end":18,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS10","POS20"],"answer":"accept"}
{"text":"Single-agent paclitaxel and vinorelbine are recommended treatments for advanced breast cancer ( ABC ) non-responsive to hormone therapy and without visceral crisis .","paragraph":"<h3><u>Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial).</u></h3> <b style='color:DodgerBlue;'><i>Single-agent</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>vinorelbine</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>treatments</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ABC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>non-responsive</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>hormone</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>without</i></b> <b style='color:DodgerBlue;'><i>visceral</i></b> <b style='color:DodgerBlue;'><i>crisis</i></b> <b style='color:DodgerBlue;'><i>.</i></b> This phase II trial compared first-line oral <b style='color:Tomato;'><i>vinorelbine</i></b> versus weekly <b style='color:Tomato;'><i>paclitaxel</i></b> for ABC. ### methods Eligible female patients had measurable locally recurrent/metastatic estrogen receptor-positive HER2-negative breast cancer and had received prior endocrine therapy (any setting) but no chemotherapy for ABC. Patients were stratified by prior taxane and visceral metastases and randomized to either oral <b style='color:Tomato;'><i>vinorelbine</i></b> 80\u202fmg/m ### results The 131 randomized patients had received a median of 2 prior endocrine therapies; >70% had prior (neo)adjuvant chemotherapy and 79% visceral metastases. DCR was 75.8% (95% confidence interval: 63.6-85.5%) with <b style='color:Tomato;'><i>vinorelbine</i></b> and 75.4% (63.1-85.2%) with <b style='color:Tomato;'><i>paclitaxel</i></b>. The most common grade 3/4 adverse events were neutropenia (52%), fatigue (11%), and vomiting (5%) with <b style='color:Tomato;'><i>vinorelbine</i></b>, and neutropenia (17%), dyspnea (6%), hypertension (6%), and peripheral sensory neuropathy (5%) with <b style='color:Tomato;'><i>paclitaxel</i></b>. Grade 2 alopecia occurred in 2% of <b style='color:Tomato;'><i>vinorelbine</i></b>-treated and 34% of <b style='color:Tomato;'><i>paclitaxel</i></b>-treated patients. Neither arm showed relevant global health status changes. ### conclusion Oral <b style='color:Tomato;'><i>vinorelbine</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b> demonstrated similar DCRs (\u223c75%). Safety profiles differed and, together with administration route and convenience, may influence treatment choice (EudraCT number, 2012-003530-16).","tokens":[{"text":"Single-agent","start":0,"end":12,"id":0,"ws":true},{"text":"paclitaxel","start":13,"end":23,"id":1,"ws":true},{"text":"and","start":24,"end":27,"id":2,"ws":true},{"text":"vinorelbine","start":28,"end":39,"id":3,"ws":true},{"text":"are","start":40,"end":43,"id":4,"ws":true},{"text":"recommended","start":44,"end":55,"id":5,"ws":true},{"text":"treatments","start":56,"end":66,"id":6,"ws":true},{"text":"for","start":67,"end":70,"id":7,"ws":true},{"text":"advanced","start":71,"end":79,"id":8,"ws":true},{"text":"breast","start":80,"end":86,"id":9,"ws":true},{"text":"cancer","start":87,"end":93,"id":10,"ws":true},{"text":"(","start":94,"end":95,"id":11,"ws":true},{"text":"ABC","start":96,"end":99,"id":12,"ws":true},{"text":")","start":100,"end":101,"id":13,"ws":true},{"text":"non-responsive","start":102,"end":116,"id":14,"ws":true},{"text":"to","start":117,"end":119,"id":15,"ws":true},{"text":"hormone","start":120,"end":127,"id":16,"ws":true},{"text":"therapy","start":128,"end":135,"id":17,"ws":true},{"text":"and","start":136,"end":139,"id":18,"ws":true},{"text":"without","start":140,"end":147,"id":19,"ws":true},{"text":"visceral","start":148,"end":156,"id":20,"ws":true},{"text":"crisis","start":157,"end":163,"id":21,"ws":true},{"text":".","start":164,"end":165,"id":22,"ws":false}],"spans":[{"start":13,"end":23,"token_start":1,"token_end":1,"label":"DRUG"},{"start":28,"end":39,"token_start":3,"token_end":3,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30802822/","_input_hash":824817462,"_task_hash":979881391,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Nal-IRI with 5-fluorouracil ( 5-FU ) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial ( AIO-YMO HEP-0315 )","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Nal-IRI</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>5-fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5-FU</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>leucovorin</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>biliary</i></b> <b style='color:DodgerBlue;'><i>tract</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>NIFE</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AIO-YMO</i></b> <b style='color:DodgerBlue;'><i>HEP-0315</i></b> <b style='color:DodgerBlue;'><i>)</i></b></u></h3>Biliary tract cancer (BTC) has a high mortality. Primary diagnosis is frequently delayed due to mostly unspecific symptoms, resulting in a high number of advanced cases at the time of diagnosis. Advanced BTCs are in principle chemotherapy sensitive as determined by improved disease control, survival and quality of life (QoL). However, median OS does not exceed 11.7\u2009months with the current standard of care <b style='color:Tomato;'><i>gemcitabine</i></b> plus <b style='color:Tomato;'><i>cisplatin</i></b>. Thereby, novel drug formulations like nanoliposomal-<b style='color:Tomato;'><i>irinotecan</i></b> (nal-IRI) in combination with 5- <b style='color:Tomato;'><i>fluorouracil</i></b> (5-FU)/<b style='color:Tomato;'><i>leucovorin</i></b> may have the potential to improve therapeutic outcomes in this disease. ### methods NIFE is an interventional, prospective, randomized, controlled, open label, two-sided phase II study. Within the study, 2\u2009\u00d7\u200946 patients with locally advanced, non-resectable or metastatic BTC are to be enrolled by two stage design of Simon. Data analysis will be done unconnected for both arms. Patients are allocated in two arms: Arm A (experimental intervention) nal-IRI mg/m ### discussion The NIFE trial evaluates the potential of a nanoliposomal-<b style='color:Tomato;'><i>irinotecan</i></b>/5-FU/<b style='color:Tomato;'><i>leucovorin</i></b> combination in the first line therapy of advanced BTCs and additionally offers a unique chance for translational research. ### Trial Registration Clinicaltrials.gov NCT03044587. Registration Date February 7th 2017.","tokens":[{"text":"Nal-IRI","start":0,"end":7,"id":0,"ws":true},{"text":"with","start":8,"end":12,"id":1,"ws":true},{"text":"5-fluorouracil","start":13,"end":27,"id":2,"ws":true},{"text":"(","start":28,"end":29,"id":3,"ws":true},{"text":"5-FU","start":30,"end":34,"id":4,"ws":true},{"text":")","start":35,"end":36,"id":5,"ws":true},{"text":"and","start":37,"end":40,"id":6,"ws":true},{"text":"leucovorin","start":41,"end":51,"id":7,"ws":true},{"text":"or","start":52,"end":54,"id":8,"ws":true},{"text":"gemcitabine","start":55,"end":66,"id":9,"ws":true},{"text":"plus","start":67,"end":71,"id":10,"ws":true},{"text":"cisplatin","start":72,"end":81,"id":11,"ws":true},{"text":"in","start":82,"end":84,"id":12,"ws":true},{"text":"advanced","start":85,"end":93,"id":13,"ws":true},{"text":"biliary","start":94,"end":101,"id":14,"ws":true},{"text":"tract","start":102,"end":107,"id":15,"ws":true},{"text":"cancer","start":108,"end":114,"id":16,"ws":true},{"text":"-","start":115,"end":116,"id":17,"ws":true},{"text":"the","start":117,"end":120,"id":18,"ws":true},{"text":"NIFE","start":121,"end":125,"id":19,"ws":true},{"text":"trial","start":126,"end":131,"id":20,"ws":true},{"text":"(","start":132,"end":133,"id":21,"ws":true},{"text":"AIO-YMO","start":134,"end":141,"id":22,"ws":true},{"text":"HEP-0315","start":142,"end":150,"id":23,"ws":true},{"text":")","start":151,"end":152,"id":24,"ws":false}],"spans":[{"start":13,"end":27,"token_start":2,"token_end":2,"label":"DRUG"},{"start":41,"end":51,"token_start":7,"token_end":7,"label":"DRUG"},{"start":55,"end":66,"token_start":9,"token_end":9,"label":"DRUG"},{"start":72,"end":81,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/31646981/","_input_hash":-1862521886,"_task_hash":-1288207837,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":2,"child":7,"head_span":{"start":13,"end":27,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":41,"end":51,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":9,"child":11,"head_span":{"start":55,"end":66,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":72,"end":81,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"}],"radio":[],"answer":"accept"}
{"text":"Ten patients were withdrawn from the terbutaline group because treatment was insufficiently effective , whereas only one dropped out of the budesonide group .","paragraph":"<h3><u>Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma.</u></h3>The presence of airway inflammation even in mild asthma points to the potential value of antiinflammatory therapy. We compared the effect of an inhaled corticosteroid, <b style='color:Tomato;'><i>bu<b style='color:Tomato;'><i>desonide</i></b></i></b>, with that of an inhaled beta 2-agonist, <b style='color:Tomato;'><i>terbutaline</i></b>, in the long-term treatment of newly detected asthma. ### methods We studied 103 patients (29 male and 74 female patients 15 to 64 years old) in whom asthma had appeared within the previous year. The patients were randomly assigned in blinded fashion to two treatment groups: one to receive 600 micrograms of inhaled <b style='color:Tomato;'><i>bu<b style='color:Tomato;'><i>desonide</i></b></i></b> twice a day, and the other to receive 375 micrograms of inhaled <b style='color:Tomato;'><i>terbutaline</i></b> twice a day. The study period was two years. ### results After six weeks of treatment, the patients treated with <b style='color:Tomato;'><i>bu<b style='color:Tomato;'><i>desonide</i></b></i></b> tolerated inhaled histamine better than the patients treated with <b style='color:Tomato;'><i>terbutaline</i></b> (a difference of one doubling dose step, P less than 0.001), and the difference was sustained. Patients' diaries kept during the first three months of the study and during the last month of the first and second years showed <b style='color:Tomato;'><i>bu<b style='color:Tomato;'><i>desonide</i></b></i></b> to be more effective than <b style='color:Tomato;'><i>terbutaline</i></b> in improving peak expiratory flow in the morning (average increase from the pretreatment value, 32.8 liters per minute for <b style='color:Tomato;'><i>bu<b style='color:Tomato;'><i>desonide</i></b></i></b> vs. 4.8 liters per minute for <b style='color:Tomato;'><i>terbutaline</i></b>; P less than 0.001) and in the evening (P less than 0.01). <b style='color:Tomato;'><i>bu<b style='color:Tomato;'><i>desonide</i></b></i></b> was also more effective in reducing the symptoms of asthma (P less than 0.01) and the use of supplemental beta 2-agonist medication (P less than 0.01). <b style='color:DodgerBlue;'><i>Ten</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>withdrawn</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>terbutaline</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>because</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>insufficiently</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>whereas</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>one</i></b> <b style='color:DodgerBlue;'><i>dropped</i></b> <b style='color:DodgerBlue;'><i>out</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>budesonide</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The adverse reactions to both treatments were few and mild. ### conclusions Antiinflammatory therapy with inhaled <b style='color:Tomato;'><i>bu<b style='color:Tomato;'><i>desonide</i></b></i></b> is an effective first-line treatment for patients with newly detected, mild asthma, and it is superior to the use of <b style='color:Tomato;'><i>terbutaline</i></b> in such patients.","tokens":[{"text":"Ten","start":0,"end":3,"id":0,"ws":true},{"text":"patients","start":4,"end":12,"id":1,"ws":true},{"text":"were","start":13,"end":17,"id":2,"ws":true},{"text":"withdrawn","start":18,"end":27,"id":3,"ws":true},{"text":"from","start":28,"end":32,"id":4,"ws":true},{"text":"the","start":33,"end":36,"id":5,"ws":true},{"text":"terbutaline","start":37,"end":48,"id":6,"ws":true},{"text":"group","start":49,"end":54,"id":7,"ws":true},{"text":"because","start":55,"end":62,"id":8,"ws":true},{"text":"treatment","start":63,"end":72,"id":9,"ws":true},{"text":"was","start":73,"end":76,"id":10,"ws":true},{"text":"insufficiently","start":77,"end":91,"id":11,"ws":true},{"text":"effective","start":92,"end":101,"id":12,"ws":true},{"text":",","start":102,"end":103,"id":13,"ws":true},{"text":"whereas","start":104,"end":111,"id":14,"ws":true},{"text":"only","start":112,"end":116,"id":15,"ws":true},{"text":"one","start":117,"end":120,"id":16,"ws":true},{"text":"dropped","start":121,"end":128,"id":17,"ws":true},{"text":"out","start":129,"end":132,"id":18,"ws":true},{"text":"of","start":133,"end":135,"id":19,"ws":true},{"text":"the","start":136,"end":139,"id":20,"ws":true},{"text":"budesonide","start":140,"end":150,"id":21,"ws":true},{"text":"group","start":151,"end":156,"id":22,"ws":true},{"text":".","start":157,"end":158,"id":23,"ws":false}],"spans":[{"start":37,"end":48,"token_start":6,"token_end":6,"label":"DRUG"},{"start":140,"end":150,"token_start":21,"token_end":21,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/2062329/","_input_hash":-1100714668,"_task_hash":1982259093,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"We conducted a double-blind cross-over study in ten volunteers aged from 19 to 30 years , to compare the pain control effects of a single oral dose of two analgesic compounds ( drug A : propyphenazone mg 250 , ethylmorphine mg 5 , caffeine mg 5 ; drug B : dipyrone mg 500 , diphenhydramine mg 12.5 , adiphenine mg 5 , ethyl aminobenzoate mg 2.5 ) in an experimental pain model using stimulation of dental pulp .","paragraph":"<h3><u>[Electric stimulation of the dental pulp in the evaluation of the central effect of analgesics].</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>double-blind</i></b> <b style='color:DodgerBlue;'><i>cross-over</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>ten</i></b> <b style='color:DodgerBlue;'><i>volunteers</i></b> <b style='color:DodgerBlue;'><i>aged</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>19</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>30</i></b> <b style='color:DodgerBlue;'><i>years</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>compare</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>pain</i></b> <b style='color:DodgerBlue;'><i>control</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>analgesic</i></b> <b style='color:DodgerBlue;'><i>compounds</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:MediumOrchid;'><i>propyphenazone</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>250</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>ethylmorphine</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>caffeine</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>dipyrone</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>500</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>diphenhydramine</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>12.5</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>adiphenine</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>ethyl</i></b> <b style='color:DodgerBlue;'><i>aminobenzoate</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>2.5</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>experimental</i></b> <b style='color:DodgerBlue;'><i>pain</i></b> <b style='color:DodgerBlue;'><i>model</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:DodgerBlue;'><i>stimulation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>dental</i></b> <b style='color:DodgerBlue;'><i>pulp</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Constant voltage stimuli were delivered through silver chloride electrodes placed in contact with the vestibular surface of the upper medial incisor. At the beginning of the session, the pain input was graded by asking the subject to identify the weakest stimulus perceived (threshold level) and the strongest stimulus endurable (tolerance level). The range between threshold and tolerance level was divided in nine steps plus a subliminal step. The ten steps were delivered randomly, and each series of steps was repeated eight times. The subjects were instructed to rate the pain sensation in an arbitrary scale of 5 degrees. The procedure was repeated at 60 min and 180 min after drug administration. Each subject received two tablets of drug A or drug B in two different sessions at weekly intervals. Statistical analysis of the procedures showed that neither drug A nor drug B significantly affected the pain threshold. Drug A significantly reduced the total pain score (P less than 0.01) and its action peaked 60 min after administration.(ABSTRACT TRUNCATED AT 250 WORDS)","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"conducted","start":3,"end":12,"id":1,"ws":true},{"text":"a","start":13,"end":14,"id":2,"ws":true},{"text":"double-blind","start":15,"end":27,"id":3,"ws":true},{"text":"cross-over","start":28,"end":38,"id":4,"ws":true},{"text":"study","start":39,"end":44,"id":5,"ws":true},{"text":"in","start":45,"end":47,"id":6,"ws":true},{"text":"ten","start":48,"end":51,"id":7,"ws":true},{"text":"volunteers","start":52,"end":62,"id":8,"ws":true},{"text":"aged","start":63,"end":67,"id":9,"ws":true},{"text":"from","start":68,"end":72,"id":10,"ws":true},{"text":"19","start":73,"end":75,"id":11,"ws":true},{"text":"to","start":76,"end":78,"id":12,"ws":true},{"text":"30","start":79,"end":81,"id":13,"ws":true},{"text":"years","start":82,"end":87,"id":14,"ws":true},{"text":",","start":88,"end":89,"id":15,"ws":true},{"text":"to","start":90,"end":92,"id":16,"ws":true},{"text":"compare","start":93,"end":100,"id":17,"ws":true},{"text":"the","start":101,"end":104,"id":18,"ws":true},{"text":"pain","start":105,"end":109,"id":19,"ws":true},{"text":"control","start":110,"end":117,"id":20,"ws":true},{"text":"effects","start":118,"end":125,"id":21,"ws":true},{"text":"of","start":126,"end":128,"id":22,"ws":true},{"text":"a","start":129,"end":130,"id":23,"ws":true},{"text":"single","start":131,"end":137,"id":24,"ws":true},{"text":"oral","start":138,"end":142,"id":25,"ws":true},{"text":"dose","start":143,"end":147,"id":26,"ws":true},{"text":"of","start":148,"end":150,"id":27,"ws":true},{"text":"two","start":151,"end":154,"id":28,"ws":true},{"text":"analgesic","start":155,"end":164,"id":29,"ws":true},{"text":"compounds","start":165,"end":174,"id":30,"ws":true},{"text":"(","start":175,"end":176,"id":31,"ws":true},{"text":"drug","start":177,"end":181,"id":32,"ws":true},{"text":"A","start":182,"end":183,"id":33,"ws":true},{"text":":","start":184,"end":185,"id":34,"ws":true},{"text":"propyphenazone","start":186,"end":200,"id":35,"ws":true},{"text":"mg","start":201,"end":203,"id":36,"ws":true},{"text":"250","start":204,"end":207,"id":37,"ws":true},{"text":",","start":208,"end":209,"id":38,"ws":true},{"text":"ethylmorphine","start":210,"end":223,"id":39,"ws":true},{"text":"mg","start":224,"end":226,"id":40,"ws":true},{"text":"5","start":227,"end":228,"id":41,"ws":true},{"text":",","start":229,"end":230,"id":42,"ws":true},{"text":"caffeine","start":231,"end":239,"id":43,"ws":true},{"text":"mg","start":240,"end":242,"id":44,"ws":true},{"text":"5","start":243,"end":244,"id":45,"ws":true},{"text":";","start":245,"end":246,"id":46,"ws":true},{"text":"drug","start":247,"end":251,"id":47,"ws":true},{"text":"B","start":252,"end":253,"id":48,"ws":true},{"text":":","start":254,"end":255,"id":49,"ws":true},{"text":"dipyrone","start":256,"end":264,"id":50,"ws":true},{"text":"mg","start":265,"end":267,"id":51,"ws":true},{"text":"500","start":268,"end":271,"id":52,"ws":true},{"text":",","start":272,"end":273,"id":53,"ws":true},{"text":"diphenhydramine","start":274,"end":289,"id":54,"ws":true},{"text":"mg","start":290,"end":292,"id":55,"ws":true},{"text":"12.5","start":293,"end":297,"id":56,"ws":true},{"text":",","start":298,"end":299,"id":57,"ws":true},{"text":"adiphenine","start":300,"end":310,"id":58,"ws":true},{"text":"mg","start":311,"end":313,"id":59,"ws":true},{"text":"5","start":314,"end":315,"id":60,"ws":true},{"text":",","start":316,"end":317,"id":61,"ws":true},{"text":"ethyl","start":318,"end":323,"id":62,"ws":true},{"text":"aminobenzoate","start":324,"end":337,"id":63,"ws":true},{"text":"mg","start":338,"end":340,"id":64,"ws":true},{"text":"2.5","start":341,"end":344,"id":65,"ws":true},{"text":")","start":345,"end":346,"id":66,"ws":true},{"text":"in","start":347,"end":349,"id":67,"ws":true},{"text":"an","start":350,"end":352,"id":68,"ws":true},{"text":"experimental","start":353,"end":365,"id":69,"ws":true},{"text":"pain","start":366,"end":370,"id":70,"ws":true},{"text":"model","start":371,"end":376,"id":71,"ws":true},{"text":"using","start":377,"end":382,"id":72,"ws":true},{"text":"stimulation","start":383,"end":394,"id":73,"ws":true},{"text":"of","start":395,"end":397,"id":74,"ws":true},{"text":"dental","start":398,"end":404,"id":75,"ws":true},{"text":"pulp","start":405,"end":409,"id":76,"ws":true},{"text":".","start":410,"end":411,"id":77,"ws":false}],"spans":[{"start":186,"end":200,"token_start":35,"token_end":35,"label":"DRUG"},{"start":210,"end":223,"token_start":39,"token_end":39,"label":"DRUG"},{"start":231,"end":239,"token_start":43,"token_end":43,"label":"DRUG"},{"start":256,"end":264,"token_start":50,"token_end":50,"label":"DRUG"},{"start":274,"end":289,"token_start":54,"token_end":54,"label":"DRUG"},{"start":300,"end":310,"token_start":58,"token_end":58,"label":"DRUG"},{"start":324,"end":337,"token_start":63,"token_end":63,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/1979494/","_input_hash":52952750,"_task_hash":1148323975,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":35,"child":39,"head_span":{"start":186,"end":200,"token_start":35,"token_end":35,"label":"DRUG"},"child_span":{"start":210,"end":223,"token_start":39,"token_end":39,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":39,"child":43,"head_span":{"start":210,"end":223,"token_start":39,"token_end":39,"label":"DRUG"},"child_span":{"start":231,"end":239,"token_start":43,"token_end":43,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":50,"child":54,"head_span":{"start":256,"end":264,"token_start":50,"token_end":50,"label":"DRUG"},"child_span":{"start":274,"end":289,"token_start":54,"token_end":54,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":54,"child":58,"head_span":{"start":274,"end":289,"token_start":54,"token_end":54,"label":"DRUG"},"child_span":{"start":300,"end":310,"token_start":58,"token_end":58,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":58,"child":63,"head_span":{"start":300,"end":310,"token_start":58,"token_end":58,"label":"DRUG"},"child_span":{"start":324,"end":337,"token_start":63,"token_end":63,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Forty-three mCRC patients who received cetuximab or panitumumab between April 2012 and December 2015 were the subjects of the present study .","paragraph":"<h3><u>Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer.</u></h3>Anti-EGFR monoclonal antibody is effective for KRAS wild-type metastatic colorectal cancer (mCRC), but frequently causes several adverse reactions, including hypomagnesemia and skin disorders. The present study was designed to investigate the relationship between the incidence of adverse reactions and therapeutic effects in mCRC patients receiving anti-EGFR monoclonal antibody in combination with first-line chemotherapy. ### methods <b style='color:DodgerBlue;'><i>Forty-three</i></b> <b style='color:DodgerBlue;'><i>mCRC</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>panitumumab</i></b> <b style='color:DodgerBlue;'><i>between</i></b> <b style='color:DodgerBlue;'><i>April</i></b> <b style='color:DodgerBlue;'><i>2012</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>December</i></b> <b style='color:DodgerBlue;'><i>2015</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>subjects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>.</i></b> All patients were pretreated with oral <b style='color:Tomato;'><i>minocycline</i></b> in combination with skin treatment using moisturizer for prevention of skin rash. Hypomagnesemia and acneiform rash were graded according to the Common Terminology Criteria for Adverse Events, version 3.0. Overall response rate (ORR) and time to treatment failure (TTF) were compared between patients with and without these adverse events. ### results The incidence rates of hypomagnesemia and acneiform rash were 32.6\u00a0% (grade 1: 20.9\u00a0%, grade 2: 11.6\u00a0%) and 93.0\u00a0% (grade 1: 41.9\u00a0%, grade 2: 41.9\u00a0%, grade 3: 9.3\u00a0%), respectively. ORR was significantly higher in patients with hypomagnesemia than in those without it (71.4 vs 34.5\u00a0%, P\u00a0=\u00a00.048). Median TTF tended to be longer, though not significantly, in patients with hypomagnesemia than in those without it. However, no significant difference in both ORR and median TTF was observed between patients with and without acneiform rash. ### conclusion Hypomagnesemia may become a predicting factor for therapeutic effects of anti-EGFR monoclonal antibody in mCRC patients.","tokens":[{"text":"Forty-three","start":0,"end":11,"id":0,"ws":true},{"text":"mCRC","start":12,"end":16,"id":1,"ws":true},{"text":"patients","start":17,"end":25,"id":2,"ws":true},{"text":"who","start":26,"end":29,"id":3,"ws":true},{"text":"received","start":30,"end":38,"id":4,"ws":true},{"text":"cetuximab","start":39,"end":48,"id":5,"ws":true},{"text":"or","start":49,"end":51,"id":6,"ws":true},{"text":"panitumumab","start":52,"end":63,"id":7,"ws":true},{"text":"between","start":64,"end":71,"id":8,"ws":true},{"text":"April","start":72,"end":77,"id":9,"ws":true},{"text":"2012","start":78,"end":82,"id":10,"ws":true},{"text":"and","start":83,"end":86,"id":11,"ws":true},{"text":"December","start":87,"end":95,"id":12,"ws":true},{"text":"2015","start":96,"end":100,"id":13,"ws":true},{"text":"were","start":101,"end":105,"id":14,"ws":true},{"text":"the","start":106,"end":109,"id":15,"ws":true},{"text":"subjects","start":110,"end":118,"id":16,"ws":true},{"text":"of","start":119,"end":121,"id":17,"ws":true},{"text":"the","start":122,"end":125,"id":18,"ws":true},{"text":"present","start":126,"end":133,"id":19,"ws":true},{"text":"study","start":134,"end":139,"id":20,"ws":true},{"text":".","start":140,"end":141,"id":21,"ws":false}],"spans":[{"start":39,"end":48,"token_start":5,"token_end":5,"label":"DRUG"},{"start":52,"end":63,"token_start":7,"token_end":7,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/27106835/","_input_hash":-1825043399,"_task_hash":-1164830701,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Furthermore , 11 AML patients at primary diagnosis , including five AML patients with P-gp overexpression , who were treated with idarubicin , vepesid , and cytarabine V ( ara-C ) showed a complete remission .","paragraph":"<h3><u>Clinical importance of P-glycoprotein-related resistance in leukemia and myelodysplastic syndromes--first experience with their reversal.</u></h3>P-glycoprotein (P-gp) expression in mononuclear bone marrow cells was analyzed in 119 patients, including 60 with chronic myelogenous leukemia (CML), 48 with myelodysplastic syndromes (MDS), and 11 with acute myelogenous leukemia (AML). For P-gp measurement an immunocytological method using monoclonal antibodies C219, 4E3, and MRK 16 and the reverse transcription-polymerase chain reaction technique were applied. According to our results obtained in healthy volunteers using the immunocytological method, the limit for P-gp overexpression was set at > or = 10% P-gp-positive mononuclear bone marrow cells and at > or = 30% P-gp-positive mononuclear peripheral blood cells. All 42 CML patients in chronic phase had normal P-gp expression. P-gp overexpression was demonstrated in four of six patients in accelerated myelogenous blast cell phase and in four of 12 CML-BC patients. Of eight CML patients in blast crisis (BC) with normal P-gp expression, partial remission was achieved in three and minor response in five after <b style='color:Tomato;'><i>prednisone</i></b>/vindesine therapy. All four of the 12 CML-BC patients with P-gp overexpression did not respond to this therapy. Normal P-gp expression was seen in 41 (85.4%) of 48 untreated MDS patients. While P-gp overexpression did not develop during therapy in any of the myelodysplastic syndrome patients treated with low-dose ara-C alone, four of eight treated with low-dose ara-C plus GM-CSF and four of 11 treated with low-dose ara-C and IL-3 developed P-gp overexpression after therapy. <b style='color:DodgerBlue;'><i>Furthermore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>11</i></b> <b style='color:DodgerBlue;'><i>AML</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>primary</i></b> <b style='color:DodgerBlue;'><i>diagnosis</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:DodgerBlue;'><i>five</i></b> <b style='color:DodgerBlue;'><i>AML</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>P-gp</i></b> <b style='color:DodgerBlue;'><i>overexpression</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>idarubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>vepesid</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cytarabine</i></b> <b style='color:DodgerBlue;'><i>V</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ara-C</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>complete</i></b> <b style='color:DodgerBlue;'><i>remission</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Additionally, one <b style='color:Tomato;'><i>daunorubicin</i></b>-<b style='color:Tomato;'><i>cytarabine</i></b>-pretreated refractory AML patient was treated with the oral form of the P-gp modulator drug dexniguldipine and achieved complete remission for a duration of 7 months. Our results suggest that in CML patients in BC, P-gp expression influences outcome after therapy. Further more, studies in a larger series of patients are necessary to prove the efficacy and toxicity of <b style='color:Tomato;'><i>idarubicin</i></b>/vepesid and cytardbine--or dexniguldipine-containing--therapy in relation to P-gp expression of AML patients.","tokens":[{"text":"Furthermore","start":0,"end":11,"id":0,"ws":true},{"text":",","start":12,"end":13,"id":1,"ws":true},{"text":"11","start":14,"end":16,"id":2,"ws":true},{"text":"AML","start":17,"end":20,"id":3,"ws":true},{"text":"patients","start":21,"end":29,"id":4,"ws":true},{"text":"at","start":30,"end":32,"id":5,"ws":true},{"text":"primary","start":33,"end":40,"id":6,"ws":true},{"text":"diagnosis","start":41,"end":50,"id":7,"ws":true},{"text":",","start":51,"end":52,"id":8,"ws":true},{"text":"including","start":53,"end":62,"id":9,"ws":true},{"text":"five","start":63,"end":67,"id":10,"ws":true},{"text":"AML","start":68,"end":71,"id":11,"ws":true},{"text":"patients","start":72,"end":80,"id":12,"ws":true},{"text":"with","start":81,"end":85,"id":13,"ws":true},{"text":"P-gp","start":86,"end":90,"id":14,"ws":true},{"text":"overexpression","start":91,"end":105,"id":15,"ws":true},{"text":",","start":106,"end":107,"id":16,"ws":true},{"text":"who","start":108,"end":111,"id":17,"ws":true},{"text":"were","start":112,"end":116,"id":18,"ws":true},{"text":"treated","start":117,"end":124,"id":19,"ws":true},{"text":"with","start":125,"end":129,"id":20,"ws":true},{"text":"idarubicin","start":130,"end":140,"id":21,"ws":true},{"text":",","start":141,"end":142,"id":22,"ws":true},{"text":"vepesid","start":143,"end":150,"id":23,"ws":true},{"text":",","start":151,"end":152,"id":24,"ws":true},{"text":"and","start":153,"end":156,"id":25,"ws":true},{"text":"cytarabine","start":157,"end":167,"id":26,"ws":true},{"text":"V","start":168,"end":169,"id":27,"ws":true},{"text":"(","start":170,"end":171,"id":28,"ws":true},{"text":"ara-C","start":172,"end":177,"id":29,"ws":true},{"text":")","start":178,"end":179,"id":30,"ws":true},{"text":"showed","start":180,"end":186,"id":31,"ws":true},{"text":"a","start":187,"end":188,"id":32,"ws":true},{"text":"complete","start":189,"end":197,"id":33,"ws":true},{"text":"remission","start":198,"end":207,"id":34,"ws":true},{"text":".","start":208,"end":209,"id":35,"ws":false}],"spans":[{"start":130,"end":140,"token_start":21,"token_end":21,"label":"DRUG"},{"start":143,"end":150,"token_start":23,"token_end":23,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/7914749/","_input_hash":-1874619752,"_task_hash":363322718,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":21,"child":23,"head_span":{"start":130,"end":140,"token_start":21,"token_end":21,"label":"DRUG"},"child_span":{"start":143,"end":150,"token_start":23,"token_end":23,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":23,"child":26,"head_span":{"start":143,"end":150,"token_start":23,"token_end":23,"label":"DRUG"},"child_span":{"start":157,"end":167,"token_start":26,"token_end":26,"label":null},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Phase Ib Study of Bavituximab With Carboplatin and Pemetrexed in Chemotherapy-Naive Advanced Nonsquamous Non-Small-Cell Lung Cancer .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Phase</i></b> <b style='color:DodgerBlue;'><i>Ib</i></b> <b style='color:DodgerBlue;'><i>Study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>Bavituximab</i></b> <b style='color:DodgerBlue;'><i>With</i></b> <b style='color:MediumOrchid;'><i>Carboplatin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Pemetrexed</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Chemotherapy-Naive</i></b> <b style='color:DodgerBlue;'><i>Advanced</i></b> <b style='color:DodgerBlue;'><i>Nonsquamous</i></b> <b style='color:DodgerBlue;'><i>Non-Small-Cell</i></b> <b style='color:DodgerBlue;'><i>Lung</i></b> <b style='color:DodgerBlue;'><i>Cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3><b style='color:Tomato;'><i>bavituximab</i></b> is an immunomodulatory chimeric monoclonal antibody that inhibits phosphatidylserine signaling, which promotes innate and adaptive immune responses. In this phase Ib trial we evaluated the safety, tolerability, and preliminary antitumor activity of <b style='color:Tomato;'><i>pemetrexed</i></b>, <b style='color:Tomato;'><i>carboplatin</i></b>, <b style='color:Tomato;'><i>bavituximab</i></b> in advanced non-small-cell lung cancer (NSCLC). ### Patients And Methods Patients with advanced nonsquamous NSCLC and performance status 0 or 1 were treated with <b style='color:Tomato;'><i>pemetrexed</i></b> 500 mg/m ### results Between March 29, 2011 and December 30, 2013, 26 patients were enrolled. Three patients each were enrolled into dose escalation cohorts of <b style='color:Tomato;'><i>bavituximab</i></b> (0.3, 1, and 3 mg/kg). Therapy was well tolerated with no DLTs, and toxicities were consistent with those expected from <b style='color:Tomato;'><i>pemetrexed</i></b>/<b style='color:Tomato;'><i>carboplatin</i></b>. Overall response was 28%, with a median progression-free and overall survival of 4.8 months and 12.2 months, respectively. ### conclusion The combination of <b style='color:Tomato;'><i>pemetrexed</i></b>, <b style='color:Tomato;'><i>carboplatin</i></b>, <b style='color:Tomato;'><i>bavituximab</i></b> is well tolerated. However, with toxicities and preliminary efficacy signal similar to <b style='color:Tomato;'><i>pemetrexed</i></b>/<b style='color:Tomato;'><i>carboplatin</i></b> alone, further studies of <b style='color:Tomato;'><i>bavituximab</i></b> should focus on ways to enhance its immunomodulatory role.","tokens":[{"text":"Phase","start":0,"end":5,"id":0,"ws":true},{"text":"Ib","start":6,"end":8,"id":1,"ws":true},{"text":"Study","start":9,"end":14,"id":2,"ws":true},{"text":"of","start":15,"end":17,"id":3,"ws":true},{"text":"Bavituximab","start":18,"end":29,"id":4,"ws":true},{"text":"With","start":30,"end":34,"id":5,"ws":true},{"text":"Carboplatin","start":35,"end":46,"id":6,"ws":true},{"text":"and","start":47,"end":50,"id":7,"ws":true},{"text":"Pemetrexed","start":51,"end":61,"id":8,"ws":true},{"text":"in","start":62,"end":64,"id":9,"ws":true},{"text":"Chemotherapy-Naive","start":65,"end":83,"id":10,"ws":true},{"text":"Advanced","start":84,"end":92,"id":11,"ws":true},{"text":"Nonsquamous","start":93,"end":104,"id":12,"ws":true},{"text":"Non-Small-Cell","start":105,"end":119,"id":13,"ws":true},{"text":"Lung","start":120,"end":124,"id":14,"ws":true},{"text":"Cancer","start":125,"end":131,"id":15,"ws":true},{"text":".","start":132,"end":133,"id":16,"ws":false}],"spans":[{"start":18,"end":29,"token_start":4,"token_end":4,"label":"DRUG"},{"start":35,"end":46,"token_start":6,"token_end":6,"label":"DRUG"},{"start":51,"end":61,"token_start":8,"token_end":8,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29631965/","_input_hash":-910966445,"_task_hash":-558478627,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":4,"child":6,"head_span":{"start":18,"end":29,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":35,"end":46,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":6,"child":8,"head_span":{"start":35,"end":46,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":51,"end":61,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"In this multicenter study , the reliability of two nonradiometric , fully automated systems , the MB/BacT and BACTEC MGIT 960 systems , for testing the susceptibilities of 82 Mycobacterium tuberculosis strains to isoniazid , rifampin , ethambutol , and streptomycin was evaluated in comparison with the radiometric BACTEC 460 TB system .","paragraph":"<h3><u>Multicenter laboratory evaluation of the MB/BacT Mycobacterium detection system and the BACTEC MGIT 960 system in comparison with the BACTEC 460TB system for susceptibility testing of Mycobacterium tuberculosis.</u></h3> <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>multicenter</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>reliability</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>nonradiometric</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>fully</i></b> <b style='color:DodgerBlue;'><i>automated</i></b> <b style='color:DodgerBlue;'><i>systems</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>MB/BacT</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>BACTEC</i></b> <b style='color:DodgerBlue;'><i>MGIT</i></b> <b style='color:DodgerBlue;'><i>960</i></b> <b style='color:DodgerBlue;'><i>systems</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>testing</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>susceptibilities</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>82</i></b> <b style='color:DodgerBlue;'><i>Mycobacterium</i></b> <b style='color:DodgerBlue;'><i>tuberculosis</i></b> <b style='color:DodgerBlue;'><i>strains</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>isoniazid</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>rifampin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ethambutol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>streptomycin</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>evaluated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>comparison</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>radiometric</i></b> <b style='color:DodgerBlue;'><i>BACTEC</i></b> <b style='color:DodgerBlue;'><i>460</i></b> <b style='color:DodgerBlue;'><i>TB</i></b> <b style='color:DodgerBlue;'><i>system</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The arbitration of discrepant results was done by the reanalysis of the strain, the determination of the MIC, and the molecular characterization of some resistance determinants. The overall level of agreement with BACTEC 460TB results was 96% with the MB/BacT test and 97.2% with the BACTEC MGIT 960 system. With both methods, the level of agreement with BACTEC 460TB results was 96.3% for <b style='color:Tomato;'><i>isoniazid</i></b>, 98.8% for <b style='color:Tomato;'><i>rifampin</i></b>, and 98.8% for <b style='color:Tomato;'><i>ethambutol</i></b>. The level of agreement for <b style='color:Tomato;'><i>streptomycin</i></b> was 90.2% with MB/BacT and 97.5% with BACTEC MGIT 960. Overall, there were 11 very major errors and 2 major errors with the MB/BacT method and 5 very major errors and 2 major errors with the BACTEC MGIT 960 system. In general, the MB/BacT and BACTEC MGIT 960 systems showed good performance for susceptibility testing with first-line antituberculosis drugs.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"this","start":3,"end":7,"id":1,"ws":true},{"text":"multicenter","start":8,"end":19,"id":2,"ws":true},{"text":"study","start":20,"end":25,"id":3,"ws":true},{"text":",","start":26,"end":27,"id":4,"ws":true},{"text":"the","start":28,"end":31,"id":5,"ws":true},{"text":"reliability","start":32,"end":43,"id":6,"ws":true},{"text":"of","start":44,"end":46,"id":7,"ws":true},{"text":"two","start":47,"end":50,"id":8,"ws":true},{"text":"nonradiometric","start":51,"end":65,"id":9,"ws":true},{"text":",","start":66,"end":67,"id":10,"ws":true},{"text":"fully","start":68,"end":73,"id":11,"ws":true},{"text":"automated","start":74,"end":83,"id":12,"ws":true},{"text":"systems","start":84,"end":91,"id":13,"ws":true},{"text":",","start":92,"end":93,"id":14,"ws":true},{"text":"the","start":94,"end":97,"id":15,"ws":true},{"text":"MB/BacT","start":98,"end":105,"id":16,"ws":true},{"text":"and","start":106,"end":109,"id":17,"ws":true},{"text":"BACTEC","start":110,"end":116,"id":18,"ws":true},{"text":"MGIT","start":117,"end":121,"id":19,"ws":true},{"text":"960","start":122,"end":125,"id":20,"ws":true},{"text":"systems","start":126,"end":133,"id":21,"ws":true},{"text":",","start":134,"end":135,"id":22,"ws":true},{"text":"for","start":136,"end":139,"id":23,"ws":true},{"text":"testing","start":140,"end":147,"id":24,"ws":true},{"text":"the","start":148,"end":151,"id":25,"ws":true},{"text":"susceptibilities","start":152,"end":168,"id":26,"ws":true},{"text":"of","start":169,"end":171,"id":27,"ws":true},{"text":"82","start":172,"end":174,"id":28,"ws":true},{"text":"Mycobacterium","start":175,"end":188,"id":29,"ws":true},{"text":"tuberculosis","start":189,"end":201,"id":30,"ws":true},{"text":"strains","start":202,"end":209,"id":31,"ws":true},{"text":"to","start":210,"end":212,"id":32,"ws":true},{"text":"isoniazid","start":213,"end":222,"id":33,"ws":true},{"text":",","start":223,"end":224,"id":34,"ws":true},{"text":"rifampin","start":225,"end":233,"id":35,"ws":true},{"text":",","start":234,"end":235,"id":36,"ws":true},{"text":"ethambutol","start":236,"end":246,"id":37,"ws":true},{"text":",","start":247,"end":248,"id":38,"ws":true},{"text":"and","start":249,"end":252,"id":39,"ws":true},{"text":"streptomycin","start":253,"end":265,"id":40,"ws":true},{"text":"was","start":266,"end":269,"id":41,"ws":true},{"text":"evaluated","start":270,"end":279,"id":42,"ws":true},{"text":"in","start":280,"end":282,"id":43,"ws":true},{"text":"comparison","start":283,"end":293,"id":44,"ws":true},{"text":"with","start":294,"end":298,"id":45,"ws":true},{"text":"the","start":299,"end":302,"id":46,"ws":true},{"text":"radiometric","start":303,"end":314,"id":47,"ws":true},{"text":"BACTEC","start":315,"end":321,"id":48,"ws":true},{"text":"460","start":322,"end":325,"id":49,"ws":true},{"text":"TB","start":326,"end":328,"id":50,"ws":true},{"text":"system","start":329,"end":335,"id":51,"ws":true},{"text":".","start":336,"end":337,"id":52,"ws":false}],"spans":[{"start":213,"end":222,"token_start":33,"token_end":33,"label":"DRUG"},{"start":225,"end":233,"token_start":35,"token_end":35,"label":"DRUG"},{"start":236,"end":246,"token_start":37,"token_end":37,"label":"DRUG"},{"start":253,"end":265,"token_start":40,"token_end":40,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/17442793/","_input_hash":-1960772817,"_task_hash":153031742,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Most frequent first line therapy was Sunitinib ( 66 % ) , followed by Sorafenib ( 20 % ) and Pazopanib ( 10 % ) .","paragraph":"<h3><u>The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort.</u></h3>Tyrosine kinase inhibitor therapy (TKI) has changed the treatment paradigm of metastatic renal cell carcinoma (mRCC). The recent CARMENA and SURTIME trials challenged the role of the cytoreductive nephrectomy (CN). ### objective To assess the impact of CN prior to TKI therapy in patients with mRCC in a real-world setting. ### methods Overall, 262 consecutive patients with mRCC were treated with CN plus TKI or TKI only at our institution between 2000 and 2016. Patients with prior immunotherapy or metastasectomy were excluded. Multiple imputation and inverse probability of treatment weighting (IPTW) were performed to account for missing values and imbalances between the treatment groups, respectively. Unadjusted and adjusted Kaplan-Meier estimates were used to determine differences in progression-free (PFS), overall (OS), and cancer-specific survival (CSS). ### results Overall, 104 (40%) patients received CN before TKI treatment. <b style='color:DodgerBlue;'><i>Most</i></b> <b style='color:DodgerBlue;'><i>frequent</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>line</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:MediumOrchid;'><i>Sunitinib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>66</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>Sorafenib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Pazopanib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> After adjustment with IPTW, there was no difference in PFS, CSS, and OS (all P > 0.05) between the treatment groups. In subgroup analyses, CSS was improved when CN was performed in patients with sarcomatoid features and clear cell histology (P\u202f=\u202f0.04 and P\u202f=\u202f0.03) and PFS was improved in patients with clear cell histology when CN was performed [0.04]). CN did not improve OS in any subgroup analysis. ### conclusion The role of CN remains controversial. We found no difference in survival outcomes between patients treated with and without CN before TKI therapy. However, CN was associated with improved survival in specific patient subgroups. Tailored, individualized treatment is key to further improve oncological outcomes for mRCC.","tokens":[{"text":"Most","start":0,"end":4,"id":0,"ws":true},{"text":"frequent","start":5,"end":13,"id":1,"ws":true},{"text":"first","start":14,"end":19,"id":2,"ws":true},{"text":"line","start":20,"end":24,"id":3,"ws":true},{"text":"therapy","start":25,"end":32,"id":4,"ws":true},{"text":"was","start":33,"end":36,"id":5,"ws":true},{"text":"Sunitinib","start":37,"end":46,"id":6,"ws":true},{"text":"(","start":47,"end":48,"id":7,"ws":true},{"text":"66","start":49,"end":51,"id":8,"ws":true},{"text":"%","start":52,"end":53,"id":9,"ws":true},{"text":")","start":54,"end":55,"id":10,"ws":true},{"text":",","start":56,"end":57,"id":11,"ws":true},{"text":"followed","start":58,"end":66,"id":12,"ws":true},{"text":"by","start":67,"end":69,"id":13,"ws":true},{"text":"Sorafenib","start":70,"end":79,"id":14,"ws":true},{"text":"(","start":80,"end":81,"id":15,"ws":true},{"text":"20","start":82,"end":84,"id":16,"ws":true},{"text":"%","start":85,"end":86,"id":17,"ws":true},{"text":")","start":87,"end":88,"id":18,"ws":true},{"text":"and","start":89,"end":92,"id":19,"ws":true},{"text":"Pazopanib","start":93,"end":102,"id":20,"ws":true},{"text":"(","start":103,"end":104,"id":21,"ws":true},{"text":"10","start":105,"end":107,"id":22,"ws":true},{"text":"%","start":108,"end":109,"id":23,"ws":true},{"text":")","start":110,"end":111,"id":24,"ws":true},{"text":".","start":112,"end":113,"id":25,"ws":false}],"spans":[{"start":37,"end":46,"token_start":6,"token_end":6,"label":"DRUG"},{"start":70,"end":79,"token_start":14,"token_end":14,"label":"DRUG"},{"start":93,"end":102,"token_start":20,"token_end":20,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/32576526/","_input_hash":-1193138832,"_task_hash":1267016825,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Treatment of unresectable GISTs involves systemic chemotherapy with tyrosine kinase inhibitors , imatinib and sunitinib being first-line and second-line drugs .","paragraph":"<h3><u>A gastrointestinal stromal tumour with pulmonary metastases mimicking unilateral gynaecomastia.</u></h3>Gastrointestinal stromal tumours (GISTs) represent 1% of primary gastrointestinal cancers. These neoplasms most frequently metastasise to the liver and peritoneum and rarely to the lungs and bones. <b style='color:DodgerBlue;'><i>Treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>unresectable</i></b> <b style='color:DodgerBlue;'><i>GISTs</i></b> <b style='color:DodgerBlue;'><i>involves</i></b> <b style='color:DodgerBlue;'><i>systemic</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>tyrosine</i></b> <b style='color:DodgerBlue;'><i>kinase</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>imatinib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>sunitinib</i></b> <b style='color:DodgerBlue;'><i>being</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>second-line</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We report the case of a 52-year-old man with GIST who developed a right-sided subareolar breast swelling and subsequently discovered to be an invasive metastatic pulmonary GIST. Given that gynaecomastia is a known adverse effect of <b style='color:Tomato;'><i>imatinib</i></b> and <b style='color:Tomato;'><i>sunitinib</i></b>, this case report illustrates the importance of including metastatic disease in the differential diagnosis of patients with GIST and with the new onset of soft tissue masses.","tokens":[{"text":"Treatment","start":0,"end":9,"id":0,"ws":true},{"text":"of","start":10,"end":12,"id":1,"ws":true},{"text":"unresectable","start":13,"end":25,"id":2,"ws":true},{"text":"GISTs","start":26,"end":31,"id":3,"ws":true},{"text":"involves","start":32,"end":40,"id":4,"ws":true},{"text":"systemic","start":41,"end":49,"id":5,"ws":true},{"text":"chemotherapy","start":50,"end":62,"id":6,"ws":true},{"text":"with","start":63,"end":67,"id":7,"ws":true},{"text":"tyrosine","start":68,"end":76,"id":8,"ws":true},{"text":"kinase","start":77,"end":83,"id":9,"ws":true},{"text":"inhibitors","start":84,"end":94,"id":10,"ws":true},{"text":",","start":95,"end":96,"id":11,"ws":true},{"text":"imatinib","start":97,"end":105,"id":12,"ws":true},{"text":"and","start":106,"end":109,"id":13,"ws":true},{"text":"sunitinib","start":110,"end":119,"id":14,"ws":true},{"text":"being","start":120,"end":125,"id":15,"ws":true},{"text":"first-line","start":126,"end":136,"id":16,"ws":true},{"text":"and","start":137,"end":140,"id":17,"ws":true},{"text":"second-line","start":141,"end":152,"id":18,"ws":true},{"text":"drugs","start":153,"end":158,"id":19,"ws":true},{"text":".","start":159,"end":160,"id":20,"ws":false}],"spans":[{"start":97,"end":105,"token_start":12,"token_end":12,"label":"DRUG"},{"start":110,"end":119,"token_start":14,"token_end":14,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/24343802/","_input_hash":-1360996283,"_task_hash":249055749,"_session_id":"drug_drug_pilot_split2c-yosi","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Such therapy has included weekly paclitaxel in combination with carboplatin/cisplatin plus topotecan , and carboplatin plus doxorubicin .","paragraph":"<h3><u>Role of weekly paclitaxel in the treatment of advanced ovarian cancer.</u></h3>Dose-dense weekly administration of <b style='color:Tomato;'><i>paclitaxel</i></b> has the potential advantage of allowing a larger percentage of cancer cells to enter the vulnerable phase of their cell cycle when cytotoxic <b style='color:Tomato;'><i>paclitaxel</i></b> concentrations are present. The lower doses and shorter infusion times used with weekly dosing should also minimize bone marrow suppression and other toxicities associated with standard <b style='color:Tomato;'><i>paclitaxel</i></b> 3-weekly administration. Clinical studies have confirmed that <b style='color:Tomato;'><i>paclitaxel</i></b> can be safely delivered on a weekly schedule as a 1-h infusion to patients with advanced ovarian cancer. Weekly administration of <b style='color:Tomato;'><i>paclitaxel</i></b> also appears to be better tolerated than 3-weekly administration. Single-agent weekly <b style='color:Tomato;'><i>paclitaxel</i></b> is associated with response rates of 20-65%. Combination therapy with weekly <b style='color:Tomato;'><i>paclitaxel</i></b> has mainly involved <b style='color:Tomato;'><i>carboplatin</i></b> and response rates with such regimens range from 60-88%. Triple-drug combination therapy has produced response rates of 42-67.5%. <b style='color:DodgerBlue;'><i>Such</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>included</i></b> <b style='color:DodgerBlue;'><i>weekly</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>carboplatin/cisplatin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In an attempt to avoid problems with high corticosteroid doses, <b style='color:Tomato;'><i>dexamethasone</i></b> doses of 10 and 8 mg have been used successfully in premedication regimens for weekly <b style='color:Tomato;'><i>paclitaxel</i></b> in ovarian cancer.","tokens":[{"text":"Such","start":0,"end":4,"id":0,"ws":true},{"text":"therapy","start":5,"end":12,"id":1,"ws":true},{"text":"has","start":13,"end":16,"id":2,"ws":true},{"text":"included","start":17,"end":25,"id":3,"ws":true},{"text":"weekly","start":26,"end":32,"id":4,"ws":true},{"text":"paclitaxel","start":33,"end":43,"id":5,"ws":true},{"text":"in","start":44,"end":46,"id":6,"ws":true},{"text":"combination","start":47,"end":58,"id":7,"ws":true},{"text":"with","start":59,"end":63,"id":8,"ws":true},{"text":"carboplatin/cisplatin","start":64,"end":85,"id":9,"ws":true},{"text":"plus","start":86,"end":90,"id":10,"ws":true},{"text":"topotecan","start":91,"end":100,"id":11,"ws":true},{"text":",","start":101,"end":102,"id":12,"ws":true},{"text":"and","start":103,"end":106,"id":13,"ws":true},{"text":"carboplatin","start":107,"end":118,"id":14,"ws":true},{"text":"plus","start":119,"end":123,"id":15,"ws":true},{"text":"doxorubicin","start":124,"end":135,"id":16,"ws":true},{"text":".","start":136,"end":137,"id":17,"ws":false}],"spans":[{"start":33,"end":43,"token_start":5,"token_end":5,"label":"DRUG"},{"start":91,"end":100,"token_start":11,"token_end":11,"label":"DRUG"},{"start":107,"end":118,"token_start":14,"token_end":14,"label":"DRUG"},{"start":124,"end":135,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/12505598/","_input_hash":1625402879,"_task_hash":-1892171795,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":5,"child":9,"head_span":{"start":33,"end":43,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":64,"end":85,"token_start":9,"token_end":9,"label":null},"color":"#c5bdf4","label":"POS1"},{"head":9,"child":11,"head_span":{"start":64,"end":85,"token_start":9,"token_end":9,"label":null},"child_span":{"start":91,"end":100,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":5,"child":14,"head_span":{"start":33,"end":43,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":107,"end":118,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#ffd882","label":"POS2"},{"head":14,"child":16,"head_span":{"start":107,"end":118,"token_start":14,"token_end":14,"label":"DRUG"},"child_span":{"start":124,"end":135,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS11","POS21"],"answer":"accept"}
{"text":"This phase II study was performed to assess the efficacy and safety of the combination regimen of temozolomide and docetaxel in patients with advanced metastatic melanoma .","paragraph":"<h3><u>Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.</u></h3><b style='color:Tomato;'><i>temozolomide</i></b> is a novel oral alkylating agent that is effective against melanoma. Moreover, <b style='color:Tomato;'><i>temozolomide</i></b> readily crosses the blood-brain barrier and may consequently be effective in patients with brain metastases. <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>performed</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>assess</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>temozolomide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>melanoma</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### Patients And Methods Sixty-five patients with metastatic melanoma were enrolled. Treatment consisted of intravenous <b style='color:Tomato;'><i>docetaxel</i></b> (80 mg/m(2)) on day 1 and oral <b style='color:Tomato;'><i>temozolomide</i></b> (150 mg/m(2)) on days 1 to 5, every 4 weeks, for a maximum of six cycles. ### results Sixty-two patients were eligible for the efficacy and safety analysis. Seventeen patients (27%) achieved an objective response, including five complete (8%) and 12 partial responses (19%). Median response duration was 9.5 months. Among responders, median time to progression (TTP) was 11.2 months and median overall survival (OS) was 16 months. For all treated patients, the median TTP was 4 months and median OS was 11 months. Three (38%) of eight patients who presented with brain metastases had a partial response for 5, 6, and 12 months. Of 52 patients who did not have brain involvement at presentation, only four (8%) developed brain metastases at a median follow-up of 14 months. Myelosuppression was the primary toxicity. ### conclusion The combination of <b style='color:Tomato;'><i>temozolomide</i></b> and <b style='color:Tomato;'><i>docetaxel</i></b> was effective and well tolerated as first-line treatment for patients with advanced metastatic melanoma and demonstrated encouraging antitumor activity against brain metastases.","tokens":[{"text":"This","start":0,"end":4,"id":0,"ws":true},{"text":"phase","start":5,"end":10,"id":1,"ws":true},{"text":"II","start":11,"end":13,"id":2,"ws":true},{"text":"study","start":14,"end":19,"id":3,"ws":true},{"text":"was","start":20,"end":23,"id":4,"ws":true},{"text":"performed","start":24,"end":33,"id":5,"ws":true},{"text":"to","start":34,"end":36,"id":6,"ws":true},{"text":"assess","start":37,"end":43,"id":7,"ws":true},{"text":"the","start":44,"end":47,"id":8,"ws":true},{"text":"efficacy","start":48,"end":56,"id":9,"ws":true},{"text":"and","start":57,"end":60,"id":10,"ws":true},{"text":"safety","start":61,"end":67,"id":11,"ws":true},{"text":"of","start":68,"end":70,"id":12,"ws":true},{"text":"the","start":71,"end":74,"id":13,"ws":true},{"text":"combination","start":75,"end":86,"id":14,"ws":true},{"text":"regimen","start":87,"end":94,"id":15,"ws":true},{"text":"of","start":95,"end":97,"id":16,"ws":true},{"text":"temozolomide","start":98,"end":110,"id":17,"ws":true},{"text":"and","start":111,"end":114,"id":18,"ws":true},{"text":"docetaxel","start":115,"end":124,"id":19,"ws":true},{"text":"in","start":125,"end":127,"id":20,"ws":true},{"text":"patients","start":128,"end":136,"id":21,"ws":true},{"text":"with","start":137,"end":141,"id":22,"ws":true},{"text":"advanced","start":142,"end":150,"id":23,"ws":true},{"text":"metastatic","start":151,"end":161,"id":24,"ws":true},{"text":"melanoma","start":162,"end":170,"id":25,"ws":true},{"text":".","start":171,"end":172,"id":26,"ws":false}],"spans":[{"start":98,"end":110,"token_start":17,"token_end":17,"label":"DRUG"},{"start":115,"end":124,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/11786569/","_input_hash":1159878705,"_task_hash":2116484808,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":17,"child":19,"head_span":{"start":98,"end":110,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":115,"end":124,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>verapamil</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>initial</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>small</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Based on experimental observations that <b style='color:Tomato;'><i>verapamil</i></b> and <b style='color:Tomato;'><i>tamoxifen</i></b> reverse multiple drug resistance, the authors investigated the feasibility of combining both agents with the initial chemotherapy of extensive small cell lung cancer. Overall, in a consecutive series of 58 patients the most important toxicity was myelosuppression, and there was a 24% rate of severe infections. Therapeutic results included 24% complete and 34% partial response rates, median time to disease progression of 32 weeks, and median survival of 46 weeks. In three consecutive cohorts of patients the dose of either <b style='color:Tomato;'><i>tamoxifen</i></b> or <b style='color:Tomato;'><i>verapamil</i></b> were escalated by 25% and 33%, respectively. The cohort of patients receiving <b style='color:Tomato;'><i>verapamil</i></b> 360 mg/day and <b style='color:Tomato;'><i>tamoxifen</i></b> 100 mg/day (level 2) had slightly more toxicity but also more responses than the other groups. Therefore, the authors recommend that these doses be used in controlled trials to confirm the promising results of their study.","tokens":[{"text":"Addition","start":0,"end":8,"id":0,"ws":true},{"text":"of","start":9,"end":11,"id":1,"ws":true},{"text":"verapamil","start":12,"end":21,"id":2,"ws":true},{"text":"and","start":22,"end":25,"id":3,"ws":true},{"text":"tamoxifen","start":26,"end":35,"id":4,"ws":true},{"text":"to","start":36,"end":38,"id":5,"ws":true},{"text":"the","start":39,"end":42,"id":6,"ws":true},{"text":"initial","start":43,"end":50,"id":7,"ws":true},{"text":"chemotherapy","start":51,"end":63,"id":8,"ws":true},{"text":"of","start":64,"end":66,"id":9,"ws":true},{"text":"small","start":67,"end":72,"id":10,"ws":true},{"text":"cell","start":73,"end":77,"id":11,"ws":true},{"text":"lung","start":78,"end":82,"id":12,"ws":true},{"text":"cancer","start":83,"end":89,"id":13,"ws":true},{"text":".","start":90,"end":91,"id":14,"ws":false}],"spans":[{"start":12,"end":21,"token_start":2,"token_end":2,"label":"DRUG"},{"start":26,"end":35,"token_start":4,"token_end":4,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/2164872/","_input_hash":-375551766,"_task_hash":-1507493145,"_session_id":"drug_drug_pilot_split2c-yosi","_view_id":"blocks","relations":[{"head":2,"child":4,"head_span":{"start":12,"end":21,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":26,"end":35,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"In a scenario analysis comparing pembrolizumab with ipilimumab , the estimated ICER was USD8,904 .","paragraph":"<h3><u>Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong.</u></h3><b style='color:Tomato;'><i>pembrolizumab</i></b> has been shown to improve overall survival (OS) and progression free survival (PFS) compared to <b style='color:Tomato;'><i>ipilimumab</i></b> in patients with <b style='color:Tomato;'><i>ipilimumab</i></b>-na\u00efve advanced melanoma; however, there are no published data on the cost-effectiveness for <b style='color:Tomato;'><i>pembrolizumab</i></b> compared to standard-of-care treatments currently used in Hong Kong for advanced melanoma. ### methods A partitioned-survival model based on data from a recent randomized phase 3 study (KEYNOTE-006) and meta-analysis was used to derive time in PFS, OS, and post-progression survival for <b style='color:Tomato;'><i>pembrolizumab</i></b> and chemotherapy, such as <b style='color:Tomato;'><i>dacarbazine</i></b> (DTIC), <b style='color:Tomato;'><i>temozolomide</i></b> (TMZ), and the <b style='color:Tomato;'><i>paclitaxel</i></b>-<b style='color:Tomato;'><i>carboplatin</i></b> combination (PC). A combination of clinical trial data, published data, results of meta-analysis, and melanoma registry data was used to extrapolate PFS and OS curves. The base-case time horizon for the model was 30\u00a0years with costs and health outcomes discounted at a rate of 5% per year. Individual patient level data on utilities and frequencies of adverse events were obtained from the final analysis of KEYNOTE-006 (cut-off date: 3-Dec-15) for <b style='color:Tomato;'><i>pembrolizumab</i></b>. Cost data included drug acquisition, treatment administration, adverse event management, and clinical management of advanced melanoma. The distribution of patient weight from the Hong Kong population was applied to calculate the drug costs. Analyses were performed from a payer's perspective. The incremental cost effectiveness ratio (ICER) expressed as cost in US Dollars (USD) per quality-adjusted life years (QALYs) was the main outcome. ### results In base-case scenario, the ICER for <b style='color:Tomato;'><i>pembrolizumab</i></b> as a first-line treatment for advanced melanoma was USD49,232 compared to DTIC, with the ICER values lower than cost-effectiveness threshold in Hong Kong. Results comparing <b style='color:Tomato;'><i>pembrolizumab</i></b> to TMZ and to PC were similar to that when compared to DTIC. Probability sensitivity analyses showed that 99% of the simulated ICERs were below three times the Gross Domestic Product (GDP) per capita for Hong Kong (currently at $119,274//QALY threshold). <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>scenario</i></b> <b style='color:DodgerBlue;'><i>analysis</i></b> <b style='color:DodgerBlue;'><i>comparing</i></b> <b style='color:MediumOrchid;'><i>pembrolizumab</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>ipilimumab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>estimated</i></b> <b style='color:DodgerBlue;'><i>ICER</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>USD8,904</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### conclusions <b style='color:Tomato;'><i>pembrolizumab</i></b> is cost-effective relative to chemotherapy (DTIC, TMZ and PC), and highly-cost-effective compared to <b style='color:Tomato;'><i>ipilimumab</i></b>, for the first-line treatment of advanced melanoma in Hong Kong.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"a","start":3,"end":4,"id":1,"ws":true},{"text":"scenario","start":5,"end":13,"id":2,"ws":true},{"text":"analysis","start":14,"end":22,"id":3,"ws":true},{"text":"comparing","start":23,"end":32,"id":4,"ws":true},{"text":"pembrolizumab","start":33,"end":46,"id":5,"ws":true},{"text":"with","start":47,"end":51,"id":6,"ws":true},{"text":"ipilimumab","start":52,"end":62,"id":7,"ws":true},{"text":",","start":63,"end":64,"id":8,"ws":true},{"text":"the","start":65,"end":68,"id":9,"ws":true},{"text":"estimated","start":69,"end":78,"id":10,"ws":true},{"text":"ICER","start":79,"end":83,"id":11,"ws":true},{"text":"was","start":84,"end":87,"id":12,"ws":true},{"text":"USD8,904","start":88,"end":96,"id":13,"ws":true},{"text":".","start":97,"end":98,"id":14,"ws":false}],"spans":[{"start":33,"end":46,"token_start":5,"token_end":5,"label":"DRUG"},{"start":52,"end":62,"token_start":7,"token_end":7,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/31969794/","_input_hash":561908098,"_task_hash":-2137009120,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
